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 Abstract 
 
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease in 
the growing population of elderly people. Although the etiology of the disease is yet to 
be fully elucidated, pathological hallmarks have been consistently described, including 
the accumulation of amyloid plaques, dysfunctional ionic homeostasis, synaptic 
disruption and neurodegeneration. The amyloid hypothesis postulates that aberrant 
production of amyloid-  (Aβ) proteins, which have a high propensity to aggregate, lies 
at the center of the pathological mechanism of AD. In particular, soluble oligomeric Aβ 
structures have been identified as primary toxic species. The interaction of these 
structures with several cellular targets, including ion channels such as nicotinic 
acetylcholine receptors (nAChR) and voltage operated Ca2+ channels (VOCC), has 
also been implicated in Aβ toxicity and AD.   
The aim of this thesis is to investigate how the acute and chronic actions of Aβ 
in vitro are affected by nicotinic ligands. Acute application of Aβ1-42 to fluo-3-loaded 
PC12 cells potentiated Ca2+ increases evoked by stimulation of nAChR and VOCC, 
while chronic application reduced redox potential, disrupted membrane integrity and 
initiated apoptosis in PC12 cells. In addition to mimicking the toxic responses of PC12 
cells, Aβ1-42 also reduced neurite outgrowth and synaptogenesis in rat primary cortical 
neurons. All actions of Aβ were prevented by inhibitors of Aβ1-42 oligomerisation, 
including the hexapeptide KLVFFA. Neuroprotection afforded by (+)-nicotine also 
occurred via inhibition of Aβ1-42 oligomerisation, rather than by a receptor-mediated 
mechanism. No other pharmacological approaches, including application of two novel 
ligands selective for 7 nAChR: the partial agonist SSR180711 and antagonist -
conotoxinArIB[V11L,V16D], characterized herein, protected against Aβ1-42 toxicity. 
While inhibiting oligomerisation prevented the actions of Aβ1-42, enhanced 
oligomerisation evoked amplified toxic responses. However, the potentiation of Ca2+ 
signalling diminished following enhanced oligomerisation. This, coupled with a lack of 
VOCC-involvement in Aβ toxicity and the differential actions of truncated Aβ peptides 
on toxicity and Ca2+ signaling, indicates that the acute disruption of Ca2+ signaling by Aβ 
does not underpin the chronic toxic effects of Aβ. 
xi 
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Auguste Deter, Nov 
1902 (Perusini et 
al. 1909) 
Introduction  
 
1.1 Alzheimer’s disease: a “Peculiar Disease” 
On November 25th, 1901, a 51-year-old woman named 
Auguste Deter was admitted to the Frankfurt hospital and 
examined by the German neuropathologist and psychiatrist Alois 
Alzheimer (1864-1915). Deter at first presented with impaired 
memory, aphasia, disorientation and psychosocial 
incompetence. As her condition progressed, she started losing 
other cognitive functions and experiencing hallucinations. 
Because of her age, Deter was diagnosed with presenile 
dementia upon admission (Alzheimer et al. 1906); today, the 
diagnosis would be early-onset Alzheimer‟s disease (AD), defined by development of 
the condition before the age of 65.  
Recent figures indicate 750,000 people in the UK suffer from dementia and 
approximately half have been diagnosed with AD (Government Actuary Department & 
Office of National Statistics, Series PP2 No 25, 2006). The economic costs of AD in the 
UK have been estimated as high as £15 billion, more than those of coronary heart 
disease, cancer and stroke combined (National Audit Office and PSSRU report, 2007). 
As the population is expanding and the incidence of AD roughly doubles every 5 years 
over the age of 65 (Ferri et al. 2005), the number of AD sufferers has been projected to 
double by 2051 (Matthews et al. 2001). In the US, The National Institute of Health 
currently estimates up to 4.5 million Americans are living with AD (www.nia.nih.gov), 
costing an estimated $148 billion each year (Alzheimer‟s Association, www.alz.org).   
 
1.2 Symptoms and Diagnosis 
Until recently, AD had only been diagnosed via patient history and mental state 
examinations, with confirmation by post mortem examination. The Diagnostic and 
Statistical Manual of Mental Disorders (Fourth Edition; DSM-IV) outlines a detailed set 
of criteria for the diagnosis of AD, which can differentiate AD from other dementias, 
such as vascular dementia (reviewed in Fladd et al. 2005). The criteria focus on 
cognitive impairment, which is remarkably pure early in the progression of AD. Patients 
lose the ability to encode new memories, first of trivial, then of important details in life. 
This occurs while the motor and sensory functions are preserved, in individuals who 
remain otherwise neurologically intact (Selkoe et al. 2002). Over time, both declarative 
and non-declarative memories become profoundly impaired. To be diagnosed as AD, 
one or more of the following must accompany memory impairment:  
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 Aphasia, a deterioration of language abilities 
 Apraxia, difficulty executing motor activities, even though movement, 
senses, and the ability to understand what is being asked are still intact 
 Agnosia, an impaired ability to recognise or identify objects, even though 
sensory abilities are intact 
 Anosmia, is a lack of functioning olfaction 
 Problems with executive functioning, such as planning tasks, organizing 
projects, or carrying out goals in the proper sequence 
The Mini-Mental State Exam is a common method to assess cognitive function 
and is frequently employed during diagnosis of AD. By assessing orientation, short-
term memory (both recall and retention) and language skills the test allows differential 
diagnosis of (what would now be termed) mild cognitive impairment (MCI), moderate 
and severe AD (Folstein et al. 1975).  
 Despite extensive mental state assessment, confirmation of AD is only possible 
upon post-mortem examination. Severity is commonly rated by a system devised by 
Braak & Braak (1994), which classifies AD into six distinct pathoanatomical stages, 
based on the topographical distribution pattern of cortical lesions (section 1.3). 
However, recent advances in brain imaging have allowed detection of pathological 
hallmarks of AD in live subjects, facilitating more accurate and earlier diagnosis 
(discussed further in section 1.3.3; reviewed in Small et al. 2008).  
 
1.3 Hallmarks of Alzheimer’s Disease 
1.3.1 Amyloid Plaques 
 The characteristic brain pathology used to confirm AD 
diagnosis was first observed by Alois Alzheimer, and led to the 
disease taking his name. In 1906, a year after the death of Auguste 
Deter, Alzheimer described her histopathology to psychiatrists at 
the 37th Meeting of Southwest German Psychiatrists in Tübingen: 
“In the centre of an otherwise almost normal cell there stands out 
one or several fibrils due to their characteristic thickness and 
peculiar impregnability. Numerous small miliary foci are found in 
the superior layers. They are determined by the storage of a peculiar material in the 
cortex. All in all we have to face a peculiar disease process” (Alzheimer et al. 1906; 
translated by Eisdorfer et al. 1969). 
 The miliary foci described by Alzheimer, now called senile- or amyloid- plaques 
(fig 1.1A), are commonly found throughout the neocortex and hippocampus of AD 
patients (Selkoe et al. 1997) where they are associated with degenerating neuronal 
Alois Alzheimer 
(Maurer 1997)  
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processes. They are complex extracellular lesions, characterised by a central core 
enveloped by a diffuse halo. This is surrounded by reactive astrocytes, while activated 
microglia are intertwined within the central deposit (reviewed in Eckman & Eckman 
2007).  
 
 
 
 
 
 
 
 
 
 
The “peculiar substance” that Alzheimer observed (Alzheimer, 1907) in the 
cerebral cortex of this patient, Auguste Deter, has been the subject of much scientific 
enquiry during the last 100 years. As it bore resemblance to the abnormal extracellular 
material seen in the liver at autopsy, which had been coined amyloid (for starch or 
cellulose, as it stained pale blue upon treatment with iodine) by the famous 19th 
century pathologist Rudolf Virchow (Falk et al. 2000), this term was also applied to 
Alzheimer‟s “peculiar substance”. The invention of the electron microscope in the 
1950‟s allowed examination of the structure of amyloid from senile plaques of AD 
patients‟ brains. It was found to consist of randomly dispersed, non-branching fibrils 
that measured 8 to 10 nm in diameter (Cohen and Calkins 1959). 70 years after the 
description of senile plaques in AD, the advent of biochemical analysis in the 1970‟s 
showed the major constituent of amyloid to be protein, rather than carbohydrate 
(Glenner et al. 1971). None the less, the erroneous term has endured (Picken et al. 
2001). Subsequent discoveries have shown amyloid to be a heterogeneous substance 
that can be derived from a variety of proteins. The term amyloid now describes an 
abnormal, insoluble proteinaceous aggregate. To date, nineteen „amyloidogenic‟ 
proteins have been identified (both synthetic and native), several of which have been 
linked with neurodegenerative diseases, including α-synuclein in Parkinson‟s disease, 
prions in spongiform encephalopathies and tau in tauopathies such as frontotemporal 
lobar dementia (Picken et al. 2001). Abnormal aggregation, the common pathogenic 
feature of these proteins, is therefore an attractive therapeutic target and will be further 
discussed below.  
In a landmark finding in 1984, Glenner and Wong published the purification and 
sequence of the primary protein component of amyloid, isolated from meningeal 
Fig 1.1 Neuropathological hallmarks of Alzheimer’s Disease. (A) a representative 
micrograph of senile plaques in the AD brain. Scale bar 125 μM (B) a representative 
micrograph of neurofibrillary tangles. Scale bar 62.5 μM (La Ferla et al. 2005) 
A B 
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vessels obtained from AD brains (Glenner et al. 1984). Size-exclusion chromatography 
revealed that the protein had an approximate molecular weight of 4200 daltons, and 
amino acid analysis and sequencing revealed a novel amino acid sequence now 
referred to as amyloid-β (Aβ; section 1.6). Detailed studies on the actions of Aβ are the 
main concern of this thesis (see section 1.14).  
 
1.3.2 Neurofibrillary Tangles 
The intracellular fibrils that Alzheimer described, now termed neurofibrillary 
tangles (NFTs; figure 1.2), are insoluble filaments that accumulate in selective (see 
section 1.3.3) neurons in the AD brain. They are predominantly composed of the 
microtubule-associated protein, tau (Grundke-Iqbal et al.1986, Goedert et al. 1988), 
which is normally an axonially-expressed soluble protein, involved in stabilizing 
microtubule assembly. In its pathological state, both in AD and taupoathies, tau is 
hyper-phosphorylated, exhibits reduced affinity for microtubules and aggregates to 
form NFTs (Grundke-Iqbal et al. 1986, Geodert et al. 1992). These abnormal activities 
have led to the Tau-tangle hypothesis of AD (section 1.7.2).  
 
(A)       (B)   (C) 
 
 
 
Fig 1.2 (A) Nissl-stained tissue section from Auguste D.‟s brain (B) Bielschowsky-stained 
section from the same patient, showing neurofibrillary tangles (C) camera lucida drawngs of the 
tangles (Perusini et al. 1909) 
 
1.3.3 Neurodegeneration 
Postmortem examination of the brains of AD patients usually reveals 
considerable shrinkage of the tissue, together with enlargement of the ventricles 
(Luxenberg et al. 1987; figure 1.3). Atrophy can occur by three mechanisms, the 
shrinkage or death of neurons, loss of neuropil or shrinkage of tracts of nerve fibres. All 
of which have been implicated in the atrophy associated with AD (Bobinski et al. 1996). 
The molecular mechanisms that have been implicated in AD-associated 
neurodegeneration are discussed in section 1.12.  
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(A)       (B) 
 
 
 
 
 
 
Fig 1.3 Coronal brain sections from (A) healthy individual (B) patient with Alzheimer‟s disease 
(Pathology Educational Instructional Resource, University of Alabama)  
 
Following widespread availability of computerised x-ray tomography in the 
1970s, studies reported specific brain regions and neural systems that are affected in 
AD, including neurons in the cortex, hippocampus, amygdala, anterior thalamus, basal 
forebrain and several brain stem monoamerinergic nuclei (reviewed in Whitehouse et 
al. 1998). The medial temporal lobe (MTL), containing the hippocampus, 
parahippocampal gyrus and amygdala, displays the highest density of AD 
histopathological markers (Pearson et al. 1985; Braak and Braak 1991; Jobst et al. 
1992) and exhibits significant AD-specific atrophy, as detected by computer 
tomography (Jobst et al. 1992) and magnetic resonance imaging (MRI; Ackl et al. 
2005). Atrophy of this region can be linked to early AD symptoms, as deficits in verbal 
memory correlate with atrophy of the left hippocampus and deficits in nonverbal 
memory correlate with atrophy of the right hippocampus (Petersen et al. 2000; de 
Toledo-Morrell et al. 2000). Recent studies indicate that increased risk of developing 
AD is associated with atrophy of specific regions of the MTL (Stoub et al. 2005; 
Apostolova et al. 2006), possibly providing a presymptomatic predictor of cognitive 
decline. This predictive capability of neuroimaging techniques has been supported by 
positron emission tomography (PET) studies that have identified patterns of parietal, 
temporal, posterior cingulate and frontal hypometabolism in the AD brain. These 
patterns can differentiate patients with AD from other dementias and healthy individuals 
(Silverman et al. 2005) and predict future cognitive decline in normal ageing individuals 
(Small et al. 1995, de Leon et al. 2001). 
The region of the MTL showing greatest atrophy during mild cognitive 
impairment is the entorhinal cortex, part of the parahippocampal gyrus (Bobinski et al. 
1999; Jack et al. 2000). This region has also been postulated to be the site where Tau 
pathology is likely to be first expressed in AD (Pearson et al. 1985; Braak and Braak, 
1991). A seminal paper by Pearson et al. (1985) indicated NFTs are not randomly 
distributed in neurons within a cortical area. Instead, the tangles are selectively 
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deposited within the pyramidal neurons that give rise to pathways that connect an area 
with other cortical areas and/or with subcortical regions. Since this paper was 
published, the progression of AD pathology has been the subject of much research. 
Using serial MRI scans, Scahill et al. (2002) showed regional atrophy progresses in a 
highly specific manner from the MTL to other parts of the brain. It was suggested that 
the strong connections with the MTL accounted for the selective distribution of AD 
pathology in the association areas of the cortex.   
Currently, a widely-accepted hypothesis (reviewed in Smith et al. 2002) posits 
that AD pathology brain starts many years (up to 50) before disease symptoms occur, 
in the parahippocampal gyrus. At some stage, the formation of pathological hallmarks 
is exacerbated and projection neurons in the MTL start to die, leading to atrophy of the 
lobe and to early symptoms including memory deficits. Accordingly, neural connectivity 
in the hippocampus, detected by diffusion tensor imaging, is impaired during MCI and 
reduced further in AD (Zhang et al. 2007). Once denuded of their input from the MTL, 
neurons in target areas of the neocortex show reduced activity and no longer function 
properly in the neural networks underlying higher cognition. As the pathology spreads 
to these cortical areas, they lose connections with other areas and the process that 
began in the MTL repeats. Not only does this explain the histopathological distribution 
of end-stage AD, but also sheds light on the symptomatic progression of the disease. 
Taking into account the implication of cortical regions in specific tasks, the pattern of 
„disconnection‟ of these regions from the MTL reflects symptomatic progression, from 
memory deficits, followed by semantic and executive function, then praxis and 
behavioural problems (section 1.2). Rat primary cortical neurons are one system 
employed in the current study to model the neurodegeneration associated with AD.  
 
1.3.4 Cholinergic  Dysfunction 
 The systematic biochemical investigation of the brains of patients with AD 
began in the late 1960s in the hope of identifying a neurochemical defect that would 
provide the basis for the development of rational therapeutic interventions analogous to 
levodopa treatment of Parkinson‟s disease. Early neurochemical analysis of AD brain 
extracts revealed a substantial depletion of the enzyme responsible for the synthesis of 
acetylcholine (ACh), choline acetyltransferase (ChAT; Bowden et al., 1976; Davies and 
Malony 1976). Subsequent studies irevealed a strong correlation between ChAT 
activity and ACh synthesis with the degree of cognitive impairment in patients with AD 
(Perry et al., 1978; Wilcock et al., 1982; Francis et al., 1993).  The reduction of choline 
uptake and ACh release coupled with a reduction of perikarya from cholinergic 
subcortical nuclei, such as the nucleus basalis of Meynert (Whitehouse et al., 1982) 
confirmed a substantial presynaptic cholinergic deficit. The distinct cell loss was 
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observed in cholinergic projections of the septohippocampal and basal forebrain-
neocortical pathways, which also exhibit senile plaques and neurofibrillary tangles 
(Whitehouse et al. 1982). The loss of neocortical cholinergic innervation is likely to be 
lost at an early stage of the disease, as evidenced by similar changes in patients that 
have displayed clinical symptoms for less than one year (Bowen et al., 1982). The 
susceptibility of cholinergic neurons may be caused by the expression of specific 
molecular targets for Aβ (discussed further in section 1.13.2), though it is not exclusive 
to AD. Amyloid deposits have been associated with abnormal cholinergic processes in 
aged macaque brains (Kitt et al. 1984, Struble et al. 1984), suggesting that plaque 
formation, coupled with axonal dystrophy, occurs in cholinergic neurons during the 
normal aging process.  
Because ACh can act on presynaptic terminals that release other 
neurotransmitters, such as glutamate and GABA in the hippocampus (reviewed in 
Lindstrom 1997; discussed further in section 6.1.2), the loss of cholinergic signalling is 
also detrimental to other signalling systems in the brain. The cholinergic deficit in the 
AD brain is therefore an attractive therapeutic target and several drugs have been 
developed which aim to restore cholinergic function. 
Numerous studies have examined the effect of cholinomimetic drugs and 
cholinergic receptor antagonists on learning and memory tasks. The most commonly 
used model is based on the finding that scopolamine, a muscarinic receptor antagonist, 
induces amnesia in young healthy subjects comparable with that in old, untreated 
subjects (Drachman and Leavitt, 1974) These deficits may be reversed by inhibiting 
acetylcholinesterase (AChE), a key enzyme in ACh degredation. Inhibition of this 
enzyme, leads to an increase in the synaptic half-life of ACh, prolonging the activation 
of cholinergic systems (Grossberg et al. 2006). Compounds that reverse these 
scopolamine-induced deficits in experimental animals may be considered as potential 
drugs to treat cognitive impairment. The effect of nicotinic ligands on memory is 
discussed further in section 1.13.2.  
These studies and the implication of cholinergic signalling in learning and 
memory (Woolf et al. 1996), suggested a direct link between the loss of cholinergic 
neurons and the symptoms of AD. Accordingly, the decrease in ACh release has been 
correlated to memory impairment in a transgenic mouse model of AD (Watanabe et al. 
2009). The therapeutic prediction of the cholinergic hypothesis is the potentiation of 
central cholinergic function should improve cognition dysfunction associated with AD.  
Several approaches have been attempted to rectify the cholinergic deficit associated 
with AD. Most have initially focused on the replacement of ACh precursors (choline or 
lecithin) but these agents failed to increase central cholinergic activity (reviewed in 
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Francis et al., 1999). Other studies have investigated the use of acetylcholinesterase 
inhibitors (AChEI).  
During the late 1980s and early 1990s, the first cholinomimetic compound, 
tacrine, underwent a large number of clinical studies. Evidence from three pivotal 
studies of tacrine has established clearly the benefits of ChE treatment in patients with 
a diagnosis of probable Alzheimer‟s disease (Davis et al., 1992; Farlow et al., 1992; 
Knapp et al., 1994).  Unfortunately, potentially serious adverse side effects have limited 
the use of this compound. Both tacrine, and the carbamate physostigmine, possess 
detrimental effects on hepatic and cardiovascular function. Indeed, perhaps the most 
often documented reason for withdrawal of tacrine is its potential hepatotoxicity. 
The second generation of cholinesterase inhibitors includes galantamine, 
rivastigmine and donepezil are AChEI (table 1; reviewed in Munoz-Torrero et al. 2008). 
However, other activities have been reported for these drugs, both at the synapse and 
other areas of the body. For example, reports suggest galantamine also interacts with 
nicotinic acetylcholine receptors (nAChR; section 1.13; Pearson et al. 2001) and may 
directly affect Aβ aggregation (section 1.10.2; Matharu et al. 2009), while donezepil has 
been shown to protect cortical neurons in vitro against Aβ toxicity by inhibition of GSK-
3β (Noh et al. 2008). 
 
Brand Name Generic Name Approved Approved for 
Namenda® memantine 2003 Moderate to severe 
Razadyne, Reminyl® galantamine 2001 Mild to moderate 
Exelon® rivastigmine 2000 Mild to moderate 
Aricept® donepezil 1996 All stages 
 
 
 
 
 
 Though these drugs alleviate symptoms and slow the progression of AD, there 
is currently no cure for the disease. An incomplete understanding of the etiology of AD 
has hindered the development of more effective pharmaceuticals.  
 
1.4 Forms of AD  
 
1.4.1 Sporadic AD 
Approximately 95 % of AD cases are sporadic, where the genetic and 
environmental basis remains unclear. However, some candidate genes have been 
Table 1.1 Drugs currently approved by the National Institute of Health for the treatment 
of AD (www.nia.nih.gov). Currently, the National Institute for Health and Clinical Excellence 
recommends donepezil, galantamine and rivastigmine as options for the treatment of 
moderate AD only, while memantine is only recommended for use only in clinical trials. 
(www.nice.org.uk)  
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reported, such as the ε-4 allele of ApoE, and several of these can be linked to A  
activity (for a comprehensive list, see the Alzgene forum at www.alzgene.org). Only 
following the identification of rare genetic forms of AD were key pathological molecular 
processes identified, which are currently targeted with novel therapeutic strategies. 
Importantly, the pathology of inherited AD is virtually indistinguishable from that of 
sporadic forms. As current therapies are effective against both forms, it is hoped that 
novel therapies will also be.  
 
1.4.2 Familial Alzheimer’s Disease 
 Since the first description of an inherited case of AD in 1932, over 100 families 
have been identified that exhibit similar clinical, neuropathological and genetic 
characteristics, including onset before the age of 60, autosomal dominant inheritance 
and clinical and pathological phenotypes indistinguishable from individuals with 
sporadic AD (Price and Sisodia 1998). The conditions harbored by these families are 
collectively referred to as familial Alzheimer‟s disease (FAD; Sorbi et al. 2001). Though 
the incidence of FAD is far less than sporadic AD, accounting for less than 5 % of all 
AD cases (Taddei et al. 2002), genetic approaches employed to understand the 
etiology of FAD have been pivotal in elucidating mechanisms behind both inherited and 
sporadic AD. However, initial evidence of the pathological mechanisms behind AD 
came from studies into another disease altogether. 
Individuals with Down‟s syndrome who live past the age of 50 exhibit amyloid 
deposits and other lesions that are strikingly similar to those associated with AD (Mann 
et al. 1988; Lemere et al. 1996). When Glenner and Wong (1984) isolated and 
analysed the cerebrovascular amyloid from Down‟s syndrome patients, they found the 
amino acid sequence of cerebrovascular amyloid in Down‟s syndrome is identical to 
that observed in AD patients. Furthermore, Aβ levels were increased significantly in 
plasma isolated from patients with Down‟s syndrome, when compared with control 
individuals (Tokuda et al. 1997). The possibility of a common pathogenic process was 
therefore proposed. Individuals with Down‟s syndrome are trisomic of chromosome 21 
(Glenner and Wong, 1984), suggesting a gene-product from this chromosome could be 
responsible for both conditions. To isolate the gene encoding Aβ, Kang et al. (1987) 
used degenerate primers targeted against amino acids 10-16 of the Aβ peptide to 
screen a complementary DNA library constructed from the brain of a 5-month old 
Down‟s syndrome fetus. They isolated a clone encoding a 695 amino acid protein that 
contained the Aβ sequence, later located to chromosome 21, termed the amyloid 
precursor protein (APP).  
The first reported mutations associated with FAD were point mutations in the 
APP gene  (Goate et al., 1991). When an APP missense mutation was identified for 
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one form of familial cerebral hemorrhage, Goate et al., (1991) adopted the published 
polymerase chain reaction (PCR) protocol to look at FAD in families with suggestive 
linkage on chromosome 21 (Levy et al., 1990). They reported an APP missense 
mutation at codon 717 in two unrelated families, one an English family (designated 
APPLondon) that they had been following and the other an American family (designated 
APPIndiana; Pericak-Vance et al., 1988). 
Subsequent studies have identified further mutations in and around the APP 
gene harbored by families with FAD. However, other mutations link to regions on 
chromosomes 1 and 14. In the largest test of the amyloid hypothesis (section 1.7.1), 
the gene products from these sites were found to process APP (Sorbi et al. 2001). 
 
1.5 Amyloid Precursor Protein 
 The first mutated gene identified in a family with a predisposition to AD was that 
encoding amyloid precursor protein (APP), a ubiquitously expressed type I membrane 
protein (containing a single transmembrane-spanning region). mRNA encoding APP is 
subject to alternative splicing, giving rise to peptides 365-770 amino acids in length; 
APP695 is preferentially expressed in neurons (Haas et al. 1991). APP peptides can 
undergo a variety of proteolytic cleavages (fig 1.4), yielding products with distinct 
biological functions (reviewed in Reinhard et al. 2005). Though some of these peptides 
can induce neuronal death (such as Aβ and β-CTFs), others are essential for cell 
survival and mediate physiological activities such as neurite outgrowth, synaptogenesis 
and transcription. Several of these activities are dependent on the abundance of the 
peptide. Aβ provides one such example, as it has been implicated in both physiological 
and pathological cellular mechanisms, which are discussed in sections 1.9 and 1.12, 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.4 Proteolytic processing 
of APP occurs via two 
alternative pathways; the non-
amyloidogenic pathway via α-
secretase or the amyloidogenic 
pathway via β-secretase. 
Further processing by γ-
secretase leads to the 
production of P3 or Aβ. 
Adapted from Crouch et al. 
2008. 
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After translation and expression at the plasma membrane, APP can follow two 
major proteolytic pathways, only one of which culminates in the generation of Aβ.  This 
amyloidogenic route is initiated by internalisation of APP from the plasma membrane to 
the late golgi and endocytic compartments, where it interacts with β-APP cleaving 
enzyme (BACE-1; Yan et al. 1999, Vassar et al. 1999, Sinha et al. 1999 nature, Vassar 
et al. 2004). Under the optimal conditions found in these organelles, BACE-1 cleaves 
APP at the amino-terminus of Aβ, forming a soluble 100 kDa amino-terminal fragment, 
sAPPβ, and the membrane-bound carboxy terminal fragment (β-CTF), C99 (McPhie et 
al. 1997, Vassar et al. 1999).  
The cytotoxic β-CTF have a short half-life in vivo as they are rapidly degraded 
by γ-secretase. This aspartyl protease complex consists of the proteins presenilin-1, 
nicastrin, Aph-1 and presenilin-2 which cleave β-CTF within the transmembrane region, 
forming 57-58 residue carboxy-terminal fragments called APP intracellular domains 
(AICDs) and the extracellular release of Aβ peptides 39-43 amino acids in length. The 
toxic accumulation of Aβ peptides forms the central premise of the „amyloid hypothesis‟ 
of AD. Although numerous APP fragments possess biological activity, including 
neurotoxicity, Aβ has received the majority of attention and will be discussed in further 
detail below.  
A non-amyloidogenic path of APP metabolism also exists, which is initiated by a 
family of metalloproteases, termed α-secretases, located on the plasma membrane 
(Lammich et al. 1999; Parvathy et al. 1999). As the cleavage site resides within the Aβ 
region of APP (fig 1.6), proteolysis by α-secretase precludes the generation of Aβ. 
Instead, another CTF, (α-CTF, C83), is generated which, upon further cleavage, 
generate shorter, non-amyloidogenic Aβ fragments (Allinson et al. 2003).  
 
1.6 Amyloid-β Peptides 
 The three distinct γ-secretase proteolysis sites (ε, δ and γ) on APP give rise to 
the formation and release of Aβ peptides between 39 and 43 residues in length. 
However, a large array of Aβ peptides has been discovered in CSF of AD patients and 
healthy individuals, attributed to Aβ degrading enzymes (Maddalena et al. 2004). The 
two major Aβ peptides will be discussed in more detail: the predominant Aβ1-40, and 
Aβ1-42, the principle component of Aβ plaques. Though Aβ1-40 is secreted at higher 
levels from neurons (Golde et al. 1992), both peptides are detected at picomolar levels 
in CSF of healthy individuals and both show a marked increase (to nanomolar 
concentrations) in CSF from AD patients (Lue et al. 1999). 
 In both healthy individuals and AD patients, approximately 90 % of secreted Aβ 
is 40 residues in length (Aβ1-40), which is produced in the endosomal-lysosomal 
systems (Golde et al. 1992). This form is the most prevalent in the brain, blood and 
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other tissues (Ishii et al. 1997). The remaining 10 % of Aβ peptides are 42 or 43 
residues long and may be released from the endoplasmic reticulum and golgi (Sorbi et 
al. 2001). The presence of two extra hydrophobic residues on the carboxy terminus 
renders Aβ1-42 more prone to aggregate (section 1.10.2) than Aβ1-40 (Jarrett et al. 
1993). This may explain why Aβ1-42 is deposited more early into diffuse plaques 
(Iwatsubo et al. 1994; Mann et al. 1996; reviewed in Younkin, 1998) and is more toxic 
than Aβ1-40.  
 Research of AD has led to the development of numerous synthetic Aβ peptides 
(467 are currently for sale by Anaspec, San Jose). The majority of these are fragments 
of the full-length peptide, designed to assign individual biological activities to isolated 
regions of Aβ. Early studies implicated residues 25-35 as the neurotoxic element of Aβ, 
as application of this decapeptide forms stable β-sheet assemblies (Pike et al. 1991) 
that are toxic to rat hippocampal neurons in vitro (Yankner, et al. 1990; Pike et al. 
1993). Subsequent studies have confirmed the toxicity and in vitro aggregation of the 
fragment (Pike et al. 1993; Weiss et al. 1994). The toxic responses of neurons to full-
length Aβ peptides and the Aβ25-35 fragment suggest that the cytotoxic mechanisms of 
the peptides share similar facets. Both interact with lipid membranes (section 1.12.3.1), 
induce oxidative stress (1.12.1.1) and disrupt calcium homeostasis (section 5.1). 
However, studies have also shown the fragment to possess biological activities distinct 
from the full-length peptides, including cytotoxic mechanisms, physiological responses 
and aggregation kinetics (discussed further in section 7.2.1).  
 
1.7 Postulated Mechanisms of Alzheimer’s Disease  
 Though the composition of plaques and NFTs has been thoroughly 
documented, the role that constituents play in AD pathogenesis is still not fully 
understood. Of the various hypotheses presented, two have received the most support: 
the „amyloid hypothesis‟ and the „tau and tangle hypothesis‟. Over the last two 
decades, the primacy of one lesion over the other has been extensively argued. 
Determining whether one lesion alone is sufficient to cause dementia, or can evoke 
manifestation of the other lesion, has been the subject of much research. Importantly, it 
is yet to be confirmed whether the plaques or NFTs play a causative role in disease 
pathogenesis, or are merely epiphenomena. Though these hypotheses are discussed 
separately here, it should be noted that plaques and NFTs are both frequently 
abundant in the AD brain and the molecular mechanism(s) underlying AD are likely to 
involve facets from both hypotheses. 
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1.7.1 Aβ hypothesis  
 Aging is by far the most prominent risk factor for the onset of AD. The age of 
normal subjects between 40-80 years, correlates with level of Aβ in the brain (Funato et 
al. 1998, Morishima-Kawashima et al. 2000) and in vivo models of aging exhibit 
enhanced Aβ production (Beach et al. 2008). In addition to an age-dependent rise in 
Aβ levels in the brain, both soluble and insoluble Aβ1-42 and Aβ1-40 are elevated in the 
brains of AD patients (Selkoe et al. 2004). Though the cause of these increases in 
sporadic AD is poorly understood, in FAD these increases have been linked to 
mutations in APP and presenilin genes of the γ-secretase complex. Levels of Aβ are 
also raised in blood plasma of FAD sufferers and found to be secreted at higher levels 
from in vitro cultures of fibroblasts extracted from FAD sufferers, compared with age-
matched controls (Felsenstein et al. 1994, Jarrett et al. 1993). Interestingly, elevated 
Aβ levels were also secreted from fibroblasts cultured from presymptomatic FAD 
sufferers (Felsenstein et al. 1994). This suggests that Aβ elevation occurs early in AD, 
and is not an epiphenomenom induced in the end stages of the disease. Supporting 
this hypothesis, Aβ levels are elevated in transgenic models (section 1.8.1) prior to 
cognitive dysfunction and Aβ deposition (Borchelt et al. 1996; Citron et al. 1997). The 
correlation between increased abundance of Aβ and disease supports the amyloid 
cascade hypothesis of AD, first proposed by Hardy and Higgins (1992), which 
postulates that the abundance of Aβ peptides is the primary cause of AD.  
The amyloid hypothesis arises from several key observations (summarised in 
fig 1.5), which implicate the peptide centrally in the pathological mechanism of the 
disease. In addition to correlating increased levels of Aβ with disease severity, in vitro 
experiments indicate synthetic, recombinant and endogenous Aβ peptides are toxic to 
brain slices, dissociated neurons and transformed neuron-like cells, implicating the 
peptide in the neurodegeneration associated with AD. Furthermore, Aβ can disrupt 
synaptic activity and inhibit mechanisms underlying learning and memory (discussed 
further in section 6.1.2), providing a direct explanation for the disease symptoms. Both 
the cytotoxic and synaptotoxic mechanisms of Aβ have been the subject of much 
research, and will be discussed separately, in sections 1.12 and 6.1.2, respectively 
The amyloid hypothesis has been constantly challenged and revised as the 
progression of technology has allowed insights into the mechanisms underpinning AD. 
Examples include the discovery of a mutation in APP (APPArctic, discussed further in 
section 1.11.2) that enhances the propensity of Aβ to aggregate, without affecting 
levels of the peptide. This suggests that it is not only the abundance of the Aβ that can 
evoke a disease phenotype, but also specific properties of the peptide. Indeed, the 
discovery of a range of soluble aggregated Aβ structures, which exhibit with distinct 
biological activities (section 1.10.3), explains how AD patients can exhibit few amyloid 
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plaques, while healthy individuals can display high numbers of plaques (section 
1.10.2).  
 
 
 
 
 
 
 
 
 
1.7.2 Tau-Tangle Hypothesis 
Although initially discovered in AD, NFTs have been identified in a number of 
other diseases („tauopathies‟) including frontotemporal dementia and parkinsonism 
linked to chromosome 17 (FTDP-17), Pick‟s disease, progressive supranuclear palsy 
and corticobasal degeneration. Mutations in tauopathies lead to self-aggregation and 
reduce microtubule binding of tau (Hasegawa et al. 1998). Although the gene encoding 
tau is not genetically linked to AD, mutations within the tau gene are sufficient to cause 
the neurodegeneration and dementia associated with FTDP-17 (Hutton et al. 1998). 
The possibility of tau as a causative agent of AD has therefore been the focus of much 
attention. 
Although several studies indicate the number of NFTs correlate better with the 
severity of dementia in AD than the number of Aβ plaques (McKee et al. 1991, Nagy et 
al. 1997), there are numerous arguments against tau being the causative agent in AD. 
Firstly, the aggregation of Aβ occurs prior to NFT formation (Hardy et al. 1998) and 
dementia (Naslund et al. 2000). This suggests that NFTs may lie downstream of Aβ 
pathology. Indeed, though inherited tauopathies result in dementia and 
neurodegeneration, they do not lead to AD-like pathology (Spillantini et al. 1998). 
Conversely, expression of genes containing mutations in APP or the presenilins 1 and 
2 give rise to both plaques and tangles (Lewis et al. 2001). Furthermore, injection of 
Aβ1-42 fibrils into the cerebellum of transgenic mice expressing a substituted gene 
identified in FTDP-17 (P301L) accelerated the formation of NFTs. This effect was 
absent in mice overexpressing wild-type tau, suggesting an excess of Aβ alone is not 
sufficient to induce tau pathology (Gotz et al. 2001), though the number of NFTs was 
reduced by antibodies targeting Aβ (Oddo et al. 2006; see section 1.11.2).  
To investigate the proteins mediating cellular responses to Aβ, specific 
inhibitors of signalling peptides have shown that Aβ can activate a number of kinases 
(discussed in more detail in sections 1.12.2.1 and 1.13.5.2.3), several of which are 
Aβ 
Increased 
Aβ1-42 
Increased 
Aβ1-42/40 ratio 
Oligomeric 
Aβ 
Alzheimer‟s Disease 
Plaques 
Fig 1.5 Aspects of the Amyloid Hypothesis, which proposes that Aβ is the primary cause of 
AD. Early studies indicated that increased Aβ levels result in plaque formation. Subsequent 
reports of FAD suggest that elevated Aβ levels are pathogenic and cause AD. As the 
hypothesis has been contested and updated, other themes have been elucidated, such as 
the ratio between Aβ1-42 and Aβ1-40 and the effect of altering the oligomerisation propensity of 
Aβ. 
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responsible for Tau hyperphophroylation, such as glycogen synthase kinase 3β (Ma et 
al. 2006) and fyn kinase (Lambert et al. 1998). Aβ can also evoke local Ca2+ increases 
(discussed further in sections 5.1.1) that promote formation of tau filaments in vitro 
(Bravo et al. 2008). Taken together, these studies suggest that although it may still act 
centrally in the pathological mechanism of AD, tau dysfunction does not play a 
causative role in AD. Currently, the amyloid hypothesis is receiving the majority of 
support and has been challenged, revised and corroborated by the generation of 
transgenic models expressing genes isolated from cases of FAD.  
 
1.8 Modelling Alzheimer’s Disease 
 Discovery of genetic defects underpinning FAD has allowed identification of 
fundamental mechanisms that mediate AD pathology. Elucidating these mechanisms 
has been greatly advanced by expressing the defective genes in cell cultures and 
transgenic animals (section 1.8.1). Genetic mapping has located APP mutations from 
FAD cases in and around the Aβ sequence, including in regions implicated in secretase 
processing and aggregation (fig 1.6). Accordingly, expression of these genes in 
mammalian systems leads to altered production or oligomerisation (section 1.10.2) of 
Aβ, respectively.  
Early work found a double-mutation identified in two large Swedish families 
(APPSwe(K670N M671L)) near the Aβ cleavage site. Overexpression of this gene in HEK cells 
led to Aβ secretion levels six to eight-fold higher than cultures transfected with wild-
type constructs (Citron et al. 1992). The relevance of Aβ overproduction by β-secretase 
activity to AD is supported by increased expression and activity of BACE1 in the 
hippocampus and cortex of AD patients (Fukumoto et al. 2002, Fukumoto et al. 2004). 
Subsequent studies of other families harboring FAD mutations have mapped mutations 
on other regions on the APP gene, which also cause increased secretion of Aβ from 
mammalian expression systems. For example, a single point mutation identified in a 
Flemish family (A692G; APPFle) reduces the efficacy of α-secretase processing in vitro, 
reducing the flux of APP down the non-amyloidogenic route, leading to increased 
production of Aβ (Tamaoka et al. 1994). This mutation increases production of Aβ1-42, 
but not Aβ1-40, supporting the role of Aβ1-42 as a key mediator in AD pathology. 
Increased production of Aβ1-42, but not Aβ1-40, has also been detected in cells 
expressing other FAD-genes that harbor mutations at residue 717 of APP (Suzuki et al. 
1994). These cells do not appear to secrete higher levels of Aβ, but secrete a higher 
fraction of Aβ1-42 peptides, relative to cells expressing wild-type APP. 
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As Aβ1-40 can form structured assemblies with Aβ1-42, the ratio between these 
two peptides, rather than simply overproduction of one peptide, may be an important 
factor in amyloid pathology. Transgenic mice harboring a mutation that enhances the 
production of Aβ1-40 do not exhibit plaques, suggesting that Aβ1-40 can retard the 
deposition of Aβ1-42 in the brain (Nilsberth et al. 2001). As structured assemblies can 
form that contain both peptides (Anderton et al. 1982), it is possible that in the healthy 
brain, the primarily toxic Aβ1-42 is sequestered by the highly-abundant Aβ1-40. In 
accordance, certain AD-causing presenilin mutations appear to decrease the 
production of Aβ1-40, rather than increase the levels of Aβ1-42 (Bentahir et al. 2006). 
Conversely, transgenic homozygous mice that express an inactive form of PS1 exhibit 
amyloid pathology in the presence of reduced levels of soluble and insoluble Aβ1-40, 
while Aβ1-42 generation is unaffected (Deng et al. 2006). 
 
1.8.1 Transgenic Models of Alzheimer’s Disease  
 Cloning the APP gene and identification of FAD-linked mutations allowed the 
generation of transgenic models of AD (table 1.2), that recapitulate one or more 
neuropathological and neurochemical features of the disease. The number of novel 
transgenic AD models has rapidly expanded in the last two decades as they offer a 
means to gain mechanistic insights into the disease process in an in vivo setting.  
 An early transgenic model harbored extra APP genes (Quon et al. 1991), 
possibly mimicking the trisomy of chromosome 21 seen in Down‟s syndrome, rather 
than specifically modeling AD. Attention has since focused on mice expressing a 
variety of APP genes with FAD mutations, both alone and in combination. Commonly 
used mice that express a single FAD gene include PDAPP (expressing APPIndiana; 
Schenk et al. 1999) and Tg2576 (expressing APPSwe; Hsiao et al. 1996). Both strains 
overexpress Aβ and form AD-like plaques. They exhibit synaptic loss, reactive 
astrocytosis and microgliosis and impaired learning and memory. Though the strains 
exhibit phosphorylation of cytoskeletal elements, they do not generate tangles or paired 
helical filaments or display any neurodegeneration (Tomidokoro et al. 2001, Chen et al. 
1998).  
668 726 
Fig 1.6 Twenty APP missense mutations mapped from FAD cases exist within or adjacent to 
the Aβ1-42 sequence (in green). Adapted from Goedert et al. 2006  
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 Generation of a more-complete model of AD pathology was achieved by 
crossing Tg2576 mice with mice expressing a mutated form of Tau associated with 
FTDP-17 (Lewis et al. 2001). In addition to displaying amyloid pathology, the resulting 
double-mutant mice exhibit enhanced neurofibrillary degeneration in the limbic system 
and olfactory cortex, areas where Aβ pathology first appears in Tg2576 mice, 
compared with mice expressing only the tau-mutant. A similar approach has been 
employed to generate mice with presenilin mutations, both alone (Duff et al. 1996) and 
in addition to mutated tau and APP genes (Oddo et al. 2003). These triple transgenic 
mice display enhanced amyloid pathology, though still lack any neurodegeneration. 
The lack of a complete AD-like phenotype is still driving the generation of novel 
transgenic mice, with Jackson Labs (Maine, USA) recently unveiling a “5xFAD” mouse 
that expresses three FAD APP genes and two presenilin-1 mutations. Generation of 
increasingly complex models is intended to more-accurately recapitulate AD pathology, 
facilitating translation of therapeutic strategies into the clinic by improving relevance of 
disease etiology. In contrast to these knock-in transgenic models, APP knock-out 
models have provided insight into the physiological actions of APP and the products of 
APP metabolism, including Aβ.  
Model Gene  Mutation Reference  
AD/Down 
Syndrome 
hAPP(WT) 
overexpression 
None Quon et al.1991  
Tg2576 hAPP(Swe) APPK670N/M671L Hsiao et al.1996 
2xTG hAPP(Swe) 
Presenilin 1  
APPK670N/M671L 
PS1A246E 
Borchelt et al.1996  
APP23 hAPP(Swe) APPK670N/M671L Sturchler-Pierrat et 
al.1997 
2xTG hAPP(Swe) 
Presenilin 1  
PPK670N/M671L 
PS1M146V 
Holcomb et al.1998 
PDAPP  hAPP(Indiana) APPV717F Schenk et al.1999 
J20  hAPP(Swe) 
hAPP(Indiana) 
APPK670N/M671L 
APPV717F 
Mucke et al. 2000 
2xTG hAPP(Swe) 
Tau  
APPK670N/M671L 
P301L 
Lewis et al. 2001 
2xTG hAPP(Lon) 
Presenilin 1  
APPV717I 
PS1A246E 
Permanne et al.2002 
3xTG hAPP(Swe) 
Presenilin 1  
Tau 
PPK670N/M671L 
PS1M146V 
P301L 
Oddo et al. 2003 
Tet-
responsive 
hAPP(Swe) 
hAPP(Indiana) 
APPK670N/M671L 
APPV717F 
Jankowsky et al. 
2005  
ARC6/ARC48 hAPP(Swe) 
hAPP(Arc) 
APPK670N/M671L 
APP 
Cheng et al. 2007 
5xTG hAPP(Swe) 
hAPP(Florida) 
hAPP(Lon) 
Presenilin 1  
APPK670N/M671L 
APP I716V 
APP V717I 
PS1M146L/LL286V 
Jackson Labs  
 
1.9 Physiological Roles of Amyloid-β 
Table 1.2 Transgenic models of AD express genes identified in cases of FAD and FTDP-
17 
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 Although Aβ has become synonymous with the pathology of AD, the peptide is 
present at picomolar in the brain and cerebral spinal fluid of individuals showing no 
signs of dementia (Selkoe & Schenk, 2003). The peptide is also constitutively secreted 
by healthy neuronal cells in culture (Tamaoka et al 1997; Haass et al. 1992), which 
suggests that amyloidogenic processing of APP has a role in normal CNS physiology. 
The full-length protein and product of APP metabolism have been implicated in 
numerous neuronal functions including cell survival, synaptogenesis and cell signalling 
(reviewed in Reinhard et al. 2005). It is therefore perhaps surprising than transgenic 
APP knock-out models show no overt neurological defects or lethality. However, 
histological analysis of APP-null mice revealed a variety of alterations in neural 
structure and function, including gliosis, decreased neocortical and hippocampal levels 
of synaptic markers, lowered dendritic lengths, and impaired long-term potentiation 
(Perez et al. 1997, Dawson et al. 1999, Seabrook and Rosahl 1999). However, 
knocking out APP also prevents the formation of biologically-active APP metabolites 
other than Aβ. More direct approaches have therefore been used to determine 
physiological roles specifically of Aβ.  
Targeting Aβ production by knocking out β-secretase in mice reduced Aβ levels 
by 90 %, compared with wild-type littermates (Luo et al.  2001). However, the knock-
out mice showed no behavioural or neurological deficits, suggesting that functional 
redundancy or compensation may occur in vivo. Inhibiting the β- or γ- secretases in 
vitro to inhibit Aβ production, or by specifically removing Aβ via immunodepletion, 
causes death of primary neuronal cultures (Plant et al. 2003). Ironically, the „toxic‟ 
protein that has been implicated at the center of AD pathology may also mediate cell 
survival (Yankner et al., 1990). Aβ should therefore only be regarded as pathologic 
when considering amounts exceeding those found physiologically (approximately 
picomolar levels in brain extracts). The acute modulation of Ca2+ signalling by 
picomolar Aβ is assessed experimentally in chapter 5.  
The deleterious effects on cell survival of removing Aβ were not replicated in a 
variety of non-neuronal cells, suggesting Aβ acts in a specific manner in neurons (Plant 
et al. 2003). Though inhibiting secretases affects multiple substrates other than APP, 
such as notch (reviewed in Fortini et al. 2009), neuron survival could be restored by 
addition of picomolar concentrations of Aβ. Interestingly, endogenous Aβ1-40 was most 
effective, while Aβ25-35 exhibited no activity (Plant et al. 2003).  
The mechanism mediating cell survival by Aβ is yet to be fully elucidated, 
though several pharmacological targets of Aβ (section 1.12.3.3) have been implicated. 
Depletion of endogenous Aβ suppressed inactivating K+ currents of neurons, which 
was also recovered by the addition of physiological levels of exogenous Aβ (Plant et al. 
2005). Potassium channels are particularly relevant as they govern excitability and 
 20 
 
hence excitotoxicity of released glutamate and cellular K+ levels are a key determinant 
of apoptosis (Yu et al. 2003).  
 As K+ channels are centrally involved in shaping action potentials and setting 
the resting membrane potential, it is possible that Aβ may be involved in excitability and 
synaptic function, in addition to cell survival. Indeed, Kamenetz et al. (2003) 
demonstrated an increase in Aβ production from APPswe mice hippocampal slices 
following electrically stimulated synaptic activity, by increasing trafficking of APP 
towards β secretase sites at the cell membrane. In addition, specific stimulation of 
NMDA receptors up-regulated APP, inhibited α-secretase activity and promoted Aβ 
production (Lesne et al. 2005). Application of Aβ, in turn, suppresses excitatory 
synaptic transmission (discussed further in section 6.1.2), suggesting a negative 
feedback loop that would prevent excitotoxicity resulting from neuronal hyperactivity. It 
is currently unknown whether mechanisms mediating Aβ-mediated neuron survival also 
underpin the neurotoxic action of Aβ in AD pathology.    
 
1.10 Amyloid-β Structure 
The tertiary structure of A  has been linked to the tendancy of the peptide to 
oligomerise into larger molecular weight stuctures, several of which have been linked to 
specific biological activities of the peptide. The pathways of A  oligomerisation, 
including key intermediates and kinetics will therefore be discussed in more detail.  
 
1.10.1 Tertiary Conformations of Aβ 
The tertiary structure of a protein is an important determinant of biological 
activity and Aβ can exist in a variety of stable conformations, often linked to the 
aggregation state of the peptide. The amino acid sequence of Aβ (fig 1.7) suggests the 
peptide is amphipathic in nature, as the amino-terminus contains hydrophilic residues, 
while the carboxy terminal residues are predominantly hydrophobic. In solution, 
monomeric Aβ can adopt various tertiary structures in an environment-dependent 
manner. As the interaction of Aβ with cellular membranes has been heavily implicated 
in the toxicity of the peptide (section 1.12.3), the conformation of Aβ in aqueous and 
lipid environments has been the subject of many, often conflicting, reports. This has 
been further complicated by the description of numerous conformations that Aβ adopts 
when inserted into a membrane.  
In a water-micelle solution, employed to simulate biological membranes, Aβ can 
form two α-helices separated by an unordered or β-turn loop region, as determined by 
NMR spectroscopy (Coles et al. 1998, Shao et al. 1999). One of these helices, formed 
by resides 39-42, may reside in the membrane (Selkoe et al. 2004), though as a 
truncated peptide, the hydrophobic carboxyl-terminal segment Aβ29-42 exists exclusively 
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as an oligomeric β-sheet, regardless of differences in solvent, pH, or temperature 
(Barrow et al. 1991). This indicates that this section of the peptide drives Aβ1-42 to 
rapidly fold from a random-coil structure (Zhang et al. 2000) into a β-sheet 
conformation at physiological pH (Barrow et al. 1991). The β-sheet conformation is a 
key determinant of Aβ aggregation and toxicity (Barghorn et al. 2005; Walsh et al. 
1999; Hashimoto et al. 2003; Hardy & Selkoe 2002), is maintained throughout Aβ 
aggregation (section1.10.2) and is evident in ex-vivo amyloid fibres, which exhibit cross 
β-diffraction pattern of X-rays (Eanes and Glenner, 1968; Sunde et al. 1997), 
suggesting the fibril is composed of a repeating core structure of monomers 
predominantly in a β-sheet structure.   
 
 
 
1.10.2 Amyloid fibril formation 
The formation of amyloid fibrils is frequently reported to occur by a process of 
nucleation-dependent oligomerisation (Harper and Lansbury 1997, Lansbury et al. 
1997), though other processes have been reported (Kelly et al. 2000). Typical Aβ fibril 
formation is characterised by three phases: lag, elongation and plateau (fig 1.8). In the 
lag phase the prevailing Aβ conformation shifts from unordered/α-helix conformation to 
β-sheet confirmation (Bartolini et al. 2007). As β-sheet conformation is required for Aβ 
oligomerisation, there is no detectable fibril formation during this time, though small, 
ordered nuclei do form (Wogulis et al. 2005), which are the site of rapid fibril formation 
in the elongation phase (Nayak et al. 2008). Thus the lag phase can be negated by the 
addition of pre-formed nuclei to a solution of monomeric Aβ (Nilsson et al. 2004). 
Modulation of these phases by nicotine and is assessed in chapter 4.   
The length of the lag phase and the rate of amyloid fibril-elongation are 
determined by factors that affect the physical state of the peptide, such as pH and ionic 
strength (Nielsen et al. 2001). Other factors include concentration of the free monomer, 
temperature (Kusumoto et al. 1998) and agitation of the solution, which affect the 
frequency of interactions between peptide molecules (discussed further in section 
2.2.7.1). 
 
 
Fig 1.7 Structure prediction studies suggests regions of Aβ have a high propensity to form β-
sheet structure (shown in grey; adapted from Serpell et al. 2000) 
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The simplest form of elongation is a process by which monomers are 
sequentially added to a fibril. Consistent with this model, Aβ fibrils have been shown to 
elongate via addition of monomeric Aβ units to the fibril end (Kusumoto et al. 1998). 
However, studies with higher resolution have identified numerous intermediate 
assemblies of varying size and geometry and form during fibril formation, or via during 
pathways distinct from fibrilogenesis (section 1.10.3.6). Although some studies suggest 
deposition of monomeric, not oligomeric Aβ, mediates the growth of amyloid plaques 
(Tseng et al. 1999), others have shown soluble intermediates can coalesce to form 
fibrils (Nybo et al. 1999).   
Despite substantial evidence supporting the amyloid hypothesis of AD (section 
1.7.1) in the 1990‟s several lines of evidence appeared to contradict the hypothesis. 
Although plaque burden frequently correlates with dementia severity in AD patients 
(Cummings et al. 1996), healthy subjects that display no cognitive dysfunction can 
exhibit extensive AD-like pathology including plaques and tangles (Davis et al. 1999) 
and there are cases of individuals exhibiting cognitive features of AD in the absence of 
plaque pathology (Terry et al. 1991; Dickson et al. 1995). The amyloid hypothesis 
appeared to be incorrect or incomplete until the discovery that levels of soluble Aβ 
assemblies correlate with disease severity (McLean et al. 1999).  
 
1.10.3 Soluble Amyoid-β 
  Synthetic and recombinant Aβ peptide can exist in a large array of soluble Aβ 
assemblies (Walsh et al. 2001). The nomenclature, describing the assemblies 
Fig 1.8 Nucleation-dependent Aβ polymerization consists of a lag phase, during which  fibril 
nuclei are seeded, followed by rapid fibril growth during the elongation phase and finally the 
plateau phase, where fibril formation slows as soluble Aβ levels are depleted. Application of 
pre-formed olgiomeric Aβ structures or can seed fibril growth, abolishing the lag phase 
(dotted line). Adapted from Nilsson et al. 2004  
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according to their solubility, morphology and size (table 1.3), is rapidly expanding and 
likely to contain assemblies that have been categorised under more than one heading.  
Following the discovery of soluble Aβ assemblies, focus has shifted away from 
amyloid fibrils and plaques, which are relatively benign in vitro (section 1.10.3.8) do not 
correlate with memory impairment in transgenic AD models (Morgan et al. 2003) or 
dementia in AD patients repetition (Walsh and Selkoe 2007). In comparison, soluble 
oligomeric assembles are potently neurotoxic, disrupt molecular models of memory at 
pathophysiological levels (section 6.1.2) and show a strong correlation with cognitive 
decline in AD patients (Lue et al. 1999, McLean et al. 1999) and transgenic models 
(section 1.8.1). Soluble A  levels also correlate with the degree of synapse loss (Lue et 
al. 1999) and can distinguish between AD from normal and pathological aging (Wang 
et al. 1999). The distinct biological activities posessed by these assemblies has lead to 
a “fundamental shift in our view of the pathogenic mechanism of AD” (Klein et al. 2004) 
and provoked a revision of the amyloid hypothesis, which now proposes that soluble 
Aβ, rather than insoluble plaques, possess a causative role in AD pathology (Hardy 
and Selkoe, 2002). 
 
1.10.3.1 Monomeric Aβ is relatively innocuous 
 A wealth of studies, directly comparing monomeric Aβ with a range of 
oligomeric Aβ species, suggests monomeric Aβ is relatively innocuous. A seminal 
study showed that solutions of Aβ kept at 37 °C for 24-72 h to „age‟ the peptide were 
toxic when applied to hippocampal cells in culture, while freshly-dissolved Aβ1-42 was 
benign (Pike et al. 1993). This suggests that assembly of Aβ into oligomeric structures 
before application to cultures is required for the peptide to evoke in vitro neurotoxic 
responses. Subsequent studies have shown that soluble oligomeric Aβ inhibits 
neuronal viability in vitro 40-fold more potently than monomeric Aβ (Dhalgren et al. 
2002) and, although monomeric Aβ is present in transgenic models of AD, levels do not 
correlate with cognitive decline (Lesne et al. 2006). In agreement, injection of 
oligomeric, but not monomeric, Aβ secreted by human cells in culture into rat ventricles 
produces cognitive defects (Cleary et al. 2005). Corroborating this finding, Aβ dimers, 
but not monomers, isolated from human CSF impaired hippocampal long term 
potentiation in vivo (Klyubin et al. 2008; discussed further in section 6.1.2). 
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Soluble Aβ 
name 
Reference Referred to 
in section 
Monomers Barrow et al.1991; Selkoe et al. 2004 Zhang et al. 
2000; Lazo et al. 2005; Xu et al. 2005  
1.10, 1.11 
4.3, 5.3, 6.3, 
7, 3.3 
 
Dimers  Garzon-Rodriguez et al. 1997; Hilbich et al. 1992;  
Roher et al. 1996; Podlisny et al. 1995; Walsh et al. 
2000; Masters et al. 1985, McLean et al. 1999, 
Podlisny et al.  1995 
1.10, 1.11, 5.3,  
3.3 
Trimers Haass et al. 2007 Lesne et al. 2006, Townsend et al. 
2006 
1.10, 5.3, 3.3 
Tetramers Masters et al. 1985 1.10, 5.3 
Aβ*56 Lesne et al. 2006 1.10, 1.11, 
3.3 
Globulomer   Barghorn et al. 2005 1.10, 3.3 
Preglobulomer Yu et al. 2009  
Annular 
Oligomers 
Kagan et al. 2002, Lashuel et al. 2002, Quist et al. 
2005, Mattson et al. 2003, Le et al. 2001 
3.3, 1.12.3 
Naturally 
Secreted 
Oligomers 
Walsh et al. 2002, Cleary et al. 2005 1.10, 1.1, 
6.1.1 
Amyloid Derived 
Diffusible Ligands 
Lambert et al. 1998 Gon et al. 2009 Walsh et al.  2002   1.10, 1.11, 
3.3 
β-balls Laurents et al. 2005  
β-Amyloid Balls Westlind-Danielson & Arnerup 2001  
Spherical 
Particles 
Gorma et al. 2003  
Spherical 
prefibrillar 
aggregates 
Frost et al.  2003  
Amorphous 
Aggregates 
Davies et al. 1988, Huang et al. 2000  
Paranuclei Bitan et al. 2003  
Preamyloid Huang et al. 2000  
Protofibril Harper et al. 1997 Walsh et al. 1997, Arimon et al. 
2005, Kheterpal et al. 2003 
1.10.1.11 3.3 
Fibrils Ross et al. 2005, Klunk et al. 1999, Levine et al. 1999,  
Stromer et al. 2005, Luhrs et al. 2005, Malinchik et al. 
1998 
1.10, 1.11, 
3.3, 4.3, 5.3 
Spherocylindrical 
Miscelles 
Lomakin et al. 1997; Yong et al. 2002  
Plaques Selkow et al. 2004, Lansbury et al. 1999, Muller- 
Hill et al. 1989, Terry et al. 1991 
1.3, 1.7, 1.8. 
1.10, 1.11 
 
 
  
 
1.10.3.2 The Role of Amyloid-β Oligomerisation in Familial Alzheimer’s Disease 
 The necessity of oligomerisation for Aβ to exhibit pathogenicity is further 
exemplified by an inherited form of AD in a family in an Arctic region of Northern 
Sweden.  As discussed in section 1.4, the majority of the FAD mutations alter the 
production of Aβ. However, despite exhibiting symptoms of early onset AD, individuals 
carrying a substitution of glycine for glutamate at codon 693 of the APP gene (E693G; 
APPArctic) actually exhibit lower plasma Aβ1-40 and Aβ1-42 levels than healthy family 
members (Nilsberth et al. 2001). Furthermore, the ratio of Aβ1-42:Aβ1-40 secreted by 
Table 1.3 Various names for soluble oligomeric Aβ species  
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cells overexpressing APPArctic was lower than cells expressing wildtype APP. Analyses 
of transgenic mice have demonstrated that the E693G substitution facilitates both the 
formation of interneuronal Aβ aggregates (Lord et al. 2006) and rapid growth of senile 
plaques (Cheng et al. 2004) in a manner similar to other models expressing FAD 
transgenes (section 1.8.1). Analysing the activity of the Aβ peptide produced from 
APPArctic (AβE22G; fig 1.6) has provided insight into the pathological mechanism that 
underpins the alteration in activity. Aβ1-40E22G  is ~100-fold more potent at blocking long-
term potentiation (LTP; section 6.1.2) in vivo (Klyubin et al. 2004) and Aβ1-42E22G is 10-
fold more toxic to neuroblastoma cells (Murakami et al. 2003) than the wild-type 
peptide. Size exclusion chromatography of synthetic Aβ1-40 showed that Aβ1-40E22G had 
a higher propensity to form neurotoxic intermediates of Aβ fibrilisation, such as 
protofibrils (section 1.10.3.7), when compared with the wild-type peptide (Nilsberth et 
al. 2001; Johansson et al. 2006). The mechanism is likely to reflect the nature of the 
residue at position 22 in the Aβ peptide.  
 In addition to APPArctic, the glutamate residue at position 22 of Aβ is 
substituted in other AD-causing APP mutations, including APPItalian (E693K) and 
APPDutch (E693Q), while other mutations lie adjacent to the residue (APPFlemish, A692G, 
Hendriks et al. 1992; APPIowa, D694N, Grabowski et al. 2001). This site is adjacent to 
the α-secretase cleavage site, though only cells expressing APPFlemish secrete 
significantly increased levels of Aβ1-40 and Aβ1-42, compared with cells expressing wild-
type APP (Nilsberth et al. 2001). Glu22 also resides adjacent to the KLVFFA motif, 
which has been implicated in peptide oligomerisation (section 1.11.3). Amyloid-β 
peptides with mutations corresponding to APPArctic and APPDutch (Watson et al. 1999) 
both polymerise into protofibrils and fibrils significantly faster then the wildtype peptide, 
whereas Aβ containing the mutation corresponding to APPFlemish displays increased 
solubility and decreased fibrillogenesis (Walsh et al. 1997; Walsh et al. 2001). Taken 
together, these studies suggest that it is not simply an overproduction of Aβ that can 
lead to AD, but also the propensity for the Aβ produced at physiological levels to 
assemble into neurotoxic structures. 
 
1.10.3.3 Dimeric and Trimeric Amyloid-β  
 Stable Aβ1-42 and Aβ1-40 dimers have been generated from synthetic peptide 
in vitro (Hilbich et al. 1992; Roher et al. 1996; Garzon-Rodriguez et al. 1997), detected 
in human brain homogenates (McLean et al. 1999) and in cell culture media (Podlisny 
et al. 1995; Walsh et al. 2000). Roher et al. (1996) found that dimeric Aβ isolated from 
AD brain homogenates killed rat primary hippocampal neurons. However, the 72 h 
application of dimeric Aβ employed in this study, coupled with the propensity for Aβ to 
aggregate, casts doubt over the purity of the Aβ species acting on the cells. The rate of 
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Aβ aggregation, coupled with the length of time required for cytotoxicity to manifest, 
makes it difficult to implicate a single small oligomeric species in Aβ neurotoxicity. Lee 
et al. (2002) attempted to circumvent this issue, by employing annexin-V, a specific 
phosphatidylserine ligand, which inhibits the binding of Aβ1-42 dimers, but not 
monomers or trimers to synthetic membranes (Hung et al. 2008). Lee et al. 2002 found 
that annexin-V inhibited Aβ1-40-induced loss of PC12 cell viability, supporting a 
neurotoxic activity of dimeric Aβ.  
 The rapid effects of Aβ on long-term potentiation (section 6.1.2) will limit the 
aggregation of a defined Aβ population, presenting an excellent model to study the 
action of oligomeric Aβ. Klyubin et al. (2008) found Aβ dimers isolated from ex vivo 
human CSF inhibited hippocampus long-term potentiation in vivo. Importantly, this 
study demonstrated for the first time that human-derived soluble Aβ has a 
pathophysiological action in the brain, disrupting mechanisms of synaptic plasticity that 
are believed to underlie memory in the hippocampal network (discussed further in 
section 6.1.2).   
 In vitro, Aβ1-42, but not Aβ1-40, forms stable trimeric and/or tetrameric 
assemblies (Haass & Selkoe 2007), though heteromeric assemblies have been found 
in vivo (Lansbury et al. 1997).  Trimeric Aβ has been isolated in young and embryonic 
Tg2576 brains and levels of trimer-multiples (hexamer, nonamer, dodecamer) increase 
with age (Lesne et al. 2006). This suggests that trimers are the building blocks of Aβ1-42 
oligomers and aging induces trimers to assemble to form higher molecular weight 
assemblies. A relative resistance to denaturation supports the hypothesis that trimers 
are the fundamental precursors of Aβ assembly in vivo (Lesne et al. 2006). 
Furthermore, Aβ trimers isolated from culture media of cells expressing human 
APPIndiana fully inhibited LTP of mouse hippocampal slices, implicating trimers in the 
synaptic dysfunction of AD (Townsend et al. 2006). Interestingly, application of isolated 
Aβ dimers and tetramers also inhibited LTP, though to a lesser extent than trimeric Aβ. 
In the current study, oligomeric Aβ of molecular weight correlating to assemblies 
ranging from trimer to hexamer are implicated in the acute modulation of Ca2+ 
signalling by Aβ1-42 (section 5.2.7). 
 The presence of Aβ dimers and trimers in the soluble fraction of human brain 
and amyloid plaque-extracts (Roher et al. 1996; Enya et al. 1999; Funato et al. 1999; 
McLean et al. 1999), coupled with the trimer-multiples detected in the Tg2576 brain, 
suggests that these low molecular weight oligomers could be the earliest mediators of 
neuronal dysfunction in AD. Another possibility, however, is that they are precursors for 
larger, more pathological assemblies.   
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1.10.3.4 Small Soluble Amyloid-β Assemblies  
 Small (globular) oligomeric Aβ species are currently receiving much interest, as 
they are more toxic than fibrillar Aβ (Dhalgren et al. 2002, McLean et al. 1999, Cleary 
et al.  2005, Lesne et al. 2006) and correlate better with AD symptoms (McLean et al.  
1999; Gong et al. 2003) and the cognitive impairment of transgenic models 
(Westerman et al. 2002). These low-molecular-weight aggregates, 3-50 monomers in 
size, have been detected in in vitro studies and in the media of Aβ-secreting cultures. 
They have also been found in cerebral spinal fluid and post mortem brain tissue 
extracts (Walsh et al. 2002, Kyo et al. 1996, Lue et al. 1999). The effect of acutely 
applying a subset of soluble Aβ assemblies, approximately 3-6 monomers in size, on 
Ca2+ signalling in PC12 cells is assessed in chapter 5.  
 A sub-group of small soluble assemblies have been referred to as Aβ-derived 
diffusible ligands (ADDLs, 17kDa to 42 kDa, corresponding to 4-mer to 10-mer). 
Though first reported in in vitro fibrillization studies, they have since been found in 
soluble extracts of hAPP mice brains (Roher et al. 1996; Enya et al. 1999, Funato et al. 
1999, McLean et al. 1999, Kawarabayashi et al. 2004, Lesne et al. 2006) and levels of 
ADDLs are far greater in homogenates from the brains of AD patients, compared with 
controls and correlates with age (Gong et al. 2003). Exposure to synthetic ADDLs is 
toxic to neuroblastoma cells (Chromy et al. 2003) and pathophysiological levels (100 
nM) suppress LTP in hippocampal cultures (Lambert et al. 1998) independently of any 
synaptic deterioration (Wang et al. 2002). Furthermore, Walsh et al. (2002) 
demonstrated inhibition of LTP by cell-derived ADDLs in both slice preparations and 
animal models (discussed further in section 6.1.2). 
 Injection of mammals with a synthetic mixture of ADDLs stimulates the immune 
system to produce oligomer-specific antibodies that can discriminate between ADDLs 
and monomers (Lambert et al. 2001). This technology has allowed detection of ADDLs 
in hAPP transgenic mouse (Chang et al. 2003), the formation of which correlates with 
cognitive decline (Westerman et al. 2002). In addition to a correlation with cognitive 
decline in AD mice models, the level of ADDLs in AD patients was up to 70-fold higher 
than aged-match controls (Gong et al. 2003). In vitro, oligo-specific antibodies can 
inhibit fibrillogenesis and prevent toxicity in neuroblastoma cells (Lafaye et al. 2008). 
Taken together, these reports position ADDLs as a key Aβ assembly in AD pathology. 
However, these studies have only investigated this group of assemblies, whereas 
others have nominated a single oligomeric structure as the prime candidate mediating 
AD pathology.  
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1.10.3.5 Amyloid-β*56 
 As stated in section 1.10.2, the abundance of amyloid plaques does not 
correlate with the disease severity. As memory deficits in Aβ-overproducing transgenic 
models occur prior to plaque formation, it was postulated by Lesne et al. (2006) that an 
oligomeric species that forms before plaques causes cognitive dysfunction. Analyzing 
Aβ assemblies from Tg2576 mice by western blot, Lesne et al. found that levels of a 
dodecameric assembly (Mw 56 KDa, termed Aβ*56) had the strongest correlation with 
memory performance. Furthermore, injection of pathophysiological levels of the 
isolated Aβ*56 into cerebroventricles of healthy mice impaired long-term spatial 
memory. Given the lack of plaques and neuron loss in Tg2576 mice, this suggests that 
Aβ*56 impairs memory in the absence of overt disease hallmarks.  
 Supporting the implication of Aβ*56 as a primary Aβ species in AD pathology, 
levels of the dodecamer in the ARC6 transgenic model correlate with deficits in 
learning and memory (Cheng et al. 2007). Atomic force microscopy (AFM) of Aβ*56 
isolated from the transgenic mouse brain indicated the structure was 1 nm in height 
and 125-175 nm3 in volume. This is similar to the early-stage synthetic oligomers 
formed in vitro in this study, but smaller than synthetic oligomers and protofibrils 
reported by others (Lambert et al. 1998; Dalhlgren et al. 2002; Harper et al. 1997). As 
the in vitro conditions of Aβ oligomerisation will vary from those found in the brains of 
AD patients and transgenic models, it is important to justify the use of synthetic ADDLs, 
to mimic those found in vivo. Comparison of synthetic ADDLs showed they are 
indistinguishable in Mw and isoelectric point form those derived from brains (Klein et al. 
2004). Brain-derived ADDLs are also equally recognised by antibodies raised against 
synthetic ADDLs, interact with the same three proteins in ligand overlay assays (Klein 
et al. 2004) and display a similar distribution pattern when exogenously applied to 
neurons (Lacor et al. 2004).  
 
1.10.3.6 Globular Aβ Assemblies Provide Insights Into Amyloid Aggregation 
Pathways 
As discussed in section 1.10.2, under most conditions Aβ peptides rapidly 
convert into fibrils, which have a cross-β conformation (Petkova et al. 2006; Kirschner 
et al. 1986), via a process of nucleation-dependent polymerisation. However, 
alternative processes (fig 1.8) have also been proposed, which involve the initial 
formation of small oligomers that can expand in a non-linear fashion. Bareghorn et al. 
(2005) detected a 38/48 KDa Aβ oligomer in the brain of patients with AD and APP 
transgenic mice, which exhibited characteristic globular nature and was therefore 
termed a „globulomer‟. Importantly, the species was stable, in comparison to other 
oligomeric structures such as the ADDLs described by Lambert et al. (1998; 
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interestingly, in Barghorn‟s hands the globulomer made up ~5% of Lambert‟s ADDL 
preparation). This allowed the generation of a homogenous preparation of the 
globulomer, setting a precedent in ascribing function to a particular oligomeric species. 
The assembly rapidly and specifically bound to neurons in a manner similar to that 
shown by Lacor et al. (2004) and inhibited LTP in hippocampal slices (section 6.1.2). In 
vitro generation of synthetic Aβ globulomers showed that the assembly is not an 
intermediate of higher molecular Aβ aggregates, in contrast to the spherical Aβ 
particles transiently detected by Harper et al. (1997) during intermediate times of 
fibrillogenesis. This indicates the globulomer forms along an aggregation pathway 
independent of Aβ fibril formation. As it would not be sequestered into non-toxic Aβ 
fibrils by further polymerisation (Caughey and Lansbury 2003), this presents the 
globulomer as a unique pathological entity in AD. 
To differentiate between Aβ assemblies that contribute to fibril formation, the 
terms „on-pathway‟ and „off pathway‟ have been coined, to indicate whether a particular 
amyloidogenic peptide can coalesce directly to form fibrils (as observed by Harper et 
al. 1997; Walsh et al. 1997; Harper et al. 1997b; Nybo et al. 1999; Walsh et al. 1999) or 
not (as observed by Naiki et al. 1996; Lomakin et al. 1996; Harper et al. 1999), 
respectively. The two pathways are populated by morphologically and immunologically 
distinct structural assemblies and do not intersect (Rangachari et al. 2007). Altering the 
flux of Aβ down the pathways is therefore a possible therapeutic strategy. Necula et al. 
(2007a) screened 42 small molecules that had been previously reported to inhibit Aβ 
aggregation and classified the compounds according to their ability to inhibit the 
either/both pathways. The study showed that some compounds specifically prevent the 
formation of on-pathway Aβ oligomers, while others selectively target the 
oligomerisation of off-pathway intermediates, in agreement with previous studies 
(Lashuel et al. 2002). Utilising the prefibrillar (on-pathway) oligomer-specific antibody 
A11, in conjunction with transmission electron microscopy and turbidity assays, Necula 
et al. (2007b) showed that methylene blue inhibited off-pathway Aβ aggregation 
concomitant with a decrease in the lag time and an increase in the fibrillization rate, 
consistent with promotion of both filament nucleation and elongation. Opposite effects 
have been detected for apomorphine and its derivatives, which can prevent 
fibrillogenesis, while enhancing off-pathway oligomer formation (Lashuel et al. 2002).  
Soluble oligomeric assemblies exhibit an ordered β-sheet structure similar to 
that detected in fibrils (Chimon et al. 2007). However, detailed structural 
characterisation of these stuctures has been hindered by their low levels, 
heterogeneity, sensitivity to solution conditions and varying preparation procedures. As 
discussed in section 1.12.3.1, Aβ peptides interact with lipid membranes and the 
addition of detergent or fatty acid can result in long-lived soluble assemblies that are 
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potent antigens in mice and rabbits, allowing the generation of antibodies specific to 
these assemblies (Barghorn et al. 2005). Taking advantage of the longevity of these 
species, Yu et al. (2009) used solution NMR to demonstrate a mixed intermolecular 
parallel and intramolecular antiparallel β-sheet that is different from all the parallel Aβ 
peptides found in strucutral studies of peptides. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.10.3.7 Protofibrils 
At longer incubation times, Aβ in solution forms curvilinear fibers that have a 
beaded appearance (Arimon et al. 2005). These structures have been termed 
“protofibrils,” as they exist as transient intermediates prior to fibril formation (Walsh et 
al. 1997; Harper et al. 1999). They are more flexible and smaller (<8 x <200 nm) than 
fibrils, but have a secondary structure characteristic of fibrils, composed of peptides in 
β-sheet confirmation (Kheterpal et al. 2003; reviewed in Finder & Glockshuber 2007). 
In vitro, protofibrils can induce acute changes in electrophysiological activity and are 
Soluble 
Oligomers  
Insoluble 
Fibrils  
Benign 
Benign 
Soluble 
Monomer  
Soluble 
Monomer  
Soluble 
Oligomers  
Insoluble 
Fibrils  
Pathogenic  
Benign Benign 
Fig 1.9 Potential Pathways of Aβ oligomerisation. Currently, little is known about how Aβ 
oligomerises in vivo. However, in vitro data suggests that distinct pathways could exist (A) a 
single, linear pathway where soluble oligomeric species exist as intermediates during the 
formation of fibril from monomers (B) Two distinct pathways may exist, one that forms 
pathogenic, soluble oligomers and one that leads to the formation of benign, insoluble fibrils 
and plaques. Reports of disaggregating Aβ assemblies suggest that these pathways exist in 
equilibrium, rather than in a unidirectional fashion (adapted from Meyer-Luehmann et al. 
2008). 
Pathogenic  A 
B 
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progressively toxic in vitro, causing a loss of membrane integrity in cortical (Hartley et 
al. 1999) and hippocampal (Isaacs et al. 2006) neurons. This toxicity may arise from 
the annular structure of the protofibrils and will be discussed further in section 
1.12.3.3). 
Although their beaded appearance suggests they are formed by the 
coalescence of the spherical subunits (Walsh et al. 1997; Arimon et al. 2005), Aβ 
protofibrils can assemble from a diversity of smaller structures and can elongate by 
association of smaller protofibrils with a rate depending on Aβ concentration, pH, ionic 
strength and temperature (Harper et al. 1999; Arimon et al. 2005). Importantly, 
protofibrils exist in dynamic equilibriium with lower-molecular weight constiutents 
(Walsh et al. 1999).  
Although elongation of Aβ fibrils can arise from sequential addition of 
monomers to the fibril end, it can also involve the incorporation of immature (short) 
protofibrils (Harper et al. 1999). Furthermore, Aβ1-42 protofibrils have been shown to 
attach laterally (end-to-end), generating short, thick fibrils with projecting 
unincorporated protofibrillar branches (Nybo et al. 1999). As more protofibrils join, the 
fibril becomes longer and thinner and the protofibrillar branches gradually recede and 
eventually disappear. This mechanism supports a previous model, which suggested 
that protofibrils undergo a “winding and a conformational change as they convert to 
fibrils” (Harper et al. 1997). Following dilution, protofibrils have been shown to 
disaggregate, though only the release of monomers has been detected (Harper et al. 
1999).  
 
1.10.3.8 Fibrils 
 Amyloid fibrils have been defined as “thermodynamically stable, structurally 
organised, highly insoluble, filamentous protein aggregates being composed of 
repeating units of β-sheets aligned perpendicular to the fiber axis” (Ross et al. 2005). In 
vitro, fibrillar Aβ can induce neuritic dystrophy, synaptic loss (Grace et al. 2002; Grace 
and Busciglio 2003), loss of membrane integrity (Isaacs et al. 2006) and apoptosis 
(Yankner et al. 1996). However, comparative toxicological studies suggest fibrils are 
relatively benign (Deshpande et al. 2006). Furthermore, levels of fibrillar Aβ do not 
correlate with memory impairment of transgenic AD models (Morgan et al. 2003) or 
dementia in AD patients (Walsh and Selkoe 2007). Fibrillar Aβ1-42 is visualised in 
section 3.3.1 and the effect of acute application of fibrillar Aβ1-42 on Ca
2+ signalling in 
PC12 cells is assessed in chapter 5.  
 Supporting a causative role of fibrils in AD, microinjection of fibrillar, but not 
soluble, Aβ into the cerebral cortex of aged rhesus monkeys caused profound neuronal 
loss, tau phosphorylation and microglial proliferation (Geula et al. 1998), suggesting 
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primate neurons are more susceptible to the neurodegenerative effects of fibrillar Aβ. 
Interestingly, the same treatment did not evoke a toxic response in young rhesus 
monkeys, consistent with the age-dependent susceptibility of AD. Much higher levels of 
fibrillar Aβ were also required to evoke neurotoxicity in rodents. This species-
dependent susceptibility, which is in agreement with other studies (Frautschy et al. 
1991; Kowall et al. 1991), suggests caution must be taken when interpreting in vivo 
toxicological reports of Aβ.  
 Interestingly, fibrillar preparations of the AβE22G (from APPArctic) and AβE22Q 
(from APPDutch) inhibited neuronal viability in vitro significantly more than fibrillar 
preparations of wild-type Aβ1-42 (Dhalgren et al. 2002). This suggests that amyloid fibrils 
are not a single population of assemblies, but may represent a family of amyloid 
structures, with distinct biological activities. 
 
1.11 Oligomerisation: a potential theraprutic target for Alzheimer’s Disease?   
 The reversible action of oligomeric Aβ on LTP (discussed further in section 
6.1.2) lead to postulation that cognitive impairment in the early stages of AD could also 
be reversible (Klein et al. 2004; Lambert et al. 1998). The prominence that oligomeric 
state plays in Aβ toxicity has focused attention on altering aggregation of the peptide, 
in the hope of reducing levels of soluble oligomeric species and attenuating toxicity. 
Strategies have been developed to modulate equilibria of aggregation and drive 
oligomerisation away from toxic soluble oligomeric species. However, since both 
monomeric Aβ and fibrillar Aβ are relatively innocuous (sections 1.11.1 and 1.10.3.8, 
respectively), compounds have been identified that enhance or inhibit fibril formation. 
These include a range of structurally diverse compounds, including antibodies (section 
1.11.2), peptides (section 1.11.3) and small molecules (section 1.11.4). 
 
1.11.1 Enhancing Fibrillogenesis 
 The majority of research into attenuating the effects of Aβ has aimed to reduce 
Aβ burden by preventing the oligomerisation of Aβ so that it may be cleared from the 
parenchyma. However, it is possible that toxic oligomeric soluble Aβ species are 
sequestered into benign fibrils and plaques. As Aβ fibril formation exists in equilibrium 
and many anti-fibrillogenic compounds are also capable of disaggregating preformed 
fibrils (Soto et al. 1998; Ono et al. 2002), introducing an anti-fibrillogenic compound in 
the presence of significant amyloid burden, as is often the case by the time AD is 
diagnosed, may actually increase the levels of soluble oligomeric structures. Another 
approach to reduce the levels of soluble oligomeric Aβ therefore aims to sequester 
soluble oligomers by enhancing the rate of fibril formation. 
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The Aβ peptide generated from APPArctic (Aβ1-42E22G) exhibits increased 
aggregation and in vitro toxicity, compared with wild-type Aβ1-42 (Murakami et al. 2003; 
section 1.10.3.2). However, mice expressing APPArctic in addition to other FAD APP 
genes (APPSwe and APPIndiana) exhibited reduced cognitive deficits when compared with 
mice expressing only APPSwe and APPIndiana (Cheng et al. 2007). Thus although Aβ1-
42E22G exhibits enhanced aggregation and toxicity in vitro, it reduces cognitive defects 
evoked by other pathological APP genes. This may be explained by the altered 
formation of Aβ oligomeric assemblies. Though the APPArctic/APPSwe/APPIndiana mice 
displayed increased plaque burden, they exhibited lower levels of Aβ*56. This indicates 
that enhancing Aβ fibril formation, with concomitant reduction in soluble oligomeric 
structures reduced the cognitive defects.  
Several compounds have been identified that reduce the toxicity to Aβ, while 
enhancing aggregation. Chondritin sulfate B (CSB) has been shown to enhance the 
formation of stable Aβ1-42 fibrils without affecting β-sheet conformation (Bravo et al. 
2008). The toxicity of CSB-induced fibrils was significantly less toxic to neuroblastoma 
cells than fibrils formed in the absence of CSB. A similar increase in Aβ aggregation 
and decreased cytotoxicity was also detected for halothane and isofluorane (Eckenhoff 
et al. 2004).  
 
1.11.2 Disrupting Oligomerisation with Antibodies 
 Administering synthetic Aβ, termed active immunisation, aims to stimulate anti-
Aβ antibody production by the immune system. These antibodies should also bind to 
endogenous, aggregated amyloid stimulating clearance from the brain. Using this 
approach, Schenk et al. (1999) prevented the onset of AD-type pathologies in young 
PDAPP mice by administration of aged Aβ1-42. In addition, immunizing older mice (11 
months), which already exhibited pathology, markedly reduced the progression of Aβ-
plaque burden, neuritic dystrophy and gliosis. Supporting this work, APP + PS1 mice 
displaying signs of pathology were vaccinated with aged Aβ and exhibited reduced 
learning and memory deficits (Morgan et al. 2000). Though these studies demonstrated 
production of anti-Aβ antibodies, other possible mechanisms exist, such the activation 
of microglial Aβ clearance by the exogenous peptide. These studies reported 
unchanged or reduced, but still substantial, amyloid burden, as determined by plaque-
number. Though this would suggest that the Aβ is not being cleared, the studies did not 
monitor levels of soluble Aβ aggregates and so only a fraction of the “Aβ burden” was 
actually assessed.  
 A therapeutic trial based on this paradigm was attempted employing synthetic 
Aβ1-42 (AN-1792; Check et al. 2002). Although some patients displayed reduced 
amyloid levels in the brain, immunisation was discontinued after a few patients (4/360) 
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developed significant meningo-encephalitic cellular inflammatory reactions. Though 
some researchers blame the type of adjuvant used for the autoimmune response 
(Wilcock and Colton 2008), others implicate the specificity of the antibody (Check et al. 
2002), which may also target APP, which also contains the Aβ epitope. A key 
difference between the mouse experiments and human trials are that mouse APP 
might not be targeted by antibodies raised against inoculations with human Aβ. 
Injecting mice with mouse Aβ may shed light on this reaction. Although no impairment 
of AD progression was reported, subsequent post mortem analysis revealed a 
dispersal of plaques, though this occurred with a concurrent increase in soluble 
amyloid levels and no change in total brain amyloid levels (Kokjohn et al. 2009).  
 Another approach to interfere with Aβ aggregation is passive immunisation, 
involving administration of exogenous antibodies. McLaurin et al. 2002 raised an 
antibody in mice that specifically targets protofibrillar Aβ aggregates, though without 
evoking an immune response. By identifying regions of the Aβ sequence that the 
antibodies interacted with, they found that anti-Aβ1-42 IgGs specifically recognised 
residues 4-10 of Aβ. Furthermore, these antibodies inhibited fibril formation and in vitro 
cytotoxicity of Aβ.  
In vivo, administration of anti-Aβ antibodies has prevented memory deficits in 
Tg2576 (Kotilinek et al. 2002; BAM-10) and PDAPP (Dodart et al. 2002; M266) mice 
without altering Aβ burden. Both studies inferred the antibody was interfering with the 
levels of soluble oligomeric Aβ. To test this hypothesis, Lee et al. 2006 ameliorated 
learning and memory deficits of Tg2576 mice by administering an antibody that 
preferentially recognises oligomeric Aβ, not APP or its non-Aβ metabolites. Based on 
the success of these transgenic mouse studies, passive immunisation has now moved 
to Phase III trials (Wilcock and Colton 2008). However, given the possible cross-
reactivity of antibodies directed at Aβ, smaller compounds have been developed which 
disrupt Aβ oligomerisation. These can be divided into two classes: peptide inhibitors 
and small-molecule inhibitors. 
 
1.11.3 Peptide Inhibitors of Oligomerisation 
Identifying regions of Aβ that are involved in oligomerisation has lead to the 
development of peptides that can disrupt oligomerisation. Initial studies focussed on 
regions that are altered in FAD, particularly those around the central hydrophobic 
region. Using site directed mutagenesis (SDM), HIllbich et al. (1992) investigated the 
role that the hydrophobic residues 17-20 (LVFF) play in the aggregation of Aβ10-42 and 
Aβ10-43. When stained with congo red, Aβ peptides in which the two phenylalanine 
residues had been changed to threonine did not exhibit the birefringence observed with 
the native peptide, suggesting a lack of aggregation. This was corroborated by circular 
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dichroism and infrared spectroscopy, which revealed reduced β-sheet content, 
suggesting the central hydrophobic region of Aβ plays a role in conformation and 
aggregation of the peptide.  
Wood et al. (1995) extended the findings of Hilbich et al. using proline-scanning 
SDM of Aβ15-23 and Aβ12-26. They found that changing any of the residues of the 
17LVFFAED23 motif to proline increased peptide solubility and essentially abolished fibril 
formation. In contrast, substituting alanine, rather than proline, at residue 19, but not 
17, 18 or 20 reduced fibril formation only by 15 %. Subsequent reports showed 
substituting phe19 of Aβ10-35 for threonine produces a marked reduction in radiolabelled 
peptide binding to human cortical sections, when compared with the wild-type peptide 
(Esler et al. 1996). NMR data indicated that the Aβ10-35[F19T] peptide was significantly 
less folded, suggesting the presence of phenylalanine at position 19 is essential for the 
peptide to fold in a manner that allows correct oligomerisation and interaction with 
neurons. Corroborating this study, Hughes et al. (1996) demonstrated that two Aβ 
monomers are capable of interacting in a eukaryotic cell, using a two-hybrid model. By 
substituting phenylalanine residues at positions 19 and 20 for threonine, Hughes et al. 
demonstrated Aβ1-40[F19T F20T] interacts poorly with the native Aβ1-40. This may explain 
the impaired fibril formation of substituted Aβ peptides observed by Wood et al. and 
Hillbich et al., who found the presence of equimolar substituted Aβ10-43 peptide 
prevented in vitro fibril formation.  
By synthesizing the isolated central hydrophobic region, Hughes et al. (1996) 
found that the presence of a 10-fold excess of QKLVTTAE (Aβ17-24[F19T, F20T]) inhibited 
fibrilisation of full-length Aβ1-40, suggesting that this sequence alone can disrupt fibril 
formation. Accordingly, decapeptides corresponding to consecutive sequences of Aβ1-
40 (Aβ1-10, Aβ2-11, Aβ3-12 etc) indicated peptides containing Aβ16-20 (KLVFF) are able to 
bind Aβ1-40 and prevent fibril formation (Terjberg et al. 1996). Alanine-scanning SDM of 
the hexapeptide KLVFFA identified Lys16, Leu17 and Phe20 as critical for Aβ1-40-
binding and inhibition of fibril formation. The KLVFFA region was termed the “self-
recognition element” in Aβ fibril formation. Several subsequent studies corroborate the 
anti-fibrillogenic activity of the hexapeptide KLVFFA (Ghanta et al. 1996; Watanabe et 
al. 2002; Chalifour et al. 2003; Chafekar et al. 2007). By treating Aβ1-40 with a series of 
twenty overlapping 6-mer and 7-mer peptides from the Aβ sequence, Chalifour et al. 
(2003) showed that the antifibrillogenic character is specific to peptides containing the 
KLVFF sequence. Furthermore, they demonstrated that the activity of the peptide is 
stereoselective, as the dextrorotatory (D) enantiomers of KLVFFA and KKLVFFA 
displayed greater inhibition of native, levorotatory (L) Aβ1-40 fibril formation than the 
levorotatory KLVFFA and KKLVFFA peptides. In a reciprocal experiment, the 
fibrillogenesis of D-Aβ1-40 was prevented by the presence of L-KLVFFA to a greater 
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degree than D-KLVFFA. By switching the chirality of individual residues, Chalifour et al. 
showed that the antifibrillogenic activity of the peptide was determined by the chirality 
of the first two and last two residues of the KLVFFA sequence.  
 
        A       B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demonstrating the biological significance of these findings, D-KKLVFFA, but not 
L-KKLVFFA, prevented Aβ1-40 and Aβ1-42 toxicity evoked in neuroblastoma cells or 
cultures of mixed primary rat cortical/hippocampal neurons, respectively (Chalifour et 
al. 2003). Corroborating this result, Evans et al. (2008) prevented dysfunctional 
synaptogenesis and neurite outgrowth of primary rat cortical/hippocampal cultures 
(discussed further in chapter 6) evoked by Aβ1-42 by co-application with D-KLVFFA. In 
addition to examining these effects of D-KLVFFA on Aβ1-42 toxicity (chapters 4 and 6) 
the effect of D-KLVFFA on Aβ1-42 modulation of Ca
2+ signalling in PC12 cells is 
assessed in chapter 5.  
 In addition to assessing the effect of chirality on KLVFFA activity, attempts have 
been made to enhance the antifibrillogenic activity of peptides containing KLVFFA. 
Amino acid substitution and chemical modification has generated a library of 
compounds based around the central hydrophobic core of Aβ.  
In agreement with Esler et al. (1996), circular dichroism spectra suggest that 
KLVFFA prevents the transition of Aβ from a random coil, to a β-sheet conformation, 
which is required for fibrillogenesis (Chalifour et al. 2003). Taking LVFF as a template 
Soto et al. (1998) added a proline residue, which is known to block the formation of β-
sheet conformation (Wood et al. 1995; Chou et al. 1978), and a charged residue to 
Fig 1.10 Oligomerisation disruption by KLVFFA. Oligomerisation (A) involves interaction 
between one or more binding sequences in the Aβ molecule. Binding of KLVFFA (blue) to Aβ 
(green) (B) prevents the interaction between Aβ peptides. Adapted from Tjernberg et al. 1996 
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increase the solubility of the peptide. The resulting LPFFD peptide prevented Aβ1-40 
and Aβ1-42 formation in vitro, dissolved preformed fibrils, protected neuroblastoma cells 
from Aβ1-42 toxicity and prevented deposition of synthetic Aβ1-42 in the rat brain. In 
contrast to the reports discussed above, the fragment LVFFA (Aβ17-21), produced no 
such effects.  
Although several studies into the effect these peptides have on Aβ 
fibrillogenesis report conflicting findings, there also clear consistencies between the 
studies. The concentration dependence of the anti-fibrillogenic peptide is one such 
example. All studies indicate that an equimolar concentration of the respective peptide 
is sufficient to inhibit fibrillogenesis of Aβ, while an excess of the peptide is required to 
abolish fibril formation. However, chemical modification of the peptide has been shown 
to modulate the efficacy of these short peptides (Laczko et al. 2008; Hughes et al. 
2000).  
 The suitability of peptides as therapeutic agents is limited by several factors, 
including those specific to disorders of the CNS, such as the ability to cross the blood 
brain barrier, and general factors, such as vulnerability to proteases. One advantage of 
D-enantiomers is an inherent resistance to physiological proteases (Findeis et al. 1999; 
Soto et al. 1996), while L-peptides must be modified to prevent digestion. In view of 
these limitations, small molecule non-proteinaceous inhibitors of Aβ oligomerisation 
have received much interest.   
 
1.11.4 Small-Molecule Inhibitors of Aβ Oligomerisation 
In a manner resembling the addition of a cyclic proline residue to Soto‟s β-
breaker peptide, many of the small molecule inhibitors contain ring structures. The 
rapidly-expanding list of inhibitors includes monosaccarides, polysaccarides, 
polyphenols, synthetic tricylcics, hormones, surfactants, flavinoids and alkaloids. 
Structural analysis of the inhibitors of amyloid formation, including those of Aβ, 
suggests a possible inhibitory core that shares conformational, sterochemical and 
physiochemical properties. Esteras-chopo et al. (2008) generated a pharmacophore 
model based on the common chemical features of a diverse set of 32 nonpeptidic 
small-molecule amyloid fibrillogenesis inhibitors. Interestingly, the fundamental features 
of the model resemble the inhibitory core identified in the active D-peptides.   
 
1.11.4.1 Nicotine inhibits Aβ fibril formation  
 At low concentrations, nicotine acts as a stimulant in mammals and is one of 
the main agents responsible for the dependence-forming properties of smoking 
tobacco. Some epidemiological studies suggest that smoking can delay the onset of 
neurodegenerative disease, including AD (discussed further in section 1.13.3). An 
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expansive body of literature on the pharmacology and toxicology of nicotine, which has 
been fuelled by the prevalence of tobacco consumption, presents nicotine as an 
attractive potential therapeutic. Numerous studies have shown nicotine to possess 
neuroprotective qualities against a range of toxins, including Aβ (section 1.13.5) and 
several mechanisms have been proposed, including mediation by nAChR (section 
1.13.5.1) and by direct interaction with Aβ.  
Using UV spectroscopy and circular dichroism, Salomon et al. (1996) showed 
that (-)-nicotine (50 μM) can inhibit the in vitro conversion of synthetic Aβ1-42 peptide 
from its soluble, freshly-dissolved form into insoluble, β-pleated sheet deposits. The 
interaction between (-)-nicotine and a truncated, R-helical Aβ1-28 peptide was examined 
by NMR spectroscopy. The study indicated (-)-nicotine binds specifically to histidine 
residues (His6, His13 and His14) of Aβ1-28 when folded in an α-helical confirmation, 
primarily involving the N-CH3 and 5‟CH2 pyrrolidine moieties of nicotine (Salomon et 
al. 1996, Moore et al. 2004). Thus it appears that nicotine retards amyloidosis by 
preventing a transformation in confirmation from α-helix to β-sheet that is crucial for 
fibrillogenesis, in a manner similar to that of substitutions within the central hydrophobic 
region of Aβ and by peptides related to this region (section 1.11.3).  
Interest in nicotine as an antifibrillogenic agent increased following a report that 
200 μg/ml nicotine in drinking water for 5.5 months from 9 months of age significantly 
inhibited the accumulation of Aβ deposits in the brains of transgenic mice expressing 
APPSwe (Nordberg et al. 2002). Another recent study suggests that (-)-nicotine not only 
inhibits aggregation of Aβ1-40 and Aβ1-42 but can also disaggregate fibrils preformed 
from both of these peptides in vitro (Ono et al. 2002). The reduction of Aβ burden could 
therefore be due to the inhibition and/or reversal of Aβ aggregation, or alternatively, (-)-
nicotine could influence Aβ deposition via the stimulation of nAChR with consequent 
modulation of APP processing (section 1.5; Kim et al. 1997, Hellstrom-Lindahl et al. 
2000, Seo et al. 2001).  
 Naturally occurring nicotine is dominated by the levorotatory (L)-enantiomer 
(traditionally termed L- or (-)-nicotine, molecular structure is shown in fig 1.11). The 
content of the dextrorotatory (D)-enantiomer (D- or (+)-nicotine; fig 1.11) in tobacco 
does not usually exceed a few percent (Yildiz et al. 1998, Tang et al. 1998). In a direct 
comparison of nicotine stereoisomers, employing the thioflavin T (ThT) assay (section 
2.2.7.1) to monitor Aβ1-40 aggregation, Moore et al. (2004) found the biologically less 
active (+)-nicotine was at least equally effective at inhibiting Aβ1-40 aggregation as the 
biologically more active and more abundant (-)-nicotine. The study suggests that the 
inhibitory effects of nicotine are not mediated by specific, stereoselective binding to any 
form of the soluble or aggregated Aβ, but could be due instead to weak, nonspecific 
binding to the peptide, or to some other property of nicotine and mechanism of action. 
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Other mechanisms by which nicotine disrupts Aβ fibril formation are discussed in 
section 7.3.2.  
 
 
 
 
 
 
 
 Confirming the result of the ThT assay, Moore et al. (2004) used electron 
microscopy to show a lack of fibril formation when Aβ1-40 was incubated in the presence 
of (+)-nicotine. Furthermore, an immunoassay involving an antibody that specifically 
recognises soluble Aβ1-40 oligomers suggested nicotine acts at an early step in the 
formation of Aβ1-40 fibrils and it appears that this delays, rather than permanently 
inhibits fibril formation. This may explain why previous studies employing a single, long 
incubation with nicotine did not detect any inhibition of Aβ1-40 fibirllogenesis (Kihara et 
al. 1999).  
 To determine whether nicotine affects the biological activity of Aβ1-40 
fibrillogenesis, Moore et al. 2004 also showed that both enantiomers of nicotine 
attenuated cytotoxic responses of neuroblastoma cultures to Aβ1-40. This effect was 
only observed when nicotine was present during peptide aging, as addition of nicotine 
to Aβ1-40 after aging had no effect on cytotoxic responses.  Although nicotine is reported 
to disaggreate preformed Aβ1-40 and Aβ1-42 fibrils (Ono et al. 2002), it seems this is not 
sufficient to prevent the peptide from evoking toxic responses in vitro. The effects of 
nicotine enantiomers on Aβ1-42 toxicity is assessed in chapter 4 and 6, while the 
modulation of Ca2+ signalling by Aβ1-42 is assessed in chapter 5.   
 
1.11.4.2 Nicotine Metabolites also inhibit Aβ fibril formation  
 In addition to nicotine, a number of compounds in tobacco are 
pharmacologically active and could therefore be responsible for the putative effects of 
smoking tobacco on AD symptoms (section 1.13.3). Furthermore, compounds present 
in tobacco and others generated by nicotine biotransofrmation are reported to modify 
the aggregation of Aβ peptides. Circular dichroism and ultraviolet spectroscopy have 
shown that cotinine, the major metabolite of nicotine, can also inhibit in vitro formation 
of Aβ amyloid plaques (Salomon et al. 1996; Nordberg et al. 2002; Moore et al. 2004). 
 Nornicotine, an alkaloid present in tobacco, and also one of the major 
nicotine metabolites, has been found to covalently modify the Aβ peptide by 
nonenzymatic glycation of the lysine residue within the KLVFFA central hydrophobic 
(+)-nicotine  (-)-nicotine  Fig 1.11  
Chemical structures of (+)-nicotine 
and (-)-nicotine 
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region (section 1.11.3). As this residue is reported to be located on the surface of the 
peptide when folded in β-sheet conformation, it is believed that glycation of the residue 
physically blocks a critical site in the formation of aggregated amyloid structures (fig 
1.10) reducing aggregation of the peptide (Dickerson and Janda, 2003). Proposed 
consequences of reduced aggregation by nornicotine catalysis include reduced plaque 
formation, altered clearance of Aβ, attenuated toxicity of soluble oligomeric Aβ 
structures and conformational modification of the peptide (Pogocki et al. 2003, 2004; 
Butterfield and Kanski 2002, Dickerson and Janda 2003).  
 
1.12 Mechanism of Aβ Toxicity 
Understanding the mechanisms that underpin cellular responses to A  will 
facilitate the development of therapeutic strategies against AD. Various physiological, 
cellular and molecular alterations have been reported to occur in response to Aβ-
exposure, indicating a number of cellular systems are sensitive to the peptide. 
Unraveling the directional causality of these effects is proving to be a challenging task 
and may highlight the complex, highly integrated nature by which cellular components 
interact. Although linear, unidirectional mechanisms of A  toxicity have been 
postulated, none have been universally accepted. Several facets of Aβ toxicity have, 
however, been consistently reported, including the induction of oxidative stress (section 
1.12.1.1) and disruption of calcium homeostasis (section 5.1.1).  
 
1.12.1 Oxidative stress in AD 
A common characteristic of neurodegenerative diseases is an imbalance 
between antioxidants and reactive oxygen species (ROS), termed oxidative stress. The 
high metabolic rate, low concentrations of glutathione and catalase, coupled with a high 
proportion of polyunsaturated fatty acids makes the brain particularly susceptible to 
oxidative damage (Smith et al. 1996; Smith et al. 1998). Post mortem analysis of brain 
tissue from healthy individuals indicates the levels of oxidised protein (carbonyl 
moieties) and DNA adducts correlate with age (Smith et al. 1991; Mecocci et al. 1993). 
However, in cases of AD, additional, specific elevations have been detected in the 
hippocampus and parietal cortex (Hensley et al. 1995; Mecocci et al. 1994). In a similar 
manner, products of lipid peroxidation are increased in numerous regions of the AD 
brain, though most significantly in the hippocampus and pyriform cortex (Lovell et al. 
1995). Reviewing these and similar studies, Markesbury proposed the „Oxidative 
Stress Hypothesis‟ of AD in 1997 (Markesbury et al. 1997), which proposes that 
reactive oxygen species are a key mediator of AD pathology.   
Elevated markers of oxidative stress have been detected in the urine, plasma 
and CSF early in AD progression, during mild cognitive impairment (Pratico et al. 2002; 
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Migliore et al. 2005), in which antioxidant capacity is low (reviewed in Sompol et al. 
2008). Postmortem study of AD brains also indicates the accumulation of oxidative 
stress precedes the formation of amyloid plaques (Nunomura et al. 2001; Pratico et al. 
2001). It has since been shown that soluble oligomeric structures can induce the 
generation of ROS, presenting oxidative stress acts as a key mediator of A  toxicity.  
 
1.12.1.1 A -evoked oxidative stress  
In agreement with the amyloid hypothesis of AD, numerous lines of evidence 
indicate A  generates oxidative stress when applied to cells in vitro, including 
attenuation of toxicity by exogenous antioxidants, stimulation of ROS-specific dyes and 
detection of oxidative endpoints (Cardoso et al. 2003; Melo et al. 2003). Oxidative 
stress has also been implicated in A -induced neurotoxicity in vivo. 
Intracerebroventricular injection of A 1-42 to rats is reported to elevate levels of protein 
and lipid oxidation products, coupled with enhanced activities of endogenous 
antioxidant enzymes in the hippocampus and cerebral cortex (Pratico et al. 2008). 
Furthermore, memory deficits induced in rats by administration of A 1-42 were 
significantly reduced with subsequent, chronic administration of -tocopherol (vitamin 
E), suggesting antioxidant therapy may be efficacious following AD diagnosis. A range 
of antioxidants have been reported to protect neurons in vitro and in vivo against A  
toxicity, including peptides (Resende et al. 2008), enzymes (Tabner et al. 2002), lipids 
(Siedlak et al. 2009) and smaller molecules such as nicotine (section 1.13.5). 
Transgenic AD models treated with antioxidants also display reductions in oxidative 
stress, behavioural dysfunction, A  levels and A  deposition (Lim et al. 2001; Sung et 
al. 2003 Conte et al. 2004; Matsubara et al. 2003). Furthermore, epidemiological 
studies suggest that dietary intake of antioxidants also reduces the risk of AD (Morris et 
al. 2002). However, out of two clinical trials investigating vitamin E supplementation in 
AD patients, one only showed a positive effect, which was marginal (Pratico et al. 
2008). 
Elucidating the source of ROS generation following exposure of neurons to A  
is critical to understand the toxic mechanism of the peptide. Mass spectrometry and 
electron paramagnetic resonance spin-trapping evidence indicate that A  peptides in 
aqueous solution can form free radical peptides (Hensley et al. 1994). Furthermore, 
when incubated in solution at 37 C, A 1-40 and A 1-42 spontaneously evoke hydrogen 
peroxide (Huang et al. 1999; Bush et al. 2000). Interestingly, Hensley et al showed that 
A 25-35 undergoes rapid radicalization, whereas A 1-40 has a lag-time period, mirroring 
the neurotoxicity (Pike et al. 1993; section 1.10.3) and oligomerisation kinetics (section 
7.2.1) of these peptides. Importantly, the time taken for A 25-35 to evoke a toxic 
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response in hippocampal neurons in culture was found to be within the time frame for 
the generation of ROS. Differential toxic responses evoked by Aβ1-42 and A 25-35 are 
demonstrated in chapter 4. 
 
1.12.1.2 Nicotine is an antioxidant  
Nicotine has been shown to possess free radical-scavenging characteristics in 
vitro, which may reduce oxidative stress generated by A  (Linert et al. 1999; Ferger et 
al. 1998; Moore et al. 2004). Interestingly, ROS are proposed to be pro-fibrillogenic 
(Tabner et al. 2005), so removal of ROS may explain the antifibrillogenic activity of 
nicotine and other antioxidants, such as curcumin (Yang et al. 2005; discussed further 
in section 7.4.2). In addition, nicotine is reported to inhibit complex I of the electron 
transport chain, with a consequent reduction in the levels of reactive oxygen species 
(Cormier et al. 2001, 2003; Newman et al. 2002). Accordingly, application of nicotine to 
SHSY-5Y cells was found to decrease spontaneous ROS generation in mitochondria in 
the presence of the nAChR antagonist mecamylamine (MEC; Xie et al. 2005). Though 
this suggests a nAChR-independent mechanism, activation of nAChR has also been 
shown to prevent the production of reactive oxygen species in microglia when 
stimulated with fibrillar Aβ1-42 (Moon et al. 2008). 
 
1.12.2 Process of cell death in AD 
Morphological and biochemical endpoints are commonly assessed to classify 
cell death as apoptotic (also referred to as programmed cell death) or necrotic (fig 
1.12). Both of which are assessed in parallel in the current study, in order to achieve a 
more-complete understanding of the cellular responses to A  and nicotinic ligands.  
Programmed cell death, by definition, is a controlled event, offering the potential 
for intervention, whereas necrosis is a more stochastic process. For this reason, 
interest has focussed on apoptotic, rather than necrotic cell death in AD. A variety of 
histopathological studies employing the TUNEL technique have detected increased 
DNA-fragmentation, an indicator of apoptosis, in tissue sections of the brain of AD 
patients, in comparison with age-matched controls (Su et al. 1994; Smale et al. 1995; 
Cotman et al. 1995; Troncoso et al. 1996). In some studies, the TUNEL-labelled nuclei 
were also characterised by shrunken cell morphology and apoptotic bodies (Su et al. 
1994; Cotman and Anderson 1995), though other studies could find no such 
morphological features (Lassmann et al. 1995; Troncoso et al. 1996). Indeed, some 
studies report a complete lack of apoptotic morphology in AD tissue and only observed 
necrotic markers (Lucassen et al. 1997; Stadelmann et al. 1998). Although numerous 
cells exhibited DNA fragmentation eg in the AD hippocampus, these reports indicated 
only a small portion of cells display morphological features of apoptosis. Despite these 
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studies, numerous subsequent reports support a role of apoptosis in both the 
neurodegeneration mechanism in AD and the toxicological mechanism of A . Key 
studies have shown that inhibitors of protein synthesis, operating at both transcriptional 
and translational levels can prevent in vitro neurotoxicity of A 25-35 (Virmani et al. 2001) 
and A 1-42 (Zheng et al. 2002), suggesting the process of cell death is an active, rather 
than a passive, cellular process. Although these peptides are reported to evoke 
morphological and biochemical characteristics of apoptosis in cortical and hippocampal 
cultures (Loo et al. 1993), other reports have detected no such changes, instead 
observing rapid disintegration of mitochondrial and plasma membranes, indicating a 
necrotic mechanism of cell death (Behl et al. 1994a). As some primary cell culture 
systems possess an inherent high rate of spontaneous apoptosis, Behl corroborated 
the findings using a cell line.   
 
 
 
 
 
 
 
 
 
 
 
 
 
It is increasingly recognised that apoptosis and necrosis are not mutually 
exclusive in cellular populations or indeed, individual cells. Agents that induce 
apoptosis at low doses can cause necrosis at higher doses (McConkey et al. 1989; 
Lennon et al. 1991; Kunimoto et al. 1994) and longer exposures (Ankarcrona et al. 
1995). This picture is further complicated by studies indicating apoptosis and necrosis 
are not disparate mechanisms, but may represent polar extremes on a spectrum of 
toxicological characteristics (Fietta et al. 2006). Thus, A -evoked necrosis in vulnerable 
neurons may evoke apoptosis in neighbouring cells. During the chronic exposure of A  
that is required for A  to induce neurotoxicity, the ratio of necrotic- to apoptotic-markers 
will vary from one timepoint to another, which may account for conflicting reports.   
Attention has focused on apoptosis because its inhibition is more tractable as a 
potential therapy; mediators of apoptosis have been assessed in post mortem tissue 
Fig 1.12 Typical cellular responses 
following induction of apoptosis and 
necrosis. Initiation and execution of 
apoptosis by caspase activity results in a 
series of biochemical and morphological 
changes occur over time, including of 
membrane asymmetry, cell shrinkage, 
nuclear fragmentation, chromatin 
condensation, and chromosomal DNA 
fragmentation. In contrast, necrosis 
involves the rupture of the plasma 
membrane and release of cellular 
contents, such as lactate dehydrogenase 
in (LDH) a caspase-independent manner. 
Both mechanisms involve a loss of redox 
potential in the cell. Changes in caspase 
activity, LDH release and redox potential 
following the application of Aβ peptides 
are assessed in chapters 4 and 6.   
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from AD patients, transgenic models and neuronal cultures treated with A . A variety of 
proteins have been implicated, including those specifically involved in the apoptotic 
machinery, such as caspases (fig 1.13, section 1.12.2.1), but also more promiscuous 
signalling proteins such as kinases and transcription factors (section 1.13.5.2.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.12.2.1 Caspase activity in AD  
A family of cysteine-aspartic acid proteases, the caspases, are implicated in the 
induction and execution of apoptosis (Hengartner et al. 2000). Compared to age-
matched controls, cortex and hippocampi from AD patients exhibit increased neuronal 
immunoreactivity of caspase-3, a key effector in the apoptotic mechanism (Masliah et 
al. 1998; Selznick et al. 1999), which co-distributes with DNA fragmentation (Masliah et 
al. 1998). Interestingly, enhanced casapse-3 reactivity was not associated with senile 
plaques or neurofibrillary tangles (Selznick et al. 1999). A similar pattern was also 
observed in transgenic mice expressing APPSwe; increased caspase-3 immunoreactivity 
was not associated with amyloid deposition (Selznick et al. 1999), in agreement with 
studies indicating that insoluble A  is relatively inactive (section 1.10.3.1).  
Supporting the possible therapeutic intervention of apoptosis, inhibition of 
caspases with short peptides can prevent A 1-42 neurotoxicity in vitro (Zhang et al. 
2002). Accordingly, neuronal cultures generated from caspase-12 knockout mice 
displayed reduced apoptosis following A 1-40 exposure (Nakagawa et al. 2000), though 
whether this simply forced degenerating neurons to follow an alternative process of 
cell-death was not addressed. Since these studies, monitoring apoptosis, and caspase 
activity in particular, has become common when assessing neuroprotective 
possibilities. The action of nicotinic- and VOCC-ligands on Aβ-induced caspase 
activation is assessed experimentally in the current study (sections 4.1 and 6.2). 
Fig 1.13 The apoptotic cascade can be 
induced in a Ca
2+
-dependent or -independent 
manner. Dysfunctional homeostasis of Ca
2+
 is 
well established in AD (section 5.1). The release 
of cytochrome C (Cyt C) from the mitochondria 
can be triggered by toxic insults or elevated 
Ca
2+
 levels spontaneously, or via protein kinase 
C δ (PKCδ). Cyt C interacts with and activate 
caspase 9 in a Bcl-2 senstive manner. Toxic 
insults and Ca
2+
 can also activate caspase  9 
via the activation of caspase  12, which in turn 
can also be activated by calpain in a Ca
2+
-
dependent manner. Caspase 9 intiates 
apoptosis via the activation of caspases 3 and 
7, the „effector caspases‟. Adapted from Matson 
et al. 2003, some steps are omitted.  
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1.12.3 Role of Membranes in A  Toxicity 
 The interaction of A  with cellular membranes has been implicated in several of 
its biological activites, including perturbation of ionic homeostasis and and toxicity. The 
mechanisms of this interaction and subsequent actions will therefore be discussed in 
more detail.  
 
1.12.3.1 A  interacts with Membranes 
Given the therapeutic desire to interrupt cytotoxic mechanisms as early as 
possible, numerous primary targets of A  have been reported. By virtue of its amino 
acid sequence, A  has an amphipathic character and is able to bind a variety of lipids 
in biological membranes (reviewed in Verdier et al. 2004). Interactions of A  with 
components of the plasma membrane and membranes of subcellular organelles have 
been described, including lipids, phospholipids and proteins. These interactions have 
been implicated in key facets of A  toxicity, including sites of A  oligomerisation, 
primary toxicological targets of the peptide and downstream effectors of the cellular 
response.  
A  can interact with membranes via its hydrophobic carboxy-terminal domain 
(Ambroggio et al. 2005; Bhatia et al. 2000) or via electrostatic interactions mediated by 
the charged amino acids in the amino-terminal domain (Lau et al. 2006). Both full-
length A  peptides and the A 25-35 fragment are reported to associate with lipid 
membranes (Muller et al. 1995; McLaurin et al. 1997; section 1.12.3.1), though 
discrepancies in membrane-insertion have been reported (Lau et al. 2007). The 
environment of the methionine at residue 35 of A  has been implicated in this 
discrepancy and is discussed further in section 7.2.1. Oxidising the sulphur atom of 
Met35 to a sulfoxide is reported to prevent A 25-35 penetrating lipid membranes 
(Barnham et al. 2003; Ciccotosto et al. 2004), which may explain a lack of toxicity 
reported by Varadarajan et al. (2001) and Varadarajan et al. (1999), though no such 
attenuation was observed by Barnham et al.. Conversely, increasing the hydrophobicity 
of Aβ25-35 by replacing Met35 with valine increased the binding affinity of the peptide 
two-fold with concomitant increase in vitro neurotoxicity (Ciccotosto et al. 2004). 
Accordingly, the human lymphoma cell line U937 (Mazziotti et al. 1998), which does 
not bind A 1-42, is resistant to A  cytotoxicity (Bateman et al. 2007). This suggests that 
a physical interaction between the peptide and the cell membrane is required to evoke 
toxicity in mammalian cells.   
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1.12.3.2 Membranes enhance A  oligomerisation      
Membranes not only increase the local concentration of A , but also induce 
unfolding of the peptide into a partially-folded conformation, distinctive from 
conformations present in solution, with an enhanced propensity to oligomerise (Bokvist 
et al. 2004; reviewed in Gorbenko et al. 2006). Thus, A -rich membranes may serve as 
a conformational catalyst or a chaperone, generating a conformational change in Aβ 
that favours nucleus seeding (Kakio et al. 2003). Supporting this hypothesis, binding of 
A  to gangliosides in membranes enhances peptide fibril formation (McLaurin et al. 
1996; Choo-Smith et al. 1997; Bokvist et al. 2004). It has been postulated that the 
hydrophobic interior of the plasma membrane favours structural changes of peptides, 
forming „molten‟ globule states that are considered to be the most likely fibrillogenic 
intermediates (Uversky and Fink, 2004).  
Several reports indicate that the process of amyloid fibrillation on a bilayer 
surface causes perturbation of the membrane (Jayasinghe & Langen 2007; Murphy, 
2007). Assessing the kinetics of membrane damage in parallel with fibrillogenesis of an 
amyloidogenic protein, Engel et al. (2008) reported a correlation between fluorescent 
probe release from artificial vesicles and the lag phase of fibril formation during which 
fibril nuclei form (section 1.10.2). However, molecular dynamics simulations indicate 
leakage from lipid vesicles is caused primarily by the growth of filaments associated 
with the elongation phase (Friedman et al. 2009). In contrast, mature fibrils were 
predicted not to damage the vesicle, in agreement with studies indicating amyloid fibrils 
are relatively innocuous (section 1.10.3.8).  
 
1.12.3.3 A  disrupts membrane function 
In addition to affecting the activity of Aβ, interaction with biological membranes 
can affect the physicochemical properties of the membrane, disrupting physiological 
functions, such as ion homeostasis and signal transduction. Application of full-length 
A  peptides are reported to increase the bulk of isolated synaptic plasma membranes 
(Mason et al. 1999), as well as lysosomal, endosomal and golgi membranes (Waschuk 
et al. 2001), indicating a physical interaction between the lipids and Aβ. This was 
coupled with decreased fluidity of the fatty acyl and head groups of the lysosomal and 
endosomal membranes, consistent with Aβ insertion into the bilayer (Waschuk et al. 
2001), which is supported by data from SHSY-5Y cell membranes (Small et al. 2005). 
In contrast, A -exposure is reported to increase fluidity of the golgi membrane 
(Waschuk et al. 2001) and liposomes (Small et al. 2005), suggesting the activity of Aβ 
may be determined by membrane composition, providing a possible explanation for 
conflicting reports of Aβ activity in different biological systems. A similar increase in 
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membrane fluidity has also been observed in synaptic plasma membranes following 
application of both soluble and aggregated Aβ1–40 (Mason et al. 1999) and the size of 
the A  aggregate positively correlated with the increase in fluidity (Kremer et al. 2000).  
Sphingolipid- and cholesterol-rich bilayer domains, termed lipid rafts (Simons et 
al. 2004) have been found to be enriched in A  peptides (Riddell et al. 2001; Wahrle et 
al. 2002; Lee et al. 1998), possibly due to the high affinity of Aβ for cholesterol (Kakio 
et al. 2002). A  is concentrated in lipid rafts from 6 month old Tg2576 mice, in a form 
that corresponded almost exclusively to dimeric bands on SDS-PAGE gels, which 
increased over 500-fold within 24 months (Shoji et al. 2004). In addition to encouraging 
Aβ oligomerisation (section 1.12.3.2), accumulation of A  at lipid rafts is reported to 
initiate several processes that can ultimately lead to perturbation of the membrane. 
ROS generated by Aβ would be concentrated at these sites, causing focal points of 
lipid peroxidation, which is reported to alter membrane order (Rego and Oliveria 1995) 
and permeability (Butterfield & Hensley, 1994). Monitoring the anisotropy of a 
fluorescent probe, Melo et al. (2003) reported an increase in cell membrane fluidity in 
the presence of A 25-35. This was inhibited by the -tocopherol, supporting the role of 
oxidative stress and lipid peroxidation (section 1.12.1).  
Arispe et al. (1993) first showed that addition of Aβ peptides to artificial planar 
lipid bilayers evokes an increase in monovalent and divalent cation flux across the 
bilayer. Since this study, a number of groups have demonstrated an increase in ion 
permeability of membranes by Aβ (Arispe et al. 1996; Kawahara et al. 2000; Kawahara 
et al. 2000; Lin et al. 1997; Mirzabekov et al. 1994). The mechanism underpinning the 
increase in permeability is currently the subject of conflicting hypotheses. Arispe et al. 
(1993) postulated that annular Aβ oligomers form artificial cation channels traversing 
the membrane. Subsequent work has identified such channels in artificial and 
biological membranes, including neuronal plasma membranes (Kawahara et al. 2000; 
Zhu et al. 2000). Others, however, have failed to detect such pores (detailed below). 
Fluorescent dyes such as fluo-3, which undergo a change in emission spectra 
upon binding Ca2+ (Minta et al. 1989), have been invaluable in assessing changes in 
intracellular Ca2+ levels and are employed in the current study. Application of 
oligomeric, but not monomeric or fibrillar, A 1-42 to fluo-3-loaded SHSY-5Y cells 
elevated levels of intracellular Ca2+, which persisted after depletion of intracellular Ca2+ 
stores (Demuro et al. 2005). Small increases were also evident when A 1-42 was 
applied in Ca2+-free medium, indicating contributions from both extracellular and 
intracellular Ca2+ sources. This study indicated that the rise in intracellular Ca2+ was not 
due to activation of endogenous Ca2+ channels, as responses were unaffected by the 
potent Ca2+-channel blocker cobalt, in disagreement with other reports (section 5.1.2). 
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Indeed, the rapid cellular leakage of anionic fluorescent dyes suggests a generalised 
increase in membrane permeability.  
Perturbation of membrane integrity by protein aggregates is not limited to A . 
An increase in artificial membrane conductance evoked by oligomers, but not fibrils or 
monomers, has been demonstrated with a number of other amyloidogenic proteins 
(Kayed et al. 2004). This occurred in the absence of discrete channel or pore formation 
or ion selectivity. The conductance was also dependent on the concentration of 
oligomers and was reversed by an anti-oligomer antibody. In agreement, Sokolov et al. 
(2006) reported A  oligomers, but not fibrils or monomers increased the conductance 
of lipid bilayers and patch-clamped mammalian cells. By assessing the compressibility 
of the membranes, the authors concluded that A  oligomers increase the area per 
molecule of the membrane-forming lipids, thus thinning the membrane, lowering the 
dielectric barrier and increasing ion-conductance. 
In addition to interacting with the lipid component of lipid bilayers, Aβ is reported 
interact with a number of proteins in biological membranes (reviewed in Small 2001). 
Of importance to the current study, disruption of Ca2+ homeostasis by Aβ can also 
occur via the modulation of endogenous membrane channels and Ca2+-efflux pumps 
(Berrocal et al. 2009), including channels stimulated by membrane potential (see 
Verdier et al. 2004 for review; section 5.1.2.1) and ligand-gated ion channels. Given the 
disruption of Ca2+ homeostasis in AD, two channels permeable to Ca2+, which have 
been implicated in AD, will be discussed in more detail, VOCC (section 5.1.2.1) and 
nAChR (section 1.13). 
 
1.13 Nicotinic acetylcholine receptors 
Nicotinic acetylcholine receptors (nAChR) are of interest to AD because of their 
positive contribution to cognitive processes and their marked decline in post-mortem 
tissue from AD patients. nAChR are ligand gated ion channels consisting of five 
subunits arranged around a central, cation-selective channel, which opens upon the 
binding of an agonist, allowing influx of Ca2+ and Na+, coupled to efflux of K+. Mammals 
have 16 nAChR subunit-encoding genes (fig 1.14a), five of which function at the 
neuromuscular junction while the remaining subunits are expressed exclusively in the 
CNS. Though these subunits are termed „neuronal‟, it should be noted that expression 
on non-neuronal cells in the CNS has also been detected (reviewed in Sharma et al. 
2002). Neuronal subunits are divided into two groups, defined by the presence ( -
subunits) or absence ( -subunits) of a pair of adjacent cysteine residues in the 
extracellular N-terminal domain, where they contribute to a loop involved in agonist 
binding (reviewed in Changeux et al. 2008). Neuronal nAChR can be composed of (2-
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10) and (2-4) subunits (Dani and Bertrand 2007), leading to a diversity of receptor 
subtypes (Lindstrom et al. 2003). Of these subunits, the 7 subunit is unique, as it 
forms homomeric channels, while nAChR composed of the other subunits are 
heteromeric (fig 1.14b).  
Subtypes of nAChR can be distinguished by their differing affinities for ligands. 
To this end, selective agonist, antagonists and modulators have been employed to 
identify subtypes responsible for nicotinic activities. The subtypes also differ in their 
expression profiles, channel characteristics, Ca2+ permeability and tendency to 
desensitise (Gotti et al. 2007 for review). Furthermore, nAChR subtypes can modulate 
distinct signalling cascades (section 1.13.5.2.1), which may result from discrete cellular 
distribution (Dajas-Bailador & Wonnacott 2004; Dickinson et al. 2007; Dickinson et al. 
2008). 
In comparison with other ligand-gated ion channels, gene expression of the 
neuronal nAChR is generally low in the brain and expression can vary across brain 
regions and during development. The family of α4β2* (* denotes the subtype can 
contain additional subunits, eg α4α6β3β2; Azam et al. 2002) nAChR are the most 
abundant in the mammalian brain (reviewed in Leonard et al. 2001). Other nAChR 
subunits are also expressed at relatively high levels, though with a more specific 
expression profile. For example, the α3 subunit is expressed at high levels in the 
thalamus, but low levels in the hippocampus, where the β2 and α7 subunits are 
expressed at high levels (Rubboli et al. 1994; discussed further in section 6.1.2). The 
subcellular pattern of nAChR distribution indicates receptors are expressed at 
postsynaptic, presynaptic or even axonic areas (Wonnacott et al. 1990), where they 
have been implicated in several physiological functions.  
The relationship between nAChR and cognition is well established. Several 
drugs that selectively activate nAChR have cognition-enhancing effects (section 
1.13.1), while diseases associated with dysfunctional cognition are also found to have 
altered nAChR function (section 1.13.2). Furthermore, nicotine is reported to induce 
and enhance different forms of hippocampal long term potentiation (LTP), a widely 
accepted model of synaptic plasticity that is thought to underlie learning and memory 
processes (reviewed in Kenney et al. 2008). One possible mechanism that nicotine 
may do this by modulating neurotransmitter release, as Ca2+ influx through presynaptic 
nAChR increases the probability of neurotransmitter release. Indeed, the role that 
neuronal nAChRs play in controlling release of many different neurotransmitters is well-
established (Guo et al., 1998; Lena & Changeux, 1997; McGehee & Role, 1995; 
Pidoplichko et al. 1997; Wonnacott, 1997; discussed further in section 5.3.7). Ca2+ 
influx is also involved in the modulation of signalling cascades by nAChR that are 
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implicated in cellular survival (section 1.13.5.2.1). Thus, nicotine is proposed to provide 
both palliative and protective benefits for AD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.14 (A) mammals possess 16 nAChR genes. The most abundant nAChR subtypes 
expressed in the brain consist of 7, 4 2, and 3 4. (B) The 7 subunits form homomeric 
nAChRs, whereas 4 2 and 3 4 form heteromeric receptors. Adapted from Buckingham et al. 
2009. 
 
1.13.1 nAChR-loss in AD 
A disruption in the balance of cholinergic signalling has been implicated AD 
(section 1.3.4). Reduced levels of nAChR has been reported in AD, schizophrenia, 
Parkinson‟s disease and dementia (Picciotto and Zoli, 2002; Lindstrom, 1997), while 
over-activation can also be detrimental, causing epilepsy (Damaj et al. 1999) and cell 
death (Abrous et al. 2002; Orb et al. 2004; Labarca et al. 2001; Orr-Urtreger et al. 
2000). A loss of nAChRs during normal aging is particularly apparent in the cortex and 
hippocampus (Perry et al. 2000; Graham et al. 2002). However, this loss is 
substantially greater in neurodegenerative disorders, including AD (section 1.3.3).   
Postmortem analyses have identified a significant reduction in α4, but not α7 or 
α3, subunit immunoreactivity in the AD brain (Martin-Ruiz et al. 1999), which explains a 
loss of high high-affinity agonist binding in the cortex (Sugaya et al. 1990; Graham et 
al. 2002). However, a greater loss of α7 subunits has been detected in the midtemporal 
gyrus, but not in the frontal cortex or hippocampus, of the AD brain (Davies and 
Feisullin 1981; Sugaya et al. 1990; Warpman and Nordberg 1995), though a loss of α7 
in the hippocampus was detected by Guan et al. (2000). The association α7 nAChR 
with amyloid plaques is discussed in section 5.1.2.  
 The loss of nAChR does not appear to result from modulation of transcription, 
as levels of mRNA for α3 and α4 subunits are reported to be similar in AD brain and 
age-matched controls (Hellstrom-Lindahl et al. 1999; Terzano et al. 1998). In fact, an 
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increase in the level of α7 mRNA has been reported (Hellstrom-Lindahl et al. 1999), 
which agrees with reports that Aβ can increase α7 nAChR expression (section 5.1.2.2).  
 
1.13.1.1 Smoking and AD 
Because of the cholinergic hypothesis and the changes in nAChR, in particular, 
in AD brains, the possibility that nicotine from tobacco consumption influences the 
development or progression of AD has been explored in epidemiological studies. 
Though smoking tobacco is well-established to protect against Parkinson‟s disease 
(Morens 1994), the effect on AD is less clear. A number of epidemiological studies 
exploring correlations between smoking tobacco and AD have produced conflicting 
results. In a thorough meta-analysis, Almeida et al. (2002) concluded that decreased 
risk for developing AD in smokers was generally reported by case- but not cohort-
controlled studies. A possible reason for this disparity is bias in case-controlled studies, 
such as differential mortality. For example, the increased rate of mortality of demented 
compared with non-demented subjects (Wang et al. 1999), would lead to under-
representation of demented smokers (Kukull et al. 2001, Letenneur et al. 2004). Other 
meta-analyses have since been published supporting the findings of Almeida et al. 
(Juan et al. 2004; Ott et al. 2004; Sabbagh et al. 2005; Tyas et al. 2003). Furthermore, 
several of these studies actually indicate that smoking can increase the risk of 
developing AD (Ott et al. 2004; Juan et al. 2004; Tyas et al. 2003).  
 
1.13.2 nAChR are involved in memory function 
In human studies, nicotine is reported to improve acquisition and retention of 
verbal and visual information and decrease errors in cognitive tasks, as well as improve 
accuracy and response time (Newhouse et al. 2001) and improve learning and memory 
(Warburton et al. 1986). Other studies, however, have reported no improvement in 
memory following nicotine administration (Dunne et al. 1986; Newhouse et al. 1988; 
Parrott et al. 1989). The role of nAChR activity in cognitive performance has been 
assessed by various behavioural tests in rats, monkeys and humans, and effects on 
specific aspects of cognition have been reported, including attention, learning, sensory 
perception, memory consolidation and arousal (Levin and Simon, 1998). Acute and 
chronic nicotine administration has been shown to improve memory performance and 
cognition in non-human primates and rodents, which can persist even after 
discontinuation (Levin et al. 1996a, Levin et al. 1997, Gould and Stephen, 2003; 
Buccafusco et al. 2005). Accordingly, blockade of nAChR with antagonists impairs 
memory function (Levin et al. 1992; Levin and Rezvani, 2000).  More than one nicotinic 
receptor subtype seems to be involved in cognitive function and subtype-selective 
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drugs have been developed, aiming to provide cognitive improvement with fewer side 
effects. 
 
1.13.3 Both 7 and non- 7 nAChR are involved memory function  
Homomeric 7 nAChR are expressed early in development, where they have 
been implicated in the control of neurite outgrowth, and in synaptic remodelling in the 
adult nervous system (Pugh and Berg 2004). A high density of 7 has been found in 
the hippocampus, concordant with a role of 7 nAChR in modulation of synaptic 
plasticity and memory formation (Small et al. 2001; Mudo et al. 2007). Accordingly, 7-
selective agonists are reported to enhance a variety of cognitive behaviors in mice, 
monkeys, rats and rabbits (Meyer et al. 1994; Arendash et al. 1995; Meyer et al. 1997; 
Levin et al. 2002; Kem et al. 2001; Li et al. 2008; Buccafusco et al. 2007). Activation of 
7 nAChR is reported to facilitate LTP induction in the rat hippocampus (Hunter et al. 
1994; Matsuyama et al. 2003). Accordingly, blockade of 7 with the α7 nAChR-
selective antagonist methyllycaconitine (MLA) reduces memory performance in rodents 
(Felix  et al. 1991; Bancroft et al. 2000; Felix et al. 1997; Bettany et al. 2001), while 
nicotine enhancement of hippocampal LTP was absent in 7 nAChR-null mice (Welsby 
et al. 2007). 
The role of nAChR in memory is not limited to the 7 subtype. Learning and 
memory performance in a variety of experimental animal studies has been enhanced 
by synthetic 4 2-selective agonists (Arneric et al. 1994; Buccafusco et al. 1995; 
Decker et al. 1994; Vernier et al. 1999; Lippiello et al. 2006; Christopher et al. 2002; 
Decker et al. 1997), which are also reported to enhance spatial learning and memory in 
humans (Potter  et al. 1999; Wilens et al. 2006). In addition to demonstrating an 
increase in memory performance with agonists of 4 2 nAChR, blockade of this 
subtype also disrupts memory performance (Bancroft et al. 2000; Felix  et al. 1991; 
Felix et al. 1997; Levin et al. 2002; Kim and Levin 1996). Interestingly, chronic systemic 
nicotine administration is reported to overcome the cognitive deficit evoked by the β2* 
nAChR-selective antagonist dihydro-β-erythoidine (DH E; Bancroft and Levin 2000), 
but not MLA (Bettany and Levin 2001), suggesting 7 nAChR may be more involved in 
nicotine-enhanced working memory performance than 4 2 subtype. The loss of 
nAChR in the brain may therefore explain the specific deficit in memory function that is 
evident early in the progression of AD.   
 
1.13.4 Nicotine and AD  
Improved attention in AD patients has been demonstrated after a single 
subcutaneous dose of nicotine or a chronic, up to 4-week administration via 
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transdermal patch (Jones et al. 1992; Sahakian et al. 1989; White and Levin, 1999; 
Wilson et al. 1995). Supporting the therapeutic potential of nicotine in AD, a reduction 
in A 1-40 and A 1-42 levels has been observed in the brains of smoking controls and AD 
patients (Hellström-Lindahl et al. 2004b). In agreement, decreased density of A  
immunoreactivity in the entorhinal cortex, coupled with a decrease in extractable A 1-42, 
but not A 1-40, was reported for brains from elderly smokers compared with age-
matched non-smokers (Court et al. 2005). Accordingly, Tg2576 mice chronically 
treated with nicotine exhibited reduced plaque-load and decreased levels of insoluble 
A 1-40 and A 1-42 (Nordberg et al. 2002), though soluble A  levels were unaffected 
(Nordberg et al. 2002; Oddo et al. 2005). However, Liu et al. (2007) reported a 
reduction in A 1-42-positive plaques and insoluble Aβ and soluble A 1-40 and A 1-42 in 
the cortex and hippocampus of APPIndiana mice. 
Chronic nicotine treatment is also reported to prevent numerous in vivo 
responses to A , including impaired memory performance in rats treated with A 1-40, 
A 1-42 (Srivareerat et al. 2009) and A 25-35 (Hiramatsu et al. 2004), impaired LTP in rats 
treated with A 1-40 and A  1-42 (Srivareerat et al. 2009; Welsby et al. 2007), impaired 
short-term memory in a transgenic model expressing APPSwe (Shim et al. 2008) and 
apoptosis in a transgenic model expressing APPLon (Liu  et al. 2007). It is possible that 
stimulation of nAChR may not specifically target pathological mechanisms induced by 
Aβ, but instead act on general physiological functions, which restore function, as 
nicotine has been shown to also block stress-induced impairment of spatial memory 
and LTP (Aleisa et al. 2006a and b).  
 
1.13.5 Nicotine neuroprotection 
Nicotine protection against cytotoxic responses induced by various insults, 
including exposure to A , has been well-established in a range of models. Several 
actions of nicotine have been implicated nicotine protection, including inhibition of A  
oligomerisation (section 1.11.4.1), ROS scavenging (section 1.13.5) and stimulation of 
nAChRs. Identifying the receptor subtypes responsible for nAChR-mediated 
neuroprotection is a key goal, as subtype-selective drugs have fewer non-specific 
interactions, producing reduced side effects. For example, the 7 nAChR-selective 
agonist DMXB is much less toxic than nicotine and does not affect autonomic and 
skeletal muscle systems at doses that enhance cognitive behavior (Kem et al. 2001).  
 
1.13.5.1 nAChR neuroprotection 
 A seminal study reported attenuation of Aβ25-35-induced reduction in 
hippocampal neuron viability in vitro by nicotine in a dose-dependent manner (Zamani 
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et al. 1997). The protective action of nicotine was blocked by the broad-range nAChR 
antagonist MEC, implicating nAChR. In the same year, in vitro protection by nicotine 
against Aβ25-35-induced toxic responses in cortical neurons was also reported (Kihara et 
al. 1997; Kihara et al. 2001). In agreement with Zamani et al., protection was inhibited 
by MEC and another broad-range nAChR antagonist, hexamethonium, but not the 
muscarinic acetylcholine receptor antagonist atropine. Subsequent reports have 
corroborated the protective action of nicotine, reporting reduction of various toxic 
responses evoked by A 1-42, in several in vitro systems (discussed further in section 
7.3). However, the extent of protection often varies between reports, with some 
indicating a complete prevention of Aβ toxicity and others demonstrating only partial 
inhibition. Although fewer in number, there are also studies that report a total lack of 
nicotine protection against toxic responses evoked by Aβ (Cardoso et al. 2001; Li et al. 
2003; discussed further in section 7.3).  
 
1.13.5.1.1 7 nAChR-mediated protection  
In addition to blocking nicotine protection with broad-range nAChR antagonists, 
Kihara et al. (1997) also observed a block with the 7 nAChR-selective antagonist 
bgt, indicating a contribution from the 7 subtype. Accordingly, the allegedly- 7 
nAChR-selective agonist DMXB inhibited toxicity in a similar manner to nicotine and 
has also been shown to attenuate A 25-35-evoked decreases in SHSY-5Y cell viability 
(Qi et al. 2007). Subsequent in vitro studies have confirmed the involvement of 
α7nAChR in nicotine protection against A  toxicity. Other α7 nAChR-selective agonists 
are reported to protect against synaptotoxicity in neuronal cultures (Hu et al. 2007; 
chapter 6), while nicotine protection has been blocked by other 7 nAChR-selective 
antagonists, such as MLA (Kihara et al. 2004; Arias et al. 2005). Intriguingly, 
application of nAChR antagonists alone has also been reported to protect neurons 
against A  toxicity. MLA is reported to partially protect against Aβ1-42-induced reduction 
in cell viability in mouse cortical cultures (Martin et al. 2004) and attenuate Aβ1-42 
reduction in neurite outgrowth in cortical cultures (Hu et al. 2007; discussed further in 
section 6.1.2). However, other studies have shown a lack of protection by nAChR 
antagonists (Zamani et al. 1997). 
7 nAChR have been further implicated in nAChR-mediated protection against 
A  toxicity by studies employing galantamine (section 1.3.4), which improves cognitive 
functional and behavioural symptoms in patients with AD (Maelicke et al. 2001) and 
protects neurons in vitro against A  toxicity (reviewed in Geerts, 2005). Though the 
primary mechanism by which galatamine acts in AD was originally believed to be via its 
action as an AChEi, it has been also been shown to inhibit A  oligomerisation (Matharu 
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et al. 2009), prevent oxidative stress (Melo et al. 2009) and interact with all nAChR as 
an allosteric potentiator (Coyle et al. 2007). Prevention of in vitro A  toxicity by 
galantamine, tacrine and donezepil, but not rivastigmine, has been prevented by MEC, 
tubocurarine and MLA, suggesting actions independent of AChEi activity mediate 
neuroprotection (Kihara et al. 2004; Arias et al. 2005).  
 
1.13.5.1.2 Non- 7 nAChR mediated protection  
The most abundant nAChR subtype in the mammalian brain, 4 2, has also 
been implicated in nicotine neuroprotection against A . Similar to evidence implicating 
7 nAChR, the in vitro data is more abundant than that produced in vivo. Kihara et al. 
(1998) demonstrated protection with cytisine, which selectively interacts with 4 2 
nAChR at nanomolar concentrations (Marks et al. 1996; Eaton et al. 2003). However, 
the micromolar concentrations employed by Kihara et al. are also likely to stimulate 7 
nAChR (Peng et al. 1994; Chavez-Noriega et al. 1997). More convincing data 
indicating involvement of non-α7 nAChR arises from selective antagonism of nicotine 
protection. In cortical cultures, Shimohama et al. (2001) demonstrated an inhibition of 
in nicotine protection against A 25-35 toxicity by DHβE, which has subsequently been 
corroborated (Gahring et al. 2003). In disagreement with the studies discussed in 
section 1.13.5.1.1, Gahring et al. observed no inhibition of nicotine protection by MLA, 
in disagreement with Kihara et al. (2000) and Arias et al. 2005). Interestingly, MLA did 
prevent nicotine neuroprotection against toxic responses induced by N-methyl-D-
aspartate (NMDA), which were not sensitive to DH E. This suggests that the 
mechanism of protection is dependent on nAChR subtype, concordant with distinct 
signalling systems (section 1.13.5.2.1).  
The generation of α7 nAChR null mice has also facilitated the implication of 
non-α7 nAChR in nicotine neuroprotection. Gahring et al. (2003) also demonstrated a 
loss of nicotine protection against toxicity evoked by NMDA, but not Aβ25-35, in neurons 
cultured from transgenic mice expressing a dominant negative form of α7 nAChR, 
suggesting functional 7 nAChR are not required for nicotine-mediated neuroprotection 
(Gahring et al. 2003). This highlights significant discrepancies in reports of Aβ-
mediated protection against Aβ toxicity.  
 
1.13.5.2 Mechanism of nAChR neuroprotection 
In vitro, the homomeric 7 nAChR has been implicated in neuroprotection 
against a range of toxic insults, including A  (Kihara et al. 1999, 2001; Shaw et al. 
2002) and other toxic fragments of APP (Svensson et al. 1998; Seo et al. 2001; Pettit 
et al. 2001), hypoxia (Tohgi et al. 2000; Hejmadi et al. 2003), ethanol (Li et al. 1999; de 
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Fibre et al. 2003), arachadonic acid (Garrido et al. 2000), glucose and oxygen 
deprivation (Rosa et al. 2006; Egea et al. 2007), serum deprivation (Li et al. 1999; 
Jonnala et al. 2001) and lesions that deplete ACh (Ren et al. 2007; Casamenti et al. 
1986) suggesting 7 nAChR operate in a general pro-survival mechanism. 
Furthermore, this mechanism may not be restricted to neurons or neuron-like cell lines 
as hepatic vagus nerve activity has been shown to protect hepatocytes from Fas-
induced apoptosis via activation of 7 nAChRs (Hiramoto et al. 2008). Elucidating the 
signalling systems operating downstream of nAChR may reveal novel therapeutic 
targets and provide insight into AD etiology. Several functions of nAChR have been 
implicated in neuroprotection, including Ca2+ flux, desensitization, upregulation and 
modulation of signalling cascades.  
 
1.13.5.2.1 nAChR activities implicated in neuroprotection: 1) Ca2+ flux  
Activation of nAChR causes influx of Na+ and Ca2+ directly though the intrinsic 
ion-channel of the receptor, which can consequently activate other Ca2+ channels, 
depending on which nAChR subtype is initially activated (fig 1.15). Membrane 
depolarisation following activation of 4 2 nAChR has been reported to stimulate 
VOCC in a variety of systems (Rathouz et al. 1994; Dajas-Bailador et al. 2002; 
Dickinson et al. 2007; Dickinson et al. 2008). The role of VOCC in A  toxicity is 
discussed further in sections 4.3 and 6.3. The effect of acute application of Aβ on Ca2+ 
signalling mediated by nAChR and VOCC is investigated in chapter 5.  
Calcium-induced calcium-release, mediated by receptors sensitive to inositol 
trisphosphate and ryanodine, can also be stimulated by activation of neuronal nAChR 
(Tsuneki et al. 2000; Sharma and Vijayaraghavan 2003; Dajas-Bailador et al. 2002; 
Gueorguiev et al. 2004). In particular, 7 nAChR activity is coupled to ryanodine-
sensitive Ca2+ stores (Dajas-Bailador et al. 2002; Dickinson et al. 2007; Dickinson et al. 
2008) and this interaction is reported to be involved in neuroprotection mediated by α7 
nAChR. Chelation of intracellular Ca2+ is reported to prevent protection by 7 nAChR 
activation against serum factor withdrawal (Ren et al. 2005) and NMDA-induced 
excitotoxicity (Dajas-Bailador et al. 2000). Furthermore, selective inhibition of inositol 
trisphosphate and ryanodine receptors has also been reported to prevent 
neuroprotection by the α7 nAChR agonist GTS-21 in vitro (Stevens et al. 2003; Ren et 
al. 2005).   
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Fig 1.15 Several routes of Ca
2+
 flux have been identified following nAChR stimulation. 
Opening of the nAChR channel allows ion flux across the membrane. This depolarisation 
stimulates the opening of VOCC, causing further influx of Ca
2+
. Activation of α7 nAChR is 
coupled to Ca
2+
-induced Ca
2+
-release from intracellular stores, such as the endoplasmic 
reticulum (ER), mediated by ryanodine receptors (RyR) and ins(1,4,5)P3 receptors (IP3R).  
Ins(1,4,5)P3 might be generated by Ca
2+
-dependent activation of phospholipase C (PLC). 
Adapted from Dajas-Bailador et al. 2004.  
 
1.13.5.2.2 nAChR activities implicated in neuroprotection: 2) desensitization and 
upregulation  
In vitro protection against A  by nAChR antagonists (section 1.13.5.1.1) raises 
the possibility that neuroprotection by 7 ligands may act through receptor 
desensitization rather than activation (fig 1.16). Of the nAChR subtypes assessed, the 
α7 subtype has the highest propensity to desensitise (Fenster et al. 1997), though this 
subtype also recovers relatively quickly. Micromolar concentrations of nicotine, which 
are unrealistic in vivo, are frequently required for neuroprotection, are likely to 
completely desensitise 7 nAChR, suggesting neuroprotection may be achieved by 
maintaining the receptor in its desensitised state. Furthermore, induction of 
desensitization by chronic nicotine treatment may be important for learning and 
memory (Lindstrom et al. 1987). 
Desensitization of nAChR will inhibit prolonged excitation induced by excessive 
opening of the channel. In addition to being prone to desensitise, the α7 subtype 
exhibit the highest permeability to Ca2+, equating to that of NMDAR, which are heavily 
implicated in glutamate excitotoxicity (Olney et al. 1987). Accordingly, mutation at the 
position leucine 247 of the α7 subunit significantly inhibits desensitization. Mice 
homozygous for this mutation exhibit increased neuronal apoptosis and die within 
hours after birth (Broide et al. 2000), suggesting desensitization is part of the normal 
function of nAChR in neuron survival.  
 
EC 
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Fig 1.16 Upon agonist binding, nAChRs undergo a conformational transition from the resting, 
closed state to an open state. Under normal physiological conditions, this allows influx of Na
+
 
and Ca
2+
, and efflux of K
+
. Despite continued presence of the agonist, the channel 
spontaneously closes, within seconds to minutes depending on the subtype, into a desensitised 
state (Reviewed in Giniatullin et al. 2005) 
 
Galatamine is reported to slow the rate of nAChR recovery from desensitization 
(Fayuk et al. 2004), while chronic donepezil exposure, in addition to protecting cultured 
rat cortical neurons, increased the number of 4* and 7 nAChR (Kume et al. 2005). 
Upregulation of nAChR may not just be limited to protection against A  toxicity; the 
effectiveness of various chronically-applied nicotinic ligands to protect PC12 cells from 
serum-deprivation correlates well with their ability to upregulate 7 nAChR (Jonnala 
and Buccafusco, 2001). Paradoxically, however, Aβ has also been reported to 
upregulate α7 nAChR (section 1.5.2.2). 
 
1.13.5.2.3 nAChR activities implicated in neuroprotection: 3) activation of 
signalling cascades 
The regulation of diverse neuronal functions by nAChR is mediated by specific 
signalling cascades (fig 1.17). The activation of cAMP response element binding 
protein (CREB) following nAChR activation in an extracellular signal-regulated protein 
kinase (ERK)-dependent manner has been reported in PC12 cells (Nakayama et al. 
2001; Nakayama et al. 2006) and in vivo (Brunzell et al. 2003). The role that this 
signalling cascade plays in memory is well-established (Weeber et al. 2002), providing 
a molecular mechanism by which nAChR may facilitate memory function.  
In addition to acting in a classic ionotropic manner, nAChR can interact directly 
with, and modulate the activity of, various proteins involved in signalling cascades. The 
phosphoinositide 3-kinase (PI3K) and Akt signalling pathway is a well-established anti-
apoptotic pathway and has been frequently implicated as an important component of 
nicotine neuroprotection. Activation of PI3K has been reported via 7 (Kihara et al. 
2001) and non- 7 nAChR (Dasgupta et al. 2005). Kihara et al. 2001 reported a 
physical association of PI3K with 7 nAChR, supported by a block of nicotine 
Resting Active 
Desensitised 
Channel 
open 
Channel 
closed 
Channel 
closed 
Agonist 
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protection by PI3K inhibition. Other components of this signalling complex have also 
been identified, including the tyrosine kinases Fyn and janus-kinase 2 (JAK2; Kihara et 
al. 2001; Shaw et al. 2002), which may mediate activation of the PI3K-Akt pathway by 
7 nAChR, with subsequent increase in levels of the anti-apoptotic proteins Bcl-2 ad 
Bcl-xl (Kihara et al. 2001; Shimohama et al. 2001) and inactivation of pro-apoptotic 
proteins bad and bax (Jin et al. 2004; Xin and Deng 2005).  
 
 
Fig 1.17 Key signalling cascades in Ca
2+
-dependent nAChR-mediated neuronal 
processes. The increase in Ca
2+
 resulting from nAChR activation can stimulate adenyl cyclase 
(AC), protein kinase A (PKA) and Ca
2+
-calmodulin-dependent protien kinase (CaMK) and 
phosphatidylinositol 3-kinase (PI3K). Consequential activation of downstream targets, such as 
extracellular signal-regulated protein kinase (ERK) leads to the activation of transcription factors 
such as cAMP response element-binding protein (CREB). A cascade implicated in neuron-
survival is initiated by PI3K/JAK2 (janus-activated kinase 2), via the stimulation of protein kinase 
B (PKB; Akt), resulting in activation of anti-apoptotic factors, such as Bcl-2 and inactivation of 
pro-apoptotic factors, such as caspases. Adapted from Dajas-Bailador et al. 2004  
 
Thus, in addition to stimulating signalling cascades implicated in memory, 
nAChR also modulate signalling systems involved in cell survival and death. The effect 
of nicotinic ligands on Aβ1-42 toxicity is assessed experimentally in chapters 4 and 6, 
while the effect of Aβ peptides on signalling evoked by nAChR stimulation is examined 
in chapter 5.  
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1.14 Aims of Thesis 
 
As discussed in the introduction, oligomerisation is a key determinant of the 
biological actions of Aβ, several of which may be modulated by the activity of nAChR. 
Therefore the aims of this thesis were:  
 
1) Determine the role of oligomerisation in toxicity evoked by chronic application of 
Aβ to PC12 cells and rat primary cortical neurons 
2) Investigate the effect of nicotinic ligands on toxicity evoked by Aβ 
3) Determine the role of oligomerisation on the modulation of Ca2+ signalling by 
acute application of Aβ 
4) Assess the role of the acute modulation of Ca2+ signalling by Aβ in the toxic 
mechanism of the peptide 
 
 61 
 
 
 
 
 
 
Chapter 2 
 
 
Materials and Methods 
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2 Materials and Methods 
 
2.1 Materials  
 
[3H]epibatidine (54 Ci/mmol) and 125Iα-bungarotoxin (125IαBgt; 242 Ci/mmol) were 
purchased from GE Healthcare (Chalfont St Giles, UK). [3H]methyllycaconitine 
([3H]MLA; 60 Ci/mmol) and 5-iodo-A-85380 (5-I-A-85380) were obtained from Tocris 
Cookson Inc. Avonmouth, Bristol, UK). PC12 cell line was a gift from Dawin K. Berg 
(University of California, USA). RPMI 1640, horse serum, fetal bovine serum, l-
glutamine, penicillin and streptomycin, poly-D-lysine, (-)nicotine hydrogen tartrate, 
mecamylamine, dihydro-β-erythrodine, nifedipine, verapamil, 3-[4,5-dimethylthiazol-2-
y]-2,5-diphenyltetrazolium bromide (MTT), bisbenzimide H 33342 trihydrochloride, (+)-
nicotine (+)-di-p-toluoyltartrate salt and Aβ16-21 (KLVFFA)  were purchased from Sigma-
Aldrich Co. (Poole, UK). Neurobasal media, Earl‟s Balanced Salt Solution (EBSS), B27 
supplement and B27 supplement containing antioxidants were obtained from Invitrogen 
(Washington, DC). Papain tissue dissociation kit was purchased from Worthington 
(Lakewood, NJ). Aβ1-42, Aβ42-1 and Aβ25-35 were obtained from California Peptide 
Research (Napa, CA). 6-carboxy-fluorescein(FAM)-labelled Aβ1-42 was purchased from 
Anaspec (San Jose, CA). Apo-ONE™ homogenous caspase 3/7 assay and Cytotox-
ONE™ homogenous membrane integrity assay were obtained from Promega 
(Madison, WI). α-bungarotoxin, α-bungarotoxin AlexaFluor™ 488 (α-bgt488), fluo-3 
AM, fura-2 AM, pluronic F127 and all fluorescent secondary antibodies were purchased 
from Molecular Probes (PoortGebouw, Leiden, The Netherlands). Anti-synapsin-1 
primary antibody was obtained from Synaptic Systems (Göttingen, Germany). Anti-
GFAP (rabbit, polyclonal) was purchased from BioGenex (San, Ramon, CA). Anti-
tubulin antibody was pobtained from Covance (Berkeley, CA). Vectorshield™ mountant 
was purchased from Vector Labs Inc. (Burlingame, Canada). Optiphase „Safe‟ was 
obtained from Wallac Scintillation Products, Fisher Chemicals (Loughborough, UK). 
GFA/E filter paper was purchased from Gelman Sciences (Ann Arbor, MI). Coomassie 
Plus  and BCA™ protein assay was obtained from Pierce Biotechnology (Rockford, 
IL). 1-(5-chloro-2,4-dimehtoxy-phenyl)-3-(5-methyl-isoxazol-3-yl) urea (PNU-120596) 
and (R)-N-(1-azabicyclo[2.2.2.]oct-3-yl)(5-(2-pyridyl)thiopene-2-carboxamide 
(compound A) were gifts from J. Kew (GSK, Harlow, UK). 1,4-
Diazabicyclo[3.2.2]nonane-4-carboxylic acid, 4-bromophenyl ester (SSR180711) was a 
gift from C. Hille (GSK, Harlow, UK). α-Conotoxin ArIB[V11L,V16D] was a gift from M. 
McIntosh (University of Utah, Salt Lake City). All other chemicals used were of 
analytical grade and obtained from Sigma-Aldrich Co. (Poole, UK). Female Wistar and 
Male Sprague-Dawley (250 - 350 g) rats were obtained from the University of Bath 
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animal house breeding colony. Female Charles River CD® rats (Sprague-Dawley-
derived) were purchased from Charles River, Margate, UK.  
 
ANTIGEN/LIGAND SPECIES SOURCE DILUTION 
Neurofilament Rabbit Sigma 1:200 
β-tubulin Rabbit Covance 1:1000 
Tau5 Mouse Biosource 1:1000 
AT8 (PHF Tau) Mouse Autogenbioclear 1:20 
Synapsin-1 Mouse Synaptic Systems 1:500 
Synaptophysin Rabbit Chemicon 1:1000 
GFAP Rabbit Chemicon 1:1000 
Alexa 488/596/633 Mouse/Rabbit/G. Pig Molecular Probes 1:750 
Topro-3 --- Molecular Probes 1:1500 
H 33342 --- Sigma 15 μg/ml 
DAPI --- Sigma 10 μg/ml 
HRP-linked anti- 
mouse IgG 
Mouse Amersham 1:3000 
α-Bgt-488 --- Molecular Probes 1:500 
flAβ1-42 Human Anaspec --- 
 
Table 2.1 Antibody and Fluorescent Probes: sources and concentrations 
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DRUG PREFERENTIAL TARGET ACTION 
Nicotine  nAChR (non-specific) Agonist 
Mecamylamine nAChR (non-specific) Antagonist 
SSR180711 7 nAChR Partial agonist 
Compound A  7 nAChR Agonist 
PNU120596 7 nAChR PAM (type II) 
5-hydroxyindole 7 nAChR PAM (type I) 
GSK985881A 7 nAChR PAM (type II) 
GSK918716A 7 nAChR PAM (type II) 
Methyllycaconitine 7 nAChR Antagonist 
-bungarotoxin  7 nAChR Antagonist 
α-CtxArIB[V11L,V16D] 7 nAChR Antagonist 
5-I-A85380 2/ 4*  Agonist 
DH E  2* Antagonist 
Epibatidine  2/ 4* Agonist 
Verapamil L-type VOCC Antagonist 
Nifedipine L-type VOCC Antagonist 
KCl N/A  Depolarisng 
agent 
 
Table 2.2 Summary of drug targets and actions 
 
2.2 Methods 
 
2.2.1 PC12 Cell Culture 
 
 The PC12 cell line (fig 2.1) was maintained as described previously  
(Blumenthal et al., 1997 PC12-C; Dickinson et al., 2007), cultured in RPMI 1640 
supplemented with 10 % heat-deactivated donor horse serum, 5 % fetal bovine serum, 
2 mM L-glutamine, 50 U/ml penicillin and 50 μg/ml streptomycin in 100 mm cell culture 
dishes at 37 ºC in a humidified chamber under 7 % CO2. Cultures were seeded on 
poly-D-lysine (5 μg/ml)-coated plastic-ware or coverslips and allowed to attach for 24 h 
before treatment. Seeding density varied with assay requirements, see Table 2.2. 
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A              B 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.1 PC12 cells seeded at 3.5 x 10
4
 cells/cm
2
, cultured for 48 h and viewed under (A) 20x 
magnification (B) 20x magnification with 3x optical zoom 
 
ASSAY VESSEL/SURFACE DENSITY (CELLS/CM2) 
Ca2+-imaging (single cell) 25 mm glass coverslip 9.5 x 104 
Ca2+-imaging (population) 96-well plate 7.5 x 104 
Toxicology Assays 96-well plate 3.5 x 104 
Immunocytochemistry 22 mm glass coverslip 3.5 x 104 
Binding Assay 24-well plate 3.5 x 104 
 
Table 2.3 PC12 seeding densities 
 
2.2.2 Primary rat cortical cultures  
 
2.2.2.1 Cortical dissection 
Cortical cultures were prepared from E18 wistar rat foetuses by micro-
dissection as described previously (Goslin and Banker, 1991; Barrantes et al., 1995). 
Briefly, a time-mated pregnant rat was sacrificed by cervical dislocation and the entire 
uterus removed. The umbilical cord was cut and the foetuses were separated from the 
amniotic sac. Following decapitation, the foetal brain was removed and cerebral 
hemispheres separated from the diencelphalon and brainstem using fine sprung 
mounted scissors and style forceps, under 20x magnification. The meninges were then 
removed in one piece. 
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2.2.2.2 Preparation of cortical cultures 
The dissected cortices were cut into pieces in PBS containing 10 mg/ml glucose 
and incubated with DNase I (30 Kunitz) and trypsin (0.025 % w/v) for 20 min at 37 oC. 
This reaction was terminated by addition of supplemented neurobasal medium (B27 
supplement, 1 mM sodium pyruvate, 2 mM L-glutamine, 50 U/ml penicillin and 50 μg/ml 
streptomycin) containing 10% heat-inactivated (56 oC, 30 min) foetal bovine serum. 
Tissue was centrifuged and the pellet triturated using a pasteur pipette. Following 
settling of undissociated tissue, the cell suspension was removed and cell density 
determined. Cultures were seeded in poly-D-lysine (5 μg/ml)-coated plastic-ware or 
coverslips at the requisite density (see Table 2.3) and allowed to attach for 3-5 h before 
replacement with serum-free medium. Subsequently, half the medium was replaced 
every 3-5 days and assays completed within 14 days in vitro (DIV). 
 
ASSAY VESSEL/SURFACE DENSITY (CELLS/CM2) 
Ca2+-imaging 25mm glass coverslip 1 x 104 
Toxiciology Assays 96-well plate 5 x 104 
Fluorescence Microscopy 96-well plate 3 x 104 
Immunocytochemistry 22mm glass coverslip 1 x 104 
 
 
 
   1 DIV      3 DIV  
 
 
 
 
 
 
 
   6 DIV  
 
    
 
 
 
 
 
 
Figure 2.2 Timecourse of neuronal culture 
development 
A mixed culture of cortical and hippocampal 
neurons was seeded at 10
3
 cells/cm
2
 as 
described in the methods, mounted on the 
day in vitro (DIV) indicated and viewed under 
10x magnification. Neuronal processes are 
apparrent after 24 h in culture, forming 
extended neurite networks within 6 DIV. 
Several morphologies can be distinguished, 
including bipolar, pyramidal, stellate and cells 
with a single dominat process. Neurons were 
cultured for up to 14 DIV before experiments. 
Table 2.4 Seeding density for Primary cortical cultures 
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A 
B 
The protocol, developed by this research group (Barrantes et al., 1995), 
generates a population of cortical neurons with less than 5 % glial contamination 
(representative images in fig 2.2 and 2.3). The in vivo requirement for glia is avoided by 
culturing neurons at high density. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Rat primary cortical neurons labelled for (A) glial fibrillary acidic protein (B) 
neurofilament and viewed by confocal microscopy as described in section 2.2.8.2 (20x; 12 DIV; 
3 separate culture preparations). 
 
2.2.3 Amyloid-β Preparation  
Aβ1-42, Aβ25-35, Aβ16-21, Aβ42-1 and flAβ1-42 were prepared identically, based on a 
method designed to generate globular oligomeric species (Klein et al. 2002). Briefly, 
lyophilised Aβ (1 mg) was dissolved in 400 μl 1,1,1,3,3,3-hexafluoro-2-propanol to 
disaggregate any olgiomeric species and aliquotted accordingly. Following evaporation 
of the solvent under a stream of air, the protein residue was lyophilised with 
centrifugation (Modulyo Vacuum Pump, Edwards, Wivelsfield Green, UK with a Savant 
Speedvac Concentrator, GMI, Ramsey, MI) for 10 min at -30 C and stored in a 
desiccator at -80 C. Aliquotted protein residues were dissolved in DMSO to give 5.0 
mM Aβ. Trifluoroacetic acid (TFA; 0.1 %) was then added to give 1.9 mM Aβ. After 10 
min, medium/buffer was added to give the required concentration. Unless stated, no 
ultracentrifugation was employed to remove fibrillar species. For co-applications, 
solutions of Aβ peptides were mixed after dissolving in DMSO.     
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2.2.4 Cytotoxicity Assays 
 
2.2.4.1 Metabolic Viability  
 The mitochondrial function of the cultures was by monitored by conversion of 
the tetrazolium salt, 3-[4,5-dimethylthiazol-2-y]-2,5-diphenyltetrazolium bromide (MTT) 
(Mosmann, 1983) as described previously (Hanrott et al., 2006). In viable cells, 
mitochondrial succinate dehydrogenase reduces MTT via cleavage of the tetrazolium 
ring, producing dark blue formazan crystals.  
 Cultures were washed with warm media prior to addition of 100 μl of MTT dye 
(2.5 mg/ml media). Following incubation at 37 ˚C for 90 min, the dye was removed, 
cells washed with PBS and the formazan crystals dissolved in 100 μl propan-2-ol, on a 
plate shaker for 20 min. Optical density at 570 nm was determined using a colorimetric 
plate reader (Anthos 2020 microplate reader; Labtec Instruments, Austria). Data are 
expressed as a percentage of the untreated control values, determined in parallel.  
 
2.2.4.2 Membrane Integrity 
 Lactate dehydrogenase (LDH) release was measured using the CytoTox-
ONE™ Homogeneous Membrane Integrity Assay, according to the manufacturer‟s 
instructions, as described previously (Hanrott et al., 2006). The amount of LDH 
released from the cells is quantified by addition of resazurin to the media. This pro-
fluorescent compound is metabolised by LDH forming fluorescent resorufin. Briefly, 
medium removed from the cultures (which were then assayed for metabolic viability, 
section 2.2.4.1) was allowed to cool to 22 ºC and added to an equal volume of 
CytoTox-ONE™ reagent. Fluorescence (excitation 560 mM, emission 590 nm) was 
measured using a fluorescence plate reader (Fluoroskan Ascent; Labsystems, Helsinki, 
Finland).  Data are expressed as a percentage of maximum LDH release (determined 
by incubation of cells with 9 % Triton X-100 for 45 min), following subtraction of 
background fluorescence (determined by reagent response to medium alone).  
 
2.2.4.3 Induction of Apoptosis 
 The activity of caspases 3 and 7 was determined using an Apo-ONE™ 
homogenous caspase 3/7 assay, according to manufacturer‟s instructions, as 
described previously (Hanrott et al., 2006). Cleavage of the pro-fluorescent substrate 
(Z-DEVD-R110) at the rhodamine-conjugated aspartate residue by caspases 3 and/or 
7 yields a fluorescent product. Briefly, equal volumes of DMEM and Apo-ONE™ 
caspase reagent (1:100 profluorescent substrate:lysis buffer) were added to cells and 
incubated for 5 h. Fluorescence (excitation, 485 nm; emission, 538 nm) was measured 
using a fluorescence plate reader (Fluoroskan Ascent; Labsystems, Helsinki, Finland). 
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Background fluorescence was determined by fluorescent response to media alone and 
subtracted from all experimental values. 
 
2.2.5 Calcium Fluorimetry  
 
2.2.5.1 Cell populations 
 Increases in intracellular Ca2+ in cultures grown in 96-well plates were 
monitored as described previously (Dajas-Bailador et al., 2002). Cells were washed 
twice with Tyrode‟s Salt Solution (TSS; 137 mM NaCl, 2.7 mM KCl, 1.0 mM MgCl2, 2.5 
mM CaCl2, 0.2 mM NaH2PO4, 12 mM NaHCO3, 5.5 mM glucose; pH 7.4) and incubated 
with the membrane-permeable Ca2+-sensitive dye fluo-3-AM (10 µM) and 0.02% 
pluronic F127 for 1 h at room temperature in the dark. After washing the cells twice with 
TSS, cells were pre-incubated with 80 µl TSS, with or without antagonist (20 min for 
αBgt; 10 min for all others). Where used, PNU-120596 was added I min prior to the end 
of pre-incubation.  Basal fluorescence (excitation 485 nm, emission 538 nm) was 
recorded for 5 s in a fluorescent plate reader (Fluoroskan Ascent; Labsystems, 
Helsinki, Finland). Then nAChR agonist, KCl or vehicle (20 µl) was added and the 
change in fluorescence was recorded for a further 20 s. Under all conditions examined, 
increases in fluorescence reached a maximum level within 5 s and this response was 
sustained over the remainder of the time course of the experiment. In order to 
normalise fluo-3 signals, the maximum and minimum fluorescence from each well was 
determined by addition of 0.2 % Triton-X100 (Fmax) followed by 40 mM MnCl2 (Fmin).  
Drug-evoked responses were expressed as a percentage of the corresponding (Fmax-
Fmin) value. Values in the presence of inhibitors were expressed as a percentage of the 
control responses carried out in parallel in the absence of blockers. None of the drugs 
or vehicles used significantly altered the basal level of fluorescence. 
 
2.2.5.2 Timecourse experiments  
 Intracellular Ca2+ changes of individual cells and populations were monitored 
using dynamic video imaging (Concord System, Perkin Elmer, UK). Cells cultured on 
coverslips were washed twice with Ca2+ buffer (140 mM NaCl; 5.0 mM KCl; 1.0 mM 
MgCl2; 1.8 mM CaCl2; 10 mM glucose; 5.0 mM HEPES; pH 7.4) and incubated with 
fura-2 AM (5 µM) and 0.02 % pluronic F127 for 1 h at room temperature (22 °C) in the 
dark. Coverslips were encased in a pre-heated (37 ºC) microscope chamber (Series 20 
PH2 platform with a RC-21BR chamber, both from Harvard Apparatus, MA) and 
perfused (5 ml per min) with heated (37 ºC) buffer. Fura-2 was excited at 340 and 380 
nm using a SpectroMaster I and emssions at 510 nm detected with an intensified 
Ultrapix PDCI low light level CCD camera. Data collected from responding cells was 
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analysed using Ultraview software and expressed as a ratio of F340:F380.  
 Fluorescence was calibrated by perfusing cultures with buffer containing 10 mM 
Ca2+ containing 2 μM ionomycin until the fluorescence stabilised at a maximum plateau 
(Rmax). Cultures were then perfused with Ca
2+-free buffer containing 2 μM ionomycin 
and 1 mM EGTA until the fluorescence stabilised at a minimum trough (Rmin). These 
values were analysed with Ultraview software to calculate Gyrnkievwicz parameters 
assuming a Kd of 224 nM of Ca2+ for Fura-2 (Grynkiewicz et al. 1985). These 
parameters were then used to calibrate fluorescence to Ca2+ concentration.  
 
2.2.6 Radioligand Binding 
 
2.2.6.1 Preparation of P2 membranes  
 P2 membranes were prepared from the rat brain as described by (Davies et al., 
1999). Brains were frozen in liquid nitrogen and stored at –20 C until required. The 
cerebellum was discarded and the whole brain homogenised (10 % w/v) in 0.32 M 
sucrose containing 1 mM EDTA, 0.1 mM PMSF, 0.01 % w/v sodium azide, pH 7.4. The 
homogenate was centrifuged at 1000 g for 10 min (Avanti™ J-25 centrifuge with 
JA25.15 rotor; Beckman Coulter, Fullerton, CA). The supernatant was removed and 
kept on ice while the pellet was resuspended in 0.32 M sucrose and re-centrifuged at 
1000 g for 10 min. The two supernatant fractions were combined and centrifuged at 
12,000 g for 30 min. The resulting pellet was re-suspended in phosphate buffer (40 mM 
K2HPO4, 10 mM KH2PO4, 1 mM EDTA, 0.1 mM PMSF, 0.01 % w/v sodium azide; pH 
7.4), protein concentration determined (Coomassie PlusTM Protein Assay Kit) and 
stored at –20 C in 1 ml aliquots.  
 
2.2.6.2 125IαBgt competition binding to P2 membranes  
 All assay conditions were carried out in triplicate, as described previously 
(Whiteaker et al., 2000). For inhibition of 125IαBgt binding to brain membranes 25 µl of 
drug was added to 50 µl P2 membranes (~ 250 µg of protein). 125IαBgt (25 µl, final 
concentration 1 nM in phosphate buffer, 40 mM K2HPO4, 10 mM KH2PO4, 1 mM EDTA, 
0.1 mM PMSF, 0.01 % sodium azide,; pH 7.4) was added and the total volume was 
made up to 100 µl with PBS. For total binding the drug was replaced with phosphate 
buffer with 0.1 % (w/v) BSA. For non-specific binding drug was replaced with nicotine 
(final concentration 1 mM). Samples were vortexed and incubated for 4 h at 37 C, 
before addition of 1 ml phosphate buffer and further incubation at 37 C for 1 h; 
samples were then chilled at 4 C for 30 min. Samples were filtered using a Brandel cell 
harvester, through a double thickness of Gelman GFA/E filter paper, bottom filter 
soaked overnight in 0.3 % polyethyleneimine (PEI) in water, top filter soaked in 4 % 
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milk powder in PBS overnight. Filters were counted for 125I in 4 ml Optiphase „Safe‟, 
using a Packard Tri Carb 1600® TR Liquid scintillation analyser (counting efficiency = 
65 %). 
 
2.2.6.3 [3H]epibatidine competition binding to P2 membranes 
 All assay conditions were carried out in triplicate as described previously 
(Davies et al., 1999). For inhibition of [3H]epibatidine binding to brain membranes, 20 μl 
of drug was added to 2 ml of P2 membranes diluted 1:40 with phosphate buffer (40 mM 
K2HPO4, 10 mM KH2PO4, 1 mM EDTA, 0.1 mM PMSF, 0.01 % sodium azide; pH 7.4; ~ 
250 μg tissue) followed by [3H]epibatidine (20 μl, final concentration 200 pM).  For total 
binding the drug was replaced with phosphate buffer, for non-specific binding drug was 
replaced with nicotine (final concentration 1 mM). Samples were vortexed and 
incubated for 2 h at 22 ºC; samples were then chilled at 4 C for 30 min. Samples were 
filtered using a Brandel cell harvester, through a double thickness of Gelman GFA/E 
filter paper soaked in 0.3 % PEI overnight. Filters were counted for 3H in 4 ml 
Optiphase „Safe‟, using a Packard Tri Carb 1600® TR Liquid scintillation analyser. 
 For all competition binding assays, non-specific binding was subtracted and 
IC50 values determined by non-linear regression analysis, by fitting data to the Hill 
equation using SigmaPlot V2.0 for Windows (Jandel Corp., San Rafael, USA). Ki 
values were calculated from the IC50 values using the Cheng and Prusoff relationship 
(Cheng & Prusoff, 1973) assuming Kd values of 0.55 nM (Davies et al. 1999) and 0.31 
nM (Dajas Bailador et al. 2005) for 125IαBgt and [3H]epibatidine binding to rat brain 
membranes, respectively.  
 
2.2.6.4 In situ radioligand binding to nAChR in PC12 cells 
 Total [3H]epibatidine, [3H]MLA or 125IαBgt binding to PC12 cells was determined 
as described previously (Ridley et al., 2001). Culture medium was removed from the 
wells and replaced with medium containing 0.1 % BSA and 10 nM [
3
H]MLA, 10 nM 
125IαBgt or 2 nM [3H]epibatidine. Cultures were then incubated at 37 °C for 2 h 
([
3
H]MLA and [3H]epibatidine) or 4 h (125IαBgt). Non-specific binding was determined in 
the presence of 1 mM nicotine.  Specific binding at the cell surface was determined in 
the presence of 5 mM carbamoylcholine (Whiteaker et al 1999). Cultures were washed 
3 times in warm PBS and solubilised in 0.5 ml 0.1 M NaOH. Optiphase „Safe‟ (2 ml) 
was added and the samples were counted for radioactivity in a Packard Tri Carb 1600® 
TR Liquid scintillation analyser. Protein analysis was carried out using Coomassie 
PlusTM Protein Assay Kit. 
 Specific binding and surface-specific binding were calculated by subtraction of 
non-specific binding in the presence of nicotine or carbamoylcholine from total binding.  
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For saturation binding experiments specific binding was calculated following 
subtraction of non-specific binding from total binding. Bmax and Kd were calculated using 
the non-linear regression equation      where y = [radioligand] (nM) and x = 
total binding.  
 
2.2.7 Amyloid-β Characterisation 
 
2.2.7.1 Thioflavin T Fibrillogenesis Assay 
 
 A 50 μg aliquot of Aβ1-42 in a microfuge tube was prepared as described in 
section 2.2.3. Following addition of TFA, thioflavin T (ThT; final concentration 20 μM in 
10 mM Tris; pH 7.5; 37 C) was added to give a final Aβ1-42 concentration of 30 μM. 
Following vortexing for 10 s, an aliquot (150 μl) was transferred to a 96 well plate and 
fluorescence (excitation 444 nm, emission 485 nm) was measured using a fluorescent 
plate reader (Fluoroskan Ascent; Labsystems, Helsinki, Finland). After taking the 
reading, the aliquot was returned to the stock solution and incubation continued at 37 
C in the dark. Subsequent readings were taken in a similar manner: after vortexing for 
10 s, 150 μl were transferred to a 96 well plate and fluorescence measured. Data are  
expressed as the average of five readings and fitted to a 3 parameter rectangular 
hyperbola using the equation    where y is the fluorescence emission (in 
arbitary units), x is the time (in hrs), a is the maximum fluorescence emitted and 1/b is 
the first order constant for fibril growth or “aggregation coefficient” (Necula et al. 2007). 
     
2.2.7.2 Polyacrylamide Gel Electrophoresis 
 Aβ1-42 (200 nM aliquot) was prepared as described (section 2.2.3) in the 
presence or absence of 0.1 % TFA in media or water and incubated for 30 min at room 
temp. Laemmli loading dye (4 x; bromophenol blue 0.02 % (w/v), SDS 4 % (w/v), 
glycerol 50 % (w/v), 125 mM Tris; pH 6.8) was added and 10 µg Aβ1-42 resolved using 
15 % agarose SDS-PAGE run at 100 V for 1.5 h. The gel was submerged in coomassie 
stain (5 % coomassie blue in 40 % methanol, 10 % acetic acid) with agitation for 30 
min, followed by de-stain solution (40% methanol, 10 % acetic acid) with agitation for 
10 min.  
 
2.2.8 Microscopy  
 
2.2.8.1 Atomic Force Microscopy 
 A 50 μg aliquot of Aβ1-42 in a microfuge tube was prepared as described in 
section 2.2.3. Following addition of TFA, water was added to give a final Aβ1-42 
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concentration of 30 μM and the sample was incubated at 37 C for the required time. 
Samples were diluted 1:500 immediately prior to deposition on freshly cleaved mica. 
Images were collected using a Digital Instruments Nanoscope III (Veeco Instruments, 
Plainview, NY) in non-contact (tapping) mode using silicon cantilevers with a 
resonance spring constant of 50 N/m and a frequency of 284 kHz (Park Scientific). At 
least three regions of each surface were examined to verify that similar structure 
existed throughout the sample. 
 
2.2.8.2 Confocal microscopy 
 Cells labelled with fluorescent ligands or antibodies were analysed using an 
LSM 510 confocal system equipped with an Axiovert 100 M microscope (Zeiss, 
Welwyn Garden City, UK). The Zeiss multi-tracking protocol was used, to eliminate the 
possibility of fluorochrome interference through the use of sequential fluorochrome 
excitation; fluorochromes were excited using a blue diode laser (emission at 405 nm), 
an argon laser at 488nm (505-530nm emission filter), a helium-neon laser at 543nm 
(560-615nm filter) and a helium-neon laser at 633nm (650nm emission filter). To 
ensure that the respective fluorescence emissions were recorded at the same level, the 
emission pinhole for each track was set at 1 airy unit.  
 
2.2.8.3 α-Bgt-488 labelling 
 Cells were rinsed in PBS before incubation for 10 min in the presence or 
absence of 1 mM nicotine at room temperature. Coverslips were inverted onto α-Bgt-
488 (200 nM) in PBS containing 0.1 % BSA in the presence or absence of 1 mM 
nicotine for 1 h at room temperature. Following thorough washing (3 x 5min PBS), cells 
were fixed in 4 % formaldehyde for 20 min. Coverslips were washed thoroughly again, 
mounted in Vectorshield  and viewed as described above. 
 
2.2.8.4 Immunocytochemistry  
 Cells were rinsed in PBS before fixing in 4 % formaldehyde for 20 min. 
Following thorough (3 x 5min PBS) washing, cells were incubated with 10 % normal 
goat serum (NGS), 0.5 % BSA and 0.05 % Triton-X100 in PBS for 30 min. Primary 
antibodies were applied to the cells diluted in 1 % NGS, 0.5 % BSA and 0.05 % Triton-
X100 in PBS overnight at 4 °C in a humidified chamber. Coverslips were washed 
thoroughly before addition of appropriate secondary antibody in 1 % NGS, 0.5 % BSA 
and 0.05 % Triton-X100 for 1 h at room temperature in the dark. Coverslips were 
washed thoroughly again, mounted in Vectorshield  and viewed under the Zeiss 
Axiovert 100 M microscope combined with an LSM 510 confocal system (Zeiss, 
Welwyn Garden City, UK). 
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2.2.9 Monitoring Neurite Outgrowth and Synaptogenesis of Primary Cortical 
Cultures  
 Data were generated while on placement at GlaxoSmithKline (Neurology and 
GI CEDD, New Frontiers Science Park, Harlow, UK), hence the cell culture protocol 
varies from that described in section, 2.2.2.  
 
2.2.9.1 Primary Cortical Culture Seeding 
 Cortical neurons were cultured from gestational day 18 rat embryos (strain: 
CD®, Charles River, Margate, UK) as previously described (Skaper et al, 1990; Skaper 
et al., 2006), with minor modifications. Briefly, cortices were dissected (in a manner 
similar to that described in section 2.2.2) into Earls‟s Balanced Salt Solutions and 
dissociated with a papain tissue dissociation kit (Worthington, Lakewood, NJ) following 
the manufacturer‟s instructions. Cells were resuspended in neurobasal medium 
containing B27 supplement with antioxidants, 1 mM sodium pyruvate, 2 mM L-
glutamine, 50 U/ml penicillin and 50 μg/ml streptomycin and strained through a 70 um 
strainer (BD Falcon, NJ) before addition to poly-D-lysine-coated 96-well plates. Prior to 
cell seeding, the poly-D-lysine-coated culture wells were exposed overnight to medium 
containing 10 % fetal bovine serum. After 2 days, cultures received 0.35 ml per well of 
plating medium, containing B27 supplement without antioxidants. Cultures were 
maintained at 37 ˚C in a 5 % CO2 humidified atmosphere. On DIV5, medium was 
replaced with 100 μl medium with or without drugs for 24 h, then replaced with 100 μl 
medium containing Aβ1-42 with or without drugs for 72 h. 
 
2.2.9.2 Immunocytochemistry 
 After 72 h Aβ1-42 treatment, cultures were fixed with 100 μl of 4% (w/v) 
paraformaldehyde, 10 % (w/v) sucrose and 15 g/ml H 33342 in PBS, added directly to 
the well, for 15 min. Following aspiration, cultures were washed twice with 100 ul PBS 
before blocking with 10% (v/v) goat serum, 1% (w/v) BSA in PBS for 1 h. Blocking 
solution was replaced with anti-synapsin-1 mAb, diluted 1:500 in buffer (1 % w/v BSA, 
0.1% v/v trtiton TTX-100 in PBS) containing 10 % normal goat serum for 1 h. Following 
thorough washing (3 x 5 min PBS), cells were incubated for 1 h in anti-tubulin Ab, 
diluted 1:1000 in buffer containing 10 % normal goat serum. After thorough washing, 
Alexa-488 anti-mouse mAb & Alexa-568 anti-rabbit mAb, both diluted 1:300 in buffer 
containing 10% normal goat serum, were added for 1 h. Cultures were then thoroughly 
washed again with PBS.  
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2.2.9.3 Fluorescence microscopy 
 After fixing and labelling cells, images of nuclei (350 nm excitation and 440 nm 
emission, 0.2 s exposure), neurites (550 nm excitation and 570 nm emission, 0.25 s 
exposure) and synapses (490 nm excitation and 520 nm emission filters, 0.55 s 
exposure) were obtained using an Arrayscan (Cellomics, Pittsburgh, USA), with a Fluar 
10x objective (Zeiss, NY) with a Hamamatsu ORCA ER camera (Leeds Precision 
Instruments, MN). Treatments were replicated in at least three wells for each treatment 
condition and images collected from 6 fields within each well. Metamorph imaging 
software (Molecular Devices, Sunnyvale, CA) was used to determine the number of 
neurons, total neurite outgrowth, total number of processes, number of synaptic spots 
and total number of equivalent nuclei.  
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Chapter 3: Novel compound and model characterisation  
 
Aims of Chapter 
 
In order to assess interactions between A  and nicotine/nAChR, several features of the 
in vitro systems employed herein must first be characterised:  
1) The pharmacological complement of the PC12 cells and primary cortical 
cultures must be determined, in particular the presence and activity of nAChR 
and VOCC, as drug specific for these will be tested for neuroprotective potential 
in chapters 4, 5 and 6.  
2) This will then allow the characterisation of novel drugs specific for nAChR, 
before testing for neuroprotective potential.  
3) To determine which oligomeric structures are mediating the activities described 
in chapters 4, 5 and 6, the oligomerisation kinetics of A  must be characterised.  
 
3.1 PC12 cells   
 PC12 cells are employed in chapters 4 and 5 to examine toxicological and 
pharmacological interactions between nicotinic ligands and A  peptides, respectively. 
The expression and function of nAChR in this cell line is experimentally assessed in 
this chapter. The PC12 cell line was originally isolated in the 1970s from a transferable 
rat adrenal pheochromocytoma (Greene et al. 1976). This neuroendocrine line shares 
several functions with neurons, such as expression of neurotransmitter receptors and 
ion channels. They also synthesise, store, uptake and secrete catecholamines (Greene 
and Tischler 1976). This has led to frequent employment of PC12 cells in investigations 
of neurological disorders, such as Alzheimer‟s disease, including studies of Aβ toxicity 
(Zhou et al. 1996, Ueda et al. 1997) and pharmacology (Green & Peers et al. 2001). 
Compared with other rat and human cell lines of neuronal background, the PC12 line 
has been identified as particularly sensitive to Aβ (Sherman et al. 1994). Despite this 
sensitivity, several compounds have displayed neuroprotective properties against Aβ 
toxicity in PC12 cells. In particular, nicotine is reported to protect PC12, in a nAChR-
dependent manner  (Kihara et al. 1997).  
The presence of nAChR in PC12 cells was initially reported by Greene and 
Rein in 1976. Inhibition of nAChR-mediated Ca2+-dependent [3H]noradrenaline release 
by mecamylamine and d-tubocurarine indicated the receptors are active in 
physiological responses. Numerous subsequent reports have confirmed the presence 
of nAChR subunit mRNA and functional nAChR subtypes. mRNA encoding α3, α5, α7, 
β2 and β4 nAChR subunits have been consistently detected in PC12 cells (Boulter et 
al. 1990, Rogers et al. 1992, Henderson et al. 1994, Blumental et al. 1997; Takahashi 
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et al. 1999), while mRNA encoding the β3 subunit has only been reported by Rogers et 
al. 1992. Other reports, however, report a lack of mRNA encoding α2, α4 and α6 
nAChR subunits in PC12 cells (Boulter et al. 1990, Rogers et al. 1992, Henderson et 
al. 1994). Assembled nAChR have also been reported in PC12 cells, including 
heteromeric α3β2* and α3β4*, which may include the α5 subunit, and the homomeric 
α7 nAChR (Rogers et al. 1992, Blumenthal et al. 1997, Avila et al. 2003).  
Although the expression of these nAChR subtypes has been consistently 
documented (Greene & Rein 1976; Rogers et al., 1992; Blumenthal et al. 1997), there 
is a high level of heterogeneity between separate sub-clones of PC12 cells. Blumenthal 
(1997) compared the expression of nAChR receptors in three lines of PC12 cells by 
analysing mRNA and protein levels, assembled receptor number and functional 
responses. One of these lines, designated clone „C‟, exhibited a significantly greater 
surface expression of α7 nAChR and total α3* nAChR. This clone was therefore 
selected for use in the current study, following characterisation that substantiates 
functional nAChR in this cell line (Dickinson et al. 2007). As spontaneous mutation and 
altered expression can occur in continually proliferating cells, in situ radioligand binding 
and calcium fluorimetry were employed to continually monitor nAChR expression and 
function, in parallel with other assays involving PC12 cells.  
 
3.1.1 Characterisation of nAChR expression by PC12  
The cellular population of α7 nAChR was quantified by [3H]-MLA and 125I-α-
Bungarotoxin (125I-αBgt) binding. The concentrations of radioligands employed to 
determine the number of binding sites is sufficiently greater than the dissociation 
constant (Kd), in order to bind all of the sites. The volume of the ligand and tissue is 
adjusted to ensure the number of binding sites is not limiting such that the specific 
binding sites are saturated.  
Cultures of PC12 cells exhibited specific [3H]-MLA binding (161.6  63.1 
fmol/mg; table 3.1) that was similar to the non-specific [3H]-MLA binding (172.1  33.9 
fmol/mg; table 3.1). For this reason, 125I-αBgt was also employed, and exhibited 
comparable specific binding (110.8  8.1 fmol/mg; table 3.1), with less non-specific 
binding (30.6  5.7 fmol/mg; table 3.1). The specific binding of both radioligands is less 
than the 420 fmol/mg detected previously using this protocol in this lab (Dickinson et al. 
2007) and ~250 fmol/mg detected by others (Blumenthal et al. 1997). This discrepancy 
may be due to variation in α7 nAChR expression between cultures, as the activities of 
the two ligands employed in this study were not assessed in direct comparison. 
Inherent differences between the two ligands may also explain this discrepancy, 
including ligand binding kinetics (Davies et al. 1999) the different isotopes and their 
specific activities.  
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The expression of β2* nAChR was quantified by incubating PC12 cells with 
[3H]-epibatidine. The membrane permeability of this ligand was taken advantage of to 
assess distinct cellular populations of α3* nAChR, as the majority of assembled nAChR 
are retained in an intracellular pool (Whiteaker et al. 2000). The overall expression of 
β2* nAChR (316.0 ± 45.3 fmol/mg protein; table 3.1) was established in the presence 
of nicotine, a membrane-permeable ligand employed to displace the radioligand from 
both intracellular and extracellular sites. The expression of nAChR at the plasma 
membrane (111.4 ± 8.3 fmol/mg protein) was then quantified by difference after 
selectively displacing the radioligand from surface sites with membrane impermeable 
carbamoylcholine  (Whiteaker et al. 2000). In agreement, this indicates that ~35 % of 
β2* nAChR expressed by this cell line were located on the cell surface, (p=0.051 
student‟s t-test, n=3).  In contrast, the majority of α7 nAChR appear to be expressed at 
the surface as the specific binding of membrane-permeant [3H]-MLA, indicating the 
total α7 nAChR expression, is not much greater than specific binding of membrane-
impermeant 125I-αBgt. 
 
 Radioligand binding (fmol/mg protein) 
Radioligand  TB NSB (nic)  SB (nic) NSB (CCh)  SSB 
[
3
H]MLA 333.6  50.8 172.1  33.9 161.6  63.1 n/a  n/a 
125
I-aBgt 141.4  7.6 30.6  5.7 110.8  8.1 n/a  n/a 
[
3
H]epibatidine  633.5  73.9 317.4  95.6 316.0  45.3 492.7  57.2 137.2  57.2  
 
Table 3.1 In situ [
3
H]MLA, 
125
I Bgt and [
3
H]epibatidine binding to PC12 cells 
PC12 cells were incubated with [
3
H]MLA (10 nM; A), 
125
I Bgt (10 nM; B) or [
3
H]epibatidine (2 
nM; C) as described in the materials and methods. Non-specific binding was determined in the 
presence of 1 mM nicotine. Specific binding of [
3
H]epibatidine at the cell surface was 
determined in the presence of 5 mM carbamoylcholine. Specific binding was calculated by 
subtraction of non-specific binding from total binding. Surface-specific binding was determined 
by subtraction of non-specific binding (nic) from non-specific binding (CCh). Data represent the 
mean  SEM of at least three independent experiments, each performed in triplicate. TB = Total 
binding, NSB (nic) = Non-specific binding in the presence of nicotine, NSB (CCh) = Non-specific 
binding in the presence of carbamoylcholine, SB = Specific-binding, SSB = Surface-specific 
binding.  
 
The α7 nAChR expression indicated by 125I-αBgt-binding was corroborated by 
labelling non-permeablised cultures with fluorescent (Alexafluor-488 conjugated)-αBgt 
(fig 3.1). Approximately 70 % of PC12 cells displayed positive labelling, albeit to 
varying degrees, highlighting the heterogeneous nature of α7 nAChR expression in this 
cell line. Labelling was negated in the presence of nicotine (fig 3.1B), indicating the 
interaction was specific.  
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3.1.2 PC12 cells express functional nAChR   
PC12 cells were loaded with the Ca2+-indicator fluo-3, which undergoes a 
conformational change upon the specific binding of Ca2+, with concomitant shift in 
emission spectra (Minta et al. 1989; Kao et al. 1989). For each reading, the basal level 
of fluorescence of the fluo-3-loaded cells was determined prior to stimulation. Following 
stimulation, fluorescence was monitored for 20 s, to allow responses to reach a 
maximum effect-plateau. The maximum fluorescence reached over 20 s was obtained, 
from which the basal fluorescence was subtracted. Though cells were seeded at a 
consistent density, the fluorescence evoked within the field of view was normalised to 
account for variation in cell distribution and size. The maximum fluorescence that could 
be reached was determined by lysing cells and a minimum reading obtained by 
quenching all fluorescence. The rise in fluorescence elicited by the stimulation was 
expressed at the (maximum fluorescence reached following stimulation minus the 
basal level) divided by (highest fluorescence achievable minus quenched minimum). 
Where appropriate, this value was expressed as a percentage of the fluorescence 
increase evoked by a comparative stimulant, such as nicotine.   
Application of nicotine to PC12 cells loaded with fluo-3 increased fluorescence 
in a concentration-dependent manner (fig 3.2A) with IC50 42.2 ± 4.7 μM, consistent with 
previous reports (Sabban & Gueorguiev, 2002) and maximally effective concentration 
of 100 μM. The general nAChR antagonist mecamylamine (MEC) inhibited the rise in 
fluo-3 fluorescence evoked by 30 μM nicotine by 82.1 ± 5.0 %. The remaining increase 
in fluorescence does not significantly differ from stimulation with buffer alone (p=0.06, 
student‟s t-test, n=4). This indicates that the rise in intracellular Ca2+, as indicated by 
fluo-3 fluorescence, evoked by nicotine is mediated by nAChR.    
To elucidate the nAChR subtype(s) mediating nicotine‟s increase in intracellular 
Ca2+, PC12 cells were incubated with maximally-effective concentrations of nAChR 
subtype-selective antagonists (Dickinson et al. 2007). The α7 nAChR antagonist αBgt 
significantly inhibited rises in fluorescence evoked by 30 μM nicotine by 26.8 ± 5.5 % 
(fig 3.2B). Additionally, the β2*-selective antagonist DHβE, which when applied at 1μM 
will preferentially compete for β2* sites (Harvey & Luetje 1996), significantly inhibited 
rises in fluorescence evoked by 30 μM nicotine by 36.3 ± 11.0 % (fig 3.2B). These 
results indicate both α7 and β2* nAChR, in part, mediate the rises in intracellular Ca2+ 
elicited by 30 M nicotine. 
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Fig 3.1 Bgt-488 labelling of PC12 cells 
Representative images of unifxed, non-permeabilised PC12 cells labelled with 200 nM αBgt-488 
in the (A; n = 2) absence or (B; n = 1) presence of 1 mM nicotine and viewed by confocal 
microscopy as described in the Materials and Methods; scale bar A, 10 μm B, 20 m. Assays 
conducted in collaboration with Jane Dickinson.  
 
As discussed in section 1.13.5.2.1, α7 and non-α7 nAChR differentially couple to 
calcium-induced calcium release and voltage-operated calcium channels (VOCC) in 
PC12 cells (Dickinson et al. 2007) and nerve terminals (Dickinson et al., 2008) and 
elsewhere (discussed in Dajas-Bailador and Wonnacott 2004). In addition to 
expressing a variety of nAChR, PC12 cells also express a range of VOCC, including L-, 
N- and P/Q-type (Plummer et al. 1989, Liu et al. 1996, Solem et al. 1997). Treatment 
with the L-type VOCC inhibitor verapamil (Opie 1987; Cilia et al. 2005; table 5.1) 
blocked rises in fluorescence evoked 30 μM nicotine by 55.2 ± 4.2 % (fig 3.2B), a 
comparable block to that achieved by β2* nicotinic antagonist DHβE (fig 3.2B). 
Previous studies in this system have shown intracellular Ca2+ rises evoked by a β2* 
nAChR-selective agonist or the depolarising agent KCl are insensitive to the N-type 
VOCC blocker ω-conotoxin GVIA and the N- and P/Q-type VOCC blocker ω-conotoxin 
MVIIC (Dickinson et al. 2007). As this suggests these subtypes do not contribute to 
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nicotine-evoked Ca2+-rises in these PC12 cells, the roles played by these VOCC 
subtypes were not examined.    
 
 
        A       B 
 
 
 
 
 
 
 
 
 
 
 
       C 
 
 
 
 
 
 
 
 
 
Ca2+ rises evoked by the non-selective agonist nicotine were inhibited by 
selective antagonists, implicating α7 and β2* nAChR (fig 3.2B). To confirm this finding, 
these subtypes were stimulated with agonists that selectively activate α7 and β2* 
nAChR (fig 3.2C). The α7 nAChR-selective agonist compound A displays high 
selectivity and high potency in several reports (Cilia et al. 2005; Visanji et al. 2006; 
Dickinson et al. 2008). However, previous studies using this system reported 0.1 nM – 
10 μM compound A failed to evoke any increase in fluo-3 fluorescence when applied 
alone (Dickinson et al. 2007). As with previous studies (Dickinson et al. 2007, Innocent 
et al. 2008), a positive allosteric potentiator was applied in conjunction with the agonist 
to reveal the response mediated by α7 nAChR. 
 
 
Fig 3.2 Nicotine evokes increases in Fluo-3 
fluorescence 
PC12 cells loaded with Fluo-3 were stimulated 
with (A) increasing concentrations of nicotine (B) 
30 μM nicotine in the presence and absence of 
mecamylamine (MEC; 20 μM; 10 min 
preincubation), -bungarotoxin ( Bgt; 5 μM; 20 
min preincubation), dihydro-β-erythrodine (DHβE; 
10 μM; 10 min preincubation) or verapamil (Vera; 
10 μM; 10 min preincubation) (C) nicotine (Nic; 
100 μM), 5-I-A85380 (5-I-A; 30 μM) or compound 
A (CA; 10 nM) following a 1 min preincubation with 
PNU-120596 (PNU; 10 μM). Data represent 
maximum fluorescence reached over 20 s, as a 
percentage of Fmax-Fmin. Data expressed as mean 
± SEM from at least four separate experiments, 
each with 4 replicates. Significantly from 30 μM 
nicotine *p<0.05, *** p<0.001, one –way ANOVA 
and post-hoc Dunnet‟s test. 
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Previous reports indicate a 1 min pre-incubation with 10 μM PNU120596 (Hurst 
et al. 2005) produces maximal Ca2+ rises in PC12 cells stimulated with 10 nM 
compound A (Dickinson et al., 2007). In this study, stimulation of PC12 cells with 10 nM 
compound A with 10 μM PNU120506 evoked a rise in fluo-3 fluorescence that was 
134.9 ± 12.1 % of the response produced by 100 μM nicotine (fig 3.2C). To confirm the 
specificity of this response, PC12 cells were incubated with nAChR antagonists. 
Responses evoked by compound A and PNU120596 were blocked by mecamylamine 
(by 88.2 ± 27 %) and αBgt (by 82.4 ± 6.7 %), but not DHβE, confirming selective 
activation of α7 nAChR (fig 3.3A). Furthermore, the responses were not inhibited by 
verapamil, confirming α7 nAChR activation does not operate via L-type VOCC (fig 
3.3A). 
The β2* nAChR-selective agonist 5-Iodo-A85380 (5-I-A; Mukhin et al. 2000, 
Mogg et al. 2004) was utilised to evoke Ca2+ rises by non-α7 nAChRs. Previous studies 
have shown 30 μM 5-I-A to be maximally effective at producing fluorescence-rises in 
this system (Dickinson et al. 2007). Accordingly, 30 μM produced a response 80.1 ± 
5.1% of the response evoked by 100 μM nicotine. This response was inhibited by 
mecamylamine (by 87.2 ± 2.2 %) and DHβE (by 82.8 ± 4.9 %), but not αBgt, confirming 
Fig 3.3 nAChR agonists and KCl evoke 
increases in fluo-3 fluorescence in PC12 cells   
PC12 cells loaded with Fluo-3 were stimulated 
with (A) compound A (10 nM) and PNU-120596 
(10 μM; applied 1 min before the end of 
preincubation (B) 30 μM 5-I-A85380 (C) 30 mM 
KCl in the presence and absence of 
mecamylamine (MEC; 20 μM; 10 min 
preincubation), -bungarotoxin ( Bgt; 20 min 
preincubation), dihydro-β-erythrodine (DHβE; 10 
μM; 10 min preincubation) or verapamil (Vera; 10 
μM; 10 min preincubation). Data represent 
maximum fluorescence reached over 20 s, as a 
percentage of Fmax-Fmin. Data expressed as mean 
± SEM from at least three separate experiments, 
each with 4 replicates. 
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specific interaction with non-α7 nAChR (fig 3.3B). Incubation with verapamil also 
inhibited the responses, implicating L-type VOCC in Ca2+-responses mediated by non-
α7 nAChR. Increases in fluo-3 fluorescence evoked by the depolarising agent KCl were 
insensitive to α-Bgt, DHβE and MEC, but were blocked by verapamil (by 81.2 ± 3.7 %; 
fig 3.3C).         
As the PC12 cells displayed heterogeneous expression of α7 nAChR (fig 3.1), 
the variation in α7 nAChR function was assessed by dynamic video imaging 
fluorescence microscopy. PC12 cells loaded with the Ca2+-indicator Fura-2 were 
continuously perfused with buffer while monitoring emission at 340 and 380 nm (fig 
3.4A). Addition of the α7 agonist choline (1 mM; 1 min) with PNU-120596 (10 μM) to 
the perfusing buffer elicited increases in the ratio of fluorescence at 340:380 nm in ~40 
% of cells (fig 3.4B). An image from the maximum change in fluorescence was used to 
determine the number of responsive cells). 
PC12 cells were loaded with fura-2 AM and perfused with buffer as described in 
Materials and Methods (fig 3.4). Representative images from 5 separate experiments 
of (A) emission at 380 nm, indicating the total number of cells in the field of view (B) 
maximum change in ratio of fluorescence (340:380 nm) in response to one minute 
application of 3 mM choline and 10 μM PNU-120596, indicating responsive cells. 
A               B 
 
 
 
 
 
 
 
 
 
 
Fig 3.4 Heterogeneity of α7 nAChR-responses in the PC12 cell line 
 
3.2 Novel drug characterisation 
Drugs that selectively interact with specific receptor subtypes are essential 
research tools for elucidating and clarifying the molecular and cellular mechanisms that 
under-pin physiological and pathological activity. Research into α7 nAChR has profited 
from the availability of a handful of agonists that preferentially stimulate α7 nAChR, 
including AR-R17779, choline, compound A, GTS-21 (DMXB) and PNU282987 and 
two useful antagonists, αBgt and MLA (for review, see Jensen et al. 2005). As each of 
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these compounds harbours inherent limitations (several of which are discussed below), 
much interest remains focussed on the generation of novel subtype-specific ligands. In 
this study, two novel α7 nAChR-selective ligands are characterised: the small-molecule 
partial agonist SSR180711 and a modified peptide antagonist α-CtxArIB[V11L,V16D].  
 
3.2.1 Characterisation of SSR180711  
Recently, the novel α7 nAChR-selective partial agonist, SSR180711 (1,4-
diazabicyclo[3.2.2]nonane-4-carboxylic acid, 4-bromophenyl ester; fig 3.5 inset) was 
described  (Biton et al. 2007). In Xenopus oocytes or GH4C1 cells expressing human 
7 nAChR, SSR180711 generated currents consistent with partial agonism while small 
Bgt sensitive currents were evoked in cultures of rat hippocampal neurons (Biton 
2007). Null mutation of the 7 nAChR gene totally abolished SSR180711-induced 
modulation of LTP in mice, confirming selectivity at α7 nAChR.  
Subsequent reports have shown SSR180711 to be efficacious in models of 
learning and memory associated with schizophrenia (Pichat et al. 2007) (Barak et al. 
2009) and to increase the expression of activity-regulated cytoskeleton protein (Arc), 
an important immediate early gene in memory consolidation (Kristensen, et al. 2007). 
In the present study, the pharmacological character of SSR180711 was assessed in 
the PC12 cell line.  
 
3.2.1.1 SSR180711 selectively binds to and activates α7 nAChR   
SSR180711 was synthesised by GlaxoSmithKline, UK. In agreement with Biton 
et al. (2007), SSR180711 displaced 125I- Bgt binding to rat brain P2 membranes with Ki 
35.2 ± 4.4 nM (fig 3.5), confirming its potent interaction with α7 nAChR.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.5 SSR180711 inhibits 
125
I-αBgt 
binding to rat brain membranes  
Inhibition of 
125
I-αBgt binding to rat P2 
brain membranes by SSR180711 
(solid black line) or nicotine (dashed 
red line). Data points were fitted to the 
Hill equation, giving Ki values of 35.2  
44.0 nM and 1.4  0.6 μM, 
respectively. Data represent mean ± 
SEM, from at least three separate 
experiments each with three replicates 
Inset: Chemical structure of 1,4-
diazabicyclo[3.2.2]nonane-4-
carboxylic acid, 4-bromophenyl ester 
(SSR180711)  
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Interaction of SSR180711 with nAChR was then functionally assessed by 
monitoring intracellular Ca2+ concentration in PC12 cells loaded with fluo-3. PC12 cells 
are employed to examine the effect of SSR180711 on A 1-42 toxicity and the effect of 
A 1-42 on SSR180711-evoked Ca
2+ rises in chapters 4 and 5, respectively. Acute 
application of SSR180711 alone (10 nM – 10 μM) produced no increase in 
fluorescence (fig 3.6A). However, when applied following a 1 min incubation with the 
positive allosteric modulator PNU120596 (10 μM; Hurst et al. 2005), rises in fluo-3 
fluorescence were detected (fig 3.6A), as seen for compound A (fig 3.3) Examination of 
the Ca2+ rise over 20s following SSR180711 application in the presence of PNU120596 
(fig 3.6B) indicates that both the initial rate of Ca2+ increase and maximum level of 
fluorescence achieved increase in a concentration-dependent manner. As all increases 
in fluorescence reached a maximum within 20 s after application of SSR180711, the 
maximum fluorescence achieved within this time was selected for analysis, and 
provided an EC50 49.4 ± 17.3 nM (fig 3.6A). 
  A        B 
 
 
 
 
 
 
 
 
 
Fig 3.6 SSR180711 elicits concentration-dependent rises in intracellular Ca
2+
 
SSR180711 (1 nM – 10 μM) applied to PC12 cells loaded with fluo-3 in the presence and 
absence of PNU120596 (10 μM; 1 min pre-incubation). Data represent maximum fluorescence 
reached over 20 s, as a percentage of response to 100 μM nicotine. Data expressed as mean ± 
SEM from at least three separate experiments each with four replicates. B Inset: Representative 
trace of responses to SSR180711 with PNU120596.  
 
 Having examined the efficacy and specificity of SSR180711 in PC12 cells 
loaded with fluo-3, we took advantage of the compound to explore the presence of 7 
nAChR in rat cortical primary cultures, for comparison with the effect of SSR180711 on 
A 1-42 toxicity described in chapter 6. The expression of α7 nAChR in mixed 
hippocampal and cortical cultures is well established. To examine α7 nAChR 
expression on a cell-by-cell basis, dynamic video imaging was employed. Cultures 
were loaded with fura-2 and constantly perfused with buffer. Addition of 1 μM 
SSR180711 with 10 μM PNU120596 evoked an increase in the ratio of fura-2 
fluorescence (340:380; fig 3.7), indicating a rise in intracellular Ca2+, in approximately 
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10 % of cells (fig 3.7c-f). By calibrating this system according to the manufacturer‟s 
instructions (Grynkievicz et al. 1985), concentrations of Ca2+ can be calculated. The 
average basal Ca2+ concentration of responsive cells was 34.9 ± 10.7 nM (fig 3.7B), 
increasing to 187.3 ± 23.7 nM upon addition of 1μM SSR180711 + 10 μM PNU120596. 
Application of MLA (50 nM, 30 sec pre-incubation) blocked responses by 86.6 % (fig 
3.7B). Application of 10 nM 5-I-A85380 also evoked increases in the ratio of fura-2 
fluorescence in a population of cells (fig 3.7B), which DH E (10 M; 30 sec pre-
incubation) blocked by 91.8 %.  
 
3.2.1.2 At higher concentrations, SSR180711 interacts with non-α7 nAChR 
To assess nAChR subtypes mediating SSR180711-evoked increases in Ca2+, PC12 
cells were pre-incubated with a range of nAChR antagonists. The broad-range nAChR 
antagonist mecamylamine (MEC) completely abolished rises in fluo-3 fluorescence 
evoked by 1 M SSR180711, as did the α7 nAChR-selective antagonist αBgt, 
confirming activity at α7 nAChR (fig 3.8).  
Previous studies (Biton et al. 2007) indicate higher micromolar concentrations 
of SSR180711 can activate non-α7 nAChR. Here, the β2* nAChR-selective antagonist 
DHβE slightly reduced responses evoked by 1 μM SSR180711, although this was not 
statistically significant (fig 3.8). The trend for DHβE to inhibit SSR-evoked responses 
was not observed when the agonist was applied at a lower concentration (30 nM; fig 
3.8).    
Co-applying a partial agonist with a positive allosteric modulator enhances the 
cellular response to the partial agonist, obscuring the pharmacological efficacy. 
Consistent with this view, the response evoked by 1 μM SSR180711 in the presence of 
PNU120596 was of similar magnitude to the response evoked by the full agonist 
compound A (section 3.1.2).  
As partial agonists occupy the agonist-binding site on the receptor, they prevent 
other agonists from binding, thus inhibiting the action of full agonists. This phenomenon 
was taken advantage of to confirm SSR180711-selectivity at α7 nAChR in PC12 cells 
and a second agonist was therefore co-applied with SSR80711. However, as this 
system requires a positive allosteric modulator to reveal responses evoked by all α7 
nAChR-selective agonists examined, the selectivity of SSR180711 could not be 
demonstrated with another α7-nAChR agonist. For this reason, the non-selective 
agonist nicotine was chosen for co-application with SSR180711 (in the absence of 
PNU120596). 
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Fig 3.7 nAChR responses in primary neuronal cultures 
On DIV10, cultures of mixed cortical and hippocampal neurons were loaded with fura-2 AM and 
perfused with buffer as described in Materials and Methods. Fluorescence changes in response 
to a one-minute application of 1 μM SSR180711 (SSR) and 10 μM PNU-120596 (PNU) or 10 nM 
5-I-A85380 were monitored. (A) representative traces from 5 cells that responded to SSR180711 
and PNU120596 application are shown (B) the maximum change in Ca
2+
 concentration per cell in 
response to agonist stimulation in the absence and presence of MLA (50 nM) or DH E (10 M). 
Data are expressed as mean ± SEM from at least 5 separate experiments, each with four 
replicates, using cultures from three separate animals; *** p<0.001, ### p<0.001 significantly 
different from stimulation with SSR180711+PNU12506 or 5-I-A85380, respectively; one –way 
ANOVA and post-hoc Dunnet‟s test (C) representative image of fluorescence at 340 nm, 
indicating total cell number, prior to treatment with SSR180711 and PNU 120596 (D, E, F) ratio of 
fluorescence emission (340:380 nm), indicating [Ca
2+
] concentration (C) at t=0, indicating basal 
[Ca
2+
] (D) 130s (E) 180 s (E) indicating responsive regions (circled).  
 
High 
[Ca
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] 
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] 
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Fig 3.8 SSR180711 responses are sensitive to α7, but not β2* nAChR Inhibition 
SSR180711 applied with PNU120596 (10 μM; 1 min pre-incubation) to PC12 cells loaded with 
fluo-3 in the presence and absence of mecamylamine (MEC; 20 µM; 10 min), α-bungarotoxin 
(α-Bgt; 5 µM; 20 min) or dihydro-β-erythoidine (DHβE; 1 µM; 10 min). Data represent maximum 
fluorescence reached over 20 s, as a percentage of response to 100 μM nicotine. Data 
expressed as mean ± SEM from at least three separate experiments each with four replicates. 
Significantly from SSR180711 (1 μM) plus PNU120596 *** p<0.001, one –way ANOVA and 
post-hoc Dunnet‟s test 
 
When co-applied with 30 μM nicotine, 1 μM SSR180711 inhibited nicotine-
evoked Ca2+ rises by 41.5 ± 10.8% (fig 3.9A).  When increased to 10 μM, SSR180711 
produced a greater block, inhibiting nicotine-evoked Ca2+ rises by 57.2 ± 6.1%. This 
inhibition is significantly larger than the inhibition of the nicotine response by αBgt, 
suggesting that SSR180711 is interacting with non-α7, in addition to α7 nAChR. To 
confirm this, nicotine was replaced with 30 M nAChR-selective agonist 5-I-A85380, 
which will selectively activate heteromeric nAChR. Co-application of 1 μM SSR180711 
with 30 μM 5-I-A85380 did not affect responses evoked by 5-I-A85380 (fig 3.9B). In 
contrast, 10 uM SSR180711 inhibited 5-I-A85380-evoked responses by 60.5 ± 6.8 % 
(fig 3.9B), suggesting interaction with non-α7 nAChR at higher micromolar 
concentrations, in agreement with previous studies (Biton et al. 2007).  
Together these results indicate that SSR180711 is a potent agonist at α7 
nAChR endogenously expressed in PC12 cells and cortical neuronal cultures. In 
agreement with Biton et al. (2007), SSR180711 preferentially stimulates α7 nAChR at 
nanomolar concentrations, but blocks non-α7 nAChR at higher, micromolar, 
concentrations. The presence of PNU120596 is required to reveal the agonist action of 
SSR180711 at α7 nAChR. Allosteric modulators can shift the concentration-response 
curves of full agonists to the left without affecting the maximum response. However, 
when acting in concert with a partial agonist, these allosteric modulators also increase 
the maximum response. This has lead to the proposition of two possible mechanisms 
of action for the effects of allosteric modulators on partial agonist receptor activation: 
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binding of the modulator may cause a conformational change that translates to the 
agonist binding site, resulting in altered agonist affinity for the open/closed state, or 
translate to the channel, directly alter the gating process itself (Maksay et al. 2000). 
  
(A) (B)  
 
 
 
 
 
 
 
 
Fig 3.9 SSR180711 inhibits responses evoked by β2* nAChR agonists 
(A) Nicotine (30 μM) was applied in the presence or absence of SSR180711 (0.1, 1, 10 μM; co-
application) or α-bungarotoxin (α-Bgt; 5 µM; 20 min) (B) 5-I-A84380 (30 μM) was applied in the 
presence or absence of SR180711 (0.1, 1, 10 μM; co-application) to PC12 cells loaded with 
fluo-3. Data represent maximum fluorescence reached over 20 s, as a percentage of response 
to 100 μM nicotine. Data expressed as mean ± SEM from at least three separate experiments 
each with four replicates. Significantly different from 30 μM nicotine alone *p<0.05, *** p<0.001, 
one –way ANOVA and post-hoc Dunnet‟s test. Significantly from 30 μM 5-I-A85380 alone 
#p<0.05, one –way ANOVA and post-hoc Dunnet‟s test. 
 
 
These results indicate that SSR180711 preferably interacts with and activates 
7 nAChR, though at higher micromolar concentrations can also activate heteromeric 
nAChR. The effect of nanomolar concentrations of SSR180711 on A 1-42 toxicity in 
PC12 cells and rat primary cortical neurons is assessed in chapters 4 and 6, 
respectively, while the effect of acute application of A 1-42 on SSR180711-evoked rises 
in PC12 cells is examined in chapter 5.    
  
3.2.2 Characterisation of the novel α-conotoxin, α-CtxArIB[V11L,V16D] 
  As mentioned in section 3.2, the commonly used α7 nAChR-selective 
antagonists have some intrinsic disadvantages. α-Bgt, from the venom of the Elapidae 
snake Bungarus multicinctus, is a large polypeptide with slow binding kinetics. This 
confers high-affinity binding with very slow dissociation, an advantage for some 
studies. It can also be a limitation in functional assays because increased incubation 
times and/or concentrations are required to achieve blockade. Moreover, the slowly 
reversible block limits recovery in experiments where repeated agonist application is 
desirable, and the large size of the toxin can compromise its access to α7 nAChR in 
intact preparations.  
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The norditerpenoid MLA from Delphinium and Consolida sp. is also a 
competitive antagonist of α7 nAChR. It binds to α7 nAChR with nanomolar affinity (Ki ~ 
1 nM; Davies et al. 1999). In addition, it exhibits moderately high affinity for α6β2-
containing nAChRs (Ki 33 nM; Mogg et al. 2002), which compromises its utility for 
identifying α7 nAChR in areas where the α6 subunit is expressed, notably 
catecholaminergic and visual pathways. Furthermore, both αBgt and MLA interact with 
high affinity with nAChR containing α9 and α10 subunits (Elgoyhen et al. 2001; Baker 
et al. 2004). The potential colocalization of α7, α9, and α10 subunits in sympathetic 
neurons (Lips et al., 2006) and non-neuronal cells (Bschleipfer et al. 2007) demands 
more discriminating antagonists. 
The α-conotoxins, small peptides from the venom of Conus sp., can exhibit 
exquisite specificity for nAChR subtypes (McIntosh et al. 1999; Nicke et al. 2004). In a 
recent study (Whiteaker et al. 2007), an α-conotoxin (α-Ctx) gene was cloned from 
Conus arenatus and predicted peptides were synthesised and found to potently block 
α3-, α6-, and α7-containing nAChRs expressed in Xenopus oocvtes. Taking account of 
structure-activity information from conotoxins found in distantly-related Conus species, 
a peptide from C. arenatus, α-CtxARIB, was modifed by amino acid substitution. This 
generated the novel, highly-selective α7 nAChR antagonist, α-CtxArIB[V11L,V16D] (fig 
3.10A), which exhibited low nanomolar affinity for rat α7 nAChR expressed in Xenopus 
laevis oocyte.  
In the current study, α-CtxArIB[V11L,V16D] displayed high potency and 
specificity for discriminating a7 nAChRs (Ki, 7 nM) from all other nAChR subtypes 
tested in binding assays. Functionally, α-CtxArIB[V11L, V16D] specifically blocked 
currents evoked by stimulation of rat homomeric α7 nAChRs expressed in Xenopus 
oocytes, whereas it was without effect on heteromeric nAChRs (including α9α10 
nAChR) in the same expression system when tested previously (Whiteaker et al. 
2007). However, the subunit composition of native nAChRs can be more diverse and 
more complex than that of recombinant receptors. Here, the ability of α-
CtxArIB[V11L,V16D] to antagonise responses to native nAChRs was assessed. 
 
3.2.2.1 α-CtxArIB[V11L,V16D] selectively displaces α7 nAChR ligands 
α-CtxArIB[V11L,V16D] potently displaced 125I-α-Bgt binding to rat P2 
membranes with a Ki value of 4.0 ± 0.6 nM (fig 3.10B), confirming α-
CtxArIB[V11L,V16D] interacts competitively at α7 nAChRs, as previously described 
(Whiteaker et al. 2007). α-CtxArIB[V11L,V16D] did not compete for [3H]epibatidine (0.2 
nM) binding to rat brain membranes (fig 3.10C). At this concentration, [3H]epibatidine 
will not label α7 nAChRs (Ki ~ 0.2uM; Davies, et al. 1999; see Marks et al. 2006). 
Therefore this result indicates that over the concentration range 0.1 nM – 1 μM α-
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CtxArIB[V11L,V16D] does not interact with non-α7 nAChRs. α-CtxArIB[V11L,V16D] 
was then tested for functional potency at native nAChRs. 
 
3.2.2.2 Effects of α-CtxArIB[V11L,V16D] on nAChR-mediated Ca2+ responses in 
PC12 cells 
To assess the potency of α-CtxArIB[V11L,V16D] at nAChR, PC12 cells were 
loaded with the Ca2+ indicator fluo-3, and stimulated with choline to selectively activate 
α7 nAChRs (Alkondon et al. 1997). As discussed in section 3.1.2, the α7 nAChR 
response in this system is revealed only in the presence of a positive allosteric 
modulator (Dickinson et al. 2007, Innocent et al. 2008). Choline (1 mM) elicited very 
small increases in fluorescence in PC12 cells loaded with fluo-3, but these responses 
were substantially amplified in the presence of 10 μM PNU-120596 (fig 3.11A).  
α-CtxArIB[V11L,V16D] was tested over the concentration range 10 - 300 nM 
against α7 nAChR responses evoked by 1 mM choline applied in the presence of 10 
μM PNU-120596. α-CtxArIB[V11L,V16D] blocked α7 nAChR-mediated responses in a 
concentration-dependent manner with an IC50 of 88.0  17.4 nM (fig 3.11B). Maximum 
inhibition of 83.6 % was observed with 300 nM α-CtxArIB[V11L,V16D]. Higher 
concentrations were not tested in order to conserve the toxin.   
 
(A) 
 
(B)      (C) 
 
 
 
 
 
 
 
 
 
 
Fig 3.10 (A) Peptide sequence of α-CtxArIB[V11L,V16D]. Bars indicate the disulphide bond 
pattern and the mutated amino acids are underlined. (B) Inhibition of 
125
I-αBgt binding to rat 
brain membranes by α-CtxArIB[V11L,V16D] (black solid line) or nicotine (red dashed line). Data 
points were fitted to the Hill equation, giving Ki values of 4.0  0.6 nM and 2.3  0.6 μM, 
respectively. Data represent mean ± SEM, n = 3 (C) α-CtxArIB[V11L,V16D] has no effect on 
[[
3
H]epibatidine binding to rat brain membranes (solid line), whereas nicotine displaced 
[
3
H]epibatidine binding, Ki value 22.5  16.8 nM (dashed line). Data represent mean  range, n 
= 2.  
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To assess the specificity of α-CtxArIB[V11L,V16D] for α7 nAChR, its effects on 
responses evoked by a non-selective nAChR agonist (nicotine), an agonist selective for 
β2-containing nAChRs (5-I-A85380) and a general depolarising agent (KCl) were 
examined (Dickinson et al. 2007). Nicotine (100 μM), 5-I-A85380 (30 μM) and KCl (60 
mM) elicited increases in fluorescence of 26.7 ± 2.1 %, 14.8 ± 1.7 % and 44.2 ± 3.7 %, 
respectively (fig 3.11A). α-CtxArIB[V11L,V16D], tested at the highest concentration 
used previously (300 nM; fig 3.11A), failed to reduce the responses to any of these 
stimuli. However, α-CtxArIB[V11L,V16D] blocked increases in fluorescence evoked by 
the α7 nAChR partial agonist SSR180711 by 91.3 ± 2.8 %, corroborating the block of 
choline responses. To determine if 100 μM nicotine activated α7 nAChRs in addition to 
non-α7 nAChRs, it was applied in the presence of 10 μM PNU-120596. Under this 
condition responses were modestly enhanced by 40.8% (of the maximum response, in 
the absence and presence of PNU-120596 respectively). This is consistent with a 
relatively small contribution from α7 nAChR to the rise in intracellular Ca2+ evoked by 
100 µM nicotine. In the presence of α-CtxArIB[V11L,V16D], the PNU-120596-
enhanced response was not observed (fig 3.11A), indicating the component of the 
response mediated by α7, but not non-α7, nAChR is inhibited by α-
CtxArIB[V11L,V16D]. 
 
              A       B 
 
 
 
 
 
 
 
 
 
Fig 3.11 Effect of α-CtxArIB[V11L,V16D] (α-Ctx) on Ca
2+
 responses in PC12 cells 
PC12 cells loaded with fluo-3 AM were preincubated with α-CtxArIB[V11L,V16D] and/or PNU-
120596 (PNU) for 10 min and stimulated with agonist or KCl as described in Materials and 
Methods. The change in fluorescence was measured over 20 s (A) Effect of 300 nM α-
CtxArIB[V11L,V16D] (hatched bars) on increases in fluorescence in response to SSR180711 
(SSR) with 10 μM PNU-120596 (PNU), 100 μM nicotine (with or without 10 μM PNU-120596), 
30 μM 5-I-A85380 (5-I-A) or 60 mM KCl. Data are expressed as mean ± SEM, n = 3; * p < 0.05, 
student‟s t-test.. (B) The concentration-dependence of inhibition by α-CtxArIB[V11L,V16D] of 
responses to 1 mM choline plus 10 μM PNU-120596. Data points were fitted to the Hill 
equation, giving an IC50 value of 88.0  17.4 nM (mean ± SEM, n = 4) Perfomed in collaboration 
with Tracey Young 
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3.2.2.3 Recovery of responses from inhibition by α-CtxArIB[V11L,V16D]  
The timecourse of recovery from blockade by 300 nM α-CtxArIB[V11L,V16D] 
was assessed in PC12 cells loaded with fura-2 AM and monitored using dynamic video 
imaging. The response to 3 mM choline plus 10 μM PNU-120596 (60 s application) 
was blocked by 300 nM α-CtxArIB[V11L,V16D] by 87.1  1.6 % (fig 3.12; mean  
S.E.M., combined from 34 cells that responded to agonist application [40.5 % of total 
number of cells monitored] in 3 separate experiments). Following removal of the toxin 
from the perfusing buffer, responses to choline plus PNU-120596 slowly recovered, 
with complete recovery after 15 min washout, in agreement with the timecourse of 
recovery of ACh-induced currents in Xenopus Oocytes heterologously expressing 
human α7 nAChR (Innocent et al., 2008).  
Reasons for the enhanced specificity and potency of α-CtxArIB[V11L,V16D], 
compared with the native peptide, are yet to be fully elucidated. Structure-function 
modelling have implicated residues at position 11 in the binding of native -conotoxins 
(αCtx, PnIA, N11; αCtxMII, E11; αCtxPnIB, S11) to loop C of nAChR (Reviewed in 
Lewis response, 2004). It is likely that substituting a hyrdrophobic residue at this 
position of -CtxARIB for a charged residue will generate novel ionic interactions. 
These results indicate α-CtxArIB[V11L,V16D selectively and potently 
antagonises 7 nAChR. The effects of α-CtxArIB[V11L,V16D] on the toxic responses 
evoked by Aβ1-42 is tested alongside SSR180711 in chapter 6. 
 
 
 
 
 
 
 
 
 
 
Fig 3.12 Timecourse of recovery of α7 nAChR-mediated responses from α-
CtxArIB[V11L,V16D] inhibition  
PC12 cells were loaded with fura-2 AM and perfused with buffer as described in Materials and 
Methods. Fluorescence changes in response to one minute applications of 3 mM choline and 10 
μM PNU-120596 (PNU), in the presence and absence of 300 nM α-CtxArIB[V11L,V16D] (α-
Ctx), were monitored. A representative trace from one experiment in which the responses from 
13 cells that responded to agonist stimulation have been combined. 
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3.3 Amyloid-β1-42 Characterisation  
The propensity of amyloidogenic proteins to aggregate drives Aβ to 
progressively assemble into a myriad of structures. Any solution of Aβ must therefore 
be assumed to be a heterogeneous mixture of structures. As different Aβ structures 
possess distinct physiological activities (section 1.10.3), it is imperative to identify the 
species of Aβ responsible for a particular biological activity. Here, biophysical and 
biochemical approaches have been employed to assess the aggregation of Aβ1-42, in 
order to identify species responsible for the pharmacological and toxicological activities 
of A 1-42 in chapters 4, 5 and 6.   
 
3.3.1 Visualising Aβ1-42 Aggregates 
A variety of biophysical techniques is available to assess protein aggregation. 
Atomic Force Microscopy (AFM), developed in the 1980‟s (Marti et al. 1988), has been 
applied to assess aggregation of amyloidogenic proteins, including Aβ (Oda et al. 
1995; Harper et al. 1997). This technique provides quantitative three-dimensional 
morphological information, which cannot be provided by other approaches, such as 
analytical ultracentrifugation or dye-binding experiments. Furthermore, several studies 
have detected smaller oligomeric amyloid species using AFM (Kowalewski and 
Holtzman 1999; Zhu et al. 2004). This technique was therefore employed to monitor 
progression of Aβ1-42 aggregation in the preparations employed throughout this study. 
The preparation of Aβ1-42 for AFM analysis was intended to be as similar as possible to 
that employed for the pharmacological and toxicological assays, such that the 
assemblies detected by AFM should represent those in the other assays (see materials 
and methods). Storage and preparation protocols were based on those that have 
previously been reported to rapidly generate Aβ1-42 oligomeric structures (Klein et al. 
2002), though this modified by the addition of TFA to further encourage oligomer 
formation (Shen et al. 1994). Briefly, Aβ1-42 was dissolved in DMSO, followed by 
addition of 0.1 % TFA and dilution to 30 μM in cell culture media, followed by 
incubation (also described as „aging‟) at 37 °C before addition to cultures. However, 
certain aspects of the preparation could not be identically replicated, for reasons given 
below.  
An initial experiment analysing 30 μM Aβ1-42 produced cluttered images lacking 
distinct molecular assemblies (data not shown), for this reason the Aβ1-42 concentration 
was reduced. However, as peptide concentration is a key determinant of aggregation 
(reviewed in Selkoe et al. 2008), 30 μM Aβ1-42 was aged for 0.5, 12, 24 and 96 h and 
then diluted 1:500 immediately before application to freshly cleaved mica. AFM was 
conducted while the sample remained hydrated, to avoid salt crystal formation and 
peptide aggregation evoked by sample drying (Mastrangelo et al. 2006). As culture 
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media contains proteins such as bovine serum albumin that are prone to aggregation 
(Holm et al. 2007), and could therefore form structures that could be mistaken for 
amyloid assemblies, Aβ1-42 was aged in PBS for AFM analysis.    
Aging Aβ1-42 for 0.5 h (the preparation which acutely potentiated Ca
2+ responses 
of PC12 cells; section 3.1.2) generated no observable structures, even when imaged 
under maximum magnification (fig 3.13A). Incubation of vehicle (0.2 % DMSO 3.4x10-4 
% trifluoroacetic acid) in PBS for 96 h produced no detectable structures (data not 
shown). The AFM microscope used has insufficient resolution to detect monomeric 
Aβ1-42 (length ~12 nm, fully extended; Mastrangelo et al. 2006), or smaller oligomers, 
such as dimers and tetramers (diameter between 1 nm and 6 nm). It is therefore 
possible that Aβ1-42 present in solution following 0.5 h incubation exists in monomeric or 
small oligomeric forms. 
After 12 h incubation, a range of oligomeric species of diameter reaching ~30 
nm could be observed (fig 3.13B). Structures were measured using software supplied 
with the microscope, according to manufacturer‟s instructions. Approximate dimensions 
are given as the observed dimensions are exaggerated due to the size and shape of 
the silicon tip used in AFM (Goldsbury et al. 1999). The size of assemblies detected 
agrees with other AFM studies, which have observed spherical Aβ1-42 oligomers 
ranging from 4 nm to 20 nm in diameter (Mastrangelo et al. 2006; Benseny-Cases et al. 
2007).  
The range of Aβ1-42 assemblies observed after 24 h aging included structures 
up to ~400 nm in diameter (fig 3.13C), which are strikingly similar in size and shape to 
the globulomeric „ring structures‟ observed by Chromy et al. (2003). 
After 96 h incubation, linear Aβ1-42 structures (approximately 200 nm wide, of varying 
lengths; fig 3.13D) could be clearly observed. These fibrillar structures also appear to 
amalgamate, forming larger fibrilliar species (fig 3.13D inset).  
After the progression of Aβ1-42 aggregation was visualised by AFM anaylsis, a 
alternative, biochemical technique was sought that would allow higher throughput, in 
order to examine aggregation in the presence of possible inhibitors.  
 
3.3.2 Thioflavin T fluorescence  
The benzothiazole salt Thioflavin T (ThT; also known as Basic Yellow 1 or CI 
49005) has historically been used to visualise amyloid plaques in the brains of 
Alzheimer‟s disease patients (Kurucz et al. 1981). Upon binding to β-sheet structures 
which are characteristic of aggregated amyloid (section 1.10), a characteristic red shift 
in the excitation spectrum is exhibited by the dye, (Biancalana et al. 2008). The amount 
of fluorescene emitted at this wavelength (485 nm) is therefore proportional to the 
extent of Aβ aggregation. 
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As for the preparation of Aβ1-42 for AFM analysis, the preparation for ThT 
analysis was intended to replicate that used throughout this study. Again, certain 
aspects could not be tolerated by the assay and will be discussed in more detail.  
In pharmacological and toxicological assays, Aβ1-42 was often aged before 
addition to the cultures to generate oligomeric species. However, Aβ1-42 will still 
aggregate after addition to the cultures, both in solution and also on cell membranes, 
which can enhance Aβ aggregation rates by increasing local Aβ concentration, altering 
peptide structure/orientation, or increasing nucleation propensity of Aβ upon membrane 
binding (Gorbenko and Kinnunen 2006). As Aβ1-42 would continue to aggregate after 
addition to the cultures, analysis of A  oligomerisation by ThT fluorescence would 
ideally be monitored both in the presence and absence of cultures. Initial experiments 
were devised to monitor ThT fluorescence in the presence of PC12 cells. However 
application of 20μM ThT for 24 h decreased MTT reduction in PC12 cells, when 
Fig 3.13 Visualising Aβ1-42 structures 
Atomic force microscopy images (25 μm
2
) of 30 μM Aβ1-42 prepared and viewed as described in 
the materials and methods, at times indicated. Scale bars, 5 μm. Insets: Images taken at 
higher magnification (scales as indicated).  
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compared with applciation of vehicle, suggesting that this concentration of ThT is 
cytotoxic to PC12 cells (fig 3.14). Monitoring Aβ1-42-evoked changes in fluorescence in 
the presece of PC12 cells was therefore not attempted. As proteins present in cell 
culture media interact directly with ThT (Sen et al. 2009) and may also affect the 
aggregation of Aβ1-42, ThT fluorescence was compared in media and Tris-buffer, which 
was employed in previous studies (Bourhim et al. 2007; Groenning et al. 2007).  
In the absence of Aβ1-42, preparation of 20 μM ThT in cell-culture media evoked 
a marked increase in fluorescence at 485 nm when compared with preparation in Tris-
buffer, which was not significantly altered in the presence of 30 μM Aβ1-42 over 72 h 
(data not shown). ThT analysis of Aβ1-42 aggregation was therefore conducted in the 
absence of cultures, in Tris buffer, in accordance with previous studies.  
A number of studies employ constant agitation while incubating Aβ with ThT, to 
maximise interactions between peptide and dye and produce a robust fluorescence 
signal (Necula et al. 2007). As peptide-peptide interactions will also be increased, it is 
not surprising that agitation also enhances the rate of amyloid aggregation and can 
alter the aggregation pathways, generating different Aβ species (Xue et al. 2008). To 
emulate the Aβ1-42 preparation employed for toxicological and pharmacological assays, 
agitation of Aβ1-42 with ThT was therefore avoided. Unfortunately, removing agitation 
from the protocol reduced Aβ1-42-evoked ThT fluorescence, both in magnitude and 
consistency (data not shown). A compromise was therefore made to avoid disturbing 
the solution during ThT incuabtion with Aβ1-42, except for a brief agitatation immediately 
prior to fluorescence detection, as described in the materials and methods, which 
produced robust and significant responses.  
 
 
 
 
 
 
 
 
 
 
 
 
Addition of freshly dissolved 30 μM Aβ1-42 to 20 μM thioflavin T produced no 
change in fluorescent signal for approximately 10 h (fig 3.15). This is consistent with 
the „lag phase‟ of amyloid aggregation (section 1.10.2) and agrees with previous 
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Fig 3.14 ThT evoked toxic responses in 
PC12 cells. Cultures were treated with 
thioflavin T (ThT) for 48 h Data are 
expressed as a percentage of the 
response from control cells. Data 
represent the mean  SEM of at least 
three separate experiments, each with 6 
replicates. Significantly different from 
vehicle-treated cultures * p<0.05, one–way 
ANOVA and post-hoc Tukey‟s test.  
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studies employing ThT fluorescence (Chalifour et al. 2003; Ryu et al. 2008) and other 
methods of anaylsis, such as solution tubidity (Demeester et al. 2001).  After 10 h, a 
rapid increase in fluorescence was detected, corresponding to Aβ1-42 aggregation 
occuring during the fibril „elongation phase‟. While this agrees with the studies listed 
above, AFM analysis did not detect any fibril formation after 12 or 24 h (fig 3.13), 
suggesting that the increase in fluorescence is not due to fibril formation, but may be 
evoked by Aβ1-42 assembly into oligomeric strucutres. The rapid increase in ThT 
fluorescence lasted for ~14 h, before the rate of fluorescence increase slowed to form 
a plateau, presumably as the pool of monomeric Aβ is depleted, in agreement with the 
previous studies.  
Throughout this study, Aβ preparation has included treatment with 
trifluoroacetic acid (TFA), which has previously been shown to encourage Aβ 
aggregation, possibly by promoting β-sheet structure (Shen et al. 1994). Briefly, Aβ1-42 
was prepared in this study by dissolving in DMSO, followed by addition of 0.1% TFA 
and dilution in buffer (or media when applying to cell cultures), producing a final TFA 
concentration of 3.4 x 10-4 %. To assess the effect of TFA treatment on Aβ1-42 
aggregation, Aβ1-42 was prepared in the presence or absence of TFA before dilution in 
20 μM ThT. The presence of TFA increased the rate of Aβ1-42-evoked ThT 
fluorescence, with a concomitant and statistically-significant increase in aggregation 
coefficient (from 1.1 ± 0.7 to 3.2 ± 0.4, p = 0.03, based on the equation describing a 
four-parameter sigmoid curve, as detailed in the materials and methods), when 
compared with fluorescence evoked by an Aβ1-42 preparation where TFA was 
substituted with water (fig 3.15). Incubation of ThT with vehicle alone did not produce 
any change in ThT fluorescence. Thioflavin T fluorescence evoked by Aβ1-42 treated 
with TFA reached a plateau after 24 h, whereas Aβ1-42 prepared in the absence of TFA 
reached a plateau of equal magnitude after 40 h incubation, indicating a transient effect 
by TFA. The effect of TFA-treatment on toxic responses in primary cortical neurons is 
assessed in chapter 6.  
In agreement with other studies (Chalifour et al. 2003; Austen et al. 2008), an 
excess of the hexapeptide KLVFFA completely abolished increases in ThT 
fluorescence evoked by 30 μM Aβ1-42 (fig 3.15B). This indicates a lack of fibril formation 
in the presence of the hexapeptide. Although it is possible that KLVFFA prevents ThT 
binding to Aβ1-42, incubation of ThT with KLVFFA alone produced no change in 
fluorescence, suggesting the hexapeptide does not interact with the dye, or evoke the 
specific structural alterations associated with Aβ1-42 binding.  
The effect of KLVFFA on toxic responses evoked by A 1-42 in PC12 cells and 
primary cortical cultures is assessed in chapters 4 and 6, respectively. The thioflavin T 
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assay is also employed in chapter 4, to determine the effect of nicotine enantiomers on 
Aβ1-42 oligomerisation.   
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Fig 3.15 Trifluoroacetic acid and KLVFFA effects on Aβ1-42 fibril formation  
Thioflavin T fluorescence during 37 C incubation with 30 μM Aβ1-42 in the presence and 
absence of (A) 3.4 x 10
-4
 % trifluoroacetic acid (TFA) (B) 100 μM KLVFFA. At the time points 
indicated, fluorescence was measured (excitation 444 nm, excitation 485 nm) as described in 
the materials and methods. Data are expressed as mean ± SEM of three separate experiments. 
Calculation of aggregation coefficients indicates a significant difference (p<0.05; students t-test) 
between the rate of ThT fluorescence increase in the presence and absence of TFA.  
 
3.3.3 Brief aging of Aβ1-42 generates small oligomeric structures   
Following 0.5 h incubation, no Aβ1-42 aggregates were detected with AFM, nor 
was any significant increase in thioflavin fluorescence evoked. However, Aβ1-42 aged 
for 0.5 h potentiated Ca2+ responses in PC12 cells (section 5.2.2). As previous reports 
suggest monomeric Aβ is relatively inactive at Ca2+ channels (Nimmrich et al. 2008), 
SDS-PAGE was employed to detect small oligomeric Aβ1-42 species formed after 0.5 h 
aging. To emulate Aβ1-42 preparation conditions employed for the cell-based assays, 30 
μM Aβ1-42 was incubated in either cell culture media or PBS at room temperature for 
0.5 h, before being diluted to 200 nM and resolved by SDS-PAGE. 
When Aβ1-42 was aged for 0.5 h, resolved by SDS-PAGE and stained with 
coomassie blue, bands of protein corresponding to dimeric (~9 kDa) and tetrameric 
(~18 KDa) assemblies were apparent (fig 3.16). Treatment with TFA enhanced the 
apparent density of these bands, suggesting TFA encourages oligomer formation, 
corroborating enhanced ThT fluorescence by Aβ1-42 treated with TFA (fig 3.15). 
To determine whether Aβ1-42 aggregation is affected by the presence of cell 
culture media during preparation, the peptide was also prepared in PBS. No difference 
in Aβ1-42 assembly was observed in the presence and absence of media, suggesting 
that cell culture media does not significantly affect the Aβ1-42 oligomer formation over 
0.5 h incubation. This indicates that the olgiomeric structures formed by A 1-42 during 
0.5 h aging in a salt buffer (employed when assessing oligomerisation by AFM and ThT 
fluorescence) are similar to those found in cell culture media. This is important, as Aβ1-
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42 is aged in cell culture media throughout the rest of this study. Specifically, Aβ1-42 
aged for 0.5 h is shown to modulate Ca2+ signals evoked by nAChR and KCl in PC12 
cells in chapter 5, which also shows the distribution of fluorescein-labelled Aβ1-42 aged 
for 0.5 h on PC12 cells. 
 
 
 
 
 
 
 
 
 
Fig 3.16 Trifluoroacetic acid incubation encourages Aβ1-42 oligomer formation 
Aβ1-42 (30 μM) was prepared in the presence and absence of 3.4 x 10
-4
 % trifluoroacetic acid 
(TFA) in culture media or PBS and diluted to 200 nM. 10 μg was resolved by SDS-PAGE and 
stained with coomassie-blue, as described in the materials and methods. Standard protein 
band-sizes are provided in KDa. 
 
 
KDa 
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Chapter 4: chronic A  application is toxic to PC12 cells 
 
Aims of Chapter 
 
In this chapter, the toxicological profiles of A  peptides are characterised and the 
neuroprotective potential of drugs that interact with nAChR and A  is assessed.   
 
4.1 In vitro Aβ toxicity 
 Two key neuropathological features of AD, increased abundance of Aβ and 
neuronal loss, have been linked by in vitro studies demonstrating cytotoxicity of 
excessive Aβ (section 1.7.1), forming a core principle of the amyloid-hypothesis. 
Numerous cellular markers that are classically linked with cytotoxicity are altered 
following application of micromolar concentrations of Aβ to neurons in culture (section 
1.12). Understanding the combination of Aβ-induced alterations that occur in cultured 
cells may shed light on the mechanisms mediating the disruption of cellular processes 
that eventually result in cell death. Applying these findings to the disease state may 
also help to understand the changes that occur in the AD brain and facilitate new 
therapeutic strategies  
 Early i in vitro studies of Aβ toxicity often assessed only a single toxicological 
endpoint. However, subsequent studies have identified numerous mechanisms by 
which Aβ can induce cytotoxicity, though the causal interaction between these 
processes is yet to be fully elucidated. In the current study, several markers of toxicity 
were monitored: lactate dehydrogenase (LDH) release (section 2.2.4.2), caspase 3/7 
activity (section 2.2.4.3) and MTT reduction (section 2.2.4.1), indicative of plasma 
membrane integrity, apoptosis execution and redox potential, respectively. These 
toxicological markers were chosen as they mediate distinct toxic responses in the cell. 
This provides a more-thorough interpretation of the total cellular response to Aβ than 
can be achieved by monitoring changes in a single toxicological marker or cellular 
process. PC12 cells were exposed to various Aβ preparations before parallel 
assessment of these markers. 
 
4.1.1 Aging is required for Aβ1-42-induced LDH release and caspase activity 
Aβ1-42 was initially applied to PC12 cells immediately following preparation of 
the peptide (ie freshly-prepared or „unaged‟). Applying 30 μM unaged Aβ1-42 for 24 h 
decreased MTT metabolism by 29.5 ± 4.1 %, compared with vehicle-treated cultures 
(fig 4.1A). However, only aged, but not unaged, 30 μM Aβ1-42 evoked increases in LDH 
release (fig 4.1B) or caspase activity (fig 4.1C).  
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A maximal decrease in MTT reduction (by 45.4 ± 3.7 %) was achieved by 
incubating cultures with unaged 30 μM Aβ1-42 for 48 h; application for 72 or 96 h evoked 
no further decrease. Aging Aβ1-42 for 37 °C for 24 h also produced no additional 
decrease MTT reduction after 72 h exposure. In contrast, a 72 h exposure of aged 30 
μM Aβ1-42, but not unaged Aβ1-42, aged Aβ42-1 or vehicle, increased LDH release and 
caspase 3/7 activity (by 248.2 ± 29.1 and 136.5 ± 10.1 % respectively (Fig 4.1B,C). 
Exposures less than 72 h did not evoke any increase in caspase activity or LDH 
release.  
 
 
 
 
 
 
 
 
 
 
 
Fig 4.1 Aβ1-42 is toxic to PC12 cells PC12 
cells were exposed to 30 μM Aβ1-42, reverse 
peptide or vehicle (0.2 % DMSO 3.4x10
-4
 % 
trifluoroacetic acid) for indicated times. Aged 
Aβ1-42 was incubated for 24 h at 37 C 
before being applied to cultures. Toxicity 
was assessed by (A) MTT reduction (B) 
LDH release (C) caspase activity. Data are 
expressed as a percentage of the response 
from control cells (A and C) or maximum 
LDH release (B). Data represent the mean  
SEM of at least three separate experiments, 
each with 6 (A) or 3 (B and C) replicates. 
Significantly different from vehicle-treated 
cultures *** p<0.001; significantly different 
from cultures exposed to unaged Aβ1-42 for 24 h, + p<0.05; significantly different from cultures 
exposed to unaged Aβ1-42 for 96 h # p<0.001, one–way ANOVA and post-hoc Tukey‟s test. 
 
Though application of 10 μM unaged Aβ1-42 for 24 h was also found to 
significantly decrease MTT reduction (fig 4.2A), 30 μM aged Aβ1-42 was required to 
evoke significant and robust increases in LDH release (fig 4.2B) and caspase activity 
(fig 4.2C). This exposure was therefore employed in further studies to compare toxicity 
of Aβ peptides and assess neuroprotection by nicotinic ligands. 
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Fig 4.3  Distribution of unaged flAβ1-42 on PC12 cells 
PC12 cells were exposed to a mixture of FAM-labelled Aβ1-42 and unlabelled Aβ1-42 (1:2; 30 μM; 
un aged) for (A) 0.5 h and (B) 20 h. Cells were then fixed, and viewed under x63 magnification, 
as described in the materials and methods. 
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4.1.2 Exposure and aging affect distribution of fluorescently tagged-Aβ1-42  
Aβ1-42-conjugated to the fluorescein (flAβ1-42) was employed to determine 
whether aging affects the interaction of Aβ1-42 with PC12 cells. Following 0.5 h 
exposure of 30 μM unaged flAβ-42 (fig 4.3A) small fluorescent puncta are evident, which 
are predominantly distributed on the plasma membrane, though some fluorescence is 
also evident within the cytosol. Following 20 h exposure (fig 4.3B), larger puncta are 
present on the plasma membrane, consistent with oligomerisation of the peptide. A 
greater number of puncta are also apparent in the cytosol, suggesting the peptide is 
taken up by the cultures in a time-dependent manner.  
 
 
 
 
 
 
 
 
 
 
Fig 4.2 Aβ1-42 is toxic to PC12 cells in a dose dependent manner PC12 cells were exposed 
to Aβ1-42 or vehicle (0.2 % DMSO 3.4x10
-4
 % trifluoroacetic acid)for (A) 24 h (B) 72 h. Where 
indicated, aged Aβ1-42 was incubated for 24 h at 37 C before being applied to cultures. Toxicity 
was assessed by (A) MTT reduction (B) LDH release (C) caspase activity. Data are expressed 
as a percentage of the response from control cells (A and C) or maximum LDH release (B). 
Data represent the mean  SEM of at least three separate experiments, each with 6 (A) or 3 (B 
and C) replicates. Significantly different from vehicle-treated cultures *** p<0.001; one–way 
ANOVA and post-hoc Tukey‟s test. 
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Following application of 30 μM flAβ1-42 aged for 24 h at 37 °C to PC12 cells for 
20 h (fig 4.4A), numerous large puncta are evident, located both on the cells and the 
culture substratum. Diluting the aged flAβ1-42 to 3 μM immediately prior to application 
allowed a less-congested assessment of the distribution (fig 4.4B). A smaller fraction of 
the fluorescent puncta was evident on the culture substratum, in comparison with the 
amount located on cells, suggesting a preference of flAβ1-42 for interaction with the 
PC12 cells. Furthermore, puntca were evident on the plasma membrane, but not in the 
cytosol. 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.3 Aβ25-35 is more toxic to PC12 cells than Aβ1-42  
 The Aβ25-35 has been frequently employed to mimic in vitro toxicity of the full-
length peptide (section 1.6). Alteration of MTT reduction, LDH release and caspase 
activity by the Aβ25-35 fragment and full-length Aβ1-42 peptide were directly compared. 
Both peptides were aged for 37 °C for 24 h prior to a 72 h application to PC12 cells. 
Exposure of PC12 cells to 30 μM aged Aβ25-35 for 72 h fragment produced a 
similar decrease in MTT reduction when compared with the full-length peptide (fig 
4.5A). However, the fragment evoked greater caspase 3/7 activity and LDH release 
than the full length peptide (by 131.1 ± 7.4 % and 148.3 ± 8.1 % respectively; fig 4.5B, 
C). 
 
4.1.4 Effects of nicotinic receptor ligands on Aβ toxicity 
 Concentrations of (-)-nicotine that evoked increases in intracellular Ca2+ in 
PC12 cells (1, 10, 100 μM; section 3.1.2) were applied for 24 h before aged-Aβ1-42 
Fig 4.4 Distribution of aged flAβ1-42 on PC12 cells 
PC12 cells were exposed to (A) 30 μM (B) 3 uM mixture of FAM-labelled Aβ1-42 and unlabelled 
Aβ1-42 (1:2; aged for 24 h at 37ºC; green; red, neurofilament) for 20 h. Cells were then fixed, 
labelled with anti-neurofilament antibody (green) and DAPI (blue) and viewed under (A) x20 and 
(B) x63 magnification as described in the materials and methods.  
A B 
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treatment and remained throughout, in accordance with previous studies demonstrating 
a requirement of pretreatment to evoke neuroprotection by (-)-nicotine (Jonnala and 
Zamani 1993; Gahring et al. 2003; Hiramatsu et al. 2004) However, no amelioration of 
MTT reduction (fig 4.6A), LDH release (fig 4.6B) or caspase activity (fig 4.6C) was 
detected following treatment with any (-)-nicotine concentration.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In an attempt to reveal subtle protection, the same (-)-nicotine treatment was 
tested against a less potent (10 μM, unaged) Aβ1-42 insult.  Decreased MTT reduction 
following exposure to 10 μM unaged Aβ1-42 was not significantly affected by the range 
of (-)-nicotine concentrations tested (1-100 μM). The small trend towards an increase in 
cell viability may be attributed to (-)-nicotine‟s proliferative activity (Dasgupta and 
Chellappan 2006; Mudo et al. 2007) as 10 μM nicotine alone also slightly increased 
MTT reduction when compared to untreated controls (Fig 4.6D). 
As (-)-nicotine is reported to prevent the aggregation of Aβ1-42 with concomitant 
loss of toxicity (section 1.11.4.1), the aggregation of 30 μM aged Aβ1-42 was monitored 
in the absence and presence of an excess (100 μM) (-)-nicotine, using the thioflavin T 
assay in accordance with previous studies (Necula et al. 2007; Moore et al. 2004). The 
rate of increase in thioflavin fluorescence appears to be slowed in the presence of (-)-
nicotine, compared with Aβ1-42 alone (fig 4.6E). However the decrease in aggregation 
coefficient (from 3.1 to 2.8), was not statistically significant (p = 0.08), (-)-nicotine lacks 
anti-fibrillogenic effects under these conditions. 
 
 
 
Fig 4.5 Aβ25-35 evokes greater toxic responses in PC12 than Aβ1-42 
PC12 cells were exposed to aged (24 h at 37ºC) 30 μM Aβ1-42 or Aβ25-35 for 72 hrs. Toxicity 
was assessed by (A) MTT reduction (B) LDH release (C) caspase activity. Data are 
expressed as a percentage of the control cells (A and C) or maximum LDH release (B). Data 
represent the mean  SEM of at least three separate experiments, each with 6 (A) or 3 (B and 
C) replicates. Significantly different from vehicle * p<0.05, *** p<0.001; significantly different 
from Aβ1-42 # p<0.05, ## p<0.01 one–way ANOVA and post-hoc Tukey‟s test.  
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Fig 4.6 (-)-Nicotine does not prevent Aβ1-42 toxicity in PC12 cells 
 (A, B, C) PC12 cells were treated with nicotine (1, 10, 100 μM) for 24 hr before and during 
exposure to aged (24 h at 37ºC) 30 μM Aβ1-42 for 72 hrs. (D) PC12 cells treated with nicotine (1, 
10, 100 μM) for 24 hr before and during exposure to un-aged 10 μM Aβ1-42 for 24 hrs (E) 
Thioflavin T fluorescence during 37 C incubation with 30 μM Aβ1-42 in the presence and 
absence of 100 μM nicotine. Toxicity assessed by (A and C) MTT reduction (D) LDH release (E) 
caspase activity. Data are expressed as a percentage of the control cells (A and C) or maximum 
LDH release (B). Data represent the mean  SEM of six (A) or three (B C D and E) separate 
experiments, each with 6 (A and C) or 3 (D and E) replicates. Significantly different from 
untreated cultures * p<0.05, *** p<0.001, one–way ANOVA and post-hoc Tukey‟s test. Fig 4.6D 
performed in collaboration with Thea Hoskin. 
 
 
4.1.5 Effect of SSR180711 on Aβ1-42 toxicity 
 A number of studies suggest α7 nAChR agonists are protective against a 
variety of toxic insults (section 1.13.5.1.1). Activation of α7 nAChR by nicotine is limited 
by receptor desensitisation, particularly that evoked by higher, micromolar 
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concentrations (Couturier et al. 1990). As nicotine treatment proved ineffective against 
Aβ1-42 toxicity, a more directed α7-activation strategy was employed. The partial α7 
agonist SSR180711 (section 3.2.1) was tested for neuroprotective potential in a similar 
paradigm to nicotine. To circumvent receptor desensitisation, SSR180711 was also 
tested in the presence of PNU120596, an allosteric modulator that enhances receptor 
open time (Hurst et al. 2005). 
 A range of SSR180711 concentrations (0.01-1 μM), both in the absence and 
presence of PNU120596, produced no amelioration of the decreased MTT reduction 
(fig 4.7A), increased LDH release (fig 4.7B) or enhanced caspase activity (fig 4.7C) 
induced by aged-Aβ1-42. 
 
4.1.6 Effect of VOCC-inhibitors onAβ1-42 toxicity  
 The activity of L-type VOCC was essential for KCl- and nicotine-evoked 
increases in Ca2+, as treatment with the L-type VOCC inhibitor verapamil abolished 
Ca2+ increases induced by both compounds (section 3.1.2). Given the reported 
neuroprotection by L-type VOCC ligands (Ueda et al. 1997; Fu et al. 2006), the effect 
of verapamil on Aβ1-42 toxicity in PC12 cells was examined. The presence of verapamil 
did not alter the decreased MTT reduction (fig 4.8A), increased LDH release (fig 4.8B) 
or enhanced caspase activity (fig 4.8C) evoked by Aβ1-42. 
 
4.1.7 KLVFFA prevents toxicity induced by Aβ1-42 but not Aβ25-35 
 Numerous reports have identified oligomeric structures as the primary toxic 
species of Aβ (section 1.10.3). Incubation with KLVFFA prevented potentiation of Ca2+ 
responses by Aβ1-42 when applied acutely (section 5.2.4). The requirement of 
oligomerisation for Aβ1-42 toxicity was therefore assessed, by aging 30 μM Aβ1-42 in the 
presence of 100 μM KLVFFA prior to application to PC12 cells. In the presence of 
KLVFFA, Aβ1-42 elicited no change in MTT reduction (fig 4.9A), LDH release (fig 4.9B) 
and caspase activity (fig 4.9C), implying the oligomerisation of Aβ1-42 is essential for 
toxicity.  
 The specificity of the interaction between KLVFFA and Aβ1-42 was assessed 
by comparing responses to Aβ25-35 in the presence and absence of KLVFFA. The anti-
fibrilisation hexapeptide had no effect on changes in cell viability (fig 4.9A), LDH 
release (fig 4.9B) and caspase activity (fig 4.9C) evoked by Aβ25-35, in agreement with 
studies suggesting that KLVFFA interacts with the 16-21 sequence of Aβ1-42 (Tjernberg 
et al. 1996). 
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Fig 4.7 SSR180711 doesn’t prevent Aβ1-42 toxicity in PC12 cells 
PC12 cells treated with SSR180711 +/- PNU120596 for 24 hr before and during exposure to 
aged (24 h at 37ºC) 30 μM Aβ1-42 for 72 hrs. Toxicity assessed by (A) MTT reduction (B) LDH 
release (C) caspase activity. Data are expressed as a percentage of the control cells (A and C) 
or maximum LDH release (B). Data represent the mean  SEM of at least three separate 
experiments, each with 6 (A) or 3 (B and C) replicates. 
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Fig 4.8 Aβ1-42-induced toxic responses in PC12 cells are insensitive to verapamil  
PC12 cells were co-incubated with 10 μM Verapamil (Vera; hatched bars) and aged (24 h at 
37ºC) 30 μM Aβ1-42 for 72 hrs. Toxicity assessed by (A) MTT reduction (B) LDH release (C) 
caspase activity. Data are expressed as a percentage of the control cells (A and C) or maximum 
LDH release (B). Data represent the mean  SEM of at least three separate experiments, each 
with 6 (A) or 3 (B and C) replicates. 
  
4.1.8 (+)-nicotine partially inhibits Aβ1-42 aggregation and toxicity 
 Abolition of Aβ1-42 toxicity by KLVFFA highlights the requirement of 
oligomerisation for toxicity. This is supported by (-)-nicotine exhibiting neither anti-
fibrillogenic, nor protective properties in this system (fig 4.6).  As (+)-nicotine has been 
reported to possess greater anti-fibrillogenic character than (-)-nicotine (section 
1.11.4.1; Moore et al. 2004), the potency of the two nicotine enantiomers to prevent Aβ 
oligomerisation was directly compared.  
   A      B 
 
 
 
 
 
 
 
 
    C      
 
 
 
 
 
 
 
 
Fig 4.9 KLVFFA differentially affects 
amyloid-β toxicity in PC12 cells 
PC12 cells were incubated with aged (24 h 
at 37ºC) 30 μM Aβ1-42 or Aβ25-35 for 72 in the 
presence or absence of 100 μM KLVFFA 
(hatched bars). Toxicity assessed by (A) 
MTT reduction (B) LDH release (C) 
caspase activity. Data are expressed as a 
percentage of the control cells (A and C) or 
maximum LDH release (B). Data represent 
the mean  SEM of at least three separate 
experiments, each with 6 (A) or 3 (B and C) 
replicates. Significantly different from Aβ1-
42–treated * p<0.05, ** p<0.01 one–way 
ANOVA and post-hoc Tukey‟s test.  
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Fig 4.10 Stereoselective protection against Aβ1-42 toxicity by (+)-nicotine  
(A) Thioflavin T (20 μM) fluorescence during 37 C incubation with 30 μM Aβ1-42 in the absence 
(▲, solid line) and presence of 100 μM (+)-nicotine (○, dashed line) or 100 μM (-)-nicotine (■, 
dotted line), as described in the materials and methods.(B, C, D) Aβ1-42 (30 μM) was aged for 24 
h in the presence and absence of 100 μM (+)-nicotine or (-)-nicotine, before addition to PC12 
cells for 72 h. Mecamylamine (MEC; 20 μM) or α-bungarotoxin (α-Bgt; 1μM) were applied to 
PC12 cells 0.5 h before Aβ1-42/nicotine application and remained throughout. Toxicity was 
assessed by (B) MTT reduction (C) LDH release (D) caspase activity. Data are expressed as a 
percentage of the control cells (A and C) or maximum LDH release (B). Data represent the 
mean  SEM of at least three separate experiments, each with 6 (A) or 3 (B and C) replicates. 
Significantly different from un-treated cultures, * p<0.05, *** p<0.001; significantly different from 
Aβ1-42-treated cultures # p<0.05, ### p<0.001 one-way ANOVA and post-hoc Dunnett‟ test.  
 
 Increases in ThT fluorescence evoked by 30 μM Aβ1-42 over 66 h in the 
presence 100 μM (+)-nicotine, but not (-)-nicotine, exhibited significantly decreased 
aggregation coefficient (fig 4.10A) in comparison with Aβ1-42 alone. ThT fluorescence 
evoked by Aβ1-42 in the presence of (+)-nicotine reached a maximum plateau of similar 
magnitude to that achieved by Aβ1-42 alone, but required ~60 h to achieve this level, 
compared with ~24 h required by Aβ1-42 alone.  Thus, (+)-nicotine appears to delay, 
rather than prevent Aβ1-42 aggregation, in agreement with previous studies (Moore et al. 
2004). 
 Given the comparative antifibrillogenic potency of (+)-nicotine, the 
neuroprotective potential of (+)-nicotine was directly compared with (-)-nicotine. In 
A B 
C D 
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contrast to the treatment paradigm employed in all other experiments assessing the 
effect nAChR and VOCC ligands on A 1-42 toxicity, here, Aβ1-42 was aged in the 
presence of (+)- or (-)- nicotine, before addition to the cultures. Amyloid was exposed 
to nicotine in this manner in order for any interaction to occur prior to the formation of 
oligomeric structures, thus assessing the effect of inhibiting oligomerisation on toxicity.    
 Though treatment with (+)-nicotine produced no amelioration of diminished 
MTT metabolism by Aβ1-42 (fig 4.10B), LDH release was partially prevented (fig 4.10C; 
by 25.8 ± 1.7 %) and the increase in caspase activity was completely abolished (fig 
4.10D), in contrast to cultures treated with (-)-nicotine.   
 To assess the role of nAChR in this neuroprotection, cultures were 
preincubated with the nAChR broad-range antagonist MEC prior to addition of Aβ1-42, 
aged in the presence of (+)-nicotine. No significant attenuation of the reduction in LDH 
release or caspase activation evoked by (+)-nicotine was detected in the presence of 
MEC, compared with application of (+)-nicotine alone (fig 4.10C and 4.10D). This 
suggests the mechanism of neuroprotection by (+)-nicotine is not mediated by nAChR.  
 The enantiomers of nicotine exhibit stereoselective activity at nAChR. High 
affinity nicotine-binding sites, but not αBgt binding sites (α7 nAChR), exhibit a 
preference for (-)-nicotine (Wonnacott et al. 1986; (Zhang and Nordberg 1993). 
Accordingly, (+)-nicotine is reported to be less selective for α4β2 nAChR over α7 than 
(-)-nicotine (Marks et al. 1986). As this suggests that (+)-nicotine may act preferentially 
at α7 nAChR, cultures were also treated in parallel with the α7 nAChR antagonist α-
bgt. In a similar manner to MEC, no significant attenuation of the reduction in LDH 
release or caspase activation evoked by (+)-nicotine was detected in the presence of 
-bgt, compared with application of (+)-nicotine alone (fig 4.10C and 4.10D). This 
supports a lack of nAChR participation in neuroprotection by (+)-nicotine.  
 
4.2 Chapter 4: Discussion  
 In this chapter, the toxicity of Aβ1-42 was monitored in PC12 cells by assessing 
three markers of three distinct cellular processes: lactate dehydrogenase (LDH) 
release, caspase 3/7 activity and MTT reduction are indicative of plasma membrane 
integrity, apoptosis execution and redox potential, respectively. Aging Aβ1-42 was 
required for Aβ1-42 to evoke LDH release and caspase activity, suggesting 
oligomerisation is necessary for Aβ1-42 to reduce membrane integrity and induce 
apoptosis in this cell line. Accordingly, two structurally distinct compounds that inhibited 
oligomerisation of Aβ1-42 also attenuated all toxic responses to Aβ1-42. The extent of 
protection against Aβ toxicity by these compounds was mirrored by degree of 
oligomerisation-inhibition. However, attempts to prevent toxicity using a different 
approach, targeting nAChRs and VOCC, proved unsuccessful.  
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4.2.1 Aβ1-42 differentially induces cellular markers of toxicity 
 Application of aged, but not unaged, Aβ1-42 evoked LDH release and caspase 
activity, suggesting aging is required for Aβ1-42 to perturb membrane integrity and 
induce apoptosis. This agrees with previous studies that indicate freshly-dissolved or 
monomerically-defined Aβ1-42 is relatively innocuous (Shearman et al. 1994); 
Deshpande et al. 2006; Walsh et al. 2007).The results also indicate that Aβ1-42 must be 
aged in the absence of cells, as applying unaged Aβ1-42 for 96 h produced no LDH 
release or caspase activity,  while Aβ1-42 aged for 24 h, then applied to the cultures for 
72 h evoked increases in both markers.   
In contrast to the caspase- and LDH-responses, application of freshly-dissolved 
Aβ1-42 to PC12 cells for 24, 48 72 and 96 h decreased MTT metabolism, indicating 
diminished redox activity of the cultures. Though mitochondria, which mediate MTT 
reduction, have been implicated as primary targets of Aβ (Wang et al. 2007), the lack of 
concurrent LDH release or activation of caspase 3/7 suggests that decreases in MTT 
metabolism should be interpreted with caution.   
 
4.2.2 The MTT Assay: unreliable assay or early indicator of Aβ1-42-mediated 
neurotoxicity? 
 The MTT assay is extensively employed to monitor cell viability following 
toxic insults, including exposure to unaged Aβ, which consistently decreases MTT 
metabolism in this and previous studies (Kihara et al. 1997). However, neither LDH 
release nor caspase activity is apparent following any treatment with unaged Aβ1-42. 
This is consistent with reports that Aβ1-42 can decrease MTT formazan production in the 
absence of overt cell death, indicated by microscopic examination, neutral red uptake 
(Soriano et al. 2003) and LDH release (Shearman et al. 1994; Soriano et al. 2003; 
Wogulis et al. 2005). Hertel et al. (1996) showed that Aβ25-35 renders the cell 
membranes more susceptible to a secondary insult, such as MTT reduction, measured 
by LDH release. Proposed explanations for this observation include selective effects on 
membrane properties and exocytosis of MTT formazan crystals, the product of the 
assay that accumulates in the cytosol (Liu et al. 1997; section 2.2.4.1). However, if Aβ-
induced exocytosis of these crystals does impair the detection of MTT reduction, its 
interesting that verapamil did not block the decrease, as inhibition of L-type VOCC with 
nifedipine has been shown previously to prevent Aβ-induced MTT exocytosis (Liu et al. 
1997).  
 Amyloidogenic proteins such as Aβ can specifically alter the formation of 
MTT formazan crystals, generating needle-shaped crystals that puncture the plasma 
membrane (Shearman et al. 1995; Hertel et al. 1996). The uptake of typan blue in the 
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absence of LDH release (Hu et al. 1994) suggests the combined disturbance of the 
membrane by MTT and Aβ may allow passage of small molecules, but not larger 
proteins such as LDH. As these studies employed cell lines and primary cultures, 
Ronicke et al. (2008) extended the work by examining the effect of various Aβ peptides 
and oligomeric assemblies on MTT reduction in rat organotypic slices. Neither Aβ25-35 
(freshly dissolved), Aβ1-40 (oligomeric), Aβ1-40 (fibrillar) or Aβ1-42 (oligomeric) altered 
MTT reduction by the slices. This suggests the decrease in MTT reduction may 
represent an artefact of single cell culture.  In the present study, the presence of 
KLVFFA completely abolished the decrease in MTT metabolism evoked Aβ1-42, 
suggesting that, like other more reliable measures of toxicity, the effect is dependent on 
oligomerisation as Aβ1-42 . 
 The cascade(s) of events underlying Aβ1-42–evoked cytotoxicity are still 
unresolved. It may be expected that one biomarker will be detected in the absence of 
another as the processes that mediate marker generation and detection are likely to 
vary in sensitivity to a given toxicological insult. Early studies suggested that altered 
MTT reduction is an early indicator of Aβ toxicity (Shearman et al. 1994), so it is 
plausible that Aβ1-42 disruption of cellular metabolism occurs prior to activation of 
caspases and loss off membrane integrity. Supporting this hypothesis, mitochondrial 
dysfunctions have been reported in AD, including impairment of metabolic enzymes 
and respiratory chain complexes, autophagic degradation of mitochondria and high 
levels of mitochondrial DNA mutations (though none genetically linked to AD; (for 
review, see Chaturvedi et al. 2008). Levels of mitochondrial Aβ are also more prevalent 
in AD patient neurons and A  progressively accumulates in mitochondria of transgenic 
AD model neurons, where it is associated with diminished respiratory complex activity 
and oxygen consumption (Caspersen et al. 2005). In vitro, exogenous Aβ is actively 
taken up into mitochondria (Hansson and Petersen 2008), can impair mitochondrial 
transport in the absence of cell death or morphological changes (Rui et al. 2006) and 
inhibits the terminal respiratory complex, cytochrome C oxidase, of isolated 
mitochondria (Crouch et al. 2005). However, decreased cellular redox potential in the 
absence of overt cell death appears to be specific to the MTT assay and not limited to 
one Aβ peptide. Direct comparison with other redox dyes shows Aβ1-40 (Wogulis et al. 
2005) and Aβ25-35 (Hertel et al. 1996) treatment decreases MTT reduction without 
affecting alamar, XTT, MTS or WST-1 metabolism. Though the MTT assay still 
measures a cellular response to A , these reports cast suspicion over the reliability of 
the MTT assay as an indicator of Aβ-mediated neuronal cell death and highlight the 
importance of assessing multiple cytotoxic markers when investigating Aβ toxicity.  
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4.2.3 Aging is required to evoke Aβ1-42 toxicity 
 The results indicate aging is required for Aβ1-42 to evoke membrane perturbation 
and caspase activation in PC12 cells. This agrees with numerous other reports (section 
1.10.3.1), which suggest monomeric Aβ1-42 is relatively innocuous and implicate 
oligomeric assemblies in the toxicicity of Aβ. The current study also indicates that aging 
must occur in the absence of cells, as induction of LDH release and caspase activity by 
a 72 h application of Aβ1-42 aged for 24 h was not replicated by a 96 h application of 
unaged Aβ1-42. The innocuous nature of unaged Aβ may be explained by various 
interactions that Aβ is reported to have with cells in culture.  
 PC12 cells express a range of Aβ-degrading enzymes on the plasma 
membrane, including insulin degrading enzyme (IDE; Vekrellis et al. 2000; Qiu et al. 
1999) and angiotensin-converting enzyme (ACE; Dendorfer et al. 1997), which has 
been shown to inhibit aggregation, deposition and cytotoxicity by degrading Aβ1-40 (Hu 
et al. 2001). Interestingly, IDE is selective for monomeric Aβ (Vekrellis et al. 2000; 
Farris et al. 2003, 2004) and may therefore degrade unaged Aβ1-42 prior to the 
generation of toxic responses or oligomerisation. Though not attempted here, inhibition 
of ACE or IDE could determine the whether this detoxification system prevents the 
generation of toxic oligomeric species when Aβ1-42 is aged in the presence of PC12 
cells.  
 The association of Aβ with biological membranes, both synthetic and 
endogenous, has been widely reported (section 1.12.3.1). Moreover, this interaction 
has been linked to the in vitro uptake of Aβ species and accumulation in lysosomal 
compartments (Knauer et al. 1992; Chafekar et al. 2008), and corroborated by the 
subcellular topography of Aβ found in transgenic models (Langui et al. 2004). In 
agreement with these studies, PC12 displayed uptake of unaged flAβ1-42 in a time-
dependent manner.  
Several lines of evidence suggest that the uptake of Aβ is an early event in Aβ1-
42-toxicity (Yang et al. 1998), rather than a protective mechanism. In addition to poor 
degradation of Aβ1-42 in the lysosome (Knauer et al. 1992) accumulation of Aβ1-42, but 
not Aβ1-40, in this compartment can cause leakage of lysosomal enzymes (Ditaranto et 
al. 2001) resulting in apoptosis (Kroemer et al. 2005). This is supported by the 
prevention of Aβ1-42-induced reduction in MTT-metabolism by specific inhibition of 
lysosomal endocytosis (Chafekar et al. 2008). However, a reduced cytolosic 
distribution of aged flAβ1-42, compared with unaged peptide, was evident following 20 h 
application. This agrees with the size-dependance of Aβ uptake  (Chafekar et al. 2008). 
It has been proposed that larger Aβ1-42 assemblies formed during aging may remain 
bound to the plasma membrane, where they perturb membrane function, including the 
proper functioning of channels and receptors residing in the membrane (section 
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1.12.3.1), evoking dysfunctional ion homeostasis and finally resulting in a cascade of 
events leading to cell death.  
 It may be that sequestration of Aβ1-42 monomers or small oligomers prevents the 
generation of larger toxic assemblies when Aβ1-42 is aged in the presence of cells. 
Large fluorescent puncta were evident on the base of the poly-D-lysine-coated well 
following 20 h exposure of aged flAβ1-42. Thus, in addition to interacting with cells, flAβ1-
42 appears to bind to poly-D-lysine with sufficient affinity to resist displacement by 
extensive washing (section 2.2.8.2). The immobilisation of flAβ1-42 on the culture 
substratum would not only sequester oligomeric flAβ1-42 from the cultures, but also 
prevent monomeric flAβ1-42 from forming toxic oligomers in solution.   
 The correlation between aging and toxicity is reinforced by the differential 
toxicity of Aβ peptides. The decapeptide fragment, Aβ25-35, has been shown to 
aggregate under cell culture conditions at a faster rate than the full length peptide, such 
that aging is not required for the peptide to elicit toxicity (Forloni et al. 1993). In a direct 
comparison with Aβ1-42, (Pike et al. 1993) showed that aging is essential for Aβ1-42, but 
not Aβ25-35, to elicit morphological cytotoxic characteristics in hippocampal cultures. 
This has been corroborated by other studies, which have shown that aging produced 
no enhancement of LDH release evoked by Aβ25-35 (Shearman et al. 1994). Faster 
aggregation of Aβ25-35 would enhance the formation of toxic Aβ25-35 oligomers, which 
may explain the greater LDH release and caspase activity observed in the present 
studies following treatment with Aβ25-35, when directly compared with Aβ1-42.  
 
4.2.4 Oligomerisation is required for Aβ1-42 toxicity 
 The role of oligomerisation in Aβ1-42-induced toxicity was initially assessed by 
employing the hexapeptide D-KLVFFA, which corresponds to the „self recognition 
element‟ sequence located at residues 16-21 of Aβ1-42 (Tjernberg et al. 1996). In 
agreement with previous studies, an excess of D-KLVFFA prevented Aβ aggregation 
(Chalifour et al. 2003; Watanabe et al. 2002). As these reports only employed the MTT 
assay to assess Aβ-toxicity, the effect of D-KLVFFA on membrane integrity and 
apoptosis execution was also determined. An excess of D-KLVFFA prevented both 
LDH release, in agreement with Evans et al. (2008), and caspase activity induced by 
Aβ1-42. The mechanism(s) that may mediate prevention of Aβ1-42-evoked toxicity by 
KLVFFA are discussed in section 7.4.1. 
 The binding site of D-KLVFFA is located in the corresponding Aβ16-21 region 
of the full length peptide (Tjernberg et al. 1997; Tjernberg et al. 1996). The absence of 
this region from the Aβ25-35 fragment explains the lack of protection of PC12 cells by D-
KLVFFA against Aβ25-35-induced toxicity. Although the self-recognition element is 
absent in the Aβ25-35, the fragment is still capable of fibrilisation (Forloni et al. 1993), 
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suggesting that other regions are also involved in the aggregation of Aβ. This is 
supported by reports that decamer Aβ peptides consisting of sequences distant form 
the self recognition element can interact in vitro, albeit to a lesser extant than those 
peptides containing the KLVFFA motif (Tjernberg et al. 1996).  
 
4.2.5 nAChR activation does not protect PC12 cells against Aβ1-42toxicity 
 Although epidemiological meta-analyses suggest that smoking does not 
correlate with a decreased onset of AD (Almeida et al. 2002), studies indicate that 
nicotine can alleviate AD symptoms (section 1.13.4), inhibit the accumulation of Aβ 
deposits in transgenic AD models (Nordberg et al. 2002) and prevent Aβ cytotoxicity in 
vitro (Kihara et al. 1997). Furthermore, activation of α7 nAChR has been implicated in 
nicotinic protection against Aβ toxicity, as specific inhibition of this subtype prevents 
neuroprotection by nicotine (section 1.13.5.1.1). In this study, however, no amelioration 
of reduced MTT metabolism, LDH release or caspase activation by Aβ1-42 was detected 
following (-)-nicotine treatment. As the selective inhibition of α7 nAChR was therefore 
not possible, activation of α7 nAChR by the partial agonist SSR180711 (section 3.2.1) 
was undertaken.  
Application of SSR180711 failed to attenuate decreased MTT reduction, LDH 
release or caspase activation evoked by aged Aβ1-42. As α7 nAChR rapidly desensitise 
(section 1.13.5.2.2), it is possible that activation is insufficient to stimulate pro-survival 
signalling cascades. To prevent receptor desensitisation, SSR180711 was also applied 
in the presence of PNU120596, without affecting any marker of Aβ1-42 toxicity. Possible 
explanations for the lack of protection by nAChR activation and VOCC inhibition are 
discussed in sections 7.2.2 and 7.3, respectively. 
 
4.2.6 Nicotine stereoselectively inhibits Aβ fibril formation 
 Following a lack of protection evoked by activation of nAChR, the role of other, 
nAChR-independent activities of nicotine were assessed for neuroprotective potential. 
As nicotine has been reported to inhibit Aβ fibril formation (Moore et al. 2004) and to 
break down pre-formed fibrils (Ono et al. 2002), the anti-fibrillogenic character of both 
nicotine enantiomers was assessed. A direct comparison revealed that an excess of 
(+)-nicotine, and to a lesser, insignificant extent (-)-nicotine, inhibited Aβ1-42 fibril 
formation. However, rather than completely preventing aggregation like D-KLVFFA, 
(+)-nicotine merely slowed the rate of aggregation, which eventually reached the same 
state of aggregation as Aβ1-42 in the absence of (+)-nicotine. This may explain why a 
previous study, which only assessed the state of oligomerisation after a long time 
period, reported a lack of oligomerisation inhibition by (+)-nicotine  (Kihara et al. 1999).  
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 The lack of (-)-nicotine inhibition also conflicts with previous studies, but may be 
explained by the Aβ preparations used. Ono et al. 2002) reported that (-)-nicotine 
prevented Aβ1-40 and Aβ1-42 fibril formation with equal potency. However, the 
concentration of nicotine required to inhibit fibril formation was two orders of magnitude 
higher than that used in this study. To achieve these concentrations in the CNS would 
require nicotine administration beyond that tolerated in vivo (Matta et al. 2007). 
However, (Moore et al. 2004) showed equimolar nicotine can prevent Aβ1-40 fibril 
formation, with greater, but not total inhibition by an excess of nicotine. They went on to 
show that (+)-nicotine is more effective than (-)-nicotine, in agreement with the present 
study.  
   
4.2.7 Nicotine stereoselectively inhibits Aβ1-42 toxicity  
 After observing the superior anti-fibrillogenic activity exhibited by the (+) 
enantiomer, the neuroprotective action of (+)-nicotine was assessed in direct 
comparison with (-)-nicotine.  The partial inhibition of Aβ oligomerisation by (+)-nicotine 
was reflected in neuroprotective character. Although (+)-nicotine prevented caspase 
activation, it only partially inhibited LDH release and was ineffective against reduced 
MTT metabolism. In comparison, the same concentration D-KLVFFA produced a 
complete inhibition of all three cytotoxic markers.  
 The correlation between anti-fibrillogenic nature and neuroprotective 
character of D-KLVFFA, (+)-nicotine and (-)-nicotine suggests (+)-nicotine 
neuroprotection is not mediated by nAChR. Moore et al. (2004) attempted to 
investigate the role of nAChR in (+)-nicotine-neuroprotection by aging Aβ1-40 in the 
absence of (+)-nicotine. As the application of aged Aβ1-40 with (+)-nicotine produced no 
reduction in MTT metabolism, the authors ruled out the participation of nAChR. Other 
studies, however, suggest nicotine pretreatment of cultures is required (Gahring et al. 
2003). The differential pharmacology of nicotine enantiomers at nAChR is discussed in 
section 7.3.   
 The ability of (+)-nicotine to protect PC12 from Aβ1-42 toxicity when Aβ1-42 was 
aged in the absence of (+)-nicotine was not attempted as Moore et al. (2004) indicate 
that (+)-nicotine acts at an early step in Aβ aggregation, consistent with the thioflavin 
analysis here. Furthermore, NMR studies indicate nicotine interacts with monomeric Aβ 
in an α-helical conformation (Salomon et al. 1996) and small, soluble β-sheet 
aggregates, not with larger Aβ assemblies. Disaggregation of preformed fibrils (Ono et 
al. 2002) may occur by nicotine binding monomeric Aβ and shifting the dynamic 
aggregation/disaggregation equilibrium.  
Confirming that nAChR activity does not mediate this protection, (+)-nicotine 
retained neuroprotective activity in the presence of two separate nAChR antagonists.  
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This does not, however, rule out other possible actions of (+)-nicotine: both 
enantiomers can quench ROS evoked during Aβ exposure (Moore et al. 2004) and 
ROS have been shown to facilitate Aβ aggregation (section 1.12.1.1). In view of the 
majority of studies reporting neuroprotection by stimulation of nAChR, another system 
was sought to assess the neuroprotective potential of nAChR activation. The effect of 
nicotinic and VOCC ligands on Aβ1-42-evoked toxicity in rat primary cortical cultures is 
assessed in chapter 6. As nAChR activity can stimulate signalling cascades implicated 
in cellular survival and death, the effect of acute application of Aβ1-42 on Ca
2+ signalling 
evoked by nAChR and VOCC ligands is assessed in chapter 5.  
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Chapter 5: acute application of A 1-42 potentiates Ca
2+ rises in PC12 cells  
 
In this chapter, the modulation of Ca2+ levels by acute application of A  is 
assessed. As discussed in chapter 1, dysregulation of Ca2+ homeostasis is consistently 
observed in cases if AD. Here, the role of Ca2+ in the neuropathological mechanism of 
AD, the cytotoxic mechanism of A  and the pharmacological components mediating 
these effects will be discussed in further detail.  
 
5.1 Dysregulation of Ca2+ homeostasis in AD 
Maintaining Ca2+ homeostasis is critical for neuronal viability, both acutely and 
throughout the lifetime of an organism (Berridge et al. 1998; Berridge et al. 2000; 
Toescue and Verkhratsky 2003). Disruption of Ca2+ homeostasis has been linked to 
cognitive decline in normal aging processes (LaFerla et al. 2002; Mattson and Chan 
2003; Stutzmann et al. 2004; Toescue et al. 2004). However, perturbations linked to 
both inherited and sporadic forms of AD do not appear to merely be accelerated or 
amplified signalling changes associated with aging, but are specific pathogenic 
changes in the balance of Ca2+ (Stutzmann et al. 2005; Verkhratsky et al. 2005; 
Stutzmann et al. 2006). Sustained dysregulation of Ca2+ homeostasis forms the basis 
of the Ca2+ hypothesis of AD, which proposes that sustained alteration in the 
maintenance of intracellular Ca2+ homeostasis is key to neuronal perturbation in AD 
(Khachaturian et al. 1987; reviewed in Stutzmann et al. 2007).  
 
5.1.1 Aβ causes increases in intracellular Ca2+ 
In vitro, A  peptides are reported to induce a range of pathological events 
associated with Ca2+ influx, including altered Ca2+-dependent kinase activity, tau 
phosphorylation and ultimately cell death (Ekinci et al. 1999; Ekinci et al. 2000). The 
rise of intracellular Ca2+ levels has been implicated as a key mediator of Aβ toxicity, as 
removal or chelation of extracellular or intracellular Ca2+ is reported to prevent the other 
cellular responses (Ekinci and Shea 2000; Ekinci et al. 1999; Ekinci et al. 2000; Shea 
et al. 1997).  
A  was initially reported to render cortical neurons susceptible to glutamate 
excitotoxicity by an increase in intracellular Ca2+ (Mattson et al. 1992). Aβ-induced rises 
in intracellular Ca2+ have since been reported in numerous studies (Mattson et al. 1993; 
Huang et al. 2000; Price et al. 1998), which have postulated several mechanisms. In 
addition to direct alteration of membrane permeabilisation (section 1.12.3.3), Aβ is 
reported to affect Ca2+ homeostasis by modulating the activity of endogenous 
membrane channels, including Ca2+-efflux pumps (Berrocal et al. 2009), ligand-gated 
ion channels and channels stimulated by changes in membrane potential. Several of 
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these targets have also been implicated in A  toxicity, including nAChR (discussed in 
section 5.1.2.2), NMDA receptors (section 6.1.2) and VOCC (section 5.1.2.1). The 
activity of A  at these sites has been the subject of numerous, often conflicting, reports. 
Aβ is reported to both increase and decrease channel activities, acting directly, as an 
agonist, antagonist or potentiator, but also through indirect mechanisms, including 
modulating protein expression and distribution, and by interacting with membranes.    
  
5.1.2 Aβ modulates VOCC activity 
VOCC are a family of transmembrane ion channels with selective Ca2+-
permeability found in excitable cells. At resting membrane potential, VOCC are 
normally in a closed conformation. Upon depolarisation of the membrane, the channel 
opens, allowing Ca2+ flux across the membrane (Reviewed in Dolphin et al. 2006). 
Members of the VOCC family can be distinguished by their inhibition by specific drugs 
and toxins (table 5.1; section 3.1.2).  
 
Type  Selective inhibitor  Voltage-activation 
L –type 
(“Long-lasting”)  
Nimodipine 
Verapamil 
1,4-dihydropyridine 
Nifedipine 
Diltiazem 
Nimopridine 
MEM1003 
High-voltage 
activated 
N-type  
(“Neural”)  
-conotoxin GVIA  
-conotoxin MVIIC 
High-voltage 
activated 
P/Q type (“Purkinje”) -agatoxin IVA High-voltage 
activated 
R-type  
(“Residual”) 
SNX-482 Intermediate-voltage 
activated 
T-type  
(“Transient”) 
 Low-voltage 
activated 
 
Table 5.1. Selective inhibitors of VOCC (Dolphin et al. 2006) 
 
The role played by VOCC in Aβ toxicity and intracellular Ca2+ rises is assessed 
in the current study. Davidson et al. (1994) initially reported 24 h application of 
micromolar A 1-40 increased inward cation currents, measured using whole cell 
electrophsiological recording in neuroblastoma cells. Addition of the peptide to the 
pipette evoked currents indicative of an alteration in the opening of a cation channel. In 
a subsequent report, the broad-spectrum VOCC blocker chlorpromazine prevented 
45Ca2+ uptake and cytotoxic responses in rat cortical cultures induced by chronic 
exposure to micromolar A 25-35 (Ueda et al. 1997b). To identify the VOCC subtype 
mediating the response, a range of selective VOCC inhibitors was employed (Ueda et 
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al. 1997a): nimodipine, -conotoxin GVIA ( ctx-GVIA), -conotoxin MVIIC (Ueda et al. 
1997b) and -agatoxin IVA ( -aga-IVA; table 5.1). Only co-incubation of nimodipine 
with A 25-35 prevented increased 
45Ca2+ uptake and attenuated toxic responses in the 
cultures, suggesting L-type VOCC mediate Ca2+ influx and neurotoxicity induced by 
Aβ25-35. The role of L-type VOCC in A -induced rises in intracellular Ca
2+ has been 
supported by studies employing other selective inhibitors of this subtype, including 
verapamil, nifedipine and diltiazem (Silei et al. 1999). Micromolar A 1-40 has also been 
shown to increase intracellular Ca2+ in rat cortical cultures in a manner similar to A 25-
35, the action of both peptides being sensitive to the L-type VOCC blocker nimopridine, 
but not the NMDAR channel blocker MK801 (Ho et al. 2001). However, A 1-40 has also 
been shown to cause a significant increase in 45Ca2+ influx into rat cortical 
synaptosomes via activation of N-type, as well as L-type, VOCC and also increased the 
amplitude of N- and P-type Ca2+ channel currents recorded from cultured cortical 
neurons (MacManus et al. 2000).   
Extending the findings of Ueda et al, Fu et al. 2006 indicated that Ca2+ 
increases are independent of A  peptide length or aggregation; A 25-35, A 1-42 and 
soluble oligomeric A 1-42 evoked similar, nimodipine-sensitive increases in fluorescence 
in fluo-3-loaded cortical neurons. This study also demonstrated concentration-
dependent neuroprotection of cortical cultures by nimodipine against A 25-35 and 
soluble oligomeric A 1-42 toxicity. No other VOCC inhibitors, including ctx-GVIA, -
aga-IVA or SNX-482, a blocker of R-type VOCC, exhibited any protective activity. 
Furthermore, the increase in intracellular Ca2+ evoked by Aβ was dependent on 
extracellular Ca2+, in agreement with other studies (Demuro et al. 2005; Ekinci and 
Shea 2000; Ekinci et al. 1999; Ekinci et al. 2000; Shea et al. 1997), and insensitive to 
depletion of intracellular Ca2+ stores.  
The mechanism by which A  increases intracellular Ca2+ has been addressed 
by several studies. Phosphorylation of VOCC has been implicated in upregulation of 
the channels  (Lei et al. 1998; Blair et al. 1999; Martin et al. 2006). Ekinci et al. 1999 
assessed the role of kinase activity in A -induced cellular Ca2+ accumulation.  
Exposure of rat cortical neurons and SHSY-5Y cells to A 25-35 and A 1-40 increased 
levels of VOCC phosphorylation, intracellular Ca2+, oxidative stress, phospho-tau 
immunoreactivity and apoptosis, all of which were attenuated by mitogen-activated 
protein kinase (MAPK), but not PKA, inhibition. The role of MAPK in A  toxicity and 
neuroprotection will be further discussed in section 1.13.5.2.3. Interestingly, enhanced 
VOCC activity appears to be independent of, or lie downstream of, oxidative stress, as 
nimodipine is reported to have no effect on the production of ROS by A 25-35 (Ueda et 
al. 1997b). Consistent with the latter view, α-tocopherol reduced ROS levels, 
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attenuated toxicity and reduced 45Ca2+ uptake, suggesting L-type VOCC activation 
could result from Aβ-evoked ROS. 
With the exception of Fu et al. 2006, all the studies discussed so far applied 
structurally-undefined, micromolar A  and observed increased VOCC activity. 
However, pathophysiological (nanomolar concentrations) of a specific 48 kDa 
oligomeric Aβ1-42 assembly suppressed spontaneous currents mediated by P/Q-type 
VOCC (Nimmrich et al. 2008), suggesting the effect of Aβ on VOCC may be 
determined by oligomeric state and concentration. This is in contrast to the nimodipine-
sensitive increases reported by Fu et al. 2006, which were evoked by a range of Aβ 
peptides and oligomeric stuctures. A study by Rovira et al. (2002) found application of 
both oligomeric A 25-35 and A 1-40, at nanomolar levels, increased currents recorded in 
hippocampal slices, although only currents enhanced by A 25-35 were inhibited by the L-
type VOCC inhibitor nifedipine (Rovira et al. 2002). 
The role played by L-type VOCC in Aβ toxicity in vivo has also been assessed. 
Frier et al. (2003) reported an impairment of in vivo hippocampal LTP by an 
intracerebroventricular injection of A 25-35, which was inhibited by an intraperitoneal 
injection of verapamil (Freir et al. 2003). Addressing any possible systemic actions of 
the drugs, the effects on LTP in CA1 region of the hippocampal slice preparation were 
also assessed. Bath application of 500 nM A 25-35 significantly impaired LTP in the CA1 
region. This also was prevented by verapamil, in agreement with Rovira et al. 2002, 
though another study indicates A 25-35 and A 1-42 impair LTP in rat hippocampal 
neurons without affecting voltage-dependent Ca2+ currents (Nomura et al. 2005). As L-
type VOCC are postsynaptic, their activity may depend on the nature of the LTP model, 
whether or not there is a strong presynaptic facilitation.   
As many VOCC inhibitors are antihypertensive medications, their 
pharmacolvigilance, pharmacokinetics and pharmacodynamics have already been 
extensively characterised. Furthermore, several VOCC inhibitors prescribed for 
hypertension may reduce the risk of developing dementia (reviewed in Khachaturian et 
al., 2006). In particular, nimodipine is reported to have some benefits in clinical trials 
with AD patients (Fritze et al. 1995). A meta-analysis of clinical studies suggests that 
the inhibitor may slow progression of the disease rather than improve symptoms 
(Lopez-Arrieta et al. 2002). This has lead to frequent prescription of nimodipine for 
cognitive impairment and dementia in several continental European countries (Lopez-
Arrieta et al. 2002). A derivative of nimpodipine (MEM1003) with superior 
pharmacokinetic properties has exhibited similar beneficial effects (Lowe et al. 2006) 
and has completed a phase II trial. 
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5.1.3 A  interacts with nAChR 
As discussed in section 1.8.1, transgenic models develop learning deficits well 
before neuron death (Irizarry et al. 1999), indicating a disturbance of normal cholinergic 
signalling prior to neuronal loss. Supporting this notion, A 1-42 has been reported to 
bind competitively to 7 nAChRs with picomolar affinity (Wang et al. 2000a; Wang et 
al. 2000b) and to 4 2 nAChRs with nanomolar affinity (Wang et al. 2000b). Interaction 
with nAChR has been proposed to serve as a nucleation point of amyloid plaques 
(Clifford et al., Siu et al., 2008) and the resulting perturbation of the membrane (section 
1.12.3.3) may explain the predominant degeneration of cholinergic systems. 
Furthermore, competition with Aβ at the agonist binding site may explain why both 
agonists and antagonists at nAChR can be neuroprotective against A  (section 1.13.5).  
A similar interaction with α7 nAChR has been reported with A 1-40 (Wang et al. 
2000a). The expression 7 and 4 subunits is also reported to positively correlate with 
A -accumulating neurons, while 7 nAChR have been found to co-distribute with senile 
plaques (Wevers et al. 1999). A  has also been shown to co-immunoprecipitate with 
7 nAChR in human (Wang et al. 2000b) and rat (Soderman et al. 2008) brain 
homogenates, which was prevented with the peptide fragment A 12-28, suggesting the 
binding site lies within the residues 12-28 of A . Accordingly, A 12–28 reduced 
carbachol-induced currents in stratum radiatum interneurons in hippocampal slices via 
a decrease in the probability of a7 nAChR-gated channel opening (Pettit et al. 2001).  
Like so many activities of A , the interaction of A  with nAChR is the subject of 
conflicting reports. Binding of A 1-42 to 7 nAChR is also reported to be irreversible, 
while A 1-40 is reported to exhibit lower, reversible, inhibitory activity (Lee et al. 2003). 
Other studies, however, have detected no displacement of nAChR-radioligands by A  
peptides from endogenous or recombinant 7 nAChR, in cultured cell lines, slices nor 
brain extracts (Small et al. 2007; de Fibre et al. 2005). A 1-42 was also found not to 
influence the activity of 7 nAChRs heterologously expressed in Xenopus oocytes, 
while plasmon resonance data suggested A  interacts with lipid, rather than protein 
components of the membrane (Small et al. 2007). Other targets of A  on cholinergic 
neurons have been identified, such as the high-affinity choline transporter (Bales et al.  
2006), and proposed to account for the specific loss of cholinergic neurons in AD.  
 
5.1.3.1 Activity of A  at nAChR 
The functional consequences of A  interacting with nAChR are also the subject 
of conflicting reports. Initial studies indicated A  can inhibit single channel nAChR 
currents in rat hippocampal interneurons (Pettit et al. 2001), currents recorded from 
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Xenopus oocytes heterologously expressing human 7 nAChR (Tozaki et al. 2002; 
Grassi et al. 2003; Pym et al. 2005) and from a desensitization-resistant 7 nAChR 
mutant (Dineley et al. 2002; Grassi et al. 2003). The latter studies indicate A  
desensitises the receptor, rather than blocks the channel, which is supported by a lack 
of outward current resulting from channel de-block. Furthermore, nicotine was able to 
fully and rapidly activate 7 nAChR following removal of A , consistent with an 
unblocked channel. In vivo, SSR180711-evoked increase in Fos (section 3.2.1) in the 
shell of the nucleus accumbens is not evident in mice overexpressing hAPPSwe 
(Soderman et al. 2008), suggesting Aβ1-42 overexpression blocks α7 nAChR activity. 
 
 128 
 
 
 
 
 
 129 
 
Several groups have reported a reduction of 7 nAChR-mediated currents by 
Aβ in hippocampal (Liu et al. 2001) and cortical (Kar et al. 2004) neurons in culture. 
However, others have detected no block of 7 nAChR-mediated currents in Xenopus 
oocytes (Small et al. 2007). A 1-42 is also reported to block 4 2, 2 2 and 4 5b2 
nAChR subtypes expressed in ooctyes (Lamb et al. 2005) and 4 2 nAChR expressed 
in human SH-EP1 cells (Wu et al. 2004). Furthermore, A 1-42 can suppress 
hippocampal LTP in vivo in an 4 2 nAChR-dependent manner. In a rare comparative 
study, A 1-42 was reported to block 7 nAChR heterologously expressed in oocytes, to 
transiently activate 4 2 nAChR, while 3 4 activity was unaffected (Pym et al. 2005). 
This subtype specificity was not reproduced by the toxic fragment Aβ25-35 (Pym et al. 
2007).  
So far, only inhibition of α7 nAChR by Aβ has been discussed. However, A 1–42 
is also reported to activate heterologously expressed nAChRs (Dineley et al. 2002), 
and Aβ25-35 has been shown to activate non- 7 nAChRs in rat basal forebrain neurons 
(Fu and Jhamandas, 2003) and to evoke a 7- mediated Ca2+ increases in presynaptic 
terminals isolated from rat hippocampus and neocortex (Dougherty et al. 2003). The 
conflicting reports may be explained by concentration-dependence. At 10pM A  is 
reported to evoke rat (Dineley et al. 2002), but not human (Pym et al. 2005), 7 
nAChR-mediated currents in oocytes, while 100 pM of the same A  preparation 
blocked nicotine responses via desensitization (Dineley et al. 2002; Puzzo et al. 2008). 
A likely explanation for many discrepancies may be the aggregation state of the A  
used, which is notoriously sensitive to the method of preparation and storage (Teplow 
et al., 2006; discussed further in section 7.3). 
 
5.1.3.2 Mediation of A -evoked cellular responses by nAChR  
Though nAChR have been implicated in nicotine neuroprotection against A , it 
appears that the receptors may also mediate the toxicity of A . A reduction in 7 
nAChR levels by siRNA is reported to attenuate Aβ-induced reductions in cell viability, 
suggesting the receptor mediates toxicity of the peptide (Nordberg et al. 2007). 
However, cortical cultures from an 7 nAChR-null mouse did not display reduced A  
toxicity, suggesting A  may also act through other mechanisms (de Fiebre et al. 2005).  
Binding of A  to α7 nAChR is reported to induce internalisation of the 7 
nAChR-A  complex, as the rate of intracellular A  accumulation in human 
neuroblastoma SH-SY5Y cells is dependent on the level of 7 expression (Nagele et 
al. 2002). This may be important, as intracellular accumulation of A  is believed to 
contribute to cell death (D‟Andrea et al. 2001). Neurons in AD brains expressing high 
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levels of α7 nAChR have also been found to contain large amounts of intracellular Aβ 
(Nagele et al. 2002). The signalling pathways evoked by the accumulation of 
intracellular Aβ resemble those evoked by extracellularly applied A  and found to be 
activated in transgenic models.  
A  is reported to initiate intracellular signalling cascades via nAChRs, including 
the MAPK kinase signalling pathway, resulting in cell death. In hippocampal slices, A -
induced activation of the MAPK, Erk-2 was blocked by α7 antagonists, suggesting that 
Aβ stimulates the cascade through α7 nAChRs (Dineley et al. 2002).  Paradoxically, it 
appears that both Aβ and nicotine (Nakayama et al. 2001; Dickinson et al. 2008) can 
activate the MAPK pathway via α7 nAChR, though they may do so via distinct 
intermediate kinases (Bell et al. 2004). The extent of activation may also determine 
whether the MAPK activation results in pro-survivial or neurotoxic signalling. Chronic 
activation of the MAPK pathway by A 1-42 eventually leads to down-regulation of 
MAPK, which is proposed to induce a positive feedback for A -accumulation and 
decreased phosphorylation of the cAMP-regulatory protein, a necessary component for 
hippocampus-dependent memory formation in mammals (Reviewed in Weeber et al. 
2002). The activation of kinases by 7 nAChR-mediated A  activity has also been 
linked to Tau hyperphosphorylation (section 1.3.2; Wang et al. 2003; Hu et al. 2008) 
and dopamine release in the prefrontal cortex (Wu and Khan 2007).  
In addition to the downregulation of Erk2 by A 1-42, Dineley et al. (2001) 
reported a concomitant increase in 7 nAChR expression in the hippocampal slices. 
This was also observed in the Tg2576 transgenic model, and correlated with Morris 
water maze performance. Thus, although a reduction in 7 nAChR is associated with 
AD, A  may increase the expression of 7 nAChR in some environments (Fodero et al. 
2004), but not others. In PC12 cells, Guan et al. 2001 reported suppressed expression 
of nAChR by nanomolar A . In agreement, levels of 4, 7 and 2 nAChR subunits in 
the hippocampal CA1 region were substantially reduced in rats treated chronically with 
a mixture of A 1-40 and A 1-42 (Srivareerat et al. 2009). This reduction was attenuated 
by treatment with nicotine before and during A  administration. In addition to improved 
behavioural impairments, an increase in 7 nAChR in the CA3 region was exhibited by 
mice expressing APPSwe following treatment with nicotine, compared with saline-treated 
controls (Unger et al. 2006; Shim et al. 2008). 
The lack of consensus about the effects and mode of action of A  on Ca2+ 
signalling and nAChR function may reflect, in part, diversity of the cellular models used 
and variation in the aggregation state of A . This has prompted a systematic study to 
examine the effects of A  on nAChR-mediated Ca2+ signalling in vitro.  
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5.2 Results: Acute Aβ1-42 application potentiates Ca
2+ responses 
 
Experimental Aims 
 
1) The effect of acute application of A  peptides on Ca2+ levels are compared in 
PC12 cells.  
2) The pharmacological components mediating the change in Ca2+ levels is 
assessed.  
3) The oligomeric species of A 1-42 responsible for  the change in Ca2+ levels is 
determined.  
 
5.2.1 Efect of Aβ1-42 on intracellular Ca
2+ levels 
A  was examined for effects on Ca2+ levels in PC12 cells using fluorescent 
assays as described in section 3.1.2. Different species of A  were compared at  
concentrations detected physiologically (picomolar) and pathologically (nanomolar). To 
generate low moleucular weight olgiomeric assembles, 30 μM Aβ1-42 was aged for 0.5 h 
at 37°C and diluted immediately before addition to PC12 loaded with fluo-3. Acute 
application of 0.1 pM – 100 nM Aβ1-42 did not alter the fluorescence (fig 5.1A), 
indicating a lack of change in intracellular Ca2+ concentration. Several reports suggest 
Aβ1-42 acts as an agonist at α7 nAChR (section 5.1.2). As a positive allosteric 
modulator is required to reveal α7 nAChR activity in this and other in vitro systems 
(Dickinson et al. 2007; Innocent et al. 2008; see section 3.1.2), Aβ1-42 was also applied 
in the presence of PNU120596 (10 μM, 1 min preincubation; fib 1B). Even in the 
presence of this modulator, Aβ1-42 evoked no change in fluorescence, in contrast to the 
application of 30 uM nicotine that produced a robust increase in fluorescence that was 
further increased in the presence of PNU120596 (fig 5.1A). The lack of effect of Aβ1-42 
suggests that it does not directly affect Ca2+ levels in PC12 cells when applied acutely.  
 
5.2.2 Aβ1-42 potentiates nicotine-evoked increases in intracellular Ca
2+  
In addition to reports of Aβ1-42 acting as an agonist at nAChR, studies have also 
found that Aβ1-42 can inhibit and potentiate Ca
2+ currents mediated by these receptors 
(section 5.1.2). As the binding kinetics of Aβ1-42 at nAChR is the subject of conflicting 
reports, PC12 cells were incubated with the same concentrations of Aβ1-42 aged for 0.5 
h at 37°C for 10 min, the time period employed for α-bgt, which exhibits relatively slow 
binding kinetics. Application of A 1-42 potentiated nicotine-evoked increases in 
fluorescence by 152.3 ± 19.0 % (fig 5.2A). Examination of the change in fluorescence 
over 20s following nicotine application (fig 5.2B) shows Aβ1-42 treatment enhanced both 
the initial rate of fluorescence increase and the maximum fluorescence achieved. In 
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contrast, parallel treatment of cultures with the Aβ25-35 fragment, which is frequently 
employed as a substitute for the full-length peptide (section 1.6), produced no effect on 
nicotine-evoked responses (fig 5.2A). 
 
  A      B 
 
 
 
 
 
 
 
 
Fig 5.1 Acute application of Aβ1-42 produces no change in Fluo-3 fluorescence  
Acute application of Aβ1-42 (aged for 0.5 h at 37 ºC) or 100 uM nicotine to PC12 cells loaded 
with fluo-3 in the absence (A) or presence (B) of PNU120596 (10 uM, 1 min preincubation). 
Change in fluorescence was monitored over 20 s following stimulation. (Inset) Representative 
traces of change in fluorescence in response to 100 uM nicotine in the presence and absence 
of PNU120596 and Aβ1-42 in the presence of PNU120596. Data represent maximum 
fluorescence reached over 20 s, as a percentage of response to 100 μM nicotine. Data 
expressed as mean ± SEM from at least three separate experiments each with 4 replicates. 
Assays performed in collaboration with Thea Hoskin.  
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Fig 5.2 Aβ1-42 potentiates nicotine-evoked increases in fluo-3 fluorescence 
PC12 cells loaded with fluo-3 were preincubated for 10 min with amyloid-β peptides (100 pM 
aged for 0.5 h at 37 ºC) or vehicle (0.2 % DMSO 3.4x10
-4
 % trifluoroacetic acid) and stimulated 
with 30 μM nicotine. (A)Data represent maximum fluorescence reached over 20 s, as a 
percentage of response to 30 μM nicotine. Data expressed as mean ± SEM from at least three 
separate experiments, each with 4 replicates. Significantly from vehicle-treated control *** 
p<0.001; significantly from Aβ1-42-treated cultures  ### p<0.001, one–way ANOVA and post-hoc 
Tukey‟s test. (B) Representative trace of change in fluorescence evoked by to 30 μM nicotine in 
the presence and absence of 100 pM Aβ1-42. Assay performed in collaboration with Thea 
Hoskin.  
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Pretreatment with the broad-range nAChR antagonist mecamylamine prevented 
stimulation by nicotine in the presence and absence of Aβ1-42, confirming an absolute 
requirement for nAChR activation in order to observe Aβ1-42-potentiaiton of nicotine-
evoked increases (fig 5.2A) 
 
5.2.3 α7 and non-α7 nAChR-mediated responses are potentiated by Aβ1-42 
As Aβ1-42 is reported to interact with both α7 and non-α7 nAChRs (section 
5.1.2), the subtypes responsible for amplifying nicotine-evoked rises in Ca
2+
 were 
examined by employing subtype-selective agonists.  
 
          A             B          C   
 
 
 
 
 
 
 
 
 
Fig 5.3 Aβ1-42 potentiates increases in fluo-3 fluorescence evoked by selective nAChR 
agonists 
Following a 10 min incubation with Aβ1-42 (100 pM aged for 0.5 h at 37 ºC), PC12 cells loaded 
with fluo-3 were stimulated with (A) 10 nM compound A in the presence and absence of PNU-
120596 (10 μM; added 1 min before the end of pre-incubation) (B) 1 μM SSR180711 in the 
presence and absence of PNU120596 (10 μM; added 1 min before the end of pre-incubation) 
(C) 30 μM 5-I-A85380 and change in fluorescence monitored for 20 s. Data represent maximum 
fluorescence reached over 20 s, as a percentage of response to 30 μM nicotine. Data are 
expressed as mean ± SEM from at least three separate experiments, each with 4 replicates. 
Significantly different from cultures lacking Aβ1-42 pre-incubation * p<0.05, *** p<0.001; 
significantly different from cultures preincubated with Aβ1-42 and PNU120596 and stimulated 
with SSR180711, # p<0.05, one-way ANOVA and post-hoc Tukey‟s test.  
 
A 10 min preincubation with 100 pM Aβ1-42 (aged for 0.5 h at 37 °C) enhanced 
increases in fluorescence evoked by the α7 agonist compound A plus PNU12596 by 
25.1 ± 3.6 % (fig 5.3A). Fluorescence rises evoked by the α7 partial agonist 
SSR180711 plus PNU120596 were amplified to a similar extent, by 27.4 ± 12.0 % (fig 
5.3B). Interestingly the presence of PNU120596 was still required for α7 nAChR 
stimulation to evoke a detectable rise in fluorescence; treatment with Aβ1-42 was not 
sufficient for stimulation by either α7 agonist alone to evoke an increase in 
fluorescence. This suggests that Aβ1-42 and PNU120596 potentiate α7 nAChR 
responses by distinct mechanisms.   
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To assess the contribution of non-α7 nAChR in Aβ1-42-potentiation of nicotine 
responses, heterologous nAChR were selectively stimulated with 5-I-A85380 in the 
absence and presence of Aβ1-42. Increases in Fluorescence evoked by 5-I-A85380 
were potentiated by Aβ1-42 (100 pM, aged for 0.5 h at 37 °C), by 121.4 ± 32.0 % (fig 
5.3C). This amplification was greater than that of the α7-selective compounds, although 
that was only statistically significant when cells were stimulated with SSR180711 plus 
PNU120596 (p = 0.016 one-way ANOVA and post-hoc Tukey‟s test) and not 
compound A plus PNU120596 (p = 0.053, one-way ANOVA and post-hoc Tukey‟s 
test).  
 
5.2.4 Oligomerisation is essential for Aβ1-42 potentiation of nicotine responses 
To determine whether the physical state of Aβ1-42 influences the potentiation of 
nAChR-mediated responses, we employed the hexapeptide D-KLVFFA. This peptide 
corresponds to the self-recognition element (Aβ16-21) of the full-length peptide and 
prevents the oligomerisation of Aβ (Chalifour et al. 2003; fig 3.3.2). Several 
investigations of this and other peptides developed around the Aβ16-21 sequence, 
suggest that an excess of KLVFFA is required to prevent Aβ1-42 aggregation and 
neurotoxicity (Chalifour et al. 2003; Datki et al. 2004; Evans et al. 2008; sections 3.3.2, 
4.1.7 and 6.2.5). Incubating 100 pM Aβ1-42 with 1 μM KLVFFA abolished the 
potentiation of fluorescence rises evoked by nicotine (fig 5.4), implying that 
oligomerisation of Aβ1-42 is essential for Aβ1-42-potentiation of nicotine-evoked Ca
2+ 
rises. 
As discussed in section 1.13.5.2.1, membrane depolarisation resulting from 
nAChR activation can induce the opening of VOCC, allowing further Ca2+ entry. The L-
type VOCC inhibitor verapamil was employed to determine whether Aβ1-42–potentiation 
of nicotine-evoked Ca2+ increases required the activity of this subtype of VOCC. 
Increases in fluorescence elicited by nicotine in the absence (fig 3.2) and presence (fig 
5.4) of Aβ1-42 are both prevented by verapamil. This suggests L-type VOCC operate 
downstream of nAChR activation when nicotine is applied alone and in the presence of 
Aβ1-42. 
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Fig 5.4 Inhibiting nAChR, VOCC activity or Aβ1-42 oligomerisation prevents Aβ1-42 
potentiation of nicotine responses 
PC12 cells loaded with fluo-3 were preincubated with 100 pM Aβ1-42 in the presence and 
absence of 1 μM KLVFFA, 20 μM mecamylamine (MEC) or 10 μM verapamil (Vera) stimulated 
with 30 μM nicotine. Data represent maximum fluorescence reached over 20 s, as a percentage 
of response to 30 μM nicotine. Data expressed as mean ± SEM from at least three separate 
experiments, each with 4 replicates. Significantly different from cultures treated with Aβ1-42 *** 
p<0.001, one–way ANOVA and post-hoc Dunnet‟s test. 
 
5.2.5 Potentiation of KCl-evoked fluorescence increases are VOCC– and 
oligomerisation-dependent   
As Aβ1-42 is also reported to directly interact with VOCC (Ueda et al. 1997), the role of 
this channel in the potentiation of nicotine responses by Aβ1-42 was further assessed. 
To determine whether potentiation by Aβ1-42 was specific to the stimulation of nAChR, 
the effect of Aβ1-42 on membrane depolarisation evoked directly by the addition of KCl 
was assessed. A concentration of KCl was chosen that produced a similar rise in fluo-3 
fluorescence as 30 uM nicotine (section 3.1.2) 
Consistent with the potentiation of nicotine-evoked fluorescence increases, Aβ1-
42 (100 pM aged for 0.5 h at 37 ºC) amplified KCl-evoked fluorescence increases by 
120.0  8.9 % (fig 5.5A). Again, the Aβ25-35 fragment produced no effect. Preincubation 
with verapamil reduced KCl-evoked increases in fluorescence in the presence of Aβ1-42 
indicating VOCC activity is also essential for Aβ1-42-potentiation of KCl-evoked rises in 
intracellular Ca2+. In agreement with effects on nicotine-evoked increases in fluo-3 
fluorescence, Aβ25-35, Aβ42-1 and vehicle did not alter rises in fluorescence evoked by 
KCl (fig 5.5A), while KLVFFA and verapamil prevented potentiation (fig 5.5B). 
 
 
 
 
Nic 30 M 
F
lu
o
re
s
c
e
n
c
e
 c
h
a
n
g
e
 (
%
n
ic
o
ti
n
e
-s
ti
m
u
la
te
d
 c
o
n
tr
o
l)
0
50
100
150
200
250
300
350
VeraKLVFFA
A 1-42
KLVFFA
***
***
 136 
 
KCl 30mM 
F
lu
o
re
s
c
e
n
c
e
 c
h
a
n
g
e
 
(%
 K
C
l-
s
ti
m
u
la
te
d
 c
o
n
tr
o
l)
 
0
50
100
150
200
250
VeraKLVFFA
##
A 1-42
KLVFFA
###
F
lu
o
re
s
c
e
n
c
e
 c
h
a
n
g
e
 
(%
 K
C
l-
s
ti
m
u
la
te
d
 c
o
n
tr
o
l)
0
50
100
150
200
250
300
42-1 1-42Veh 25-35
**
KCl 30mM 
 
(A) 
 
 
 
 
 
 
 
 
 
  (B) 
          
 
 
 
 
 
 
 
Fig 5.5 KLVFFA and verapamil prevent Aβ1-42-specific potentiation of KCl responses 
PC12 cells loaded with fluo-3 were stimulated with 30 mM KCl (A) in the presence and absence 
of Aβ1-42, Aβ42-1, Aβ25-35 or vehicle control (100 pM; 10 min pre-incubation) (B) following 10 min 
incubation with 100 pM Aβ1-42 in the presence and absence of 100 μM KLVFFA or verapamil 
(Vera; 10 μM). Data represent maximum fluorescence reached over 20 s, as a percentage of 
response to 30 mM KCl. Data expressed as mean ± SEM from at least three separate 
experiments, each with 4 replicates. Significantly different from vehicle-treated control ** p<0.01, 
p<0.001 one –way ANOVA and post-hoc Tukey‟s test. Significantly different from Aβ1-42–treated 
## p<0.01, ### p<0.001 one –way ANOVA and post-hoc Dunnet‟s test.  
 
5.2.6 Extended aging of Aβ1-42 reduces potentiation   
As the extent of amyloid aggregation is time-dependent, the size and diversity 
of oligomeric species is dependent on the length of aging (section 3.3). Fig 3.17 
suggested that the aging period of 0.5 h, employed to assess the acute activity of Aβ1-42 
on Ca2+ signalling, allows the formation of small oligomeric species up to tetramers. To 
assess the effect of larger oligomeric species, 30 μM Aβ1-42 was aged for extended 
time points, before dilution to 100 pM and application to PC12 cells for 10 min before 
stimulation with KCl.   
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Fig 5.6 Aging Aβ1-42 reduces potentiation of KCl responses 
Aβ1-42 (30 μM) was aged by incubation at 37 C for the times indicated, diluted to 100 pM and 
applied to PC12 cells loaded with fluo-3 (plated 24 h in advance of each time point). Cells were 
then stimulated with 30 mM KCl. Data represent maximum fluorescence reached over 20 s, as a 
percentage of response to 30 μM nicotine. Data expressed as mean ± SEM from at least three 
separate experiments, each with 4 replicates. Significantly different from Aβ1-42–treated ** 
p<0.01, *** p<0.001, one –way ANOVA and post-hoc Dunnet‟s test. 
 
After 24 h, the amplification of KCl-evoked fluorescence increases reached a 
maximum (fig 5.6; although this was not significantly different from Aβ1-42 aged for 0.5 
h), indicating that the oligomeric species responsible for potentiation of KCl-evoked 
responses are most abundant following aging for 24 h. Extending the length of aging 
past 24 h reduced the ability of Aβ1-42 to potentiate KCl-evoked fluorescence increases. 
Aβ1-42 aged for 72 and 96 h produced significantly less potentiation than Aβ1-42 aged for 
0.5 or 24 h. Responses to 30 mM KCl alone (assayed in parallel) were consistent 
between cultures (data not shown), indicating that the variation in potentiated response 
was not an artefact of fluctuating KCl-response between cultures. This result suggests 
that the larger filbrillar species observed by AFM after 96 h aging (section 3.3.1) are not 
responsible for potentiation of Ca2+ increases. 
 
5.2.7 Isolating small Aβ1-42 oligomers responsible for potentiation 
Selective filtration using centrifugal filters of known molecular weight cut-off 
(Huang et al. 2008) were employed to determine the size of the oligomeric species 
responsible for Aβ1-42 potentiation of Ca
2+ responses. The filters permitted recovery of 
the retentate, allowing parallel application of both filtrate and retentate to cultures. 
Application of filtrates containing molecules smaller than 30 KDa potentiated KCl-
evoked fluorescence rises, by 87.8 %  (30 KDa) and 103.4 % (50 KDa). Treating cells 
with the reciprocal retentates, containing molecules larger than 30 KDa, produced no 
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potentiation. In contrast, application of filtrates containing molecules smaller than 10 
KDa produced no potentiation, while retentates containing molecules larger than 10 
KDa potentiated rises, by 60.6 %, which was statistically insignificant from unfiltered Aβ 
(p = 0.13, one –way ANOVA and post-hoc Dunnet‟s test).  
Therefore Aβ1-42 species that potentiated KCl-evoked fluorescence changes 
were larger than 10 kDa (activity retained on 10 kDa filter) but smaller than 30 kDa (all 
activity recovered in the filtrate). Given that monomeric Aβ1-42 has a molecular mass of 
4.5 kDa, this result is compatible with the potentiating activity residing in small 
oligomers of between 3 and 6 molecules of Aβ1-42. This is supported by atomic force 
microscopy that shows the appearance of small species after aging for 24 h (section 
3.3.1). The retained Aβ1-42 evoking smaller (though not significantly different) 
potentiation than unfiltered Aβ1-42 may be attributed to some Aβ1-42 remaining bound to 
the filter, decreasing the concentration applied to the cultures. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.7 Approximate molecular weight of Aβ1-42 species are sponsible for potentiation of 
KCl responses 
Aβ1-42 (30 μM) was incubated at 37 C for 24 h and filtered through a 10, 30 or 50 kDa 
centrifugal filter, as described in the materials and methods. The filtrate and recovered retentate 
were diluted 1:300 and applied to PC12 cells loaded with Fluo-3. Cells were then stimulated 
with 30 mM KCl and fluorescence monitored for 20 s. Data represent maximum fluorescence 
reached over 20 s, as a percentage of response to 30 mM KCl. Data expressed as mean ± SEM 
from at least three separate experiments, each with 4 replicates. Significantly different from 
cultures treated with unfiltered Aβ1-42 *** p<0.001, one –way ANOVA and post-hoc Dunnet‟s 
test.  
 
 
5.3 Chapter 5: Discussion   
 
5.3.1 A 1-42 potentiates nicotine and KCl-evoked Ca
2+ increases 
 Under these experimental conditions, acute application of Aβ1-42 aged for 0.5 h 
to PC12 cells loaded with fluo-3 did not produce any change in fluorescence, indicating 
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intracellular Ca2+ levels were unaffected. The range of A  concentrations applied 
covers those detected both physiologically (picomolar; puzzo et al. 2008) and 
pathologically (nanomolar; Nakamura et al. 1994; Seubert et al. 1992; Fagan et al. 
2006; Nitsch et al. 1995; Samuels et al. 1999). A lack of Aβ1-42-evoked intracellular Ca
2+ 
rise contrasts with numerous studies that report elevated levels of intracellular Ca2+ 
after application of Aβ peptides. Under similar conditions, a rapid change in 
fluorescence following application of oligomeric Aβ1-42 to cortical neurons loaded with 
fluo-3 was reported by Fu et al. 2006, while A 25-35 is reported to rapidly increase Ca
2+ 
in undifferentiated PC12 (Zhou et al. 1996). Numerous studies indicate that the rise in 
Ca2+ evoked by A  persists for at least 24h (Fukuyama et al. 1994), suggesting that 
elevated Ca2+ levels were not missed during the 10 min application employed in this 
study.  
In agreement with the current study, other groups have also reported a lack of 
elevated Ca2+ levels evoked by Aβ peptides. However, in these studies, Aβ inhibited 
intracellular Ca2+ increases evoked by membrane depolarisation and nicotine 
application (Takenouchi et al. 1994; Li and Buccafusco 2003), which were not detected 
in the current study. Instead, a potentiation of both nicotine- and potassium-evoked 
rises in Ca2+ by aged A 1-42 was detected. This agrees with other studies reporting 
potentiation of channel-mediated Ca2+ influx by A  peptides, including VOCC and 
nAChR. For example, MacManus et al. (2000) reported enhanced 45Ca2+ influx and 
VOCC activity in KCl-stimulated rat cortical synaptosomes following a 1 h application of 
1 M A 1-40.  
Interestingly, a 5 min exposure of Aβ1-42 potentiated nicotine-evoked Ca
2+ rises 
in dissociated rat forebrain neurons by with EC50 10 nM (Chin et al. 2006), consistent 
with the current study. As nanomolar concentrations of Aβ are present in the disease 
state, this activity may also occur in the AD brain.   
 
5.3.2 A 25-35 does not potentiate nicotine and KCl-evoked Ca
2+ increases 
 No potentiation of nicotine- nor KCl-evoked Ca2+ rises was detected following 
treatment with the A 25-35 fragment, despite the peptide evoking toxic responses in this 
cell line (chapter 4). This is consistent with another comparative study, which found a 
24 h exposure A 1-40, but not A 25-35, potentiated cation currents in differentiated mouse 
N1E-115 neuroblastoma cells, despite both peptides evoking toxic responses in the 
cells (Davidson et al. 1994). Other reports indicate that the A 25-35 fragment can 
potentiate Ca2+ currents in hippocampal neurons in culture and enhance Ca2+ uptake 
through L-type VOCC in cortical neurons (Ueda et al. 1997b). Furthermore, A 25-35 is 
reported to mimic full-length A  peptide-evoked potentiation of K+-currents in cultures 
 140 
 
of rat cerebellar granule and cortical neurons (Ramsden et al. 2001) and nicotine-
evoked Ca2+ rises in rat basal forebrain neurons (Chin et al. 2006). Possible reasons 
for the distinct activities of A 25-35 and the full-length Aβ fragments are discussed in 
section 7.2.1.  
 
5.3.3 Responses to selective nAChR agonists are potentiated by A 1-42 
Nicotine (30 M) evoked rises in Ca2+ that were sensitive DH E and bgt 
(section 3.1.2), indicating a contribution from 7 and 2* nAChR. To date, no studies 
have assessed the contribution of nAChR subtypes in potentiation of nicotine-evoked 
Ca2+ rises by A .  
Ca2+ rises evoked by agonists selective for both 7 and non- 7 nAChR were 
potentiated by A 1-42, albeit to different extents. Potentiation of 5-IA was of a similar 
magnitude to 30 M nicotine. This may be expected, given that Ca2+-rises evoked by 
30 μM nicotine are inhibited to a greater extent by an antagonist selective for non- 7-
nAChR than α7 nAChR (section 3.1.2), suggesting a greater contribution from non-α7 
nAChR. This suggests that cellular responses to 5-IA are likely to be similar to 
responses to 30 μM nicotine. In direct comparison, only modest potentiation of Ca2+-
rises evoked by SSR180711 and compound A, both in the presence of PNU120596, 
were observed. This may be explained by the cellular distribution of A 1-42 following 
acute exposure of flA 1-42 (section 4.1.2). As discussed in section 1.13.5.2.1, nAChR 
couple to distinct Ca2+-signalling pathways, with 7 nAChR activation stimulating CICR 
via intracellular Ca2+ stores and non- 7 activation stimulating VOCC on the plasma 
membrane. Following a 10 min exposure of PC12 cells to flA 1-42, the majority of 
fluorescence was evident on the plasma membrane, rather than in the cytosol. It is 
possible that the enhanced potentiation of 5-IA is due to the greater accessibility of A 1-
42 to VOCC than ryanodine receptors. Even though ryanodine receptors would need to 
be close to the plasma membrane to be stimulated by 7 nAChR activity, Aβ1-42 would 
still have to be taken up by the cell to interact with intracellular Ca2+ stores.  
 
5.3.4 KCl reponses are also potentiated by A 1-42  
 Blocking nAChR with the broad-range antagonist MEC prevented rises in Ca2+ 
evoked by nicotine alone (section 3.1.2) and rises potentiation by presence of A 1-42. 
As discussed in section 3.1.2, depolarisation of the membrane following activation of 
non- 7 nAChR subtypes is reported to activate VOCC, causing further Ca2+ influx. In 
section 3.1.2, verapamil inhibited Ca2+ increases evoked by 30 M nicotine by ~60%, 
indicating the majority of the Ca2+ influx induced by 30 M nicotine is mediated by 
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VOCC. Furthermore, verapamil inhibited nicotine-induced Ca2+ rises to the same extent 
as DH E, suggesting Ca2+ influx through 2* nAChR is barely detectable in the system 
employed. For this reason, the effect of A  peptides specifically on the Ca2+ influx 
mediated by the nAChR alone could not be assessed, only effects on the global Ca2+ 
incorporating the entire signalling cascade(s) stimulated by nAChR activation.  
Inducing membrane depolarisation with application of KCl, rather than nAChR -
stimulation, also resulted in Ca2+ rises that were potentiated by A 1-42. In a similar 
manner to potentiated nicotine-evoked Ca2+ increases, potentiation of KCl-evoked Ca2+ 
rises was prevented by verapamil, implicating L-type VOCC. Inhibition of other VOCC 
subtypes was not attempted, so a contribution from non-L-type VOCC cannot be ruled 
out. This is due to a previous study demonstrating no significant reduction of KCl-
evoked rises in Ca2+ by -conotoxin GVIA or -conotoxin MVIIC in this system 
(Dickinson et al. 2007).  
Potentiation of KCl-evoked Ca2+ rises indicates that only membrane 
depolarisation is required for Aβ1-42 activity, rather than the presence of nAChR. This 
suggests that A  may not interact directly with nAChR during potentiation of nicotine-
evoked Ca2+ increases, but may instead interact with components downstream of the 
receptor, either directly at L-type VOCC or via interaction with the plasma membrane. 
Whether A 1-42 potentiates Ca
2+ rises evoked by other receptors that induce membrane 
depolarisation upon activation, such as NMDAR, could confirm this.   
 
5.3.5 Possible mechanisms of potentiation 
In addition to L-type VOCC, A  is reported to potentiate other VOCC subtypes, 
including N-type in cortical synaptosomes (MacManus et al.  2000) and cerebellar 
granule neurons (Price et al. 1998) and N- and P-type in cultured cortical neurons 
(MacManus et al. 2000). The apparent lack of specificity of Aβ for VOCC subtypes 
suggests that the peptide acts on an aspect of VOCC-signalling common to all 
subtypes. Thus, the reported selectivity of A  may be due to the complement of VOCC 
expressed by the test system, rather than by a specific interaction with one subtype 
over another.  
 Permeabilisation of the plasma membrane would lower the threshold of 
stimulation required for depolarisation, leading to a greater number of VOCC opening 
upon stimulation by nicotine or KCl.  It is possible that slight permeabilisation of the 
membrane by Aβ1-42, which was insufficient to evoke a detectable rise in fluo-3 
fluorescence, led to amplification of the VOCC response. This is reminiscent of 
detecting Ca2+ increases evoked by α7 nAChR-selective agonists in this system; the 
presence of a PAM was required to reveal the activation of α7 nAChR, suggesting that 
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the lack of fluorescence-increase detected following application of agonist alone does 
not indicate a lack of α7 nAChR activity, but rather that the Ca2+ influx is insufficient to 
trigger a detectable change in fluo-3 fluorescence. Other mechanisms by which Aβ1-42 
may potentiate Ca2+ rise have also been proposed.    
Following prevention of VOCC stimulation by A  with a MAPK inhibitor, Ekinci 
et al. 1999 proposed that a 30 min exposure of A  peptides was sufficient to upregulate 
VOCC via a MAPK-dependent mechanism. Whether this process could occur in 10 min 
is debateable; though upregulation of 7 nAChR activity within 5 min has been 
reported by the tyrosine kinase-inhibitor genistein (Cho et al. 2005), this compound has 
also been reported to act as a PAM (Grønlien et al. 2007). It is possible that A 1-42 may 
also act as a positive allosteric modulator VOCC, consistent with the rapid effect on 
Ca2+ influx. An immediate modulation of P/Q-VOCC by A 1-42 oligomers has also been 
reported (Nimmrich et al. 2008). 
 
5.3.6 The role of oligomerisation in potentiation of KCl-evoked Ca2+ increases by 
A  
Despite numerous reports demonstrating prevention of Aβ cytotoxicity by 
inhibition of oligomerisation (section 1.11), no studies have assessed the effect that 
oligomerisation-inhibition has on the modulation of Ca2+ signalling by acute application 
of Aβ. In the current study, the presence of KLVFFA blocked Aβ1-42-potentiation of Ca
2+ 
rises elicited by nicotine and KCl, indicating a requirement for oligomerisation. 
KLVFFA-evoked inhibition of A -potentiation is consistent with other studies that have 
demonstrated a loss of Aβ-activity in the presence of the hexapeptide (Chalifour; 
Evans). This finding is also consistent with the prevention of Ca2+ rises evoked by 
chronic A  exposure in vitro by curcumin (Park et al. 2008), which is reported to inhibit 
A  oligomerisation (Yang et al. 2005). Possible mechanisms of KLVFFA-action on Aβ 
oligomerisation are discussed in section 7.4.1. 
Despite the requirement of oligomerisation for potentiation of Ca2+ increases by 
Aβ1-42, the magnitude of potentiation was found to decrease with extended aging of 
peptide. This indicates that larger filbrillar species, which were observed by AFM after 
96 h aging (section 3.3.1), are less effective at potentiating Ca2+ increases. The 
reduction in potentiation is likely to be due to a smaller number of active Aβ oligomers, 
which have been sequestered into larger, less-active assemblies. This is in agreement 
with some reports indicating chronic application of fibrillar A  does not affect Ca2+ 
levels (section 5.1.1). However, Fu et al. 2006 demonstrated increased Ca2+ levels 
minutes after application of fibrillar A  to cortical neurons loaded with fluo-3, suggesting 
that acute application of fibrillar Aβ can increase Ca2+ signalling. This acute rise in Ca2+ 
 143 
 
may be responsible for the elevated levels of Ca2+ detected following chronic 
application of fibrillar A  (Davidson et al. 1994; Ueda et al. 1997a).  
This study suggests Aβ oligomers most abundant after 24 h aging are 
responsible for Aβ-potentiation of KCl-evoked Ca2+ increases. Considering the amount 
of evidence implicating elevated Ca2+ in A  toxcity (section 5.1), this finding is 
consistent with greater toxicity associated with oligomeric A  than fibrillar (Loo et al. 
1993, Dahlgren et al. 2002; Fu et al. 2006). It is also consistent with another 
comparative study employing chronic, rather than acute, exposures of Aβ. A 24 h 
exposure of unaggregated, but not aggregated, A  was reported to enhance currents 
arising from channels permeable to Ca2+ (Ramsden et al. 2002) and K+ (Ramsden et 
al. 2001) in cortical neurons and cerebellar granular neurons. However, a diversity of 
A  structures is likely to arise during 24h exposure, as indicated in section 3.3.1. 
Therefore, by the time current were recorded, the „unaggregated‟ A  applied in this 
study is likely to have formed oligomers similar to those implicated in the current study. 
Furthermore, the 5-7 day aging employed by Rasmden et al. is likely to sequester 
these oligomers into fibrils. In agreement with the current study, Ramsden et al. 
reported no potentiation of currents following application of this A  preparation.   
Analytical filtration suggests that oligomeric species responsible for A 1-42 
potentiation of KCl-evoked Ca2+ rises are 3 to 6 monomers in size. AFM analysis 
indicates that structures of correct approximate size are generated within 24 h in vitro 
(section 3.3.1). This finding is physiologically relevant, as stable trimers and hexamers 
have been isolated from Tg2576 brains (lesne et al. 2006). Furthermore, trimers, 
hexamers and to a lesser extent tetramers, isolated from culture media of cells 
expressing human APPindiana fully inhibited LTP in mouse hippocampal slices 
(Townsend et al. 2006). 
 
5.3.7 Physiological ramifications of A  potentiation of Ca2+ signalling 
The role of VOCC in synaptic function is well established (see Catterall et al. 
2008 for review). A presynaptic function of L-type VOCCs has been described in 
cerebellar granule neurons (Huston et al. 1995) and cortical synaptosomes (Boess et 
al. 1990; Macmanus et al.  2000). In agreement with the current study, A 1-40 
potentiation of KCl-induced increase in 45Ca2+ influx in cortical synaptosomes was 
prevented by nifedipine (Macmanus et al. 2000), indicating L-type VOCCs are targets 
for presynaptic modulation by A . This suggests that A  is likely to have a significant 
impact on Ca2+-dependent neuronal functions such as synaptic plasticity (chapter 6) 
and neurotransmitter release.  
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 L-type VOCC have been implicated in nicotine-evoked release of [3H]-dopamine 
from striatal synaptosomes (Prince et al. 1996) and KCl-evoked secretion of aspartate 
and glycine from cortical neurons in culture (Lopez et al. 2001). It is therefore plausible 
that VOCC mediate the modulation of neurotransmitter release by A , which is 
reported to induce dopamine release in vivo from rat prefrontal cortex (via 7 nAChR 
activation; Wu et al. 2007) and potentiate Ca2+-dependent release of glutamate and 
aspartate from hippocampal neurons in culture (Arias et al. 1995). Indeed, inhibition of 
VOCC is reported to prevent potentiation of glutamate and noradrenaline release from 
rat cortical nerve endings by nanomolar A 1-42 (Bobich et al. 2004), suggesting a 
physiological role of A  peptides in the presynaptic regulation of glutamate release 
from the adult rat hippocampus.  
 Modulation of glutamate release by A  is particularly pertinent to AD as VOCC 
are reported to facilitate glutamate release onto cholinergic basal forebrain neurons 
(Momiyama and Fukazawa 2007), thereby altering cholinergic transmission of neurons 
known to substantially contribute to learning and memory (Everitt and Robbins, 1997), 
and be defective in AD (Kasa et al. 1997). Acute exposure of nanomolar A 1-42, A 1-40 
and A 25-35 is reported to potentiate K
+-evoked glutamate release from the 
hippocampus and frontal cortex but not significantly from striatum, consistent with 
preferential vulnerability of these brain regions in AD (section 1.3.3; Braak et al. 1999; 
Lopez and DeKosky, 2003). Consistent with a role of glutamate release in 
excitotoxicity, potentiation of VOCC has been proposed to underpin synaptic 
degeneration evoked by Aβ. The effects of Aβ1-42 on neuronal morphology and synaptic 
connectivity of rat primary neuronal cultures, including the role of L-type VOCC, is 
assessed experimentally in chapter 6. 
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Chapter 6: chronic application of A 1-42 is toxic to rat primary neuronal cultures 
 
The cytotoxicity of A  was introduced in chapter 1 and discussed in detail in 
chapter 4. In this chapter, the specific synaptotoxic actions of A 1-42 are assessed. The 
synaptic alterations in AD and those resulting from exposure to A  will therefore be 
discussed in further detail.  
 
6.1 Synaptic Dysfunction in AD 
 Synaptic dysfunction has been implicated early in AD progression (fig 6.1) by 
diverse lines of research. PET studies indicate distinct patterns of reduced synaptic 
activity, which can distinguish AD from other dementias (Silverman and Alavi 2005) 
and predict future cognitive decline (Small et al. 1997; de Leon et al. 2001). 
Furthermore, neuropathological studies show a marked correlation between synapse 
loss and cognitive decline of AD patients (Gibson et al. 1983; reviewed in Arendt et al. 
2009), which is replicated in transgenic AD mice (reviewed in Bell and Cuello 2006). 
Both transgenic models and wild-type animals treated with Aβ exhibit disruption of 
processes implicated in synaptic plasticity and memory. By investigating these 
processes at the molecular level, several mechanisms have been implicated in the loss 
of synaptic function by Aβ, such as internalisation of synaptic signalling proteins, 
cytokine release form astrocytes (Wang et al. 2005) specific disruption of synaptic 
mitochondrial function (Reddy et al.2005) and homeostatic compensation via synaptic 
scaling (Small et al. 2008). The first of these will be discussed in more detail here.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.1 Schematic representation of the neurotransmitter-specific (cholinergic, black line; 
glutamatergic and GABA-ergic, grey line) involvement of presynaptic boutons and dystrophic 
neurites during progression of amyloid pathology. Adapted from Bell and Cuello 2006 
 147 
 
 Synaptic changes are ubiquitous features of the aging brain, as both synapse 
number and function decrease in various brain regions during aging of healthy animals 
(Scheff et al. 1985; Scheff et al. 1991) and presumably give rise to cognitive 
impairments associated with old-age. Early amnestic symptoms of AD, though subtle 
and variable in nature, specifically affect the ability to encode new memories, in the 
absence of any deficit of motor or sensory functions and in individuals who are 
otherwise neurologically intact (Selkoe et al. 2002). This suggests accumulation of Aβ 
is discreetly and specifically causing disruption of the synaptic activity required for 
memory processing.  
 Immunohistochemical techniques have shown the loss of synaptic markers in 
particular regions of the AD brain, including the cortex and hippocampus (DeKosky et 
al. 1990; Terry et al. 1991), but not the cerebellum, which remains unaffected in AD 
{Bertoni-Freddari et al. 1990). The loss shows a strong correlation with cognitive 
impairment in AD patients (Davies et al.1987; Hamos et al. 1989; Terry et al. 1991; 
Selkoe et al. 2002) and appears to provide a better predictor of cognitive decline than 
cell loss, plaque formation, neurofibrillary tangles or the extent of cortical gliosis. 
Accordingly, decreased synapse number and synaptic density occur early in disease 
progression (Gonatas et al. 1967; Suzuki et al. 1967) and are disproportionate to the 
loss of neuronal cell bodies (Davies et al. 1987; DeKosky et al. 1990; Bertoni-Freddari 
et al. 1996), suggesting synaptic degeneration may precede neuron death. 
Furthermore, functional studies indicate synaptic activity is compromised prior to the 
physical degeneration of the synapses (Palop et al. 2003; Westphalen et al. 2003; Yao 
et al. 2003).  
 Both pre- and post-synaptic markers (synaptophysin and synaptopodin/PSD95, 
respectively) are reduced in the brains of AD patients when compared with age-
matched control subjects, suggesting proteins on both sides of the synaptic cleft are 
affected during progression of AD (Reddy et al. 2004; Terry et al. 1991; Gylys et al. 
2004; Almeida et al. 2005). However, it may be the post-synaptic membrane which is 
initially affected, as PSD-95 expression in rat primary cortical neurons is reduced by 
oligomeric Aβ1-40, prior to decreases in pre-synaptic expression of AMPA subunit 
GluR2, CaMKII, cdk5 and synapsin I (Roselli et al. 2005). The latter of these is also 
monitored in the current study.   
Synapsins are neuron-specific phophoproteins that mediate synaptic vesicle 
tethering to the cytoskeleton (Benfenati et al. 1989). As discussed in section 1.3.3, 
synpasin I is abundant in pre-synpatic nerve terminals, where it is involved in regulation 
of neurotransmitter release (Chin et al. 1995). Transgenic knock-out studies have also 
implicated synapsin I in synaptogenesis and axonogenesis (Li et al. 1995). 
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The loss of pre-synaptic markers might reflect synapse degradation following 
post-synaptic protein reduction, though a loss of synaptophysin has been observed in 
patients with MCI or very mild AD, relative to age-matched subjects with normal 
memory function (Masliah et al. 2001). In addition to a loss of synaptic markers, brain 
regions affected by AD exhibit a marked reduction of microtubules and accumulation of 
vesicles, within both cell bodies and dystrophic neurites (Praprotnik et al. 1996; Cash et 
al. 2003). It is therefore possible that dysfunctional axonal transport mechanisms may 
occur in parallel with, or lie upstream of, synaptic decline.   
 
6.1.1 Modelling Synaptic Dysfunction in AD  
 Symptomatic transgenic models exhibit no loss of neurons, suggesting synaptic 
dysfunction occurs in the absence of neurodegeneration (section 1.8.1; Kamenetz et al. 
2003; Lambert et al. 1998; Walsh et al. 2002). Overexpression of human APPIndiana in 
mice decreases the density of synaptophysin-positive presynaptic terminals and 
microtubule-associated protein (MAP2)–positive neurons well before the development 
of amyloid plaques (Hsiao et al. 1999). Early synaptic dysfunction is also highlighted by 
reports of synaptic puncta loss, reduced dendritic spine density and cognition-related 
behavioural defects, all of which occur prior to plaque formation in human APP-
transgenic mice (Mucke et al. 2000; Jacobsen et al. 2006). These mice also exhibited 
cognition-related behavioural impairments and primary hippocampal cultures generated 
from the mice displayed defects in LTP.  
LTP is widely considered to be one of the major cellular mechanisms that 
underlies memory and learning (Cooke et al. 2006). This element of neuronal 
communication, which can be detected in vitro and in vivo, has been exploited to 
investigate AD etiology and identify possible treatments. Hippocampal slices 
maintained in culture exhibit a well-established rapid inhibition of LTP upon application 
of pathophysiological (nanomolar) levels of Aβ (Moechars et al. 1999; Chapman et al. 
1999; Puzzo et al. 2008). Interestingly, application of physiological (picomolar) levels of 
Aβ1-42 evoke a marked increase in hippocampal LTP, supporting a positive, modulatory 
role of Aβ on neurotransmission (Puzzo et al.2008). Accordingly, animals treated with 
picomolar Aβ exhibited a pronounced enhancement of both reference and contextual 
fear memory. This may be linked to increases in some pre-synaptic protein levels 
detected in AD patients early in AD progression (Mukaetova-Ladinska et al. 2000) and 
transiently enhanced LTP after Aβ administration (Walsh et al. 2002).   
 Aβ-evoked impairment of LTP has been pivotal for implicating specific Aβ 
assemblies in the mechanism of AD, as in vitro measurement of LTP employs an acute 
application of A  that minimises in situ aggregation. Identifying assemblies responsible 
for LTP inhibition has been approached from several angles, with the highest inhibitory 
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activity associated with soluble Aβ oligomers, rather than the insoluble fibrillar forms 
(Yun et al. 2006; Wang et al. 2002; Chen et al. 2000). Townsend et al. (2006) 
employed size exclusion chromatography to isolate distinct oligomeric species secreted 
by APPIndiana–overexpressing cell lines. The study found fractions rich in trimers 
inhibited LTP of hippocampal slices more potently than fractions enriched in dimers, 
while monomeric Aβ was shown to be relatively innocuous (Townsend et al. 2006).  
Aβ produced from APP-overexpressing cell lines has also been administered in 
vivo. Application of unrefined secreted Aβ into the lateral ventricle of wildtype adult rats 
via an implanted cannula initially increased synaptic potentiation, possibly due to an 
initially low local Aβ concentration during diffusion, which waned until LTP was inhibited 
{Walsh, 2002 #189}. In agreement with (Townsend et al. (2006), specific degradation of 
monomers with insulin-degrading enzyme did not ameliorate depression of 
hippocampal LTP, suggesting monomers do not participate in Aβ-mediated LTP 
suppression in vivo. However, Puzzo et al. (2008) showed that synthetic Aβ1-42 
monomers can inhibit LTP in hippocampal slices, possibly highlighting the variation that 
exists between Aβ prepared synthetically and that secreted by cultures overexpressing 
APP.   
 Studying LTP in slices from transgenic animals has also shed light on the 
development of synaptic dysfunction during AD progression. Several 
electrophysiological studies in young mice have revealed significant defects in 
hippocampal basal transmission and LTP in the absence of amyloid deposits 
(Moechars et al. 1999; Chapman et al. 1999). In older mice exhibiting deposits of Aβ, 
diminished LTP was correlated with impaired spatial working memory in the absence of 
synaptic marker loss (Chapman et al. 1999), indicating that structural degeneration of 
synapses may occur downstream of synaptic dysfunction, in agreement with reports 
discussed above (Palop et al. 2003; Westphalen et al. 2003; Yao et al. 2003). 
 
6.1.2 The Role of Aβ in Synaptic Impairment 
 The reduction of presynaptic markers in 2- to 4- month-old mice overexpressing 
human APP containing FAD mutations correlates with increasing cortical Aβ levels, but 
not Aβ plaque deposition (Mucke et al. 2000). In AD brain slices, immunohistochemical 
studies show a perineuronal distribution of Aβ oligomers, suggesting accumulation 
within dendritic arbours (Lacor et al. 2004). When applied to cultured hippocampal rat 
neurons, Aβ oligomers extracted from AD brains display similar attachment patterns, 
binding in small clusters to dendrites (Gong et al. 2003). Furthermore, the oligomers 
bind to solubilised membranes with ligand-like specificity, suggesting they are high-
affinity ligands for one or more membrane-associated targets (section 1.12.3.1). The 
distinct distribution pattern of Aβ on neuronal processes and synaptic terminals (Walsh 
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et al. 2000) is therefore likely to arise from selective targeting of Aβ oligomers to 
specific synaptic sites. The accumulation of Aβ at these sites occurs despite the 
predisposition of Aβ for inserting into lipid bilayers (section 1.12.3.1) and forming large 
aggregates with other proteins (Marcello et al. 2008). Interaction of Aβ with these 
synaptic targets has been proposed to initiate synaptic dysfunction that ultimately 
results in the degeneration of the synapse.  
 
6.1.3 Mechanism of Aβ-Evoked Synaptic Dysfunction 
 Exposure of rat hippocampal organotypic slices to Aβ dimers and trimers, but 
not monomers, has also been shown to trigger a reduction in dendritic spine density 
and a loss of electrophysiologically active synapses in pyramidal neurons (Shankar et 
al. 2007). Spine-loss was reversible and abolished by the prevention of Aβ aggregation 
by scyllo-inositol, implicating assembled Aβ species. In agreement, spine loss evoked 
by Aβ was also abolished by Aβ immunodepletion (Shankar et al. 2007).     
 Aβ oligomers, whether extracted from AD brain or generated synthetically, 
colocalise with postsynaptic density protein-95 (PSD-95), a post-synaptic marker found 
exclusively at synapses (Rao et al. 1998). Several molecular targets of Aβ oligomers 
have been identified in the post-synaptic membrane, including channels permeable to 
Ca2+, such as nAChR (section 1.13) and N-methyl-D-aspartate receptors  (NMDAR; 
Lacor et al., 2007). These glutamate-gated cation channels play a critical role in the 
best characterised form of LTP (Brown et al. 1988). Application of nanomolar Aβ1-42 
reduces NMDA excitatory currents in cultured hippocampal slices (Wang et al. 2004), 
consistent with its inhibition of LTP (Walsh et al. 2002, Puzzo et al. 2008). In 
agreement, application of 1 μM Aβ1-42 to primary rat cortical neurons produced a 
persistent depression of NMDA-evoked currents and reduced signalling to downstream 
targets, such as CREB, a transcription factor implicated in LTP and cell survival 
(Snyder et al. 2005). This study also found a reduction in surface-expression of 
NMDAR in cultures from mice expressing APPSwe compared with wild-type littermates. 
Internalisation of NMDAR was inferred to occur downstream of α7 nAChR activation, 
as pretreatment of cultures with α7 antagonist α-bgt or MLA partially inhibited the Aβ1-
42-evoked reduction in NMDAR surface expression. Although this agrees with an 
amelioration of Aβ modulation of LTP in α7 nAChR KO mice (Puzzo et al. 2008) and 
the prevention of Akt modulation by A 1-42 in vitro (Abbott et al. 2008), it conflicts with 
the lack of effect of α-bgt on Aβ-evoked spine-loss (Shankar et al. 2007).   
 Snyder et al. (2005) propose a neat mechanism to explain Aβ1-42-evoked 
internalization NMDAR (fig 6.2). The Ca2+ influx resulting from Aβ1-42 activation of α7 
nAChR promotes activation of protein phosphatase 2B (PP2B, also known as 
calcineurin), a Ca2+-sensitive enzyme implicated in NMDAR transmission and synaptic 
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plasticity. PP2B activates striatal-enriched tyrosine phosphatase (STEP), which in turn 
dephosphorylates a particular residue on the NMDAR subunit 2B that regulates binding 
of the receptor to the synaptic scaffold protein PSD-95. Dephosphorylation of this 
residue causes dissociation of NMDAR from PSD-95 resulting in receptor endocytosis. 
In this model, Aβ1-42 interacts α7 nAChR on the postsynaptic membrane, whereas the 
model proposed by Puzzo et al. (2008) suggests α7 nAChR located on the presynaptic 
membrane are involved in the increase of LTP by Aβ1-42.  
 
 
 
 
 
 
 
 
 
   
 
 
 In addition to specifically reducing surface expression of NMDAR, Aβ can co-
localise with, and reduce, synaptic expression of PSD-95 (Lacor et al. 2004). This 
subsequently leads to a decrease in the membrane expression of the memory-related 
proteins, such as NMDAR subunits and EphB2 (Lacor et al. 2007) and induction of 
downstream effectors, such as the immediate-early gene Arc, the overexpression of 
which has been implicated in dysfunctional learning (Guzowski et al. 2002). Treatment 
of hippocampal cultures with the Alzheimer‟s drug Namenda (memantine, an NMDAR 
antagonist) prevented this effect, suggesting NMDAR activity is required for Aβ-
mediated spine loss. Corroborating this finding, (Shankar et al. 2007) found the 
NMDAR antagonist D-CPP completely prevented Aβ1-42-evoked spine loss in 
hippocampal slices.  
 As Aβ inhibits the very early phase of LTP (1 min after High Frequency 
Stimulation), reports have identified Aβ-sensitive events early in LTP induction, 
including receptor internalisation and stimulation of kinases. Glutamate-gated α-amino-
3-hydroxyl-5-methyl-4-isoxazole-propionate receptors (AMPAR) that play a central role 
in LTP are also internalised following Aβ application. Mutation of a site on AMPAR 
involved in clathrin-mediated endocytosis (preventing receptor internalisation) blocked 
morphological and synaptic depression evoked by Aβ1-42 (Hsieh et al. 2006). 
Conversely, mutation of the site to mimic phosphorylation and induce constitutive 
Fig 6.2 Aβ1-42-evoked reduction in 
NMDAR is mediated by α7 nAChR. 
Aβ1-42 activates α7 nAChR, 
promoting Ca
2+ 
influx, with 
consequential activation of PP2B and 
STEP. When activated, STEP 
promotes dephosphorylation Tyr
1472
 
of NR2B, reducing interaction with 
PSD-95, causing endocytosis of the 
NMDAR. Adapted from Snyder et al. 
(2005)  
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retention evoked effects similar to Aβ1-42. Interestingly, expression of this AMPAR 
mutant prevented Aβ-mediated depression of NMDAR transmission, suggesting Aβ-
induced NMDAR internalisation is dependent on the endocytosis of AMPAR.  
 Multiple signalling pathways, including several protein kinases and 
phosphatases are required for LTP (Sheng et al. 2002) and cognitive functions, 
including learning and memory (Rodrigues et al. 2004). By employing specific inhibitors 
of these kinases, (Wang et al. 2004) implicated JNK, cdk5 and p38 MAPK in Aβ-
evoked inhibition of LTP in hippocampal slices. However, it is currently unknown 
whether or not these kinases drive the phosphorylation, and subsequent internalisation 
of AMPAR.  
 The above studies implicate endocytosis of AMPAR and phosphorylation-
mediated signalling pathways in Aβ1-42-induced synaptic depression and dendritic-spine 
loss. The resulting dendritic and axonal retraction can subsequently lead to neuronal 
cell death (Yankner et al. 1990). This suggests that Aβ can disrupt synaptic 
transmission and supports the notion that excessive Aβ is responsible for the early 
cognitive symptoms of AD. So far, the current study has developed a model of Aβ-
toxicity intended to replicate neurodegeneration exhibited late in the progression of AD. 
A high, micromolar, concentration of Aβ was employed to induce a rapid, gross toxic 
insult, which may have overwhelmed any pharmacological neuroprotection. In this 
chapter, a more subtle, pathologically-relevant insult is employed to disrupt synaptic 
function in the absence of neuron death to allow study of the mechanism of synaptic 
dysfunction and reveal any slight neuroprotection by nAChR and VOCC ligands.  
As nicotinic ligands failed to ameliorate Aβ1-42-induced toxicity in PC12 cells, 
another system was sought to assess the protective capability of these drugs. Primary 
neuronal cultures have been extensively employed to model aspects of Alzheimer‟s 
disease, including Aβ toxicity, and express a range of nAChR, notably α4* nAChR, that 
differs from that expressed by PC12 cells (section 3.1) In addition, several studies have 
demonstrated neuroprotection by nicotinic ligands against Aβ1-42-induced toxicity in 
primary neuronal cultures (section 1.13.5 and 5.1.2). In comparison with cell lines, 
animals and hence primary cultures, exhibit greater genetic consistency. This was 
taken advantage of to further explore in vitro neuroprotection and investigate the 
underlying mechanisms of toxicity and neuroprotection.  
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6.2 Results: chronic exposure of primary cortical cultures to amyloid-β 
 
Experimental Aims 
 
1) The effect of aging on the neuronal distribution of A  is assessed in rat primary 
cortical neurons. 
2) The effect of A  on neurite architechture and synaptic connectivity of rat 
primary cortical neurons and the role of oligomerisation is determined.  
3) The neuroprotective potential of drugs acting on the nicotinic signalling system 
are assessed.  
 
6.2.1 Aging affects Aβ1-42 distribution on primary cortical neurons  
 In chapter 4, oligomerisation (by aging for 24 h at 37 ºC) was required for Aβ1-42 
to elicit toxic responses in PC12 cells. To further examine the role of oligomerisation in 
Aβ1-42 activity in vitro, Aβ1-42 tagged with the fluorescein (flAβ1-42) was employed to 
monitor the distribution of the peptide. The effect of aging on Aβ1-42-distribution on rat 
primary cortical neurons was assessed by exposing cultures to a 3 μM mixture of Aβ1-42 
and flAβ1-42 (2:1; Aβ1-42/flAβ1-42; aged after mixing). Cultures were treated with either 
freshly-prepared Aβ1-42/flAβ1-42 (fig 6.3) or Aβ1-42/flAβ1-42 aged for 24 h at 37 ºC (fig 6.4) 
for 0.5 (A), 24 (B), 48 (C), 72 (D) or 96 (E) h prior to fixing and detecting neuronal 
markers via innumnocytochemistry. In accordance with the aging protocol for 
cytotoxicity assays, 30 μM Aβ1-42/flAβ1-42 was prepared and aged for 24 h at 37 °C. To 
excessive toxicity, Aβ1-42/flAβ1-42 was diluted to 3 μM immediately before addition to the 
cultures. 
 Cultures exposed to freshly-prepared Aβ1-42/flAβ1-42 for 0.5 h (fig 6.3A) did not 
exhibit any fluorescein fluorescence. In contrast, cultures treated with aged Aβ1-42/flAβ1-
42 for 0.5 h exhibited distinct puncta of fluorescein, distributed on both neurofilament-
positive and –negative regions. After 24 h incubation, cultures treated with freshly-
prepared Aβ1-42/flAβ1-42 also displayed fluorescein-puncta, predominantly present on 
the exterior of the neuron bodies and processes (fig 6.3B). After incubation of cultures 
with freshly-prepared Aβ1-42/flAβ1-42 for 48 h (fig 6.3C), fluorescein is evident in the 
cytosol, in addition to the neuritic processes. Co-distribution with the nuclear marker 
DAPI, suggests that flAβ1-42 is located in, or proximal to, the nucleus. 
The amount of intracellular fluorescein appeared to be larger in cultures 
exposed to Aβ1-42/flAβ1-42 for 72 h (fig 6.3D) than in cultures exposed for 48 h. This 
appeared to increase further following 96 h incubation, as exemplified by fig 6.3 (96 h), 
which shows a cell body that appears to be full of fluorescein and exhibits no 
neurofilament- or phospho-tau-labelling. While this and other neurons displayed 
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extensive distribution of flAβ1-42, other bodies and processes displayed no fluorescein 
fluorescence, suggesting a distinct absence of Aβ1-42/flAβ1-42. 
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0.5 h 
Fig 6.3 Distribution of freshly-prepared 
Aβ1-42 on primary cortical neurons  
On DIV6 primary cortical cultures were 
exposed to 3 μM un-aged mixture of FAM-
labelled Aβ1-42 (green) and unlabelled Aβ1-
42 (1:2) for times indicated. Cells were then 
fixed, labelled with anti-neurofilament 
(red), anti-AT8 (phospho-PHF-Tau; white) 
and DAPI (blue) and viewed under x63 
magnification as described in the materials 
and methods 
48 h 
24 h 96 h 
72 h 
24 h 
48 h 
96 h 
72 h 0.5 h 
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Fig 6.4 Distribution of aged Aβ1-42 on 
primary cortical neurons  
A mixture of 30 μM FAM-labelled Aβ1-42 
(green) and unlabelled Aβ1-42 (1:2) was 
aged for 24 h  and diluted to 3 μM 
immediately prior to addition to primary 
cortical cultures and incubated for times 
indicated. Cells were then fixed, labelled 
with anti-neurofilament (red), anti-AT8 
(phospho-PHF-Tau; white) and DAPI 
(blue) and viewed as described in the 
materials and methods 
 
0.5 h 
48 h 
24 h 
72 h 
96 h 
24 h 
48 h 
0.5 h 
96 h 
72 h 
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 Following 24 h exposure, cultures treated with aged Aβ1-42/flAβ1-42 exhibited a 
fluorescein distribution similar to cultures treated with freshly-prepared Aβ1-42/flAβ1-42 
(fig 6.4B). Distinct puncta of fluorescein, larger than those observed in cultures treated 
with freshly-prepared Aβ1-42/flAβ1-42, were apparent on both cell bodies and projections. 
Following a 48 h exposure (fig 6.4B), fluorescein co-distributes with DAPI, similar to 
that observed when cultures were treated with unaged Aβ1-42/flAβ1-42. However, this 
was detected in fewer cells treated with aged Aβ1-42/flAβ1-42, compared with unaged 
peptides, as exemplified in figs 6.4C, D and E (48, 72 and 96 h exposures, 
respectively). The fluorescein-puncta distribution on these cultures is confined to the 
exterior of the cell, consistent with distribution on PC12 cells (section 4.1.2), and DAPI 
colocalisation is absent. This suggests aged Aβ1-42/flAβ1-42 is not present within the cell 
and remains on the cell membrane, where the size of the puncta appears to correlate 
with the length of Aβ1-42/fl-Aβ1-42 exposure time.    
 
6.2.2 Effects of nicotinic receptor ligands on Aβ1-42–induced toxicity in primary 
cortical cultures  
Based on results above and previous studies in PC12 cells (chapter 4) primary 
cortical cultures were treated with 30 μM aged (24 h at 37 C) Aβ1-42 for 72 h. These 
cultures exhibited decreased MTT reduction (by 43.0  4.2 %; fig 6.5A), increased LDH 
release (by 285.8  18.3 %; fig 6.5B) and increased caspase activity (by 163.3  5.6 %; 
fig 6.5C), equating with responses from PC12 cells (section 4.1.1). Nicotine treatment 
identical to that applied to PC12 cells (1, 10, 100 μM; 24 h pre-incubation and present 
with Aβ1-42) had no effect on Aβ1-42–induced toxicity (data not shown). As nicotine acts 
differentially at nAChR subtypes, selective agonists were employed to determine 
whether activation of specific nAChR subtypes could protect cortical cultures against 
Aβ1-42 toxicity. Employing a dosing regimen identical to nicotine-treatment (24 h pre-
incubation and present with Aβ1-42), the α7 nAChR agonist compound A and partial 
agonist SSR180711, both alone and in the presence of a positive allosteric modulator 
(PNU120596), did not ameliorate decreased MTT reduction (fig 6.5A), increased LDH 
release (fig 6.5B) or increased caspase activity (fig 6.5C) induced by Aβ1-42. Treatment 
with the β2* nAChR-selective agonist 5-I-A85380 also had no effect on Aβ1-42–induced 
toxicity. None of the cytotoxicity markers were affected by treatment of the cultures with 
nAChR ligand(s) alone.  
The majority of studies to date implicate specific nAChR subtypes by applying a 
selective nAChR antagonist with nicotine. However, this approach does not address 
the possibility that cooperation by distinct nAChR subtypes is required for 
neuroprotection. To assess the possible co-requirement of α7 and β2* nAChR 
activation for protection, 5-I-A85380 was applied in combination with SSR180711 and  
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Fig 6.5 Toxicological responses of primary cortical cultures to Aβ1-42 are insensitive to 
treatment with selective nAChR agonists 
On DIV6 primary cortical cultures were exposed to 30 μM aged (24 h at 37 ºC) Aβ1-42 for 72 hrs. 
Cells were treated with SSR180711 (1 μM) with or without PNU120596 (10 μM), compound A 
(10 nM) with or without PNU120596, PNU120596 (10 μM) alone, 5-I-A85380 (30 μM) with or 
without SSR180711 (1 μM) and PNU120596 or the caspase inhibitor (DEVD; 100 μM) for 24 
before and remained throughout Aβ1-42 exposure. Toxicity assessed by (A) MTT reduction (B) 
LDH release (C) caspase activity. Data expressed as a percentage of the response from control 
cells (A and C) or maximum LDH release (B). Data represent the mean  SEM of at least three 
separate experiments, each with 6 (A) or 3 (B and C) replicates. Significantly different from 
untreated control *** p<0.001, one –way ANOVA and post-hoc Tukey‟s test.  
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PNU120596. However, no change in decreased MTT reduction (fig 6.5A), LDH release 
(fig 6.5B) or caspase activity (fig 6.5C) evoked by Aβ1-42 was detected. As discussed in 
section 1.13.5.1.1 and 5.1.2, 7-selective nAChR antagonists have also been reported 
to reduce toxic responses to A . However, no change in decreased MTT reduction (fig 
6.6A), LDH release (fig 6.6B) or caspase activity (fig 6.6C) evoked by Aβ1-42 was 
detected following treatment with MEC, DH E or α-CtxArIB[V11L,V16D] at 
concentrations shown to inhibit Ca2+ rises in PC12 cells (chapter 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.6 Toxicological responses of primary cortical cultures to Aβ1-42 are insensitive to 
treatment with selective nAChR antagonists  
On DIV6 primary cortical cultures were exposed to 30 μM aged (24 h at 37 ºC) Aβ1-42 for 72 hrs. 
Cells were treated with mecamylamine (MEC; 10 μM), dihydro- -erythroidine (DH E; 10 μM) or 
α-CtxArIB[V11L,V16D]  ( Ctx; 100 nM) for 24 before and remained throughout Aβ1-42 exposure. 
Toxicity assessed by (A) MTT reduction (B) LDH release (C) caspase activity. Data expressed 
as a percentage of the response from control cells (A and C) or maximum LDH release (B). 
Data represent the mean  range of two separate experiments, each with 6 (A) or 3 (B and C) 
replicates.  
 
LDH release and caspase activation are relatively late events in cell death and 
indicate that the cell has committed to a necrotic or apoptotic fate, respectively. These 
events therefore correlate with neurodegeneration occurring late in the development of 
Alzheimer‟s disease. The substantial toxic insult employed in this study, intended to 
condense decades of progressive Aβ accumulation into a few days, was not 
ameliorated by nicotine treatment. As it is possible that protective effects of nicotine are 
overwhelmed by the gross toxicity evoked by chronic micromolar Aβ1-42, an assay was 
sought to examine more subtle pathological features of the disease, occurring in the 
absence of overt cell death. 
 
6.2.3 High-content analysis of neuronal morphology and synapse formation 
 The seeding of primary neuronal cultures causes the loss of all cellular 
extensions, leaving spherical cell bodies that rapidly extend neurites (section 2.2.2) and 
develop functional synapses. Hu et al. (2007) found exposure of rat cortical cultures to 
500 nM Aβ1-42 significantly reduced the length of neurites, suggesting neurite outgrowth 
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is more sensitive to Aβ1-42 than redox potential, membrane integrity or caspase activity, 
as measured by the MTT reduction, LDH release and caspase activity, respectively.  
 The length of neurites has typically been measured by labour-intensive 
conventional microscopy. The current study, however, employed high-content analysis, 
which can generate the high number of data points required for measuring slight 
changes evoked by subtle toxic insults. A high-content imaging technology, combining 
an automated fluorescence microscope (operating on a 96-well format) with advanced 
image analysis software (Metamorph) was employed for image acquisition and 
analysis, respectively.   
 In addition to monitoring neurite outgrowth, this study also monitored 
connectivity within the cultures, by including a marker for mature synapses. 
Immunocytochemical detection of synapsin I expression allowed the quantification of 
synaptic spots present on each neuron, in parallel with the length of the neurites. By 
taking advantage of high content image analysis, other cellular morphological 
characteristics were monitored in addition to neurite outgrowth per neuron and synaptic 
spots per neuron. These included the number of neurons, processes per neuron, 
branches per neuron, synaptic spots per neurite and synaptic spots per μm of neurite. 
Changes in these measures closely mirrored the changes in outgrowth and synaptic 
spots per neuron, in response to Aβ1-42 and test compounds. For the sake of clarity, 
these parameters have been omitted from the results. 
 
6.2.4 Aβ1-42 reduces neurite outgrowth and synaptogenesis of primary cortical 
neurons 
Rat primary cortical cultures treated with aged Aβ1-42 for 72 h exhibited 
reduction of neurite outgrowth (table 6.1) and synaptic spots per neuron (table 6.2) in a 
concentration-dependent manner, in comparison with vehicle-treated cultures. 
However, low concentrations of Aβ1-42 (0.6, 0.9 and 1.3 M) appear to evoke a slight 
increase in neurite outgrowth per neuron (table 6.1) and number of synapses per 
neuron, though this was not statistically significant. A gross loss of neuronal processes 
by cortical cultures is evident following exposure to 15 μM aged Aβ1-42 (fig 6.7A) 
relative to untreated control cultures (fig 6.7B).  
The number of neurons detected in cultures treated with Aβ1-42 was equal to the 
number of neurons in vehicle-treated control cultures (fig 6.8A), indicating that the 
decrease in outgrowth and synaptogenesis was not the result of Aβ1-42-induced 
neuronal loss. In agreement, no difference in LDH release (fig 6.8B) or caspase 3/7 
activity (fig 6.8C) was detected between cultures treated with 5 uM Aβ1-42 and vehicle-
treated controls, which significantly reduced neurite outgrowth (table 6.1) and synaptic 
spots per neuron (table 6.2). 
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A        B            
 
 
 
 
 
 
 
 
 
Fig 6.7 Aβ1-42 reduces neurite outgrowth and synaptogenesis of rat primary cortical 
cultures  
On DIV6, primary cortical cultures exposed to aged (24 h at 37 ºC) Aβ1-42 for 72 hrs were fixed, 
labelled with anti-β-tubulin (red), anti-synapsin I (yellow) and H33342 (blue) and viewed as 
described in the materials and methods. Representative pictures (10x magnification) of (A) 
cultures treated with 15 μM Aβ1-42. (B) untreated control. Data in tables 6.1 and 6.2, analysed as 
described in the material and methods, are expressed as a percentage of the response from 
untreated control cultures. Data represent mean  SEM of 12 separate experiments, each 
completed in triplicate, with each replicate averaged from 6 images. Analysis carried out using 
non-linear regression (Proc NLIN in SAS V9) indicates neurite outgrowth and synaptogenesis 
significantly differ (p<0.05) from untreated controls at 1.8 and 1.0 μM Aβ1-42, respectively.  
 
 
 
 
 Outgrowth/Neuron (% con) 
[Aβ1-42] μM  Vehicle Aβ1-42 
0.4 100.8 102.1 
0.6 104.5 105.3 
0.9 100.2 106.2 
1.3 102.2 102.9 
2 101.5 95.1 
3 98.4 79.9 
4.4 101.7 72.2 
6.7 103.4 67.6 
10 101.1 58.4 
15 101.7 55.1 
 Synaptic spots/Neuron (% con) 
[Aβ1-42] μM  Vehicle Aβ1-42 
0.4 100.3 100 
0.6 100.9 101.1 
0.9 102.6 104.4 
1.3 99.8 102.6 
2 97.3 90.0 
3 99.3 79.0 
4.4 99.7 68.1 
6.7 97.7 61.5 
10 97.7 52.9 
15 100.2 46.8 
Table 6.2 Aβ1-42 reduces synaptogenesis 
in a concentration-dependent manner 
Table 6.1 Aβ1-42 reduces neurite outgrowth 
in a concentration dependent manner 
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6.2.5 D-KLVFFA prevents Aβ1-42-induced reduction of neurite outgrowth and 
synaptogenesis 
The presence of D-KLVFFA ameliorated Aβ1-42-induced reduction in neurite 
outgrowth and synaptogenesis in a concentration-dependent manner. Addition of D-
KLVFFA alone had no effect on neurite outgrowth or synaptogenesis (data not shown). 
 
         (A)              (B)        (C) 
 
 
 
 
 
 
 
 
 
Fig 6.8 Effect of 5 μM Aβ1-42 on LDH release, caspase activity and neuron number 
On DIV6 primary cortical cultures were exposed to aged (24 h at 37 ºC) Aβ1-42 for 72 hrs or 
vehicle. (A) Following A  exposure, cultures were were fixed, labelled with anti-β-tubulin (red), 
anti-synapsin I (yellow) and H33342 (blue) and viewed as described in the materials and 
methods (B) and (C) Toxicity was assessed by (A) LDH release (B) caspase activity Data 
expressed as (A) percentage of maximum LDH release (B) fluorescence at 538 nm. Data 
represent the mean  SEM of at least three separate experiments, each with 3 replicated. 
 
 A      B 
 
 
 
 
 
 
 
 
Fig 6.9 D-KLVFFA prevents Aβ1-42-induced reduction of neurite outgrowth and 
synaptogenesis  
Aged (24 h at 37ºC) Aβ1-42 was prepared with (solid lines) or without (dashed line) D-KLVFFA 
(1, 10, 100 μM) and applied to primary cortical cultures on DIV6 for 72 hrs. Cultures were fixed, 
labelled with anti-β-tubulin, anti-synapsin I and H33342 and viewed as described in the 
materials and methods. Data expressed as a percentage of the response from untreated 
controls represent the mean  SEM of at least 3 separate experiments, each with 3 replicates. 
Analysis carried out using non-linear regression (Proc NLIN in SAS V9) indicates 10 μM D-
KLVFFA significantly affects (p<0.001) maximum Aβ1-42 effect, but not IC50 value for both neurite 
outgrowth (A) and synaptic spots per neuron (B). Both maximum effect and IC50 value 
significantly differ (p<0.001) from Aβ1-42 when co-applied with 100 μM D-KLVFFA.  
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The D-KLVFFA concentration-response reveals that an excess of the 
hexapeptide (100 μM, over the maximum 15 μM Aβ1-42 applied) was required to 
completely abolish Aβ1-42-induced morphological changes in cortical cultures. When D-
KLVFFA was present at a concentration lower than that of Aβ1-42 (10 uM D-KLVFFA, 15 
uM Aβ1-42) it only partially inhibited the reduction in outgrowth and synaptogenesis. 
 
6.2.6 Treating Aβ1-42 with trifluoroacetic acid enhances toxicity 
Treatment with trifluoroacetic acid (TFA) has been shown to encourage Aβ1-42 
oligomerisation (Shen et al. 1994, sections 3.3.2 and 3.3.3). To determine whether 
enhanced oligomerisation is sufficient to alter toxicity, Aβ1-42 was prepared in the 
presence and absence of TFA, before addition to the cultures. Treating Aβ1-42 with 
0.1% TFA (concentration before dilution in media) enhanced toxicity, lowering the IC50 
of Aβ1-42–induced neurite outgrowth (from 6.9 ± 1.7 μM to 3.7 ± 0.6 μM; fig 6.10A) and 
synpatogenesis (from 7.7 ± 4.4 μM to 3.3 ± 0.4 μM; fig 6.10B). Addition of TFA in the 
absence of Aβ1-42 had no effect on neurite outgrowth or synaptogenesis.  
 A        B 
 
 
 
 
 
 
 
 
 
Fig 6.10 Treating Aβ1-42 with trifluoroacetic acid enhances toxicity 
Aged (24 h at 37 ºC) Aβ1-42 was prepared with or without 0.1% TFA and applied to primary 
cortical cultures on DIV6 for 72 hrs. Cultures were fixed, labelled with anti-β-tubulin, anti-
synapsin I and H33342 and viewed as described in the Materials and Methods. Data are 
expressed as a percentage of the response from untreated controls and represent mean  SEM 
of at least 3 separate experiments, each performed in triplicate, with each replicate averaged 
from 6 images. Analysis carried out using non-linear regression (Proc NLIN in SAS V9) 
indicates IC50 value significantly differ (p<0.001) for both (A) neurite outgrowth and (B) synaptic 
spots per neuron. 
 
6.2.7 Effect of nAChR- and VOCC- selective drugs on Aβ1-42-induced reduction in 
neurite outgrowth 
 Nicotine and modulators of α7 nAChR were examined for their ability to protect 
against Aβ1-42–evoked toxicity in rat primary cortical cultures. Nicotine (1, 10, 100 μM; 
24 pre-treatment and present with Aβ1-42) was applied to cultures in the absence and 
presence of the type I α7 nAChR PAM, 5-hydroxyindole (5-HI; 24 pre-treatment and 
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remained with Aβ1-42; 1 mM; Bertrand et al. 2007). Nicotine treatment produced no 
detectable amelioration of Aβ1-42-induced reduction in neurite outgrowth, when applied 
in the absence (fig 6.11A) or presence (fig 6.11B) of 5-HI. Reduction of all other 
parameters, including synaptic spots per neuron, by Aβ1-42 was equally unaffected 
(data not shown). 
To determine whether the lack of protection was specific to 5-HI, two other α7 
nAChR-selective PAMs, developed by GlaxoSmithKline, were also examined for 
neuroprotective potential. Type II PAMs GSK918716A and GSK985881A were 
electrophysiologically-defined „in-house‟ on ACh-evoked currents induced in cultured 
rat hippocampal neurons (EC50 7.0 and 0.8 μM, respectively; data not shown). Cortical 
cultures were exposed to GSK918716A (1, 10, 100 μM) and GSK985881A (0.1, 1, 10 
μM) alone. By excluding exogenous agonists, this treatment was expected to evoke a 
subtler nAChR response by relying on the endogenous agonist, ACh, to stimulate 
nAChR. However, cultures treated with these compounds exhibited no significant 
protection against Aβ1-42-induced reduction in neurite outgrowth (fig 6.11C and 6.11D), 
or any other parameter (data not shown).  
 Though data in section 5.1.2.1 implicates L-type VOCC in the potentiation of 
Ca2+ responses evoked by acute Aβ1-42 exposure, the L-type VOCC inhibitor verapamil 
did not ameliorate toxicity evoked by chronic Aβ1-42 exposure to PC12 cells. To further 
assess the role of L-type VOCC in Aβ1-42 toxicity, primary cortical cultures were treated 
with the L-type VOCC inhibitor nifedipine (Caterall et al. 2005; 5 μM; 24 pre-treatment 
and remained on the cultures with Aβ1-42). In agreement with the lack of 
neuroprotection of PC12 cells by verapamil (section 4.2.4), nifedipine produced no 
detectable change in Aβ1-42-induced reduction in neurite outgrowth (fig 6.11E) or 
synaptogenesis (data not shown). Treatment with any nAChR ligand or nifedipine did 
not affect neurite outgrowth or synaptogenesis in the absence of Aβ1-42 (data not 
shown). 
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Fig 6.11 nAChR- and VOCC- selective 
drugs do not prevent Aβ1-42-induced 
reduction in neurite outgrowth 
At DIV6 primary cortical cultures were 
exposed to aged (24 h at 37 ºC) Aβ1-42 
(green line; data points omitted for clarity) 
for 72 hrs. Cells were treated with (A) 
nicotine (1, 10, 100 μM) (B) 5-
hydroxyindole (1 mM) with or without 
nicotine (1, 10, 100 μM) nAChR positive 
allosteric modulators (C) GSK918716A (1, 
10, 100 μM) α7 (D) GSK985881A (0.1, 1, 
10 μM) or (E) nifedipine (5 μM) for 24 
before and remained throughout Aβ1-42 
exposure. Cultures were fixed, labelled 
with anti-β-tubulin, anti-synapsin I and H33342 and viewed as described in the materials and 
methods. Data expressed as a percentage of the response from untreated control culture 
represent the mean  SEM of at least 3 separate experiments, each with 3 replicates. Curves 
were fitted using sigmaplot v10 and analysis performed using non-linear regression (Proc NLIN 
in SAS V9) indicates no significant (p<0.05) shift in IC50 or maximal effect.  
 
6.3 Chapter 6: Discussion  
 
 Following the lack of nAChR- and VOCC-mediated protection observed in PC12 
cells, the toxicity of Aβ1-42 was assessed in primary rat cortical cultures. The cultures 
exhibited Aβ1-42-induced reduction of MTT metabolism, increased LDH release and 
increased caspase activity. In an attempt to recapitulate synaptic dysfunction in AD, 
neurite outgrowth and synaptogenesis of the cultures were also assessed following 
 
E 
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application of a non-lethal Aβ1-42 application. This allowed the screening of compounds 
against a more subtle toxic insult, using high content analysis to detect slight 
alterations in cellular responses. Although inhibition of Aβ1-42 oligomerisation by 
KLVFFA prevented Aβ1-42-evoked reduction in neurite outgrowth and synaptogenesis, 
neither nAChR- nor VOCC-ligands conferred any protection to the cultures.  
 
6.3.1 Aβ1-42 differentially distributes on primary cortical cultures 
 Employing Aβ1-42 tagged with the fluorescein allowed direct comparison of the 
distribution of freshly-prepared and aged Aβ1-42 on rat primary cortical cultures. The 
lack of fluorescein fluorescence in cultures exposed to freshly-prepared Aβ1-42/flAβ1-42 
for 0.5 h suggests this time period is insufficient for Aβ1-42/flAβ1-42 to assemble into 
species of sufficient size to be observed using this technique. It is only after cultures 
are exposed to freshly-prepared Aβ1-42/flAβ1-42 for 24 h that puncta of fluorescein are 
evident. In contrast, aging Aβ1-42/flAβ1-42 allowed assembly of Aβ1-42/flAβ1-42 into larger, 
detectable assemblies before addition to the cultures. The fluorescein distribution 
pattern was similar to that observed when aged Aβ1-42/flAβ1-42 was applied to in a 
similar manner to PC12 cells (section 4.1.2), binding to cell membranes and to the 
culture substratum.   
 The most striking difference between the distribution patterns of the unaged and 
aged Aβ1-42/flAβ1-42 is the intracellular accumulation during incubation with freshly-
prepared, but not aged, Aβ1-42/flAβ1-42. This differential uptake of Aβ1-42/flAβ1-42 can be 
explained by the relationship between size and membrane permeability of Aβ1-42 
(section 1.12.3.1). Freshly-prepared Aβ1-42/flAβ1-42, composed of monomeric and small-
oligomeric assemblies is more readily taken up than the larger assemblies present in 
aged Aβ1-42/flAβ1-42, in agreement with observations in PC12 cells (section 4.1.2), and 
previous studies (Chafekar et al. 2008). The representative image shown (fig 6.3E) 
shows one cell that appears to be completely full of unaged Aβ1-42/flAβ1-42. It is likely 
that this amount of Aβ1-42 in the cell will severely compromise cellular function. 
However, unaged Aβ1-42 failed to induce LDH release or caspase activity PC12 cells 
(section 4.1.1). It is possible that PC12 cells and rat primary cortical cultures vary in 
their sensitivity to unaged Aβ1-42. However, responses to aged Aβ1-42 are similar and 
previous studies have shown monomeric Aβ1-42 is relatively benign to primary cortical 
neurons (section 1.10.3.1). Another possibility lies in the intrinsic differential 
susceptibility of cells within the culture population. A marked variation in fluorescein 
decoration can be observed between individual PC12 cells and primary cortical 
neurons. The cells heavily-laden with fluorescein were imaged to exemplify the uptake 
of freshly prepared Aβ1-42/flAβ1-42 do not represent the population, as indicated by 
surrounding cells that do not display fluorescein fluorescence to such an extent. This 
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may explain why LDH release and caspase activity, which monitor the population-
response were not significantly altered. This differential susceptibility of cells may also 
explain the partial nature of Aβ toxicity, which will be discussed further in section 7.1. 
 
6.3.2 Aβ1-42 is toxic to primary cortical cultures 
 The decreased MTT metabolism, increased LDH release and increased 
caspase activity evoked primary cortical cultures in response to aged Aβ1-42 exposure 
equated in magnitude with responses by PC12 cells in chapter 2. This exposure 
involves a high (micromolar) concentration of Aβ1-42, in order to swiftly recapitulate 
neuron death occurring in the AD brain that results from decades of Aβ accumulation. 
The magnitude of the cytotoxic response evoked by this exposure may well be 
overwhelming any potential nAChR-mediated pro-survival signalling. For this reason, a 
more sensitive cellular marker was sought, that would report Aβ1-42 toxicity in the 
absence of overt cell death.  
 
6.3.3 Differential effects of Aβ1-42 on cortical neurons  
 The multiple, and sometimes opposing, actions of Aβ are highlighted by the 
concentration-dependent effects of Aβ1-42 on neurite outgrowth and synaptogenesis of 
rat primary cortical cultures. At high nanomolar/low micromolar concentrations, neurite 
outgrowth and synaptogenesis appear to increase. Maximal increases of outgrowth 
and synaptogenesis were observed following exposure of cultures to 900 nM aged Aβ1-
42, while 400 nM produced no effect, in agreement with Evans et al. 2008. An increase 
in neurite outgrowth was also observed by Pike et al. 1991 following treatment with 
monomeric (defined by SDS-PAGE) micromolar Aβ1-42. However, when Hu et al. 2007 
recapitulated this experiment using high content analysis, freshly-prepared Aβ1-42 
produced no such effect. Possible explanations of this discrepancy include varying Aβ 
preparations and exposures that generate distinct mixtures of Aβ species, and varying 
sensitivity of the assessment techniques (discussed further in section 7.3). 
Only when applied at concentrations of 2 μM or higher did aged Aβ1-42 reduce 
neurite outgrowth and synaptogenesis, in agreement with Evans et al. 2008. However, 
Hu et al. 2007 achieved a significant reduction in neurite outgrowth at concentrations 
an order of magnitude lower. As the methods and experimental designs employed in 
these reports are strikingly similar, the difference in Aβ preparations is likely to underlie 
the variation in efficacy. In particular, Hu et al. 2007 applied freshly-prepared Aβ1-42 to 
cortical cultures, while this study and Evans et al. 2008 applied Aβ1-42 aged for 24 h. 
Given the relatively benign nature of monomeric Aβ reported by this and other studies 
(section 1.10.3.1), it is surprising that in the study by Hu et al. 2007 application of 
freshly-prepared Aβ1-42 reduced neurite outgrowth with a higher efficacy than the aged 
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Aβ1-42 applied in this study and by Evans et al. 2008, but may be explained by the 
peptide preparations employed by these studies.  
The effect of Aβ1-42 on neurite outgrowth and synaptogenesis approaches a 
plateau; increasing Aβ1-42 concentration above 10 μM did not decrease neurite 
outgrowth or synaptogenesis past ~50 %, though Hu et al. achieved ~80 % reduction in 
neurite outgrowth by 10 μM Aβ1-42 for 72 h. However, the plateau-effect was still 
evident and is consistent with the A 1-42 exposure-time plateau exhibited by MTT in 
PC12 cells. This will be discussed further in section 7.1. 
In this study, all the characteristics of cellular morphology and synapse 
formation that were monitored (neurite outgrowth, processes per neuron, branches per 
neuron, synaptic spots per neurite and synaptic spots per μm of neurite; section 
2.2.9.3) were equally affected by Aβ1-42. This suggests they are inherently linked, 
possibly by sharing a single primary event, such as neurite retraction, which would 
likely affect of the other parameters in a similar manner. Thus rather than monitoring 
discreet entities of cytotoxicity, these parameters are likely to indicate unified facets of 
a single toxicological process.  However, modulation of these parameters by Aβ1-42 
occurred in the absence of neuron loss, caspase activation and LDH release, in 
agreement with previous studies (Hu et al. 2007; Evans et al. 2008). This suggests a 
differential sensitivity to Aβ1-42 exists, either between the cytotoxic responses, or the 
method employed to detect the response. While it is possible that morphological 
aberrations evoked by Aβ1-42 occur upstream of gross cytotoxic responses, it is 
currently unclear if the neurotoxic and synaptotoxic actions of Aβ are separate 
activities, or whether they share common mechanisms (Cappai & Barnham 2007).  
 
6.3.4 Oligomerisation correlates with Aβ1-42 toxicity  
 The preparation of Aβ before addition to cultures will determine the rate and 
manner of oligomerisation, the Aβ species present and therefore the overall biological 
activity of the peptide. So far, this study has confirmed that inhibition of Aβ1-42 
oligomerisation by D-KLVFFA abolished toxicity of the peptide, but has also 
demonstrated that oligomerisation is enhanced by trifluoroacetic acid (TFA; section 
3.3.2). To investigate whether this increase in oligomerisation alters the toxicity of Aβ1-
42, we took advantage the high-content capability of the fluorescence microscopy 
platform to assess subtle changes in cellular morphology. 
 The concentration-dependent reduction in neurite outgrowth by Aβ1-42 was 
shifted towards lower Aβ1-42 concentrations when Aβ1-42 was treated with TFA. This 
indicates that the peptide is more efficacious at reducing the neurite outgrowth of 
primary cortical cultures following TFA treatment, implying TFA encourages the 
formation of toxic oligomeric species, in agreement with Shen et al. 1994. However, it 
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is also possible that TFA treatment alters Aβ1-42 conformation, resulting in enhanced 
ThT binding and altered biological interactions, in the absence of increased Aβ1-42 
aggregation.  
The advantage of high content analysis is highlighted by this particular 
experiment, as the IC50-shift in neurite outgrowth-reduction by TFA-treatment was 
achieved by taking the range of Aβ1-42 concentrations into account. Without assessing 
such a high number of concentrations, it is unlikely that the enhanced potency of TFA-
treated Aβ would have been identified. Only one individual Aβ1-42 concentration (4 μM) 
appears to reveal a significant difference when observed alone. In addition to 
highlighting the advantage of high-content analysis, this may explain conflicting results 
between experiments employing single concentrations of Aβ. 
 
6.3.5 Effects of nAChR or VOCC ligands on Aβ1-42 toxicity  
 In agreement with observations in PC12 cells, treatment with various nAChR 
agonists (subtype-selective and broad-range), a selective partial agonist and positive 
allosteric modulators (type I and type II), both alone and in various combinations, did 
not ameliorate any toxic response to Aβ1-42. This contrasts with the protection of rat 
primary cortical cultures against Aβ1-42-evoked decrease in neurite outgrowth by α7 
nAChR activation (by PNU282987) and antagonism (by MLA; Hu et al. 2008). In 
addition, inhibition of L-type VOCC with nifedipine did not ameliorate Aβ1-42 toxicity. 
This contrasts with other studies have shown protection of rat primary cortical cultures 
by selectively inhibiting L-type VOCC. Nimodipine and bis-7-tacrine, but not N-, P/Q- or 
R-type VOCC inhibitors prevented apoptosis execution evoked by freshly-prepared 
Aβ25-35, fibrillar Aβ1-42 and soluble oligomeric Aβ1-42 (Fu et al. 2006). This is supported 
by an inhibition of Aβ25-35-evoked increases in 
45Ca2+ uptake by nimpodipine (Ueda et 
al. 1997). Both studies used concentrations of nimodipine that are selective for L-type 
VOCC (Furukawa et al. 1999), though neither assessed toxicity via the morphological 
parameters measured in this study. In addition to these two studies, there are 
numerous reports of VOCC mediating A  toxicity. However, there are discrepancies 
between studies, which will be discussed further in section 7.2.2. 
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7. General Discussion and Conclusions 
 
The findings of this study confirm that oligomerisation is a key determinant of 
A 1-42 activity. The acute effects of A 1-42 on changes in intracellular Ca
2+ and toxic 
responses to chronic exposure to A 1-42 were both reduced by compounds that 
inhibited A  oligomerisation. However, several lines of evidence in this study suggest 
that modulation of Ca2+ signalling by A  is not required for the peptide to be toxic in 
vitro. Several aspects of A  activity exhibited throughout the study are now discussed 
in more detail.  
 
7.1 Micromolar Aβ1-42 evokes partial toxicity in vitro  
The relevance of micromolar applications of A , which are required to elicit 
rapid toxic responses in vitro, to AD is currently debated. The concentration of A  
peptides found in cerebrospinal fluid and blood from AD patients is often found to reach 
nanomolar concentrations, consistent with concentrations applied acutely in chapter 5 
(Nakamura et al. 1994; Seubert et al. 1992 nature; Fagan et al. 2006; Nitsch et al. 
1995; Samuels et al. 1999). Concentrations of Aβ1-42 in homogenates from the CA1 
region of AD hippocampi only reach 10 nmol/g (Funato et al., 1998 Morishima-
Kawashima et al. 2000), while ~200 nM concentrations have been reported in the AD 
frontal cortex (van Helmond et al. 2009). However one study reported concentrations of 
A  in the AD brain as high as 100 g/g of tissue (Hyman et al. 1993), which 
corresponds to approximately 20 M, assuming a tissue density of 1 g/ml (Huang et al. 
1999; Melo et al. 2003). Furthermore, interstitial levels of A  are likely to be greater 
near the site of plaque deposition. Thus, the micromolar levels of A  required to evoke 
toxic responses in vitro may exist at localised sites in the AD brain.  
 For financial and practical reasons, the maximum concentration of aged Aβ1-42 
used in this study was 30 μM, applied for a maximum of 72 h. Though this Aβ1-42 
exposure only evoked partial toxic responses in PC12 cells and primary cortical 
neurons, it also produces a maximal effect in several toxic responses. No further 
reduction in neurite outgrowth and synaptogenesis in cortical neurons was achieved 
when A  was applied at concentrations above 10 M, consistent with previous studies 
(Hu et al. 2006; Evans et al. 2008). Evans et al. (2008) also extended the exposure of 
Aβ1-42 to 7 days, with no further reduction in neurite outgrowth or synaptogenesis, 
consistent with the maximum decreased MTT reduction in PC12 cells in the current 
study.   
 One possible explanation for the partial toxicity of A  is the selective 
vulnerability of cells to Aβ1-42. Although all regions of the AD brain seem to register 
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some levels of degenerative damage, limbic structures are most heavily affected. The 
regional progression of neurodegeneration is not uniform either, with early damage 
detected in the superficial layers of the cortex (layer II and to a lesser layer IV), before 
progressing to include deeper layers (V-VI; Hyman et al. 1984, Gomex-Isla et al. 1996). 
By taking advantage of the temporal pattern of embryonic murine cortical development, 
Romito-DiGiacomo et al. (2007) separately cultured the superficial and deeper layers of 
the cortex. They found superficial neurons (harvested at E16) were sensitive to Aβ1-42, 
while the deeper layers (harvested at E13.5) were virtually unaffected. Corroborating 
these findings, differing extents of reduction in synaptic loss have also been reported 
between different layers of the hippocampus and cortex (DeKosky and Scheff 1990; 
Terry et al. 1991).  
 Focussing at the level of single cells, the current study shows that fluorescein-
labelled A 1-42 binds to subpopulation of cells in cultures of PC12 cells and cortical 
neurons, in agreement with previous studies (Simakova et al. 2007). By isolating and 
separately culturing the subpopulations, Simakova et al. 2007 found Aβ1-42-sensitivity 
correlated with FITC-Aβ1-42 binding. Moreover, they identified several factors that 
correlate with FITC-Aβ1-42-binding, including cell size, surface phosphatidylserine 
expression, ATP content and stage in the cell cycle.  
Given the selective loss of forebrain neurons in AD, it is unsurprising that 
another determinant of Aβ1-42-vulnerability is the expression of specific neurotransmitter 
receptors. Pike et al. (1993b) found a subpopulation of cultured hippocampal neurons 
that exhibited GABA-immunoreactivity were resistant to Aβ-toxicity. This agrees with 
Lacor et al. (2007), who found that oligomeric A  selectively bound to excitatory 
pyramidal, but not GABAergic, neurons of hippocampal cultures. In the heterologous 
mixture of cells that constitute the PC12 cell line, illustrated in section 3.1.2, it is likely 
that determinants of Aβ also vary, commensurate with differential toxicological 
response. As the cytotoxicity assays assess the response of the whole culture, the 
resistance of a sub-population of cells to Aβ1-42 would be detected as partial response 
of the entire culture, as observed in both PC12 cells and cortical cultures. Attempts 
were made to minimise this variation by sub-cloning the PC12 cell line. However, 
cellular viability was compromised, so this approach was abandoned.  
 
7.2 Modulation of Ca2+ signalling by A  does not mediate toxicity 
Several pieces of evidence in this study indicate that the acute effects of A  on 
Ca2+ signalling do not mediate the cytotoxicity evoked by A . Firstly A 25-35 generated 
no potentiation of Ca2+ rises in PC12 cells evoked by nicotine or KCl, despite evoking 
superior toxic responses to A 1-42 in this cell line. Secondly, inhibitors of L-type VOCC 
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activity, implicated in potentiation of Ca2+ rises by A 1-42, did not exhibit any protection 
against toxic responses in PC12 cells or neurons in culture. This suggests that the 
toxicity of A  does not arise from the acute effects of A  on Ca2+ signalling 
(summarised in fig 7.1). It may be, however, that influx of Ca2+ via membrane 
permeabilisation was not a dominant mechanism of cytotoxicity in this environment. 
Increasing the concentration of A , or altering the preparation such that the 
concentration of a given oligomeric structure increases, is likely to evoke additional 
cellular responses, which may not be Ca2+ dependent.  
 
 
 
 
 
 
 
 
 
 
 
 
7.2.1 A  peptides act differentially on cell survival and Ca2+ homeostasis 
The peptide fragment A 25-35 has frequently been employed to mimic the 
actions of full-length A  peptides. However, direct comparison in this study found that 
A 25-35 evoked greater toxic responses in PC12 cells than the full-length peptide, in 
agreement with some previous studies (section 1.6). However, acute application of 
A 25-35 failed to potentiate rises in intracellular Ca
2+ evoked by nicotine or KCl, when 
compared with A 1-42. These findings suggest that caution should be taken when 
interpreting reports employing the A 25-35 fragment. 
 The differential responses to A 1-42 and A 25-35 may result from a distinct 
environment of the methionine residue at position 35. Oxidation of met35 in A  
peptides is thought to be an initiating step in the free radical chain reaction that causes 
oxidative damage to neurons (Butterfield and Kanski, 2002; Butterfield and Boyd-
Kimball 2005). However, it appears that it is the process of oxidation, rather than the 
final oxidised state of this residue, that mediates toxicity; oxidising the sulphur of Met35 
to sulfoxide, or substituting with the structurally-similar norleucine, abrogates the 
toxicity of both A 25-35 and A 1-42 (Varadarajan et al. 2001; Varadarajan et al. 1999). In 
Fig 7.1 Actions of Aβ1-42 on 
PC12 cells. Influx of Ca
2+
 and 
Na+ though nAChR depolarises 
the membrane, with subsequent 
activation of VOCC causing 
further Ca
2+
 influx. Aβ1-42 
enhances Ca
2+ 
influx evoked by 
nicotine or by membrane 
depolarisation evoked by KCl. 
Therefore, Aβ1-42 is unlikely to 
act directly on nAChR, but may 
act downstream at the 
membrane or VOCC. This action 
of Aβ1-42 does not mediate 
toxicity of Aβ1-42  
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agreement, much of the insoluble, relatively inoccuous A  isolated from senile plaques 
contains met35 in an oxidised state (Dong et al. 2003; Naslund et al. 1994).  
As all methionine-containing peptides are not lethal, it follows that additional 
contributing factors must be present in A  peptides that confer toxic properties on 
met35. These supplementary factors in A  could be structural, due to the unique 
sequence of amino acids adjacent to methionine. In the case of A 25-35, the methionine 
is a terminal residue. At neutral pH, the C-terminus of the peptide is a carboxylate 
anion and the negatively charged oxygen can aid in the oxidation of the sulfur and in 
the subsequent stabilization of the resultant radical cation. Modulation of the terminal 
carboxy group and neighbouring residues has been shown to affect the toxicity of A 25-
35, but not A 1-42, suggesting it is the environment generated by the neighbouring 
residues may affect the oxidative-potential of met35 (Varadarajan et al. 2001; 
Varadarajan et al. 1999).  
 
7.2.2 Inhibition of VOCC does not attenuate toxicity  
 The implication of L-type VOCC in the acute effects of Aβ1-42 on Ca
2+ signalling 
warranted investigation of the participation of this subtype in the mechanism of Aβ1-42 
toxicity. Toxic responses in PC12 cells and cortical cultures were not affected by the 
application of L-type VOCC inhibitors. This finding disagrees with a number of previous 
studies, which have implicated L-type VOCC in the mechanism of Aβ toxicity in a range 
of systems, using various inhibitors, including those employed by the current study 
(Ekinci et al. 1999; Ueda et al. 1996; Harkany et al.  2000; Ho et al. 2001; Frier et al.  
2003; Webster et al. 2006; Weiss et al. 1994; Fu et al. 2006). However, these studies 
report varying levels of protection by L-type VOCC inhibitors, with some reporting total 
prevention of toxicity (eg Ho et al. 2001) and others reporting only partial inhibition (eg 
Ueda et al. 1997a). Furthermore, other studies, albeit a minority, reported no protection 
at all (eg Zhou et al. 1996). In a similar manner, though VOCC have been implicated in 
the potentiation of hippocampal LTP by Aβ1-42 in several studies (section 6.1), other 
studies suggest this action operates independently of VOCC activity (Nomura et al. 
2005). Possible reasons for these discrepancies are discussed in section 7.2.3.  
 
7.2.3. Lack of nAChR-mediated neuroprotection  
Stimulation of nAChR with broad-range agonists, subtype-selective agonists, 
partial agonists, antagonists and positive allosteric modulators did not affect toxic 
responses generated by Aβ1-42 in PC12 cells or primary rat cortical cultures. This is 
despite a majority of studies that have reported nAChR-mediated protection (section 
1.13.5.1), using similar cellular systems, Aβ peptides and monitoring similar toxic 
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responses. Specifically, in hippocampal cultures, nicotine is reported to inhibit A 25-35- 
and A 1-40-evoked caspase activation and apoptosis, suppress oxidative stress and 
inhibit increases in intracellular Ca2+, in a MEC-sensitive manner (Liu et al. 2004). 
Similar effects have also been reported in PC12 cells; nicotine reduced Aβ1-42-induced 
caspase-3 activity (Shaw et al. 2002), suppressed lipid peroxidation and attenuated 
reduced cell viability induced by A 25-35 exposure to PC12 cells (Guan et al. 2003). In a 
similar manner to reports implicating VOCC in A  toxicity, the extent of protection in 
these studies appears to vary, with some studies showing a complete prevention of 
toxic responses by nicotine (Kihara et al. 2001; Shaw et al. 2002; Guan et al. 2003), 
while others reported only a partial inhibition (Shimohama et al. 2001; Liu et al. 2004). 
Although fewer in number, there are studies that also report a total lack of nicotine 
protection against Aβ toxicity (Cardoso et al. 2001; Li and Buccafusco 2003) and there 
may be a tendency not to publish such negative findings so they may be more 
prevalent than appears from the literature. This discrepancy in nicotinic protection is 
also paralleled by an apparent lack of consistency regarding the subtype(s) mediating 
protection (sections 1.13.5.1.1 and 1.13.5.1.2).  
The lack of protection by (-)-nicotine against A 1-42 toxicity may be explained by 
the lack of effect on Aβ oligomerisation exhibited in this study. Although the majority of 
previous reports indicate that (-)-nicotine inhibits Aβ oligomerisation, a few studies do 
agree with the current investigation. For example, Kihara et al. 1999 found that 
simultaneous incubation with nicotinic agonists, including nicotine, did not cause a 
reduction in ThT fluorescence intensity evoked by A . Differential actions of nicotine on 
A  fibrillogenesis may also explain conflicting reports of nicotine lowering Aβ levels in 
transgenic mice (Nordberg et al. 2002; Hellstrom-Lindahl et al. 2004; Unger et al. 2006; 
Johnson-Wood et al.  1997; Oddo et al. 2005; Sabbagh et al. 2008).  
Discrepancies between the cellular systems may also explain the variation in 
nAChR-mediated protection. Transformed cell lines are likely to show variation in 
expression pattern, both with passage number and between stocks. In this respect they 
are likely to be more variable than primary cultures. Heterogeneity between clones of a 
cell line is well documented and nAChR expression in PC12 cells is no exception. As 
discussed in section 3.1, Blumenthal et al. (1997) demonstrated a marked difference in 
expression of nAChR mRNA and protein levels, assembled receptor number and 
functional responses receptors in three lines of PC12 cells. Though the surface 
expression and functional competence of nAChR was confirmed in the PC12 cells used 
in this study (Dickinson et al. 2007; chapter 3), either receptor expression levels or the 
ratio of subtypes expressed may not have been sufficient for receptor activation to 
adequately evoke pro-survival signalling cascades, or coupling to downstream signals 
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may have been impaired. In support of this notion, no cell death was detected following 
application of α7 nAChR agonists with a PAM, suggesting that the level of α7 nAChR 
expression in PC12 cells and cortical neuronal cultures was also insufficient to evoke 
excitotoxicity.  
Several signalling molecules lying downstream of nAChR have been implicated 
in nicotinic neuroprotection (section 1.13.5.2.3). Differential expression or activity of 
these proteins in cellular populations may explain the conflicting reports and could be 
assessed in further studies.  
An inherent heterogeneity in cell type will exist within a culture seeded by 
dissociation of the entire embryonic rat diencephalon (section 2.2.2), though variation 
will be reduced between cultures. Cellular composition of the cultures (phenotype-
diversity and abundance) can be affected by many intrinsic and extrinsic factors, 
including brain region, neuronal birthday, gender, genetic background and in vitro age 
(Chen et al., 2008). Altering any one of these factors could potentially have an impact 
on the outcome of the experiment and may explain the contrasting results of in vitro 
studies.  
 
7.4. Oligomerisation is required for A -induced dysregulation of Ca2+ 
homeostasis and toxicity  
 
7.4.1 KLVFFA prevents in vitro actions of A 1-42  
The hexapeptide D-KLVFFA prevented acute effects of A  on Ca2+ signalling 
and cytotoxic responses evoked by chronic exposure, indicating oligomerisation is 
required for both these actions. Peptide inhibitors containing the KLVFFA motif are 
believed to function by physically associating with monomeric A  and occluding the 
self-recognition element from other A  peptides (section 1.11.3), thus preventing 
interaction between A  molecules. This is in agreement with the presence of D-
KLVFFA reducing the affinity of A  peptides for each other (Hughes et al. 1996), 
possibly by preventing A  converting to -sheet conformation (Permanne et al. 2002).  
However, A  peptides that do not contain the KLVFFA motif, including A 25-35, also 
oligomerise (Tjernberg et al. 1996), suggesting other regions of A  contribute to 
intermolecular interactions.  
Other actions of KLVFFA may also explain the prevention of A 1-42 activity in 
this study. The hexapeptide may bind to A 1-42 oligomers, preventing interaction with 
cellular targets. However, rises in ThT fluorescence during aging of A 1-42 were also 
prevented in the presence of KLVFFA, suggesting KLVFFA would have to occlude the 
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binding of cellular targets and ThT. This seems unlikely, given that ThT is reported to 
have three distinct binding sites on A  (Lockhart et al. 2005)  
 Only the action of D-KLVFFA was assessed in this study, following reports that 
the D-enantiomer is more effective in inhibiting fibrillogenesis than the L-enantiomer. It 
might be expected that the enatiomers behave differently, given the stereochemical 
aspects of A  assembly (Esler et al. 1999) and other protein/protein interactions (Milton 
et al. 1992) It is fortuitous that the unnatural isomer of this peptide exhibited 
antifibrillogenic character as D-peptides are generally less sensitive to proteases than 
L-peptides (Findeis et al. 1999; Soto et al. 1996). Thus, D-KLVFFA may show promise 
as a starting point for a novel therapy. Several modifications have been attempted to 
improve the pharmacokinetics of the peptide. Addition of proline residues to peptides 
containing the KLVF motif was found to improve the inhibitor stability without altering 
the antifibrillogenic activity (Tjernber et al. 1996). Similarly, a cholyl-modified peptide 
exhibited greater activity (Findeis et al. 1999).  
 
7.4.2 Nicotine protects via a stereoselective inhibtion of A  oligomerisation  
The lack of protection achieved by (-)-nicotine was consistent with the exhibition 
of a minimal antifibrillogenic activity. In a direct comparison, (+)-nicotine delayed A 1-42 
fibrillogenesis, attenuated capsase activity and reduced LDH release evoked by aged 
A 1-42 in PC12 cells, when present during aging of the peptide. Consistent with the lack 
of protection evoked by (-)-nicotine, this effect was not nAChR-mediated. 
Stereoselective inhibition of Aβ oligomerisation has also been reported with inositol and 
cyclohexanol, with concomitant reduction in toxicity (McLaurin et al. 2000). 
The ability of (+)-nicotine to protect against preformed A  oligomers was not 
attempted, though reports suggest that it can disaggregate preformed A  oligomers 
with concomitant prevention of toxic responses (Ono et al. 2002). This, however, does 
not agree with the „kinetic inhibitor‟ activity of (+)-nicotine, which appeared to slow, 
rather than prevent, A  oligomerisation.  
Nicotine has been reported to directly interact with Aβ peptides via specific 
residues (section 1.11.4.1) and may therefore prevent Aβ oligomerisation via a similar 
mechanism of steric hinderance described for KLVFFA (section 1.11.3). However, 
other reports suggest that (-)-nicotine does not interact with A 1-40 (Skribanek et al. 
2001), and other mechanisms have been proposed. As discussed in section 1.13.5, 
nicotine can act as an antioxidant. As ROS can facilitate Aβ oligomerisation, it is 
possible that nicotine inhibits Aβ fibril formation by scavenging ROS. In the current 
study, this mechanism seems unlikely, as although hydroxyl radicals are generated 
from Aβ in phosphate buffers (section 1.12.1.1), the TRIS buffer employed in the ThT 
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assay is an antioxidant, so will scavenge any ROS generated. It seems unlikely that the 
addition of 100 μM nicotine could exert a sufficient additional antioxidant effect over 
and above that of 10 mM Tris-HCl to inhibit the oligomerisation of Aβ1-42.  
Despite common physicochemical properties (pKa, aromaticity, solvent 
accessible area), nicotine enantiomers display tissue specific distribution. Higher brain 
and plasma levels of (-)-nicotine have been reported, compared with (+)-nicotine 
(Vincek et al. 1981; Pogocki et al. 2007). Furthermore, chronic treatment with (+)-
nicotine has also been shown to increase (-)-[3H]nicotine binding in several regions of 
the rat brain, to a greater extent than rats treated with (-)-nicotine (Zhang et al. 1994; 
Wall et al. 2000).  
It is fortuitous that (+)-nicotine is biologically less active than (-)-nicotine as it 
should evoke fewer peripheral side effects. (-)-Nicotine was found to be up to 30 times 
more active than (+)-nicotine in spontaneous-activity, Rotarod and antinociceptive tests 
and the timecourse of activity was mirrored by the distribution of (-)-[3H]nicotine (Martin 
et al. 1983). Furthermore, (+)-nicotine elicited contraction of isolated rat ileum 
preparations, but with the potency of about one-tenth that of the (-)-isomer (Shimada et 
al., 1984). This suggests that (+)-nicotine also produces fewer effects on the peripheral 
nervous system and is supported by several other studies (Ikushima et al. 1982; 
Shimada et al. 1984a,b; Ikushima et al. 1982). 
In the current study, an excess of (+)-nicotine was required to inhibit the acute 
and chronic effects of A 1-42. Although (+)-nicotine is reported to be less toxic in vivo 
(LD50 for intravenous administration is ~18 times higher than (-)-nicotine; Shimada et al. 
1984 a,b), this concentration of (+)-nicotine will not be tolerated in vivo. Furthermore, 
the concentration of (-)-nicotine, which constitutes approximately 95 % of the total 
nicotine content in tobacco, only reaches ~2 nM in the plasma of smokers (Taylor et al.  
1986). However, as the concentration of A  employed in this study to evoke rapid toxic 
responses is also higher than that found in the AD brain, the concentration of (+)-
nicotine required to inhibit A 1-42 oligomerisation in the AD brain may also be lower than 
that tested in this study. In a similar manner to that attempted with D-KLVFFA, 
chemical modification of (+)-nicotine may enhance antifibrillogenic activity and provide 
novel therapeutic strategies for AD.      
This study presents Aβ oligomerisation as a useful therapeutic target to reduce 
the deleterious effects produced by an over-abundance of Aβ in the AD brain. Inhibition 
of oligomerisation has been achieved using structurally distinct compounds, including 
the peptide KLVFFA and non-peptide (+)-nicotine. This prevention of oligomerisation 
inhibited both acute and chronic in vitro actions of Aβ, including synaptic dysfunction 
and neurodegeneration. (+)-nicotine is particularly interesting as a therapeutic, given 
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the extent of pharmacological and toxicological knowledge already existing in the 
scientific literature.   
 
7.5 Future work 
 
As indicated in the individual chapters, there are several directions that this 
study could take. The duration of exposure required for toxic endpoints to arise coupled 
with the propensity of Aβ to oligomerise rendered size exclusion filtration ineffective for 
the assessing the oligomeric Aβ species mediating toxicity. However, the extent of 
oligomerisation occurring could be examined after the chronic exposure to the cultures. 
Cells homogenates could be assessed by native PAGE (rather than SDS-PAGE) or 
isolated Aβ aggregates by SEC may provide information on the Aβ species present at 
the end of the toxic exposure, possibly ruling out the contribution of larger aggregates 
to toxicity.  
In chapter 3, ThT was found to be toxic to PC12 cells which prevented in situ 
analysis of Aβ oligomerisation. Screening other oligomerisation indicators, eg 
Pittsburgh compound B, for toxicity may reveal a compound that is tolerated by the 
cultures and allow characterisation of Aβ oligomerisation during application to the 
cultures. This may then be used to compare the oligomerisation kinetics of Aβ in the 
presence and absence of cultures.   
As discussed in section 7.2.3, several key facets of this study may account, 
wholly or in part, for the lack of observed neuroprotection. Numerous nicotinic ligands, 
with distinct activities, were screened for neuroprotective potential. The literature lists 
many more examples of nicotinic compounds that have displayed neuroprotective 
activity. As discussed in section 1.13.5 cotinine has also been shown to inhibit Aβ 
oligomerisation and toxicity, indicating the next possible nicotinic compound to be 
tested. Also, despite the employment of two in vitro systems in this study, PC12 cells 
and mixed rat primary cortical neurons, neuroprotection of other systems, such as rat 
hippocampal organotypic slices, which preserve some of the brain architecture, could 
also be attempted.  
The Aβ preparation is a major variable between studies of these peptides. 
Generation, characterisation and comparison of other Aβ preparations presents many 
future directions. However, it should be noted that no neuroprotection of primary rat 
cortical cultures or PC12 cells was detected by nicotinic or VOCC ligands against other 
toxic insults including serum withdrawal, staurosporine-treatment and 6-OHDA 
treatment (data not shown). This suggests that factors other than the Aβ preparation 
account for the lack of neuroprotection.  
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In chapter 5, oligomerisation was only implicated in Aβ-evoked potentiation of 
Ca2+ rises by inhibiting the aggregation of Aβ1-42. As in chapter 6, the role of 
oligomerisation could also have been examined by assessing the effect of enhancing 
oligomerisation by TFA treatment. Other compounds shown to enhance Aβ 
oligomerisation, such as methylene blue (section 1.11.1), could also be employed to 
cross-examine the effects of enhancing oligomerisation.  
Despite comparing Aβ1-42, Aβ25-35 and Aβ42-1, this study did not include the most 
prevalent Aβ peptide in the brain, Aβ1-40. The in vivo relevance of this study could be 
improved by applying Aβ1-42 in combination with Aβ1-40, at ratios relevant to those found 
in the healthy and diseased brain.  
Although Aβ25-35 was compared with Aβ1-42 in chapters 4 and 5, it was not 
characterised as fully. Given that the decapeptide displays altered oligomerisation 
kinetics, with parallel toxicological profile, it would be interesting to compare the 
peptides in the other assays that were employed in this study to characterise Aβ1-42.  
In addition to AFM and ThT, fluorescence microscopy of FAM-labelled Aβ 
peptides may provide further insight into oligomerisation kinetics. These assays could 
also be employed to monitor the disaggregation kinetics of KLVFFA and (+)-nicotine. 
As the toxic fragment does not contain the KLVFFA motif, the effect of (+)-nicoitine on 
Aβ25-35 oligomerisation and toxicity may reveal a distinct mechanism of oligomerisation 
from KLVFFA. Testing the effect of (+)-nicotine against Aβ25-35 may also shed light on 
the region(s) of the peptide being acted on by (+)-nicotine and may elucidate the 
mechanism of anti-oliogomerisation. The effect of (+)-nicotine on neurite outgrowth and 
synaptogenesis could also be examined, followed by in vivo investigation.  
As discussed in chapter 5, the potentiation of nicotine- and KCl-evoked Ca2+ 
rises by Aβ may be specific to the nAChR/VOCC signalling cascade, or may be a 
general action of Aβ on ion homeostasis. Other stimulants, such as glutamate, could be 
employed to further investigate this. Also, the potentiation of Ca2+ rises was only 
monitored for 20 s. Longer time scales may provide additional insight into this action of 
Aβ1-42.  
As discussed in section 4.2.3, the lack of toxicity of unaged Aβ could be 
investigated by the inhibition of ACE or IDE. This could determine the whether these 
enzymes degrade monomeric Aβ before it has the chance to form oligomeric species, 
possibly shedding light on why unaged Aβ is relatively benign, compared with aged Aβ.  
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